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 A. General Introduction 
 
1 
1 Overview 
 
Heterocyclic compounds are widely distributed in nature and are used in modern society as 
herbicides, pesticides, insecticides, dyes and copolymers.
1
 They play a vital role in many 
biological processes,
2
 there are vast numbers of pharmacologically active heterocyclic 
compounds, with many of them being used in clinical routine. In 2010, more than 80% of 
drugs sold in the United States of America contained a heterocyclic fragment.
3
 Some of these 
heterocycles are natural products, however the large majority of pharmaceuticals is of 
synthetic origin. Scientists around the world have been attempting to design new drugs for 
treatment of malignant diseases like AIDS or cancer. For the development of new drugs it is 
essential to determine the biological active site of a molecule. In order to optimize the 
biological activity, it is often necessary to create libraries of differently functionalized and 
modified scaffolds.
4
 For this purpose, scientists have developed a broad variety of synthetic 
strategies to prepare functionalized heterocycles. One method involves the construction of a 
heterocyclic core by cyclisation after functional groups have been installed.
1a
 Alternatively, it 
is possible to functionalize an existing heterocycle by replacing different substituents in a 
successive order.
1a
 This approach offers greater flexibility with respect to the choice of 
substituents and provides an easy access to various derivatives. It may include traditional 
aromatic substitution chemistry, directed metallation methods, halogen-metal exchanges, as 
well as cross-coupling reactions. 
 
  
                                                 
1
 (a) Comprehensive Heterocyclic Chemistry III, Vol. 1 (Eds.: A. R. Katritzky, C. A. Ramsden, E. F. V. Scriven, 
R. J. K.Taylor), Elsevier, Oxford, United Kingdom, 2008, p. xxii. (b) Heterocycles in Live and Society (Eds.: A. 
F. Pozharskii, A. T. Soldatenkov, A. R. Katrinzky), John Wiley & Sons, Chichester, United Kingdom, 2011. 
2
 Medicinal Natural Products, 3. Edition (Ed.: P. M. Dewick), John Wiley & Sons, United Kingdom, 2009, p. 1.  
3
 A. Gomtsyan, Chem. Heterocycl. Compd. 2012, 48, 7. 
4
 N. A. Meanwell, J. Med. Chem. 2011, 54, 2529. 
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2 Organometallic Chemistry 
2.1  Historical Background 
Historically, the beginning of organometallic chemistry can be traced back to the research of 
the French chemist L. C. Cadet (1760), who prepared As2Me4 while working on the 
preparation of invisible ink.
5
 Nearly 150 years later, Victor Grignard received the Nobel Prize 
for his pioneering work on organomagnesium reagents. Since then, organometallic chemistry 
has remained a constantly growing field and a powerful tool in both academia and industry.
6
 
The significance of organometallic reagents in catalysis and in general synthetic chemistry, is 
underlined by further Nobel Prizes awarded in these fields: 1963 to Ziegler and Natta, 1973 to 
Wilkinson and Fischer, 1989 to Brown and Wittig, 2001 to Knowles, Noyori and Sharpless, 
2005 to Chauvin, Grubbs and Schrock, and 2010 to Heck, Negishi and Suzuki. A large 
number of organometallic reagents have been prepared and their chemical properties vary 
widely, but they can roughly be classified by the polarisation of the metal-carbon bond. In 
general, the reactivity of an organometallic species increases with the ionic character of its 
carbon metal-bond (Figure 1).
7
  
 
 
Figure 1: Functional group tolerance and polarity of organometallic reagents.
8
 
 
                                                 
5
 D. Seyferth, Organometallics 2001, 20, 1488. 
6
 (a) Organomagnesium Compounds (Eds.: Z. Rappoport, I. Marek), John Wiley & Sons, Chichester, United 
Kingdom, 2006. (b) Main Group Metals in Organic Synthesis (Eds. H. Yamamoto, K. Oshima), VCH, Wiley, 
Weinheim, Germany, 2004. 
7
 (a) Organometallics in Organic Synthesis (Ed.: N. Negishi), VCH, Wiley, Weinheim, Germany, 1996. (b), 
Applications of Organometallic Compounds (Ed.: I. Omae), VCH, Wiley, Chichester, United Kingdom, 1998. 
(c) Handbook of Functionalized Organometallics (Ed.: P. Knochel), VCH, Wiley, Weinheim, Germany 2005. 
(d) The Chemistry of Organometallic Compounds (Eds.: E. G. Rochow, D. T. Hurd, R. N. Lewis), VCH, Wiley, 
New York, United States 1957. (e) Principle of Organometallic Chemistry (Ed.: Powell), Chapman and Hall, 
London, United Kingdom, 1988. 
8
 B. Haag, M. Mosrin, H. Ila, V. Malakhov, P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 9794. 
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Highly reactive organometallics derived from alkali metals such as organo lithium, sodium 
and potassium reagents, have a strongly ionic carbon-metal bond, which drastically lowers 
their functional group tolerance. Lithium compounds are the only of these polar 
organometallic reagents that display a broad field of application.
9
 At the other end of the 
spectrum, covalent bonded organometallics like organoborons,
10
 and organosilicons
11
 provide 
a high functional group tolerance.  
2.2 Organomagnesium Reagents 
Although organomagnesium compounds were among the earliest reported organometallic 
compounds, their synthetic potential was recognized only at the beginning of the last century.
6
 
In 1900, Victor Grignard
12
 introduced the first organomagnesium reagents; the importance of 
this work was underlined by the Nobel Prize awarded in 1912. The facile synthesis of the so-
called Grignard reagents, their good stabilities and excellent reactivities towards a wide range 
of different electrophiles made them important nucleophiles in both chemical laboratories and 
in industrial processes.
13
 The reactivity of the carbon-magnesium bond depends strongly on 
the reaction temperature. At temperatures above 25 °C, Grignard reagents react with most 
functional groups containing polar multiple bonds, strained rings, acidic protons, and highly 
polar single bonds.
14
 The oxidative insertion of magnesium into alkyl or aryl halides is still 
the most straightforward method for the preparation of organomagnesium reagents (A, 
Scheme 1).
13c
  
 
                                                 
9
 (a) R. Chinchilla, C. Nájera, M. Yus, Chem. Rev. 2004, 104, 2667. (b) The chemistry of 
organolithium compounds (Eds.: Z. Rappoport, I. Marek), John Wiley & Sons, Chichester, United 
Kingdom, 2004. (b) Lithium Compounds in Organic Synthesis: From Fundamentals to Applications (Eds.: R. 
Luisi, V. Capriati), VCH, Wiley, Weinheim, Germany, 2014.  
10
 Handbook of Functionalized Organometallics (Ed.: P. Knochel), VCH, Wiley, Weinheim, Germany 2005, p. 
45-103. 
11
Handbook of Functionalized Organometallics (Ed.: P. Knochel), VCH, Wiley, Weinheim, Germany 2005, p. 
173-197. 
12
 V. Grignard, Compt. Rend. Acad. Sci. Paris 1900, 130, 1322. 
13
 (a) Grignard Reagents (Ed.: H. G. Richey), VCH, Wiley, New York, 2000. (b) Handbook of Grignard-
Reagents (Eds.: G. S. Silverman, P. E. Rakita), Marcel Dekker, New York, 2000. (c) Handbook of 
Functionalized Organometallics (Ed.: P. Knochel), VCH, Wiley, Weinheim, Germany, 2005, p. 109-164.  
14
 Handbook of Grignard-Reagents (Eds.: G. S. Silverman, P. E. Rakita), Marcel Dekker, New York, 1996. 
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Scheme 1: Synthetic methods for the preparation of Grignard reagents. 
 
According to standard protocols, the insertion reaction is highly exothermic and is normally 
performed under reflux conditions in Et2O or THF,
15
 precluding the presence of most 
functional groups. If, however, the oxidative addition reaction is conducted at low 
temperature, sensitive groups can be tolerated. This can be achieved by using activated 
magnesium (Rieke magnesium, Mg*)
16
 or by the addition of LiCl.
17
 The halogen-magnesium 
exchange is the method of choice for the preparation of Grignard reagents containing sensitive 
functionalities, since they can be performed at low temperatures assuring a higher functional 
group tolerance (B, Scheme 1).
18
 The addition of LiCl enhances the exchange reaction and 
thus provides the possibility of using less reactive substrates like bromides in Br/Mg 
exchange.
19
 A further prominent method to generate organometallic compounds is the direct 
metallation by deprotonation of organic molecules by organometallic bases (C, Scheme 1).
8,20
 
Magnesium reagents can also be prepared by transmetallation from a corresponding 
organoalkali metal reagent, by the addition of magnesium salts (D, Scheme 1).
21
   
  
                                                 
15
 Organikum (Ed.: H. G. O. Becher), VCH, Wiley, Weinheim, Germany, 2004.  
16
 (a) R. D. Rieke, Science 1989, 246, 1260. (b) R. D. Rieke, M. V. Hanson, Tetrahedron 1997, 1925. 
17
 F. M. Piller, P. Appukkuttan, A. Gavryushin, M. Helm, P. Knochel, Angew.Chem. Int. Ed. 2008, 47, 6802.  
18
 For a review see: P. Knochel, W. Dohle, N. Gommermann, F. F. Kneisel, F. Kopp, T. Korn, I. Sapountzis,  
V. A. Vu, Angew. Chem. Int. Ed. 2003, 42, 4302. 
19
A. Krasovskiy, P. Knochel, Angew. Chem. Int. Ed. 2004, 43, 3333. 
20
 K. W. Henderson, W. J. Kerr, Chem. Eur. J. 2001, 7, 3430. 
21
 Main Group Metals in Organic Synthesis (Eds.: H. Yamamoto, K. Oshima), VCH, Wiley, Weinheim Germany 
2004, p 55. 
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2.3 Organozinc Reagents 
Organozinc compounds have been known since the pioneering work of Frankland on 
diethylzinc in 1849.
22
 These carbon–metal bonds have a covalent character and a relatively 
low polarity, therefore they are unreactive towards a number of electrophiles. Historically, 
organozinc reagents have therefore been rarely used, in comparison to the more reactive 
magnesium reagents.
23
 Their true potential as carbon nucleophiles in organic chemistry today 
lies in the combination of this functional group tolerance and the potential of transmetallation 
with transition metals, allowing the formation of reactive organometallic intermediates, which 
can perform reactions like cross-couplings efficiently.
24
 The most common method to prepare 
organozinc reagents is the oxidative addition of zinc dust to functionalized organic halides (A, 
Scheme 2).
24b,25,
 This allows the preparation of a broad range of organozinc reagents bearing 
various functionalities like esters, acetates, cyano groups, halides and ketones.
26,24c
 The 
activation of the zinc dust is of great importance for a successful insertion, since the metallic 
zinc is covered by an oxide layer.
27
 Treating zinc with 1,2-dibromoethane and Me3SiCl 
removes this oxidation layer chemically,
28,27
 and thus activates it. Furthermore, the use of 
Rieke-zinc (Zn*),
29
 Li salts like LiCl
30
 or polar co-solvents is known to accelerate the 
insertion reaction. Alternatively, organozinc reagents can also be prepared via halogen-zinc 
exchange using transition metal catalysed reaction with Et2Zn (B, Scheme 2)
31
 or by direct 
metallation (C, Scheme 2).
8
 Furthermore transmetallation from more polar organometallic 
reagents is a method that is often performed to prepare organozinc reagents (D, Scheme 2).
32
 
 
                                                 
22
 E. Frankland, Liebigs Ann. Chem. 1849, 71, 171. 
23
 (a) S. Reformatsky, Chem. Ber. 1887, 20, 1210 (b) S. Reformatsky, Chem. Ber. 1895, 28, 2842 (c) H. E. 
Simmons, R. D. Smith, J. Am. Chem. Soc. 1958, 80, 5323. (d) H. E. Simmons, T. L. Cairns, A. Vladuchick, C. 
M. Hoiness, Org. React. 1972, 20, 1. (e) J. Furukawa, N. Kawabat, J. Nishimma, Tetrahedron Lett. 1966, 7, 
3353. 
24
 (a) E. Negishi, L. F. Valente, M. Kobayashi, J. Am. Chem. Soc. 1980, 102, 3298. (b) E. Erdik, Tetrahedron 
1992, 48, 9577. (c) P. Knochel, J. J. Almena-Perea, P. Jones, Tetrahedron 1998, 54, 8275. (d) Organozinc 
Reagents. A Practical Approach (Eds.: P. Knochel, P. Jones), Oxford University Press, New York, 1999. (c) A. 
Sidduri, J. W. Tilley, N. Fotouhi, Synthesis 2014, 46, 430. (d) E. Erdik, Tetrahedron 1992, 48, 9577. 
25
 Chemistry of Organozinc Compounds (Eds.: Z. Rappoport, I. Marek), John Wiley & Sons Ltd., Chichester, 
United Kingdome, 2006. 
26
 P. Knochel, R. D. Singer, Chem. Rev. 1993, 93 2117.   
27
 E. Erdik, Tetrahedron 1987, 2203. 
28
 (a) J. K. Gawronsky, Tetrahedron Lett. 1984, 25, 2605. (b) G. Picotin, P. Miginiac, Tetrahedron Lett. 1987, 
28, 4551. (c) P. Knochel, M. C. P. Yeh, S .C. Berkam, J. Talbert, J. Org. Chem. 1988, 53, 2390. 
29
 R. D. Rieke, Science 1989, 246, 1260. (b) M. V. Hanson, R. D. Rieke, J. Org. Chem. 1991, 56, 1445.  
30
 A. Krasovskiy, V. Malakhov, A. Gavryushin, P. Knochel, Angew. Chem. Int. Ed. 2006, 45, 6040. 
31
 (a) M. J. Rozema, A. R. Sidduri, P. Knochel, J. Org. Chem. 1992, 57, 1957. (b) H. Stadtmüller, R. Lentz, W. 
Dörner, T. Stüdemann, C .E. Tucker, P. Knochel,  J. Am. Chem. Soc. 1993, 115, 7027.  
32
 Handbook of Functionalized Organometallics (Ed.: P. Knochel), VCH, Wiley, Weinheim, Germany, 2005, 
p. 261. 
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Scheme 2: Synthetic methods for the preparation of organozinc reagents.  
 A. General Introduction 
 
7 
2.4 Direct Metallation  
Direct functionalization of unsaturated heterocycles can be performed by metallation, using a 
stoichiometric amount of a metal base followed by subsequent trapping with electrophiles. 
Since the pioneering work by Gilman,
33
 Wittig,
34
 and Snieckus,
35
 directed ortho-metallation 
(DoM) has been widely used for the regioselective functionalization of aromatic and 
heteroaromatic systems. Substituents such as a carbamates, amides, methoxy, or cyano groups 
proved to ortho direct the metallation with strong lithium bases. Organolithium reagents, such 
as BuLi (butyl lithium), as well as lithium amides, such as LDA (lithium diisopropylamide) or 
LiTMP (lithium 2,2,6,6-tetramethylpiperidinyl) are among the most frequently used bases for 
direct lithiations.
8
 The major drawback of organolithium reagents is their high reactivity 
towards functional groups, since aryl lithium compounds react with most functional groups at 
temperatures above –20 °C.
36
 To overcome these limitations, the corresponding magnesium 
reagents which have a less polarized carbon–metal bond can be prepared. In 1947, Hauser and 
Walker reported magnesium amide bases of the general formula R2NMgX and (R2N)2Mg, 
(Hauser bases).
37
 The group of Eaton demonstrated the potential of Hauser bases for the 
directed ortho-magnesiation of aromatic compounds.
37c
 Despite the use of several magnesium 
bases in organic synthesis,
38
 their general use was limited due to their low solubility in 
common organic solvents providing a low kinetic basicity. These limitations were overcome 
in 2006, when Knochel and co-workers reported the first LiCl-solubilized TMP base 
TMPMgCl·LiCl (1).
39
 Since then a number of these bases were prepared, the most important 
being lithium chloride solubilized magnesium and zinc bases [(TMPMgCl·LiCl (1),
39
 
TMP2Mg·2LiCl (2),
40
 TMPZnCl·LiCl (3),
41 
and TMP2Zn·2LiCl (4)
42
]. Due to an increased 
negative charge on nitrogen in TMP2Mg·2LiCl (2) compared to TMPMgCl·LiCl (1), 
                                                 
33
 H. Gilman,W. Langham, A. L. Jacoby, J. Am. Chem. Soc. 1939, 61, 106. 
34
 G. Wittig, G. Fuhrmann, Ber. Dtsch. Chem. Ges. 1940, 73, 1197. 
35
(a) V. Snieckus, Chem. Rev. 1990, 90, 879, (b) T. K. Macklin, J. Panteleev, V. Snieckus, Angew. Chem. Int. 
Ed. 2008, 47, 2097. 
36
 (a) P. Stanetty, M. D. Mihovilovic, J. Org. Chem. 1997, 62, 1514. (b) Handbook of Functionalized 
Organometallics, Vol. 1 (Ed.: P. Knochel), Wiley-VCH, Weinheim, Germany 2005, p. 7. 
37
 (a) C. R. Hauser, H. G. Walker, J. Am. Chem. Soc. 1947, 69, 295. (b) K. W. Henderson, W. J. Kerr, Chem. 
Eur. J. 2001, 7, 3430. (c) P. E. Eaton, C. H. Lee, Y. Xiong, J. Am. Chem. Soc. 1989, 111, 8016. (d) P. E. Eaton, 
Y. Xiong, R. Gilardi, J. Am. Chem. Soc. 1993, 115, 10195. (e) P. E. Eaton, K. A. Lukin, J. Am. Chem. Soc. 1993, 
115, 11370. (f) M. X. Zhang, P. E. Eaton, Angew. Chem. Int. Ed. 2002, 41, 2169. (g) P. E. Eaton, M. X. Zhang, 
N. Komiya, C. G. Yang, I. Steele, R. Gilardi, Synlett. 2003, 1275. 
38
 (a) W. Schlecker, A. Huth, E. Ottow, J. Mulzer, J. Org. Chem. 1995, 60, 8414. (b) W. Schlecker, A. Huth, E. 
Ottow, J. Mulzer, Liebigs Ann. Chem. 1995, 1441. (c) W. Schlecker, A. Huth, E. Ottow, J. Mulzer, Synthesis 
1995, 1225. 
39
 A. Krasovskiy, V. Krasovskaya, P. Knochel, Angew. Chem. Int. Ed. 2006, 45, 2958.  
40
 G. C. Clososki, C. J. Rohbogner, P. Knochel, Angew. Chem. Int. Ed. 2007, 46, 7681. 
41
 M. Mosrin, P. Knochel, Org. Lett. 2009, 11, 1837.  
42
 S. Wunderlich, P. Knochel, Angew. Chem. Int. Ed. 2007, 46, 7685. 
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TMP2Mg·2LiCl (2) displays a higher reactivity, allowing metallation of aromatic substrates 
bearing electron-donating or weakly electron-accepting substituents. Whereas the use of 
magnesium bases displays a high tolerance toward nitriles, esters, and aryl ketones, there are a 
number of important functional groups, such as nitro, aldehyde, methyl ketone, or electron-
poor N-heterocycles, that are not compatible with their use. A higher functional group 
tolerance is achieved either by transmetallation of the corresponding magnesium reagent with 
ZnCl2 or by using the milder base TMPZnCl·LiCl (3), since the formed carbon–zinc bonds 
have essentially covalent character. Zincation mediated by TMPZnCl·LiCl (3) is possible 
over a broad temperature range; even temperatures up to 100 °C are feasible. The base 
TMP2Zn·2MgCl2·2LiCl (4) is more reactive than TMPZnCl·LiCl (3) due to the increased 
negative charge on the nitrogen, providing the possibility to zincate relatively unreactive, 
unsaturated substrates.  
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3 Allylic Organometallics 
3.1  General Introduction 
Allylic organometallics have been thoroughly described since the 1960s. In the beginning, 
scientists focused mainly on structural determinations
43
 of allylmetals such as the 
stereochemistry of the double bond and the regioselectivity of reactions with electrophiles. 
Since the 1970s, the focus has shifted towards the controlling of the stereochemistry for the 
C-C bond formation. This was mainly triggered by the pioneering work of Gaudemar
44
, 
Heathcock,
45
 Hoffmann
46
 and Yamamoto
47
 who studied the stereocontrolled allylation of 
carbonyl derivatives. The reaction of allylic organometallic reagents with aldehydes
48
 is 
synthetically analogous to the aldol addition of metal enolates, since the resulting homoallyl 
alcohol can be easily converted to the aldol product by ozonolysis (Scheme 3).
49
 The double 
bond can participate in other synthetically useful transformations, like cycloadditions, 
dihydroxylation, hydro- or carbometallations, hydrogenation and olefin methathesis, making 
it a versatile tool in organic synthesis (Scheme 3).  
 
Scheme 3: Synthetically useful transformations of homoallyl alcohols.  
                                                 
43
 (a) R. A. Benkeser, Synthesis 1971, 347. (b) G. Courtois, L. Miginiac, J. Organomet. Chem. 1974, 69, 1. (c) E. 
A. Hill, J. Organomet. Chem. 1975, 91, 123.  
44
 (a) E. Favre, M. Gaudemar, J. Organomet. Chem. 1974, 76, 297. (b) E. Favre, M. Gaudemar, J. Organomet. 
Chem. 1974, 76, 305. (c) E. Favre, M. Gaudemar, J. Organomet. Chem. 1975, 92, 17. 
45
 C. T. Buse, C. H. Heathcock, Tetrahedron Lett. 1978, 1685. 
46
 R. W. Hoffmann, H. J.  Zeiss, Angew. Chem. Int. Ed. 1979, 18, 306.  
47
 Y. Yamamoto, H. Yatagai, Y. Naruta, K. Maruyama, J. Am. Chem. Soc. 1980, 102, 7107. 
48
 Modern Carbonyl Chemistry (Ed.: J. Otera), VCH, Wiley, Weinheim, Germany, 2000. 
49
 Y. Yamamoto, N. Asao, Chem. Rev. 1993, 93, 2207. 
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3.2 Regioselectivity in Allylic Reactions 
The regioselectivity of allylic organometallics depends on the organometallic compound, the 
nature of the electrophile, the steric hindrance in the vicinity of the site of the reaction, and the 
reaction conditions, like solvent and temperature.
50,51
  
 
Figure 2: Allylic organometallic reagent. 
 
While unsymmetrical allyl lithium reagents react with aldehydes nonselectively, with a slight 
preference for attack at the most substituted allyl terminus,
52
 Grignard and zinc reagents 
generally react with aromatic and aliphatic aldehydes via an allylic rearrangement in the γ-
position (Figure 2). However, despite the difficulty in obtaining an α-adduct from organozinc 
reagents, some examples of α-regioselective allylation of aldehydes and ketones have been 
reported.
53
  
3.3 Diastereoselectivity in Allylic Rearrangements 
Substituted allylic organometallics display a high level of diastereoselectivity, since they 
usually react at the γ-position through an ordered cyclic or acyclic transition state 
(Scheme 4).
54
 The diastereoselectivity of the reaction of aldehydes with allylic 
organometallics can be rationalized by a six-membered Zimmerman-Traxler
55
 like transition 
state of type A in which the metal center is coordinated by the oxygen (Scheme 4). The most 
favored transition state structure, with R in the pseudo-equatorial position, provides the 
relative stereochemistry in the product. Therefore, E-allylic organometallics provide 
selectively the anti-alcohol, while Z-allylic organometallics provide the syn-products. 
                                                 
50
 A. Yanagisawa, S. Habaue, H. Yamamoto, J. Org. Chem. 1989, 54, 5199. 
51
 F. Barbot, P. Miginiac, Tetrahedron Lett. 1975, 3829.  
52
 T. Cohen, B. S. Guo, Tetrahedron 1986, 42, 2803.   
53
 (a) B. S. Guo, W. Doubleday, T. Cohen, J. Am. Chem. Soc. 1987, 109, 4710. (b) A. Yanagisawa, S. Habaue, 
H. Yamamoto, J. Am. Chem. Soc. 1991, 113, 8955. (c) A. Yanagisawa, S. Habaue, K. Yasue, H. Yamamoto, J. 
Am. Chem. Soc. 1994, 116, 6130. (d) R. E.  Estevez, R. E., J. Justicia, B. Bazdi, N. Fuentes, M. Paradas, D. 
Choquesillo-Lazarte, J. M.  Garcia-Ruiz, R. Robles, A, Gansauer, J. M. Cuerva, J. Oltra, Chem. Eur. J. 2009, 15, 
2774. (e) L. M. Zhao, H. S. Jin, L. J. Wan, L. M. Zhang, J. Org. Chem. 2011, 76, 1831. 
54
 M. Yus, J. C. González-Gómez F. Foubelo, Chem. Rev. 2011, 111, 7774. 
55
 H. E. Zimmerman, M. D. Traxler, J. Am. Chem. Soc.1957, 79, 1920. 
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Scheme 4: Diastereoselectivity obtained for the cyclic or acyclic transition state. 
 
However, the BF3 mediated reaction of 2-butenylstannane with benzaldehyde exhibits an 
entirely different stereochemistry, where the syn-homoallyl alcohol is obtained from both E- 
and Z-allylic organometallic reagents.
49,56
 Y. Yamamoto proposed that the coordination of the 
Lewis acid BF3 to the oxygen prevents the coordination of the carbonyl to the metal atom.
56b
 
The reaction was proposed to proceed over an acyclic transition state B, providing the syn-
homoallyl alcohol from both E- and Z-allylic organometallic reagents. Therefore, the Lewis 
acid serves both as a stereoshielding group, as well as an activator for the carbonyl group.  
3.4 Preparation of Allylic Zinc Reagents 
Allylic zinc reagents are especially versatile organometallic species since their behavior is 
more predictable than the behavior of the corresponding allylic magnesium or lithium 
reagents.
57
 Several methods have been described for their preparation.
58,7c
 In 1962, Gaudemar 
reported the preparation of allylic zinc reagents from allylhalides via zinc insertion reactions 
(A, Scheme 5).
59
 Allylic zinc reagents can also be prepared from the corresponding allylic 
benzoates by an umpolung reaction (B, Scheme 5)
60
 or by fragmentation of sterically hindered 
homoallylic alcohols (C, Scheme 5).
61
 
                                                 
56
 (a) Y. Yamamoto, Y. Yatagai, Naruta, K. Maruyama, J. Am. Chem. Soc. 1980, 102, 7107. (b) Y. Yamamoto, 
H. Yatagai, Y. Ishihara, N. Maeda, K. Maruyama, Tetrahedron 1984, 2239. (c) S. E. Denmark, J. Fu, Chem. Rev. 
2003, 103, 2763. 
57
 (a) G. Courtois, L. Miginiac, J. Organomet. Chem. 1974, 69, 1. (b) Y. Yamamoto, Acc. Chem. Rev. 1987, 20, 
243. (c) M. Schlosser, O. Despond, R. Lehmann, E. Moret, G. Rauchschwalbe, Tetrahedron 1993, 49, 10175. 
58
 (a) Organozinc Reagents, A Practical Application (Ed.: Paul Knochel), Oxford University Press, Oxford 
United Kingdom, 1999. 
59
 M. Gaudemar, Bull. Soc. Chim. Fr. 1962, 974. 
60
 (a) Y. Masuyama, N. Kinugawa, N. Kurusu, J. Org. Chem. 1987, 52, 3702. (b) W. Qui, Z. J. Wang, J. Chem. 
Soc. Chem. Commun. 1989, 356. (c) K. Yasui, Y. Goto, T. Yajima, Y. Taniseki, K. Fugami, A. Tanaka, Y. 
Tamaru, Tetrahedron Lett. 1993, 34, 7619. (d) Y. Tamaru, A. Tanaka, K. Yasui, S. Goto, S. Tanaka, Angew. 
Chem. Int. Ed. 1995, 34, 787. (e) J. A. Marshall, Chem. Rev. 2000, 100, 3163. 
61
 (a) P. Jones, N. Millot, P. Knochel, Chem. Commun. 1994, 2405. (b) P. Jones, P. Knochel, Chem. Commun. 
1994, 2407. (c) P. Jones, P. Knochel, J. Org. Chem. 1994, 64, 186. 
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Scheme 5: Synthetic methods for the preparation allylic zinc reagents. 
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4 Metallation of Chromone, 4-Pyrone, Uracil and Uridine 
4.1  General Concept 
Numerous important heterocycles contain a pyrone-like core structure having a carbonyl 
group in conjugation with a heteroatom X via a double bond (Figure 3). 
 
 
 
 
  
Figure 3: Naturally occurring heterocyclic scaffolds possessing this structural motive. 
 
 If the heteroatom X is more electronegative than the carbon (X = O, N), an electron 
withdrawal reduces the electronic density in C(2), resulting in an increased acidity of the 
proton in C(2) compared to C(3) (Figure 3). As a result of the conjugation of the heteroatom 
X to the carbonyl group, the carbonyl oxygen becomes more basic.
62
 If more than one Lewis 
acid is present in a reaction, the strongest Lewis acid (LA) will coordinate to the carbonyl 
oxygen (A, Scheme 6). Since the metal center of an organometallic base (R-Met) can be 
considered as Lewis acidic, it was envisioned, that depending on the reaction conditions, the 
regioselectivity of the metallation could be directed. Coordination of the carbonyl group to the 
organometallic reagent will direct the metallation at C(3) via the DMG (directing metallation 
group) effect, providing the kinetic product (B, Scheme 6). However, if a stronger Lewis acid 
than the cation of the organometallic base is present, this Lewis acid will coordinate to the 
C(4) carbonyl, and the metallation will occur at C(2), providing the thermodynamic product 
(C, Scheme 6). 
                                                 
62
 “Chromone is a weak base (pKa –2.00) which is protonated on the carbonyl oxygen to afford hydroxyl 
benzopyrylium salts.” From: Chromenes, Chromanones and Chromones (Ed. G. P. Ellis), John Wiley & Sons, 
United Kingdom, 1977, p. 561.  
“4-Pyrone is a weak base, pKa –0.03 which is protonated on the carbonyl oxygen to afford often crystalline 4-
hydroxypyrylium salts.” From: Heterocyclic Chemistry, 4. Edition, (Eds.: J. A. Joule, K. Mills), Blackwell 
Publishing, Oxford, United Kingdome, 2000, p.165. 
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Scheme 6: Concept for the metallation of chromone by kinetic or thermodynamic deprotonation.  
4.2 Metallation of Chromone  
4.2.1  General Introduction  
The chromone scaffold (5, Figure 4) is the core structure of a major class of oxygen 
containing heterocycles that are abundant in nature.
63
 
 
  
 
 
 
 
Figure 4: IUPAC numbering of Chromone (5).
64
  
 
They are common secondary metabolites and accumulate in almost every part of the plant, 
from the roots to the flower petals. They make up flower pigments,
65
 and flavones like 
quercetrin obtained from the inner bark of Quercus velutina, have been used as dyes, as they 
impart various shades of yellow to wool (Figure 5).
65 
 Considerable amounts of chromones are 
consumed daily since they are present in regularly consumed food, like vegetables, fruits, 
                                                 
63
 Flavonoids: Chemistry, Biochemistry and Applications (Eds.: O. M. Andersen, K. R. Markham), CRC Press, 
Boca Raton, United States, 2006. 
64
The Alkaloids, Vol. 31 (Eds.: P. J. Houghton, A. Brossi), Academic Press, San Diego, USA, 1987, p. 67. 
65
 Heterocyclic Chemistry, 4. Edition, (Eds.: J. A. Joule, K. Mills), Blackwell Publishing, Oxford, United 
Kingdome, 2000, p. 170. 
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olive oil, and in beverages like tea and wine.
66
 Apart from their physiological role in plants, 
some derivatives have been reported to possess various biological properties such as anti-
inflammatory, antiplatelet, anticancer, and antimicrobial activity.
67
 For example, the 
isoflavone daidzein from Trifolium, has oestrogenic activity and affects the reproduction of 
grazing animals (Figure 5).
68
  
 
Figure 5: Examples of the naturally occurring chromones. 
The role of plants and their extracts in various traditional medicines has spurred scientific 
interest in the isolation of the pharmaceutically active compounds.
69 
Khellin and visnagin are 
found in the fruits of Ammi visnaga, and are the active principle of a plant drug that has been 
used in folk medicine in Egypt (Figure 5).
70
 The chromone core structure is found in marketed 
drugs
71
 like cromoglycate (Lomudal
®
),
70
 diosmin (Daflon
®
), and Flavoxate
®
 (Figure 6).
72
 
Owing to the interesting bioactivity, the chromone system has been thoroughly described in 
the literature.
73,67a  
 
 
 
 
Figure 6: Examples of commercially available drugs containing a chromone scaffold.  
                                                 
66
 F. Chimenti, R. Fioravanti, A. Bolasco, P. Chimenti, D. Secci, F. Rossi, M. Yáñez, F. Orallo, F. Ortuso, S. 
Alcaro, R. Cirilli, R. Ferretti, M. L. Sanna, Bioorg. Med. Chem. 2010, 18, 1273. 
67
 (a) A. Gaspar, M. J. Matos, J. Garrido, E. Uriarte, F. Borges, Chem. Rev. 2014, 114, 4960. (b) S. Khadem, R. 
J. Marles, Molecules 2012, 17, 191. 
68
 (a) Medicinal Natural Products, 3. Edition, (Ed.: P. M. Dewick), John Wiley & Sons, United Kingdom, 2009, 
p. 175. (b) K. R. Price, G. R.  Fenwick, Food Addit. Contam. 1985, 73, 106. (c) D. A. Shutt, R. H. Weston, J. P. 
Hogan, Aust. J. Agric. Res. 1970, 21, 713. 
69
 S. T. Saengchantara, T. W. Wallace, Nat. Prod. Rep. 1986, 465. 
70
 Medicinal Natural Products (Ed. P. M. Dewick), John Wiley & Sons, United Kingdom, 2009, p. 112.  
71
 R. S. Keri, S. Budagumpi, R. K. Pai, R. G. Balakrishna, Eur. J. Med. Chem. 2014, 78, 340. 
72
 M. S. Butler, A. A. Robertson, M. A. Copper, Nat. Prod. Rep. 2014, DOI: 10.1039/c4np00064. 
73
 Comprehensive Heterocyclic Chemistry III, Vol. 7 (Eds: D. S. C Black, A. R. Katritzky, C. A. Ramsden, E. F. 
V. Scriven, R. J. K.Taylor), Elsevier, Oxford, United Kingdom, 2008, p. 337-418. 
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4.2.2  State of Research for the Metallation of Chromone 
Generally, the total synthesis of simple chromones can be attained using starting materials 
that do not have a γ-pyran ring in their structure.
67a
 Many of these synthetic approaches have 
been known for a considerable time and are still in use because of their efficiency and 
simplicity.
67a
 However, there is a need to speed up the drug discovery process, for 
establishing structure-activity relationship studies in medicinal chemistry programs, and 
consequently a number of methods have been developed to functionalize the molecule after 
the chromone scaffold has been installed.
73
  
 
 
Scheme 7: Literature reported metallation of chromone. 
 
Relatively few examples are reported for the direct metallation of chromone (5). It has been 
determined that chromones in which the C(2) position is blocked provide the C(3) lithiated 
chromone when treated with LDA
 
(A, Scheme 7).
74 
Chromones that are unsubstituted at the 
C(2) are prone to Michael addition and concomitant ring opening. Consequently, lithiation of 
C(2) is difficult to achieve and requires assistance of a DMG in position C(3) to proceed 
adequately.
75,74a 
 The lithiation of chromone-3-carbaldehyde acetal at C-2 is reported in the 
literature (B, Scheme 7).
 
However, for unsubstituted chromones, a selective metallation in 
                                                 
74
 (a) A. M. S. B. R. C. S. Costa, F. M. Dean, M. A. Jones, R. S. Varma, J. Chem. Soc. Perkin Trans. I 1985, 
799. (b) A. M. S. B. R. C. S. Costa, F. M. Dean, M. A. Jones, D. A. Smith, R. S. Varma, J. Chem. Soc. Chem. 
Commun. 1980, 1224. 
75
 G. E. Daia, C. D. Gabbutt, J. D. Hepworth, B. M. Heron, D. E. Hibbs, M. B. Hursthouse, Tetrahedron Lett. 
1998, 39, 1215.  
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position C(2) or C(3) has not yet been achieved. The lithiation of unsubstituted chromone 
with TMP-Li or LDA produces a complex mixture of products.
74,75
 Selective C(3) zirconation 
of chromone with TMP4Zr·6LiCl was recently achieved (C, Scheme 7).
76
 
4.2.3 Metallation of Chromone: General Concept 
The chromone system contains two directing groups,
35
 the vinyl-etheral oxygen and the 
carbonyl oxygen, which are next to the protons in C(2) or C(3), respectively. Theoretical 
calculations
77,78
 showed that the thermodynamically most acidic hydrogen of chromone (5) is 
attached to C(2) (Figure 7).  
 
 
 
Figure 7: Calculated pKa-values of chromone in DMSO. 
The metallation of vinyl ethers usually occurs predominantly at the 2-position, as 
coordination with the oxygen atom increases the inductive effect and brings the base closer to 
the α-position.
79,74a
 However, the carbonyl oxygen in chromone is highly negatively charged 
due to the pyrone system.
 62
 Therefore, the Lewis acid coordinates more effectively at the 
carbonyl oxygen than at the etheral oxygen. Coordination of the C(4) carbonyl to the metal 
base (R-Met) would lead to ortho metallation and the formation of the kinetic product A 
(pathway a, Scheme 8). In the presence of a stronger Lewis acid than the metallating base, 
complexation of the Lewis acid occurs at the carbonyl group and the thermodynamic C(2)-
metallated heterocycle is obtained (pathway b, Scheme 8). 
 
                                                 
76
 M. Jeganmohan, P. Knochel, Angew. Chem. Int. Ed. 2010, 49, 8520. 
77
 L. Klier, T. Bresser, T. A. Nigst, K. Karaghiosoff, P. Knochel, J. Am. Chem. Soc. 2012, 134, 13584. 
78
 The theoretical calculations were performed by Dr. Tobias A. Nigst (Ludwig-Maximilians-Universtät 
München).   
79
 (a) R. K. Boeckman, K. J. Bruza, Tetrahedron Lett. 1977, 4187. (b) F. T. Oakes, J. F. Sebastian, J. Org. Chem. 
1980, 45, 4959. 
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Scheme 8: Regioselective metallation of chromone in the kinetic and thermodynamic position. 
 
4.2.3.1 Metallation Conditions and Optimisation of the Reaction80 
In accordance with the proposed concept, treatment of chromone (5) with 1.2 equiv. of the 
amide base TMPZnCl·LiCl (3) at 25 °C in THF, provided the zincated chromone (6) in a 
regioselectivity of 1:28 C(2):C(3) as confirmed by GC analysis of reaction aliquots quenched 
with iodine (Scheme 9).
81
 Full conversion was observed after 15 min. The regioselectivity of 
the metallation was determined by 2D-NMR analysis of both the zincated species (6) and 
isolated iodolysis product (7a). Furthermore, the influence of the presence of additional Lewis 
acids on the zincation was investigated (Scheme 9). Metallation of chromone with 1.2 equiv. 
TMPZnCl·LiCl (3) in the presence of 2 equiv. MgCl2 proceeded best at 0 °C, providing full 
conversion to the zincated species 8 after 1 h in a regioselectivity of C(2):C(3) 30:1 (Scheme 
9).
81
 The reaction of chromone (5) with TMP2Zn·2MgCl2·2LiCl (4) at –20 °C led to a 
regioselectivity of C(2):C(3) 33:1 (Scheme 9). The regioselectivity was assigned by 2D-NMR 
analysis of both, the zincated species (8) and isolated iodolysis product (9a). A similar 
regioselectivity reversal was achieved by addition of BF3·OEt2 as Lewis acid, at a reaction 
temperature of –20 °C which was required to avoid decomposition. An excess of 
TMPZnCl·LiCl (1.6 equiv.) was neccesery to achieve full conversion. Using these conditions, 
a selectivity of 61:1 C(2):C(3) was observed (Scheme 9). 
 
                                                 
80
 Lydia Klier, Selective Functionalization of Chromone and Related Systems, M. Sc. Thesis, Ludwig-
Maximilians-Universität München, Germany, 2011. 
81
 The reaction was optimized on a 2 mmol scale. 
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Scheme 9: Regioselectivities obtained for the zincation of chromone (5) with TMPZnCl·LiCl (3) or 
TMP2Zn·2LiCl·2MgCl2 (4) at different reaction conditions, and subsequent reaction with iodine.  
 
4.2.3.2 NMR Experiments to Determine the Metallated Species and Coordination Site 
of BF3  
To prove the regioselectivity of the reaction of chromone (5) with TMPZnCl·LiCl (3) in THF, 
the obtained zinc reagent was characterized by NMR-spectroscopy. The 
1
H- and 
13
C-NMR 
spectra indicate the presence of a temperature dependent Schlenk-equilibrium.
82
 To obtain 
mainly one species, this equilibrium was shifted either by the addition of ZnCl2 or by 
changing the solvent to dioxane.
 
The obtained 
1
H, 
13
C, COSY, HSQC, and HSBC spectra 
confirmed the identity of C(3)-zincated chromone (6).
83
 The C(2)-zincation for the reaction of 
chromone (5) with TMP2Zn·2MgCl2·2LiCl (4) was confirmed by 
1
H, 
13
C, COSY, HSQC, and 
HSBC spectra.
83
 In accordance with our concept, the coordination of the carbonyl group to 
                                                 
82
 (a) R. Abegg. Ber. 1905, 26, 4112. (b) W. Schlenk, W. Schlenk, J. Chem. Ber. 1929, 62, 920. (c) 
Organomagnesium Compounds, (Eds.: Z. Rappoport, I. Marek), John Wiley & Sons, Chichester, United 
Kingdom, 2006, p. 107-109. 
83
 For further details see experimental part 7.7.1. 
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the Lewis acid BF3 could be confirmed by 
13
C-NMR experiments, while a coordination of the 
etheral oxygen to BF3 could not be measured.
83
 
 
4.2.3.3 Scalable Preparation of Chromone Derivatives via Direct Metallation Using 
TMPZnCl·LiCl 
The metallation methodology described in 4.2.3.1. was further extended from a 2 mmol scale 
to a 50 mmol scale and the scope of the reaction was tested with various electrophiles. The 
regioselectivity and progress of the reactions were monitored by GC analysis of reaction 
aliquots quenched with iodine. Treatment of 2 mmol chromone (5) with TMPZnCl·LiCl (3, 
1.2 equiv.) in THF at 25 °C for 15 minutes, resulted in a full conversion to produce the C(3)-
zincated reagent (6). After iodolysis, 3-iodo-chromone (7a) was isolated in 80% yield 
(entry 1, Table 1). When the reaction was scaled up to 50 mmol, TMPZnCl·LiCl was added 
over 30 minutes at 0 °C. The lower reaction temperature and the slow addition rate were 
necessary to avoid a decrease in regioselectivity presumably caused by an increase of the 
reaction temperature. After the addition was completed, the reaction mixture was stirred at 25 
°C for additional 7 h. Transmetallation of zincated chromone 6 with CuCN·2LiCl
 
(1.2 equiv.)
84
 and subsequent reaction with allyl bromide provided the chromone 7b in 98% 
yield after 2 h (entry 2a, 2 mmol) or 91% after 12 h (entry 2b, 50 mmol), respectively. The 
reaction with 3,4-difluorobenzoyl chloride afforded the expected ketone 7c in 82% (entry 3a, 
2 mmol) or 60% yield (entry 3b, 50 mmol). Pd-catalyzed Negishi cross-coupling
24a,85 
using 
2% Pd(PPh3)4 with 4-bromobenzaldehyde led to the cross-coupling product 7d 96% (entry 5a, 
2 mmol) and 84% yield (entry 5b, 50 mmol), respectively.  
As described in 4.2.3.1, complexation of chromone 5 with 2 equiv. MgCl2 at 0 °C for 
15 minutes and subsequent addition of TMPZnCl·LiCl (3) provided the C(2) zincated 
chromone 8 after 1 h as shown by iodolysis product 9a (entry 5a, Table 1). When the reaction 
was scaled up to 50 mmol, MgCl2 was added to a solution of chromone in THF at 0 °C and 
stirred for further 30 minutes. It was observed, that the selectivity for C(2) metallation 
depends on both the reaction temperature and the amount of MgCl2 in solution. A reaction 
temperature of –5 °C during the addition of TMPZnCl·LiCl (over 30 minutes) was necessary 
to avoid a reduced selectivity caused by higher reaction temperatures. Lower reaction 
temperatures than –5 °C caused the precipitation of MgCl2, and therefore provided lower 
selectivities. After addition of TMPZnCl·LiCl, the reaction had to be stirred for further 2 h at 
                                                 
84
 P. Knochel, M. C. P. Yeh, S. C. Berk, J. Talbert, J. Org. Chem. 1988, 53, 2390. 
85
 (a) M. Kobayashi, E. Negishi, J. Org. Chem. 1980, 45, 5223. (b) E. Negishi, Acc. Chem. Res. 1982, 15, 340. 
B. Results and Discussion 
 
21 
0 °C to obtain full conversion. Iodolysis, copper-mediated acylation or Pd-catalyzed Negishi 
cross-coupling of the C(2) zincated chromone (8) furnished the expected C(2)-substituted 
chromones 9a-9c in 62-81% yield (entries 5b, 6b, 7b, Table 1, 50 mmol). Generally, the 
reaction time increased when the reaction was scaled up from 2 mmol to 50 mmol. Even 
though full conversion was observed for both small and large scale reactions, a decrease in 
yields was observed when the reaction was scaled up.  
 
Table1: Direct Metallation of Chromone at C(2) and C(3) 
 
Entry Scale 
(mmol) 
Metallation 
Conditions 
Electrophile (E) Reaction conditions Product Yield 
(%)
a
 
1 2  
TMPZnCl·LiCl  
25 °C, 30 min, THF 
I2 25 °C, 15 min 
 
80 
2a 2 
TMPZnCl·LiCl  
25 °C, 30 min, THF  
25 °C, 2 h 
 
98
b
 
2b 50  
TMPZnCl·LiCl 
0 °C, 7 h, THF  
25 °C, 12 h 
 
91
b
 
3a 2 
TMPZnCl·LiCl 
25 °C, 30 min, THF 
 
–40 °C to 25 °C 12 h 
 
 
82
b
 
3b 50 
TMPZnCl·LiCl 
0 °C, 7 h, THF 
 
–50 °C to 25 °C  
12 h then 25 °C 36 h 
 
60
b
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Entry Scale 
(mmol) 
Metallation 
Conditions 
Electrophile (E) Reaction conditions Product Yield 
(%)
a
 
4a 2 
TMPZnCl·LiCl 
25 °C, 30 min, THF 
 
25 °C, 12 h 
 
96
c
 
4b 50 
TMPZnCl·LiCl  
0 °C, 7 h, THF 
 
25 °C, 18 h 
 
84
c
 
   
 
I2 
  
 
 
5a 2 
MgCl2, 
TMPZnCl·LiCl 
0 °C, 1 h, THF 
25 °C, 15 min 84 
5b 50 
MgCl2, 
TMPZnCl·LiCl 
0 °C, 2 h, THF 
I2 25 °C, 2 h 
 
80 
6a 2 
MgCl2, 
TMPZnCl·LiCl 
0 °C, 1 h, THF 
 
–40 °C to 0 °C 6 h 
 
98
b
 
   
 
 
  
 
 
6b 50 
MgCl2, 
TMPZnCl·LiCl 
0 °C, 2 h, THF 
–40 °C to –10 °C, 
12 h 
81
b
 
7a 2 
MgCl2, 
TMPZnCl·LiCl 
0 °C, 1 h, THF 
 
 
25 °C, 2 h 
 
 
78
c
 
7b 50 
MgCl2, 
TMPZnCl·LiCl 
0 °C, 2h, THF  
25 °C, 24 h 
 
62
c
 
a 
Yield of isolated, analytically pure product. 
b
 Obtained after transmetallation with CuCN·2LiCl (1.2 equiv., –40 °C, 30 
min). 
c
 Obtained by Negishi cross-coupling using 2% Pd(PPh3)4. 
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4.2.3.4 Application to the Total Synthesis of Naturally Occurring Chromones 
As an application of this metallation methodology, some naturally occurring flavones and 
isoflavones were prepared, starting from the common precursor 5,7-dihydroxy chromone 
(10).
86
 First, the methodology was applied on methyl protected chromone 11 in order to 
prepare 5,7,4’-trimethoxyflavone (12, TMF), a secondary metabolite isolated from the Thai 
medicinal plant Kaempferia parviflora.
87
 
 
 
Scheme 10: Preparation of 5,7,4’-trimethoxyflavone (12).  
 
Reaction of 5,7-dimethoxy chromone 11 with TMP2Zn·2MgCl2·2LiCl (4) in THF, and 
subsequent palladium catalyzed cross-coupling using 2% Pd(dba)2 and 4% tfp
88
 with 
p-iodoanisole provided the natural product TMF (12) in 73% yield (Scheme 10). Since methyl 
protecting groups generally require harsh conditions for deprotection,
89
 TIPS-protected 
chromone 13 was used for the preparation of the isoflavone biochanin A (14), which is 
commonly found in soy beans or in red clover.
90
 Metallation of 13 with TMPZnCl·LiCl (3) 
and subsequent reaction of the obtained C(3) zincated species 15 in a Negishi cross-coupling 
with p-iodoanisole, followed by deprotection, provided isoflavone 14 in a one-pot procedure 
in excellent yield (81%, Scheme 11). Further attempts were made to prepare the flavone 
chrysin (16) which is present in honey and propolis and in low concentrations in fruit and 
vegetables.
91
 Unexpectedly, the metallation concept was not applicable for the C(2) 
metallation of TIPS protected chromone 13 using TMP2Zn·2MgCl2·2LiCl (4). When TIPS 
protected chromone 13 was treated with TMP2Zn·2MgCl2·2LiCl (4), and reacted with 
                                                 
86
 T. Korenaga, K. Hayashi, Y. Akaki, R. Maenishi, T. Sakai, Org. Lett. 2011, 13, 2022. 
87
 P. Sawasdee, C. Sabphon, D. Sitthiwongwanit, U. Kokpol, Phytother. Res. 2009, 23, 1792.  
88
 dba = trans, trans-dibenzylideneacetone; tfp = tris-(2-furyl)phosphine; (a) V. Farina, B. Krishnan, J. Am. 
Chem. Soc. 1991, 113, 9585. (b) V. Farina, S. Kapadia, B. Krishnan, C. Wang, L. Liebeskind, J. Org. Chem. 
1994, 59, 5905. (c) I. Klement, M. Rottländer, C. E. Tucker, T. N. Majid, P. Knochel, P. Venegas. G. Cahiez, 
Tetrahedron 1996, 52, 7201. 
89
 Greene’s Protective Groups in Organic synthesis, 4. Edition, (Eds.: P. G. M. Wuts, T. W. Greene), VCH, 
Wiley, New Jersey, United States, 2007, p. 27. 
90
 E. Walz, Justus Liebig Ann. 1931, 489, 118.  
91
 I. C. Villar, M. Galisteo, R. Vera, F. O’Valleb, M. F. García-Saura, A. Zarzuelo, J. Duarte, J. Vasc. Res. 2004, 
41, 509.  
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iodobenzene in a cross-coupling reaction, the C(3) functionalized isochrysin 17 was obtained 
instead of  the C(2) functionalized chrysin 16 (Scheme 11). 
 
 
Scheme 11: Preparation of the natural products biochanin A (14) and isochrysin (16). 
 
Therefore, benzyl protected chromone 18 was employed. The protected flavone 21 was easily 
prepared, when 18 was treated with TMP2Zn·2MgCl2·2LiCl (4) and the obtained zinc species 
22 reacted in a Negishi cross-coupling (2% Pd(dba)2, 4% tfp) with PhI (Scheme 12). 
Deprotection of the flavone 21 with H2/Pd(OH)2 in EtOH proceeded smoothly within 6 h to 
provide full conversion and 83% yield of isolated product 16. Metallation of 18 with 
TMPZnCl·LiCl (3) leads to the C(3)-zincated intermediate 19, subsequent Pd-catalyzed cross-
coupling (2% Pd(dba)2, 4% tfp) with p-iodoanisole provided protected isoflavone 20 in 95% 
yield (Scheme 12). However, deprotection of 20 required milder reaction conditions since the 
reaction in EtOH was accompanied by ring opening. When the less polar solvent EtOAc was 
used, 90% conversion to the natural product 14 was monitored after 5 h by 
1
H-NMR of crude 
product. After purification biochanin A (14) was obtained in 88% yield (Scheme 12).  
Scheme 12: Preparation of biochanin A (14) and chrysin (16). 
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4.3 Metallation of 4-Pyrone 
4H-Pyran-4-one (23), commonly known as 4-pyrone or γ-pyrone, is found as a core structure 
in many natural products
92
 like maltol, a flavor enhancer, or allixin, a known antitumor 
promotor (Figure 8). Furthermore, γ-pyrone based heterocycles are known to possess a wide 
range of biological activity.
92b 
 
  
Figure 8: Pyrone core structure and selected natural products. 
 
Due to its similar structure to chromone, the metallation approach is extended to γ-pyrone. 
The progress and the regioselectivity of the reaction was monitored by 
1
H-NMR of the crude 
mixture of iodolysis product 25a or 27a. 
 
Scheme 13. Reactions and conditions for the preparation of C(5) and C(6) substituted pyrones 25 and 27.  
 
A selective zincation at C(3) was achieved, when pyrone (23) was treated with 
TMPZnCl·LiCl (3) at 0 °C in THF (Scheme 13). Thus, trapping of zincated pyrone 24 with 
representative electrophiles furnished the 3-substituted pyranones 25 a-d in moderate to good 
yields (61-90%, entries 1-4, Table 2). Metallation of 23 with TMP2Zn·2MgCl2·2LiCl (4), 
provided the C(2)-metallated pyranone 26 as confirmed by iodolysis product 27a (48%, entry 
5).   
                                                 
92
 (a) Science of Synthesis, Houben-Weyl, Volume14 : Pyranones and Pyrathiones (Ed.: Y. Yammamoto), Gerog 
Thime Verlag, 2004, p. 320. (b) W. Wink, H. Waldmann, M. Kaiser, Bioorg. Med. Chem. 2009, 17, 2301.  
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Table 2: Functionalizatuion of 4-pyranone 23 in C(2) and C(3) 
 
Entry Metallation Condition Electrophile (E) Product Yield (%)
a
 
1 
TMPZnCl·LiCl, 
0 °C, 2 h, THF 
I2 
 
80 
     
2 
TMPZnCl·LiCl, 
0 °C, 2 h, THF  
 
65
b
 
     
3 
TMPZnCl·LiCl, 
0 °C, 2 h, THF  
 
90
c
 
     
4 
TMPZnCl·LiCl, 
0 °C, 2 h, THF 
 
 
61
b
 
     
5 
TMP2Zn·2MgCl2·2LiCl, 
–35 °C, 2 h, THF 
I2 
 
48 
   
  
6 
TMP2Zn·2MgCl2·2LiCl, 
–35 °C, 2 h, THF  
 
56b
c
 
     
7 
TMP2Zn·2MgCl2·2LiCl, 
–35 °C, 2 h, THF 
 
 
67c
c
 
     
a
 Yield of isolated, analytically pure product.
b
 Obtained after transmetallation with CuCN·2LiCl (1.2 equiv.,  
–40 °C, 30 minutes); 
c
 2% Pd(dba)2, 4% tfp, ArI (1.2 equiv. 25 °C, 1 h). 
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The formation of a new carbon-carbon bond is readily performed by a Negishi cross-coupling 
of 26 with iodoanisole providing 27b in 58% yield (Table 2, entry 6).
93
 Furthermore the 
metallation procedure was applied to the preparation of the natural product 2-(2-
methoxyphenyl)-4H-pyran-4-one (27c), isolated from Seagrass-derived fungus polyporales 
PSU-ES44, from Thalassia hemprichii.
94
 Thus, Pd-catalyzed Negishi cross-coupling of the 
C(2)-zincated pyranon 26 with iodo-2-methoxybenzene provided the natural product 27c in 
67% yield (Table 2, entry 7). 
  
                                                 
93
 R. C. Barcelos, J. C. Pastre, V. Caixeta, D. B. Vendramini-Costa, J. E. de Carvalho, R. A. Pilli, Bioorg. Med. 
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94
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J. Toda, T. Saitoh, T. Oyama, Y. Horiguchi, T. Sano, Heterocycles 1996, 43, 2457. 
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4.4 Metallation of Uracil and Uridine 
4.4.1  General Introduction 
Figure 9 shows the structures of the pyrimidones uracil (28), thymine (29) and cytosine (30) 
and their nucleotides 31-33 that are found in the DNA and RNA.  
 
Figure 9: Pyrimidine nucleobases uracil, thymine, cytosine and their nucleosides uridine, desoxythymidine, 
desoxycytidine and cytidine. 
 
Furthermore, the pyrimidine scaffold is present in numerous natural products.
95
 Uracil is 
found in the non-proteogenic amino acid willardiine, isolated in 1959 from Acacia 
willardiana (Figure 10). The peptide penilumamide,
96
 isolated from Penecillum in 2010 and 
the alkaloide rigidin A, isolated in 1990 from Eudisromu cf. rigida, contain an uracil skeleton 
(Figure 10).
97
 
                                                 
95
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96
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97
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Figure 10: Examples for natural products containing an uracil core structure. 
 
In addition to their biological significance, pyrimidine nucleobases and nucleosides display 
important pharmaceutical properties.
98
 They are known to display antibiotic, antifungal, 
anticancer, and antiviral activity.
99
  
 
Figure 11: Examples for modified uracil and uridines, displaying biological activity. 
 
For example, 5-fluorocytosine (Flucytosine) shows antimycotic activity, while 5-fluorouracil 
(Adrucil) and 5-fluorodesoxyuridine (Floxuridine) are clinically established anticancer drugs 
(Figure 11).
99 
Many antiviral agents are based on modified nucleosides including both 
modifications at the sugar moiety or heterocyclic system. Zidovurine (Retrovit, AZT) for 
example is an anti-HIV protease inhibitor while Idoxuridine shows activity against hepatitis 
(Figure 11).
99 
  
                                                 
98
 Science of Synthesis, Houben-Weyl, Volume 6: Six-Membered Hetarenes with Two Identical Heteroatoms (Ed. 
Y. Yammamoto), Gerog Thime Verlag, 2004, p. 379 
99
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4.4.2 State of Research for the Metallation of Uracil and Uridine  
Since the uracil scaffold 28 is such an important pharmacophor, the functionalization of this 
heterocyclic system is of special synthetic importance and has been studied thoroughly in the 
literature.
100
  
 
Scheme 14: Reported examples for the metallation of uridine.  
  
                                                 
100
 Comprehensive Heterocyclic Chemistry III, Volume 8: Pyridazines and their Benzo Derivatives (Eds.: R. K. 
Alan, A. R. Christopher, F. V. S. Eric, J. K. T. Richard), Elsevier, Oxford, 2008, p. 1-253. 
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Metallation of uridine 31 has been reported to occur at the C(5) and C(6) positions 
(Scheme 14).
101,102,103 
The direct lithiation of uridine at position C(6) (A, Scheme 14)
101a
 was 
achieved either by equilibration conditions
102b
 from thr C(5) lithiated uridine, or by taking 
advantage of the coordinating effect of hydroxyl- or methoxymethyl-groups at C’(5) of the 
sugar moiety to lithiumdiisopropylamid (LDA). Direct metallation of C(5) using s-BuLi and 
further functionalizations have also been achieved, when weakly chelating siloxy groups were 
used for C’(5) protecting (B, Scheme 14).
102a
 The main limitation with the use of lithium 
reagents is their very high reactivity due to the ionic character of the C-Li bond. For this 
reason, the choice of potential electrophiles is strongly limited and the functionalized uracil 
derivatives were obtained in moderate yields. Furthermore, functionalization of protected 
uridine was achieved by halogen-metal exchange (C, Scheme 14)
103a
 or zinc insertion (D, 
Scheme 14)
103b
 and subsequent reaction with electrophile. The metallation of uracil 28 has 
been performed at C(5) and C(6), and generally requires the protection by N-alkylation or O-
alkylation (Scheme 15).
 104-107
 Several O-protected pyrimidines have been metalated at C(5) 
and C(6) via direct metallation (A, Scheme 15)
104a,105
 or halogen-metal exchange reaction (B, 
Scheme 15)
103a,104c
 at low temperatures. Zincation of N-protected uracil derivatives was 
performed via oxidative insertion (C, Scheme 15).
106
 Unprotected 5-ioduracil has also been 
metallated successfully via the formation of a trimagnesiated species (D, Scheme 15).
107
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Schene 15: Reported examples for the metallation of uracil. 
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4.4.3 Chemoselective Metallation of Uracil and Uridine Derivatives  
It was anticipated that the metallation procedure of chromone 5 could be extended to 
protected uridine 31. Thus, the strongest Lewis acid will coordinate to the C(4) carbonyl, 
directing the metallation of uracils and uridines either to position C(5) or C(6) (Figure 12).  
 
Figure 12: Regioselective metallation of uracil and uridine derivatives in position C(5) and C(6). 
 
4.4.3.1 Optimization of the Reaction Conditions  
First, the direct metallation with TMP-bases on the uracil core structure was studied. As 
model system, the metallation of methyl protected uracil 34 was examined, since this 
protecting group should not influence the reaction by coordinating or steric effects. To 
determine the optimum reaction conditions, the metallation of methyl protected uracil 34 was 
performed with different bases at varying temperatures in THF (Table 3). The progress of the 
reaction and the regioselectivity was checked by GC analysis of reaction aliquots quenched 
with iodine. 
 
The reaction of 34 with TMPZnCl·LiCl (3) at 25 °C required 2 equiv. of the base to achieve 
full conversion, providing a 1:1 mixture of C(5) and C(6) metallated products (Table 3, entry 
1). It was envisioned that lower reaction temperatures might favour the formation of the C(5) 
metallated product. When the reaction was performed at –20 °C, the regioselectivity improved 
Table 3: Observed Selectivities for the Metallation of Uracil 34 in THF 
 
entry Base Temperature Reaction time conversion C(5):C(6) 
1 TMPZnCl·LiCl 25 °C 30 min 100% 50:50 
2 TMPZnCl·LiCl –20 °C 21 h 62% 89:11 
3 TMPZnCl·LiCl –40 °C 21 h 24% 91:9 
4 TMPMgCl·LiCl –40 °C 4 h 100% 95:5 
5 TMP2Zn·2MgCl2·2LiCl –30 °C 48 h 100% 4:96 
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to 89:11, however the conversion decreased to 62%, even after 21 h reaction time (entry 2). 
Since the selectivity could only be improved at expense of the conversion (entry 3, Table 3), a 
stronger and better coordinating base was selected for metallation. Treating uracil 34 with 
1.2 equiv. TMPMgCl·LiCl (1) at –40 °C provided full conversion after 4 h, yielding 95% of 
C(5) metalated derivative 35 (entry 4, Table 3). Our concept was further confirmed by the 
selective zincation at C(6) in the presence of the Lewis acid MgCl2. Thus, the treatment of 
uracil with 0.5 equiv. TMP2Zn·2MgCl2·2LiCl (4) at –30 °C in THF, yielded the C(6) 
metallated product quantitatively. The iodolysis product 38a indicates a selectivity of 4:96 
(entry 5).  
 
 
Scheme 16: Optimized reaction conditions for the metallation of methyl protected uracil. 
 
Since the methyl protection group generally requires harsh deprotection conditions,
89
 the 
metallation of benzyl protected uracil 39 was also investigated. The progress of the reaction 
and the regioselectivity was checked by GC analysis of reaction aliquots quenched with 
iodine. Reaction of uracil 39 with TMPMgCl·LiCl (1) at –40 °C provided C(5) metallation in 
a regioselective manner, however the conversions never exceeded 78%. To improve the 
conversion, the stronger base TMP2Mg·2LiCl was used, however, even at –80 °C the reaction 
was accompanied by decomposition. When the benzyl protected uracil 39 was treated with 
TMP2Zn·2MgCl2·2LiCl (4) at –78 °C, a regioselectivity of 97:3 C(6):C(5) was observed and 
even reaction times up to 72 h did not improve the conversion beyond 58%. Since the 
protecting groups Me and Ph change the electronic properties of uracil marginally, it was 
assumed that the lower conversions are mainly caused by sterical effects.  
Furthermore, the influence of a protection group with etheral oxygen was investigated on the 
regioselectivity. The metallation of methoxymethyl protected uracil (40) and ethoxymethyl 
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protected uracil (41) was examined (Scheme 17). Thus, treatment of 40 with TMPMgCl·LiCl 
(1) at –40 °C and subsequent iodolysis provided a 1:3 mixture of C(5) and C(6) iodinated 
product 42a:43a, as observed by 
1
H-NMR analysis of the crude product (Scheme 17). 
Providing regioselectively the C(5) metallated species by varying the reaction temperature 
and the base was not possible. This is rationalized by the competing coordination of the TMP 
bases 1 and 3 to both, the C(4) carbonyl and the ethereal oxygen of the protection group. 
When TMP2Zn·2LiCl·2MgCl2 (4) was used instead, deprotonation of 40 occurred only at the 
more acidic position C(6), providing the thermodynamic metallation product 44, as confirmed 
by crude 
1
H-NMR of the iodolysis product 43a (Scheme 17). The same selectivities are 
observed for ethoxymethyl protected uracils 41. Thus, treatment of 41 with TMPMgCl·LiCl 
(1) or TMPZnCl·LiCl (2) proceeded unselectively, while the reaction of 
TMP2Zn·2LiCl·2MgCl2 (4) provided the C(6) metallated product 45, selectively as confirmed 
by 
1
H NMR analysis of the iodolydis product 46a.  
 
 
Scheme 17: Reaction conditions for the metallation of methoxymethyl and methoxyethyl protected uracil. 
 
This metallation procedure was finally extended to the nucleoside uridine 31. Since it was 
observed that the ethereal oxygen of methoxyethyl protected uracil 41 influenced the 
regioselectivity of the metallation due to competing coordination, it was anticipated, that this 
competitive coordination could be reduced by steric shielding. A bulky TBS (TBS = tert-
butyldimethylsilyl) protecting group was introduced at the C’(5)-hydroxy group, envisioning 
that the coordination of both C’(5)-oxygen and the ethereal oxygen would be less favoured. 
Metallation of 47 with TMPMgCl·LiCl yielded the C(5)-magnesiated intermediate 48 in a 
regio specific manner after 24 h, as confirmed by crude 
1
H-NMR of the iodolysis crude 
product 49a (Scheme 18). Metallation of 47 with TMP2Zn·2LiCl·2MgCl2 (4) provided the 
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C(6) zincated uridine 50 after 72 h (Scheme 18). The regioselectivity of the metallation 
product was confirmed by 
1
H-NMR of the iodolysis crude product 51a.  
 
 
Scheme 18: Reaction conditions for the metallation of protected uridine 47.  
 
4.4.3.2 Functionalization of protected Uracil 
With the optimized metallation conditions in hand, the scope of the reaction with different 
electrophiles was tested. Thus, methyl protected uracil 34 reacted with TMPMgCl·LiCl (1), 
leading to a regiospecific metallation at C(5) (35), allowing the direct functionalization at 
C(5), providing products 36a-k in moderate to good yields (Table 4). Reaction of 35 with 
aldehydes afforded the alcohols 36b-36d in 48-74% yield (entries 2a-c). Transmetallation of 
35 with CuCN·2LiCl and subsequent reaction with 3-bromocyclohexene provided the 
allylation product 36e (56% yield, entry 3). Thus, acylation with furoyl chloride or 
cyclopropanecarbonyl chloride afforded the expected ketones 36f-g in 66% and 71% yield, 
respectively (entries 4-5). Transmetallation of 35 with ZnCl2 and subsequent Pd-catalyzed 
Negishi cross-couplings (2% Pd(dba)2 , 4 mol% P(2-furyl)3 or 2% Pd(OAc)2 4 mol% X-Phos) 
with aromatic, heteroaromatic or alkenyl halides led to the cross-coupling products 36h-k (47-
78%, entries 6-9).  
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Table 4: Products Obtained by C(5) Magnesiation of Uracil (34) with TMPMgCl·LiCl (1) and Subsequent 
Reaction with Electrophiles.
 
 
Entry Electrophile Product Yield[%]
a 
1 I2 
 
72 
 
  
 
2a R = CN  70
108 
2b R = H  74
 
2c R = OMe  48
108
 
3 
 
 
56
b
 
4 
 
 
66
b
 
5 
 
 
71
b
 
 
 
 
 
6a R = I  78
c 
6b R = Br  47
c,108
 
    
                                                 
108
 The reaction was performed by Eider Aranzamendi (University of the Basque Country, Bilbao, Spain) 
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Entry Electrophile Product Yield[%]
a 
7 
 
 
78
d,108
 
8 
 
 
73
c
 
9 
 
 
56
c
 
a 
Yield of isolated, analytically pure product. 
b
 Obtained after transmetallation with CuCN·2LiCl (1.2 equiv.). 
c
 
Obtained after transmetallation with ZnCl2 (1.2 equiv.) 2 mol% Pd(dba)2 and 4 mol% P(2-furyl)3 
d 
Obtained after 
transmetallation with ZnCl2 (1.2 equiv.), 2 mol% Pd(OAc)2 and 4 mol% XPhos. 
 
The reaction of methyl protected uracil 34 with TMP2Zn·2MgCl2·2LiCl (4) at –30 °C 
provided the bis-heterocyclic zinc reagent 37 allowing the direct functionalization at C(6) 
(Table 5). Iodolysis of the zinc reagent 37 provided 6-iodouracil (38a) in 81% yield (entry 1). 
Similarly, copper-mediated allylation with ethyl 2-(bromomethyl)acrylate
109
  or acylation 
with benzoyl chloride afforded the C(6) functionalized uracil derivatives 38b (69%, entry 2) 
and 38c (84%, entry 3). Pd-catalyzed Negishi cross-coupling (2 mol% Pd(dba)2 and 4 mol% 
P(2-furyl)3) with p-iodoanisole or 1-iodooct-1-ene furnished the expected C(6)-substituted 
uracils 38d (83%, entry 4) and 38e (74%, entry  5). 
Furthermore, we examined the scope of the reaction of C(6) metallated uracil derivatives 44 
and 45 with representative electrophiles such as aryl iodides (Negishi cross-couplings) or allyl 
halides and acid chlorides (in the presence of CuCN·2LiCl) providing products 46a-d (70 to 
82% yield, Table 6, entries 2, 4-6) and 43a-c (45 to 72% yield, Table 6, entries 1, 3, 7, 8).  
 
  
                                                 
109
 J. Villieras, M. Rambaud Org. Synth. 1988, 66, 220. 
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Table 5: Preparation of C(6) Substituted Uracils 38a-e Using TMP2Zn·2MgCl2·2LiCl (2) and Subsequent 
Reaction with Electrophiles. 
 
Entry Electrophile (E) Product Yield[%]
a 
1 I2 
 
81 
2 
 
 
69
b
 
3 
 
 
84
b
 
4 
 
 
84
c
 
5 
 
 
74
c
 
a 
Yield of isolated, analytically pure product. 
b
 Obtained after transmetallation with CuCN·2LiCl (1.2 equiv.). 
c
 
Obtained after transmetallation with ZnCl2 (1.2 equiv.), 2 mol% Pd(dba)2 and 4 mol% P(2-furyl)3. 
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Table 6: Preparation of C(6) Substituted Uracils (43a-d and 46a-d) Using TMP2Zn·2MgCl2·2LiCl (2) and 
Subsequent Reaction with Electrophiles. 
 
Entry Substrate Electrophile Product Yield[%]
a 
   
 
 
1 41 I2 46a: R = methoxyethyl 81 
2 40 I2 43a: R = methoxymethyl 70
108
 
     
  
 
 
 
3 41  46b: R = methoxyethyl 82
b
 
4 40  43b: R = methoxymethyl 68
b,108
 
     
  
 
 
 
5 40  43c: R = methoxymethyl 45
b,108
 
     
  
 
 
 
6 40  43d: R = methoxymethyl 72
b,108
 
  
 
 
 
7 41  46c: R = methoxyethyl 67
b
 
  
 
 
 
8 41  46d: R = methoxyethyl 81
c
 
a 
Yield of isolated, analytically pure product. 
b
 Obtained after transmetallation with CuCN·2LiCl (1.2 equiv.). 
c
 
Obtained after transmetallation with ZnCl2 (1.2 equiv.), 2 mol% Pd(dba)2 and 4 mol% P(2-furyl)3. 
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4.4.3.3 Functionalization of protected Uridines 
With the optimized metallation conditions in hand, a number of C(5) and C(6) functionalized 
uridines were prepared. Reaction of the C(5) magnesiated uridine 48 with appropriate 
electrophiles led to products 49a-f (Table 7). Thus, after transmetallation of 48 to zinc, Pd-
catalyzed Negishi cross-coupling (2 mol% Pd(dba)2 and 4 mol% P(2-furyl)3) with p-
iodoanisole, ethyl-p-iodobenzoate or m-iodopyridine provided the products 49b-d (66-81%, 
entries 2-4). Similarly, copper-mediated allylation or alkylation with ethyl 2-
(bromomethyl)acrylate, bromocyclohexene or methyliodide afforded the C(5) functionalized 
uridine derivatives 49e-g in 31 to 86% yield (entries 5-7). The ketone 49h was obtained in 
71% yield when 48 reacted in a copper-catalyzed acylation reaction with 
cyclopropanecarbonyl chloride (entry 8). Aldehyde 49i was obtained in 30% yield, when 48 
reacted with morpholine-4-carbaldehyde (entry 10). Upon treatment of 48 with ethyl 
cyanoformate, the functionalized ester 49j was formed in 44% yield (entry 11). Furthermore 
48 reacted with various aldehydes to give the corresponding alcohols 49k-m (30 to 47%, 
entries 12-14). 
 
 
Table 7: Functionalization of Uridine 47 by C(5) Magnesiation Using with TMPMgCl·LiCl (1) and 
Subsequent Reaction with Electrophiles.
 
 
Entry Electrophile Product Yield[%]
a 
1 I2 
 
70 
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Entry Electrophile Product Yield[%]
a 
2 
 
 
81
c
 
3 
 
 
66
c
 
4 
 
 
73
c
 
5 
 
 
86
b
 
6 
 
 
60
b
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Entry Electrophile Product Yield[%]
a 
7 MeI 
 
31
b
 
8 
 
 
71
b
 
 
 
 
 
 
 
 
9 DMF  0 
10 
 
 32 
11 NCCO2Et 
 
44 
12 
 
 
47 
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Entry Electrophile Product Yield[%]
a 
13 
 
 
43 
14 
 
 
30 
a 
Yield of isolated, analytically pure product. 
b
 Obtained after transmetallation with CuCN·2LiCl (1.2 
equiv.). 
c
 Obtained after transmetallation with ZnCl2 (1.2 equiv.), 2 mol% Pd(dba)2 and 4 mol% P(2-
furyl)3. 
 
Reaction of protected uridine 47 with TMP2Zn·2MgCl2·2LiCl (4) provided zincation at C(6). 
The C(6)-zincated uridine 50 reacted in copper-mediated allylation, copper-mediated 
acylation and Pd-catalyzed cross-coupling reactions (2 mol% Pd(dba)2 and 4 mol% P(2-
furyl)3) providing the products 51a-f in 67 to 99% yield (Table 8, entries 1-6). 
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Table 8: Functionalization of Uridines at C(6) 
 
Entry Electrophile (E) Product Yield[%]
a 
1 I2 
 
95 
2 
 
 
84
c
 
3 
 
 
69
c
 
    
4 
 
 
97
c
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Entry Electrophile (E) Product Yield[%]
a 
5 
 
 
67
c
 
6 
 
 
97
b
 
a 
Yield of isolated, analytically pure product. 
b
 Obtained after transmetallation with CuCN·2LiCl (1.2 
equiv.). 
c
 Obtained after transmetallation with ZnCl2 (1.2 equiv.), 2 mol% Pd(dba)2 and 4 mol% P(2-
furyl)3 
 
4.4.3.4 Preparation of 5,6-Disubstituted Uracil Derivatives 
We further examined the effect of substituents at C(5) or C(6) on the direct metallation 
reaction. Metallation of alkyl or halogen substituted uracils (36a, 36e, 36h-k, 38a-b, 38d-e) 
using various TMP-bases and reaction temperatures gave limited results in terms of 
metallated species, as observed by TLC or 
1
H-NMR of reaction aliquots quenched with 
iodine. However, it was observed that metallation was successful when the substituent at C(5) 
or C(6) induced a strong directing metallation effect. Thus, uracils and uridines containing 
thioethers and ketones could be metallated easily. 5,6-Disubstituted uracils 52 and 53 were 
obtained by two successive metallation-functionalization sequences (Scheme 19). In the first 
step, methyl protected uracil 34 reacted with TMPMgCl·LiCl (1, 4 h, –40 °C). Copper 
mediated acylation of C(5)-zincated uracil 35 provided the ketone 36l in 83% yield 
(Scheme 19). A second metallation was performed with TMPMgCl·LiCl (1, 12 h at –30 °C) 
and subsequent iodolysis provided the 5,6-disubstituted uracil 52 in moderate yield (36%). 
Ring-closing reactions were easily performed when 52 was treated with hydrazine or 
hydroxylamine for 2 h at 80 °C in DMF, providing the pyrazole 54 and the isoxazole 55 in 
55-89% yield (Scheme 19).  
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Scheme 19: Preparation of pyrazole and isoxazole derivatives 54 and 55. 
Furthermore, a bifunctionalized uridine was performed in the presence of a directing 
thioether group. Metallation of 47 with TMPMgCl·LiCl (–40 °C, 24 h), and subsequent 
reaction with dimethyldisulfane provided 49n in 42% yield. When 49n was treated with 
TMPMgCl·LiCl at –20 °C for 20 minutes in THF, and the obtained magnesium species 56 
reacted with iodine, 53 was obtained in 87% yield (Scheme 20).  
 
 
Scheme 20: Preparation of 5,6-difunctianalized uridine 53.  
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4.5 Metallation of Cytidine 
We further expanded our metallation procedure to the nucleobase cytidine (33b, Figure 9). 
Treatment of bis-Boc protected cytidine (57) with TMP2Zn·2MgCl2·2LiCl (4) at –30 °C in 
THF provided C(6)-zincated species 58 as single regioisomer, with a maximum conversion of 
68% after 12 h, as confirmed by 
1
H NMR of the iodolysis product 59a (Scheme 21).  
 
 
Scheme 21: Regioselective C(6) zincation of cytidine 57. 
 
When cytidine 57 was treated with TMPMgCl·LiCl (1) or TMPZnCl·LiCl (3) and 
subsequently reacted with iodine, the expected C(5)-iodinated product could not be isolated 
but only the C(6)-iodinated product. Thus, the introduction of the bulky Boc protecting group 
was assumed to block the metallation at C(5). The C(6)-zincated cytidine (58) reacted with 
representative electrophiles, providing products 59a-d in moderate yields of 43-61% (Table 9, 
entries 1-4).  
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Table 9: Functionalization of Cytidine 59 in C(6) 
 
Entry Electrophile Product Yield[%]
a 
1 I2 
 
61 
    
2 
 
 
43
b
 
    
3 
 
 
52
c
 
    
4 
 
 
52
c
 
    
a 
Yield of isolated, analytically pure product. 
b
 2 mol% Pd(dba)2 and 4 mol% P(2-furyl)3
 c
 Obtained after 
transmetallation with CuCN·2LiCl (1.2 equiv). 
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5 Influence of Lewis Acids on the Regio- and Diastereoselectivity 
of the Reaction of Isoxazole Methylzinc Compounds with 
Aldehydes 
5.1 Rearrangement Concept for Heteroaryl Methylzinc Reagents 
The allylic reactivity of benzylic magnesium and zinc reagents has been reported in the 
literature (A, Scheme 22).
110
 Since benzylic zinc reagents are easily prepared via oxidative 
addition in the presence of LiCl (B, Scheme 22),
111 
it is envisioned that such an allylic 
rearrangement might be applicable to recently described heteroaryl methylzinc compounds 
(C, Scheme 22). Of special interest is the allylic addition of isoxazolemethyl zinc compounds 
to carbonyl derivatives. After ring opening, the obtained isoxazolines provide β-hydroxy 
carbonyls, which are interesting building blocks in natural product synthesis (C, Scheme 22).  
 
Scheme 22: Reported rearrangement of benzylic zinc reagents and proposed rearrangement concept. 
                                                 
110
 M. Tiffeneau, R. Delange, Compt. rend. 1903, 137, 573. (b) J. R. Johnson, J. Am. Chem. Soc. 1933, 55, 3029. 
(c) E. Sherman , E. D. Amstutz, J. Am. Chem. Soc. 1950, 72, 2195. (d) V. F. Raaen, F. Eastham, J. Am. Chem. 
Soc.1960, 82, 1349. (e) I. Klement, K. Lennick, C. E. Tucker, P. Knochel, Tetrahedron Lett. 1993, 34, 4623. 
111
 For LiCl accelerated zinc insertin for the preparation of benzylic zinc reagents see (a) A. Metzger, F. M. 
Piller, P. Knochel, Chem. Commun. 2008, 44, 5824. (b) A. Metzger, M. A. Schade, P. Knochel, Org. Lett. 2008, 
10, 1107. For LiCl accelerated zinc insertin for the preparation of heteroaryl methylzinc compounds see: (c) N. 
M. Barl, E. Sansiaume-Dagousset, G. Monzón, A. J. Wagner, P. Knochel Org. Lett. 2014, 16, 2422. 
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5.2 Reaction Conditions and Optimisation 
Thus, commercially available 4-(chloromethyl)-3,5-dimethylisoxazole (62) undergoes a zinc 
insertion using zinc powder (1.5 equiv.) in the presence of LiCl (1.5 equiv.) in THF,
30
 
providing the heterocyclic zinc reagent 63 within 24 h at 50 °C (Scheme 23).
112
 Iodometric 
titration
113
 of the reaction mixture indicated up to 90% conversion to the zinc reagent 63. This 
heterocyclic zinc reagent reacts in the benzylic position in a copper catalyzed allylation 
reaction with 3-bromocyclohexene providing product 64a.  
 
Scheme 23: LiCl-mediated zinc insertion into 4-(chloromethyl)-3,5-dimethylisoxazole (62) leading to the 
heterocyclic zinc reagent 63 and its benzylic reaction. 
 
Since benzylic zinc reagents are known to react with aldehydes without further activation,
111b
 
zinc reagent 63 was treated with 3,4-dichlorobenzaldehyde 65a (Scheme 24). The reaction 
provided both the allylic addition product 66a and the benzylic addition product 67a in a ratio 
of 83:17 (Scheme 25). The zinc reagent reacted predominantly via an allylic rearrangement
114 
(A, Scheme 24) providing the dearomatized exo-methylene product 66a in 49% yield with a 
moderate diastereomeric ratio (dr) of 61:39 (Scheme 25). Longer reaction times led to lower 
diastereo selectivities, presumably due to a retro-allylation reaction (Scheme 24).
115
 The 
relative stereochemistry of the major diastereoisomer 66a was assigned by crystal structure 
analysis (Figure 13). 
 
 
                                                 
112
 This reaction was optimized by A. Metzger and A. Wagner (Ludwig-Maximilians-Universität München). 
113
 A. Krasovskiy, P. Knochel, Synthesis 2006, 890. 
114
 For papers on allylic rearrangements see (a) G. Courtois, L. Miginiac, J. Organomet. Chem. 1974, 69, 1. (b) 
Y. Yamamoto, W. Ito, Tetrahedron 1988, 44, 5415. (b) I. Klement, K. Lennick, C. E. Tucker, P. Knochel, 
Tetrahedron Lett. 1993, 34, 4623. (c) H. Ren, G. Dunet, P. Mayer, P. Knochel, J. Am. Chem. Soc. 2007, 129, 
5376. 
115
 For papers on the reversibility of allylation reactions see (a) P. Miginiac, C. Bouchoule, Bull. Chim. Soc. Fr. 
1968, 4675. (b) F. Barbot, P. Miginiac, Tetrahedron Lett. 1975, 3829. (c) F. Barbot, P. Miginiac, J. Organomet. 
Chem. 1977, 132, 445. (d) A. Bocoum, D. Savoia, A. Umani-Ronchi, J. Chem. Soc., Chem. Commun. 1993, 
1542. (e) P. Jones, P. Knochel, J. Org. Chem. 1999, 64, 186. 
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Scheme 24: Reaction pathways of zinc reagent 63 with aldehyde 65a leading to alcohols of type 66a and 67a, 
[a] 
For Ar see Figure 13.  
 
 
Figure 13: ORTEP view of the crystal structure of 66a. 
 
Since Lewis acids are known to activate aldehydes,
48,116
 the influence of a range of Lewis acid 
promotors was examined (Scheme 25). This study showed that the addition of Lewis acids 
influences both regioselectivity and diastereoselectivity and therefore a change in the reaction 
mechanism is supposedly involved. The formation of the allylic addition product 66a 
increased when LaCl3·2LiCl and MgCl2 were added (Scheme 25). The regioselectivity was 
marginally influenced upon the addition of Sc(OTf)3 and MnCl2. However, the benzylic 
addition product 67a was the single regioisomer found when BF3·OEt2 was added to the 
reaction. These opposing selectivities were unexpected. However, similar selectivity changes 
are reported in the literature.
 110b,117,118
 In 1993, Knochel et. al. reported that when Cu(I) salts 
were added to benzylic zinc reagents and reacted with TosCN, a switch from the allylic to the 
benzylic position occurred.
110b 
Furthermore, it is reported that the addition of copper or nickel 
                                                 
116
 (a) Lewis-Acids in Organic Synthesis, Vol. 2, (Ed.: H. Yamamoto), VCH, Wiley, Weinheim, Germany 2000. 
(b) A. Metzger, S. Bernhardt, G. Manolikakes, P. Knochel, Angew. Chem. Int. Ed. 2010, 49, 4665. 
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salts change the regioselectivity for the reaction of allylic magnesium reagents.
117
 Y. 
Yamamoto et al. reported that the reaction of allylic tin reagents with aldehydes provided a 
regioreversed addition in the presence of AlCl3·i-PrOH.
118
 In the reported reactions, these 
changes in selectivity are rationalized by transmetallations to the corresponding metal species. 
However transmetallation from zinc to boron is unlikely and therefore, BF3·OEt2 is more 
likely to influence the reaction mechanism via a coordinative effect.
56b,49
  
 
Scheme 25: Allylic and benzylic reactivity observed for the reaction of (3,5-dimethylisoxazol-4-yl)methylzinc 
chloride (63) with 3,4-dichlorobenzaldehyde (65a) providing products 66a and 67a. Diastereomeric ratios and 
regioselectivities were determined by 
1
H-NMR of the crude reaction mixture after filtration through silica. 
a
 25 
°C, 4 h, 
b
 –60 °C to 25 °C, 12 h. 
 
The diastereoselectivity was also influenced by the addition of Lewis acid. The addition of 
LaCl3·2LiCl and MgCl2 provided a significant increase in the diastereoselectivity (dr = 96:4 
and dr = 94:6, respectively, Scheme 25) compared to the dr = 61:39 in the absence of Lewis 
acid. In the presence of Sc(OTf)3, only a marginal increase in dr = 74:26 was observed. 
However, addition of MnCl2·2LiCl provided a slight decrease in diastereoselectivity (dr = 
53:47). It is reported in the literature that Lewis acid mediated reactions of allylic 
organometallics exhibit an entirely different stereochemistry than in the absence of Lewis 
acids.
56b,49
 Y. Yamamoto observed that the addition of Lewis acids influenced both the stereo- 
and regioselectivity of the reaction of organotin reagents with aldehydes. He proposed that 
upon the addition of BF3·OEt2 an acyclic transition state is formed, where the Lewis acid 
BF3·OEt2 coordinates to the oxygen of the aldehyde, preventing the formation of a chairlike 
transition state (Scheme 4). The exact influence of the Lewis acid is difficult to determine, 
since an excess of Lewis acid (2 equiv.) was used, and there are several potential coordination 
                                                 
117
 (a) T. E. Stanberry, M. J. Darmon, H. A. Fry, S. R. Lenox, J. Org. Chem. 1976, 41, 2052. (b) F. Derguini-
Boumechal, R. Lorne, G. Linstrumelle, Tetrahedron Lett. 1977, 1181. (c) G. Linstrumelle, R. Lorne, H. P. Dang, 
Tetrahedron Lett. 1978, 4069. 
118
 Y. Yamamoto, H. Yatagai, Y. Ishihara, N. Maeda, K. Maruyama, Tetrahedron 1984, 40, 2239. 
B. Results and Discussion 
 
54 
sites for the Lewis acid on both reacrion partners, the isoxazolemethylzinc chloride (N(1), 
O(3) or methylzinc chloride) and the aldehyde. However, the opposing effects on the 
selectivity, observed by the addition of different Lewis acids indicate that different reaction 
pathways are possible. The formation of allylic product in the absence of additional Lewis 
acids can be explained by a Zimmerman-Traxler like transition state of type A (Figure 14). 
However, aggregates of the organometallic species might hamper the formation of this six 
membered ring, and a competing acyclic reaction mechanism could therefore explain the 
lower diastereoselectivity. The addition of Lewis acid might influence the reaction by 
breaking up the aggregation and thereby favour a cyclic transition state B, this might 
influence the dr (Figure 14). A further possible transition state structure C proceeds trough a 
five membered ring by coordination of the Lewis acid by O(2) (Figure 14).  
 
Figure 14: Possible transition states for the reaction of the heterocyclic zinc reagent 63 with aldehyde 65.  
 
Furthermore, MgCl2 and LaCl3·2LiCl proved to be the most suitable Lewis acids for the 
reaction in the allylic position, providing the best diastereomeric ratios and regioselectivities 
(dr = 94:6, 66a:67a = 94:6 and dr = 96:4, 66a:67a = 98:2, respectively). Therefore, the 
influence of the amount of MgCl2 on the diastereoselectivity ratios was studied in detail 
(Figure 15). Interestingly, it was observed that the addition of low amounts of Lewis acids 
(0.1 – 0.4 equiv.) provided a decrease in diastereoselectivity with a minimum around 0.3 to 
0.4 equiv. MgCl2 (dr = 44:66), while the addition of further Lewis acid caused an increase in 
diastereoselectivity. Upon the addition of 0.5 – 1.0 equiv., the ratio increase up to 91:9 was 
observed, while further addition of MgCl2 provided only an insignificant increase of the 
diastereomeric ratio, reaching a plateau at around 1.5 equiv. (66a:67a = 94:6). The 
progression of the curve could leads to the assumption of a change of the reaction mechanism, 
which may be explaind by different coordination states of the substrate at different MgCl2 
concentrations.  
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Figure 15. Observed diastereomeric ratio dependent on the molar ratio of MgCl2. 
a
Diastereomeric ratios were 
determined by 
1
H-NMR of the crude reaction mixture, after filtration through silica. 
5.3 Scope of the Reaction in the Benzylic Position 
The scope of the benzylic reactivity was tested with representative electrophiles such as 
allylic halides or acid chlorides in the presence of CuCN·2LiCl.
119 
Pd-catalyzed Negishi 
cross-couplings were performed using the palladium catalyst PEPPSI-iPr
120
 (Table 10). Thus, 
transmetallation of 63 with CuCN·2LiCl (1 equiv., –40 °C, 30 min), and subsequent reaction 
with allylic bromides such as 3-bromocyclohexene or ethyl-2-(bromomethyl)acrylate
121
 
(1.0 equiv., 25 °C, 6 h) provided the isoxazoles 64a,b in 73 and 77% yield (Table 10, entries 
1-2). Similarly, copper(I)-mediated acylation with aromatic or aliphatic acid chlorides 
(1.0 equiv., –40 °C to –20 °C, 24 h) gave the expected ketones 64c-e (74-81%, Table 10, 
entries 3-5). Likewise, Pd-catalyzed Negishi cross-coupling
24a,85
 with aryl iodides in the 
presence of PEPPSI-iPr (1 mol %, 25 °C, 24 h) furnished the expected coupling-products 64f-
i (65 to 85%, Table 10, entries 6-9). The benzylic reactivity of zinc reagent 63 with aldehydes 
65a, 65b and 65d in the presence of BF3·OEt2 provided isoxazoles 67a-c  in 55-65% yield 
(Table 10, entries 10-12). 
 
                                                 
119
 P. Knochel, M. C. P. Yeh, S. C. Berk, J. Talbert, J. Org. Chem. 1988, 53, 2390. 
120
 PEPPSI-iPr = ([1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(II) dichloride) 
121
 J. Villieras, M. Rambaud, Synthesis 1982, 924. 
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Table 10. Reaction of the Heterocyclic Zinc Reagent 63 with Electrophiles Leading to Substituted Isoxazoles of 
Type 64 and 67. 
 
Entry Electrophile (E) Product Yield (%)
a
 
1 
 
 
 
73
b
 
    
2 
 
 
77
b
 
    
3 
 
 
81
c
 
    
4 
 
 
74
c
 
    
5 
 
 
84
c
 
    
6 
 
 
87
d
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Entry Electrophile (E) Product Yield (%)
a
 
    
 
 
 
 
7   85
d
 
    
8 
 
 
65
d
 
    
9 
 
 
71
d
 
    
10 
 
 
55
e
 
    
11 
 
 
65
e
 
    
12 
 
 
62
e
 
    
a
 Isolated yield of analytically pure product. 
b
 Using stoichiometric CuCN•2LiCl (–40 °C 10 min, 25 °C, 6 h). 
c
 
Using stoichiometric CuCN•2LiCl (–40 °C to –10 °C, 24 h). 
d
 Using PEPPSI iPr (1 mol%, 25 °C, 12 h to 24 h) 
e 
BF3•OEt2, 25 °C, 4 h. 
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5.4 Scope of the Reaction in the Allylic Position 
The Lewis acid-accelerated reaction of the heterobenzylic organometallic reagent 63 was 
performed with various aromatic aldehydes 65b-h, affording a range of stereocontrolled 
products of type 66 (Table 11). As optimised conditions for these addition reactions, 
LaCl3·2LiCl (2 equiv., –60 °C to 25 °C, 24 h)
122
 or MgCl2 (2 equiv., 25 °C, 4 h) was used. 
Reaction of 63 with benzaldehyde (65b) provided the 4-methylene isoxazoline derivative 66b 
in a diastereomeric ratio of 95:5 (Table 11, entry 2). When electron-deficient aromatic 
aldehydes, such as p-chlorobenzaldehyde (65c), p-formylbenzonitrile (65d), methyl 
p-formylbenzoate (65e) or m-fluorobenzaldehyde (65f) were added to zinc reagent 63, the 
corresponding alcohols 66d-f were obtained in 79-96% yield (dr = 93:7 to 96:4, entries 3-6). 
The reaction with electron-rich p-anisaldehyde 65g provided the product 66g with dr = 95:5 
(entry 7). Electron-rich heteroaromatic 5-bromothiophene-2-carbaldehyde 65h gave the 
alcohol 66h in a diastereomeric ratio of 93:7 (92%, entry 8). Correlating the diastereomeric 
ratios with Hammett’s substituent constants δ
123
 showed that the electronic properties of 
aromatic aldehydes have no direct influence on the diastereoselectivity.
124
 In all cases, the 
reaction occurs predominantly at the allylic and not at the benzylic position, forming a new 
carbon-carbon bond at C3, providing the dearomatized exo-methylene products 66a-h (Table 
11). It was further attempted to expand the scope of the reaction of zinc reagent 63 with 
aliphatic aldehydes (Table 11, enteies 9-12). The resulting products 66i-l were obtained in 
modest yield (33-58%) and variable diastereoselectivity of 93:7 to 67:33 (entries 9-12, Table 
11). Competing aldol-condensation reactions could explain the lower yields. In comparison to 
aromatic aldehydes, the diastereoselectivities were more variable and higher dr values were 
only obtained with α-branched aldehydes (65k and 65l).  
  
                                                 
122
 The reaction with LaCl3 was optimized by Dr. Coura Diene (Ludwig-Maximilians-Universtät München).  
123
 C. Hansch, A. Leo, R. W. Taft, Chem. Rev. 1991, 91,165. 
124
 For further details see experimental part 7.15.13.  
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Table 11. 4-Methylene Isoxazoline Derivatives of Type 66 Obtained by the Addition of Zinc Reagent 63 
to Aldehydes 65a-l. 
 
 
Entry Aldehyde Products 
Yield/Diastereoselectivity 
 (%/dr) 
1 
  
92
a
/96:4; 
73
b
/94:6 
2 
  
91
a
/95:5; 
67
b
/95:5 
3 
  
92
a
/96:4; 
81
b
/95:5 
4 
  
96
a
/94:6
 
82
b
/94:6 
5 
  
94
a
/ 95:5 
79
b
/93:7 
6 
  
87
a
/ 95:5 
7 
  
86
a
/ 95:5 
84
b
/ 95:5 
8 
  
92
a
/93:7 
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Entry Aldehyde Products 
Yield/Diastereoselectivity 
(%/dr) 
9 
  
58
b
/ 61:39 
10 
 
 
41
b
/ 67:33 
11 
  
33
b
/ 93:7 
12 
 
 
38
b
/ 79:21 
a
 LaCl3·2LiCl (2.0 equiv., -60 °C to 25 °C, 24 h), 
b 
MgCl2 (2.0 equiv., 25 °C, 4 h-6 h). 
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5.5 Transformation of the Isoxazolines 
5.5.1 Transformation to the Homoallyl Alcohols  
The 4-methylene isoxazoline derivatives (66a-e, 66g-h) were protected as TBS-ethers by the 
treatment with TBSOTf (2.2 equiv., 0 °C to 25 °C) in 2,6-lutidine (2.5 equiv., 0 °C, CH2Cl2), 
to obtain the isoxazolines 68a-g in 72% to 99% yield (Scheme 26). The desired Baylis-
Hillman products bearing a β-quaternary center and a γ-hydroxyl function of type 69a-g are 
obtained by a reductive cleavage of the N-O bond of isoxazolines 68a-g. Such reductions of 
N-O bonds are commonly performed using catalytic hydrogenations,
125 
reactions with 
transition metals in a low oxidation state,
126 
reducing metals,
127 
or other reductive 
conditions.
128
  
 
Scheme 26. TBS protection of 4-methylene isoxazoline derivatives.  
 
All attempts for N-O bond cleavage by catalytic hydrogenation were unsuccessful due to a 
competing reduction of the conjugated olefin. Reduction of the TBS-protected isoxazoline of 
type 68 with Mo(CO)6 (1-2 h, 80 °C) in acetonitrile:H2O (10:1)
126c  
provided the 
                                                 
125
 (a) D. P. Curran,  J. Am. Chem. Soc. 1982, 104, 4024. (b) D. P. Curran, J. Am. Chem. Soc. 1983, 105, 5826. 
(c) K. B. G. Trossell, Tetrahedron 1985, 41, 5569. 
126
 (a) M. Nitta, T. Kobayashi, J. Chem. Soc. Chem. Commun. 1982, 877; (b) N. B. Das, K. B. G. Trossell, 
Tetrahedron, 1983, 39, 2247. (c) P. B. Baraldi, A. Barco, S. Benetti, S. Manfredini, D. Simoni, Synthesis 1987, 
276. (d) J. W. Bode, E. M. Carreira, Org. Lett 2001, 3, 1587. (e) J. W. Bode, E. M. Carreira, J. Am. Chem. Soc. 
2001, 123, 3611. 1949. (f) Bode, E. M. Carreira, J. Am. Chem. Soc. 2001, 123, 3611. (g) D. H. Churykau, V. G. 
Zinovich, O. G. Kulinkovich Synlett 2004, 11, 1949. 
127
 (a) D. Jiang, Y. Chen, J. Org. Chem. 2008, 73, 9181. (b) I. Karpaviciene, R. Lapinskaite, A. Brukstus, I. 
Cikotiene, Synlett, 2012, 23, 381. 
128
 (a) H. Lund, Acta Chem. Scand. 1959, 13, 249 (b) I. Surov, H. Lund, Acta Chem Scand. 1986, 40, 831 (c) V. 
F. Caetono, F. W. J. Demnitz, F. B. Diniz, R. M. Mariz, M. Navorro, Tetrahedron Lett. 2003, 44, 8217. 
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corresponding β-hydroxy-carbonyl derivatives of type 69 in low yields, since a competing 
retroaldol reaction occurred, leading to the formation of ketone 70 (Scheme 27).  
 
Scheme 27. Reductive N-O bond cleavage of TBS-protected isoxazoline 68a-g with Mo(CO)6 or Fe and NH4Cl 
providing racemic β-hydroxy carbonyls 69a-g. 
[a] 
For Ar see Table 12. 
 
Recently, the reduction of isoxazolines to conjugated β-hydroxy-carbonyls was performed 
with iron and ammonium chloride in the presence of water.
129 
Following this protocol, full 
conversion to the desired β-hydroxyl ketones could be achieved (Scheme 27). Thus, when 
isoxazolines 68a-g were heated to reflux with a suspension of Fe (5 equiv.), NH4Cl (5 equiv.) 
in EtOH:H2O (1:1) for 12 h-48 h, β-hydroxyl carbonyls 69a-g were obtained in 59-76% yield 
(Table 12). These products are analogous to those obtained by the Baylis-Hillman reaction.
130
   
                                                 
129
 (a) D. Jiang, Y. Chen,  J. Org. Chem. 2008, 73, 9181. (b) B. Han, X.-L. Yang, R. Fang, W. Yu, C. Wang, 
X.Y. Duan, S. Liu, Angew. Chem. Int. Ed.  2012, 51, 8816.  
130
 (a) A. B. Baylis, M. E. D. Hillman Acrylic compounds. De215113, 1972, 16. (b) D. Basavaiah, B. S. Reddy, 
S. S. Badsara, Chem. Rev. 2010, 110, 5447. 
B. Results and Discussion 
 
63 
 
 
Table 12: Products Obtained by Reductive N-O bond Cleavage of 4-Methyleneisoxazoline Derivatives 
 
Entry Substrate Product Yield
a
 
1 
 
 
60
b
, 18
c
 
2 
 
 
76
b
 
3 
 
 
75
b
 
4 
  
71
b
 
5 
 
 
68
b
 
6 
 
 
59
b
 
7 
 
 
69
b
, 28
c 
a
 Analyticalylly pure product.
 b
 Fe, NH4Cl, EtOH/H2O (80 °C, 12 h-48 h) 
c
 Mo(CO)6, MeCN/H2O (80 °C, 1-
2 h). 
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5.5.2 Transformation of Isoxazolines by Ozonolysis  
The obtained isoxazole can be easily converted to the ketone by ozonolysis.  
 
 
 
 
Scheme 28: Ozonolysis of isoxazoles 68e and 68c, to the corresponding ketones 71a and 71b. 
 
Ozonolysis of the obtained products 68e and 68c was performed under standard conditions in 
dichloromethane at 0 °C. Products 71a-b were obtained in moderate yields of 33-45% after 
purification (Scheme 28).  
5.5.3 Transformation of Isoxazolines by Acid Mediated Rearrangement 
When the isoxazoles 66c and 66f were heated in the presence of BF3·OEt2 or H2SO4, the 
stereochemistry was lost forming the rearrangement product 72a-b in moderate yield (Scheme 
29).  
 
 
 
 
Scheme 29: Acid mediated rearrangement of isoxazoline 66f and 66c. 
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6 Summary 
6.1 Lewis Acid Triggered Selective Metallation of Chromone, 4-Pyrone, 
Uracil and Uridine 
 
Scheme 30: Concept for the regioselective metallation of chromone, 4-pyrone, uracil and uridine. 
In summary a method was developed for the regioselective metallation of chromone (5), 
4-pyrone (23), uracil (28) and uridine (31), by thermodynamic or kinetic deprotonation 
(Scheme 30). Theoretical calculations
 
showed that the thermodynamically most acidic 
hydrogen of these molecules is attached to C(2),
 
however the most basic heteroatom of these 
heterocycles is the carbonyl oxygen. It was considered that the C(4) carbonyl functions as a 
directing metallation group (DMG-group).
35
 Coordination of the metal base (TMPZnCl·LiCl 
or TMPMgCl·LiCl) leads to the formation of complex I after metallation, the kinetic product 
is obtained (A, Scheme 30). In the presence of a stronger Lewis acid than the metallating 
base, complexation of this Lewis acid will preferentially occur with the carbonyl group (II). 
In this case, the thermodynamic C(2)-metallated heterocycle is obtained after deprotonation 
(B, Scheme 30). Trapping of the metallated species with various electrophiles easily allows 
the functionalization of the corresponding heterocycles. With this new concept, a range of 
C(3) and C(2) substituted chromones, pyrones, and C(5) and C(6) substituted uracils and 
uridines were prepared (Figure 16).   
 
 
 
 
 
Figure 16: Regioselective functionalization of chromone (5), 4-pyrone (23), uracil (34) and uridine (40). 
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6.2 Influence of Lewis Acids on the Regio- and Diastereoselectivity of 
Isoxazole Methylzinc Compounds with Aldehydes 
 
Scheme 31: Concept of allylic rearrangement of heteroaryl methylzinc compounds. 
Based on recent results for the easy accessibility of heteroaryl methylzinc (A, Scheme 31) and 
the allylic reactivity of benzylic zinc reagents (B, Scheme 31), a method was developed for 
the allylic rearrangement of isoxazolemethyl zinc compounds (C, Scheme 31), subsequent 
ring opening of the obtained isoxazolines provided β-hydroxy carbonyls. In the absence of 
additional Lewis acid, the zinc reagent (63) reacted predominantly via an allylic 
rearrangement providing the dearomatized exo-methylene product (66a) in a diastereomeric 
ratio (dr) of 61:39. Since Lewis acids are known to activate aldehydes by complexation, the 
influence of Lewis acids was examined (Scheme 32). This study showed that the addition of 
Lewis acids influences both regioselectivity and diastereoselectivity, and therefore, a change 
in the reaction mechanism is postulated. The formation of allylic addition product 66a 
increased when LaCl3·2LiCl or MgCl2 were added. Both improvements in the regioselectivity 
and diastereoselectivity were rationalized by a six-membered chair-like Zimmerman-Traxler
 
transition state. The reaction proceeded exclusively at the benzylic position when BF3·OEt2 
was added. The Lewis-acid-accelerated reaction of the heterobenzylic organometallic reagent 
63 was performed with various aromatic aldehydes affording a range of stereocontrolled 
products 66a-h in excellent yields (67-92%) and diastereoselectivities (dr = 96:4 to 93:7). The 
resulting isoxazolines provide, after reductive ring opening, β-hydroxy carbonyls of type 69a-
f in moderate yields (60-76%). 
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Scheme 32: Influence of Lewis acid on the regio- and diastereoselectivity of the reaction from isoxazole 
methylzinc compounds with aldehydes. 
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6.3  Einfluss von Lewissäuren auf die Regioselektive Metallierung von 
Chromon, 4-Pyron, Uracil und Uridin 
 
Schema 33: Metallierungskonzept für die regioselektive Metallierung von Chromon, 4-Pyron, Uracil und 
Uridin. 
Es wurde eine Methode zur regioselektiven Metallierung von Chromon (5), 4-Pyron (23), 
Uracil (28) und Uridin (31) in den Positionen C(2) oder C(3) entwickelt (Schema 33). 
Theoretischen Rechnungen
 
zufolge, befindet sich  bei den genannten Systemen das 
thermodynamisch acideste Proton in Position C(2), während das Heteroatom mit der höchsten 
Basizität der Sauerstoff der Carbonylgruppe ist. Es wurde postuliert, dass die Carbonylgruppe 
in C(4) als dirigierende Gruppe (DMG)
35
 fungiert und die stärkste Lewissäure (LS) in Lösung 
komplexiert. Die Koordination der Carbonylgruppe an die Metallbase (TMPZnCl·LiCl oder 
TMPMgCl·LiCl) führt zur Bildung eines Komplexes I, wodurch das kinetische Produkt 
erhalten wird (A, Schema 33). In Gegenwart einer stärkeren Lewissäure (MgCl2) als die 
metallierende Base (TMPZnCl·LiCl), wird die Bildung eines Komplexes II vermutet, und das 
erwartete thermodynamische Metallierungsprodukt erhalten (B, Schema 33). Die Anwendung 
des Konzeptes auf diverse Heterozyklen ermöglicht eine selektive Metallierung in den 
Positionen C(2) bzw. C(3). Die Reaktion der metallierten Verbindung mit verschiedenen 
Elektrophilen ermöglicht eine vielseitige Funktionalisierung der Heterozyklen (Abbildung 
17).  
 
 
 
 
Abbildung 17: Regioselektive Funktionalisierung von Chromon (5), 4-Pyron (23), Uracil (34) and Uridin (40).  
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6.4 Einfluss von Lewissäuren auf die Regio- and Diastereoselektivität von 
Isoxazolmethylzink Verbindungen  
 
Schema 34: Konzept der Allylischen Umlagerung von Heteroarylmethylzinkverbindungen. 
Basierend auf der Synthesemethode zur Darstellung von Heteroaryl-methylzinkverbindungen 
(A, Schema 34),
111c
 und der allylischen Umlagerungen von benzylischen 
Organometallverbindungen (B, Schema 34),
110
 wurde die allylische Addition der 
Isoxazolmethylzink Verbindung 63 mit Carbonylverbindungen (65) untersucht, da die 
erhaltenen Isoxazoline (66) durch Ringöffnung in β-Hydroxycarbonyle (69) überführt werden 
können (C, Schema 34). Die Reaktion der Zinkverbindung 63 mit 3,4-Dichlorbenzaldehyd 
(65a) führte zur Bildung der Produkte 66a und 67a in einem Regioisomerenverhältnis von 
83:17 (Schema 35). Somit verläuft die Reaktion vorwiegend über eine allylische Umlagerung 
unter Bildung des dearomatisierten exo-Methylen-Produkts (66a) in einem 
Diastereomerenverhältnis (dr) von 61:39. Aldehyde werden durch Kompexierung mit 
Lewissäuren aktiviert, deshalb wurde der Einfluss verschiedener Lewissäuren auf die 
Reaktion untersucht (Schema 35). In Gegenwart der Lewissäuren LaCl3·2LiCl (2 Äquiv.) 
oder MgCl2 (2 Äquiv.) wird sowohl die Bildung des allylischen Additionsproduktes (66a) 
verstärkt als auch die Diastereoselektivität verbessert. Diese Verbesserung der Regio- und 
Diastereoselektivität wird durch das Auflösen von Aggregaten und der dadurch erleichterten 
Bildung eines sechsgliedrigen Zimmerman-Traxler
 
Übergangszustandes erklärt. In Gegenwart 
der Lewissäure BF3·OEt2 (2 Äquiv.) wird nur das benzylische Produkt (67a) erhalten. Wir 
vermuten, dass die Koordination von BF3·OEt2 an den Aldehyd die Bildung eines zyklischen 
Übergangszustandes verhindert, und somit die Regioselektivität der Reaktion beeinflusst. Die 
durch Lewissäure beschleunigte Reaktion der heterobenzylischen organometallischen 
Verbindung (63) wurde an einer Vielzahl von Aldehyden untersucht. Die erhaltenen 
Isoxazoline wurden durch reduktive Ringöffnung in β-Hydroxycarbonyle überführt.  
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Scheme 35: Einfluss von Lewissäuren auf die Regio- und Diastereoselektivität von benzylischen Umlagerungen.
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7 Experimental Procedures and Analytical Data 
 
7.1 General 
All reactions are carried out under argon atmosphere in flame-dried glassware. Syringes 
which are used to transfer anhydrous solvents or reagents are purged with argon prior to use. 
THF was continuously refluxed and freshly distilled from sodium benzophenone ketyl under 
nitrogen. Yields refer to isolated yields of compounds estimated to be pure as determined by 
1
H-NMR (25 °C) and capillary GC. The products are prepared corresponding to known 
literature procedures. The analytical data for known compounds match the literature data. The 
stereochemistry of new compounds was determined by 2D-NMR experiments (COESY, 
HSQC, HMBC). 
7.2  Solvents 
Solvents were dried according to standard procedures by distillation over drying agents and 
stored under argon. 
CH2Cl2 was predried over CaCl2 and distilled from CaH2. 
DMF was heated to reflux for 14 h over CaH2 and distilled from CaH2. 
EtOH was treated with phthalic anhydride (25 g/L) and sodium, heated to reflux for 6 h and 
distilled. 
Pyridine was dried over KOH and distilled. 
THF was continuously refluxed and freshly distilled from sodium benzophenone ketyl under 
nitrogen. 
Toluene was predried over CaCl2 and distilled from CaH2. 
NEt3 was dried over KOH and distilled. 
Solvents for column chromatography were distilled on a rotary evaporator prior to use. 
7.3 Reagents 
All reagents were obtained from commercial sources and used without further purification 
unless otherwise stated. TMP-H, liquid aldehydes and acid chlorides are distilled prior to use. 
i-PrMgCl·LiCl solution in THF was purchased from Rockwood Lithium. 
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n-BuLi solution in hexane was purchased from Rockwood Lithium. 
LaCl3·2LiCl solution in THF was purchased from Rockwood Lithium. 
7.3.1 Preparation of the Reagent TMPMgCl·LiCl (1) 
A dry and nitrogen-flushed 500 mL Schlenk-flask, equipped with a magnetic stirring bar and a 
rubber septum, was charged with iPrMgCl·LiCl (1.31 м in THF, 229 mL, 300 mmol). Then, 
TMP-H (52 mL, 306 mmol, 1.02 equiv.) was added and the mixture was stirred until gas 
evolution ceases (48 h). The solution was titrated prior to use at 0 °C with benzoic acid using 
4-(phenylazo)diphenylamine as indicator.
 
 
7.3.2 Preparation of the Reagent TMPZnCl·LiCl (3) 
A dry and argon flushed 250 mL Schlenk-flask, equipped with a magnetic stirring bar and a 
rubber septum was charged with freshly distilled TMP-H (10.2 mL, 60 mmol) dissolved in 
THF (60 mL). This solution was cooled to −40 °C and n-BuLi (2.4 м in hexane, 25 mL, 
60 mmol) was added dropwise. After the addition was complete, the reaction mixture was 
allowed to warm slowly to –10 °C for 1 h. ZnCl2 (1.0 м in THF, 66 mL, 66 mmol) was 
dropwise added and the resulting solution was stirred for 30 min at –10 °C, then for further 
30 min at 25 °C. The solvents are removed under vacuum affording a yellowish solid. Freshly 
distilled THF was slowly added under vigorous stirring until the salts are completely 
dissolved. The freshly prepared TMPZnCl·LiCl solution was titrated prior to use at 0 °C with 
benzoic acid using 4-(phenylazo)diphenylamine as indicator.  
7.3.3 Preparation of the Reagent TMP2Zn·2MgCl2·2LiCl (4) 
A flame-dried and nitrogen-flushed 500 mL Schlenk-flask, equipped with a magnetic stirring 
bar and rubber septum, was charged with a solution of TMPMgCl·LiCl (348 mL, 400 mmol) 
and cooled to 0 °C. Then, ZnCl2 (1.0 м in THF, 200 mL, 200 mmol, 0.5 equiv.) was added 
over a period of 15 min. After stirring this mixture for 12 h at 25 °C, TMP2Zn·2MgCl2·2LiCl 
was titrated prior to use at 0 °C with benzoic acid using 4-(phenylazo)diphenylamine as 
indicator. 
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7.3.4 Preparation of CuCN·2LiCl solution  
A 250 mL Schlenk-flask, equipped with a magnetic stirring bar and rubber septum, was 
charged with CuCN (80.0 mmol, 7.17 g) and LiCl (160 mmol, 6.77 g). The mixture is heated 
under vacuum at 140 °C for 5 h. After cooling to 25 °C, 80 mL dryTHF were added and 
stirring was continued until the salts were dissolved, providing a 1.0 м solution. 
7.3.5 Preparation of ZnCl solution  
A 250 mL Schlenk-flask, equipped with a magnetic stirring bar and rubber septum, was 
charged with ZnCl2 (100 mmol, 136 g). The mixture is heated under vacuum at 140 °C for 5 
h. After cooling to 25 °C, 100 mL dry THF were added and stirring was continued until the 
salt was dissolved, providing a 1.0 м solution. 
7.4 Content determination of organometallic reagents 
Organozinc and organomagnesium reagents were titrated with I2 in a 0.5 M LiCl solution 
in dry THF at 0 °C. Color change from brown to colourles indicated the end of the titration. 
Organolithium reagents were titrated with dry 2-propanol against 1,10-phenanthroline in 
THF. Color change from red to colourles indicated the end of the titration. 
TMPMgCl·LiCl, TMPZnCl·LiCl, and TMP2Zn·2MgCl2·2LiCl was titrated against 
benzoic acid (122 mg, 1 mmol) using (4-phenylazo)diphenylamine (3 mg) as indicator in 
1 mL dry THF at 0 °C. Color change from yellow to dark violet indicated the end of the 
titration. 
7.5 Analytical Data 
1
H-NMR and 
13
C-NMR spectra were recorded on VARIAN Mercury 200, BRUKER ARX 
300, VARIAN VXR 400 S and BRUKER AMX 600 instruments. Chemical shifts are 
reported as δ-values in ppm relative to tetramethylsilane. The following abbreviations were 
used to characterize signal multiplicities: s (singlet), d (doublet), t (triplet), q (quartet), m 
(multiplet) as well as br (broadened). 
Mass spectroscopy: High resolution (HRMS) and low resolution (MS) spectra were recorded 
on a FINNIGAN MAT 95Q instrument. Electron impact ionization (EI) was conducted with 
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an ionization energy of 70 eV. For coupled gas chromatography / mass spectrometry, a 
HEWLETT-PACKARD HP 6890 / 
MSD 5973 GC/MS system was used. Molecular fragments are reported starting at a relative 
intensity of 10%. 
Infrared spectra (IR) were recorded from 4500 cm-1 to 650 cm-1 on a PERKIN ELMER 
Spectrum BX-59343 instrument. For detection a SMITHS DETECTION DuraSamplIR II 
Diamond ATR sensor was used. Wavenumbers are reported in cm-1 starting at an absorption 
of 
10%. 
Melting points (mp) were determined on a BÜCHI B-540 melting point apparatus and are 
uncorrected. Compounds decomposing upon melting are indicated by (decomp.).   
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7.6 General procedures  
7.6.1 TP 1a: Preparation of C(3) Zincated Chromone (6) on 50 mmol Scale 
A dry and argon flushed flask, equipped with a magnetic stirring bar and a 
rubber septum was charged with chromone (5, 7.31 g, 50 mmol) in dry THF 
(50 mL). The base TMPZnCl·LiCl (3, 1.2 equiv.) was added dropwise at 0 °C 
over 30 min., through an addition funnel. The reaction mixture was warmed to 25 °C and 
stirred for additional 7 h. The completion of the metallation was checked by GC-analysis of 
reaction aliquots quenched with iodine indicating a regioselectivity of C(3):C(2) = 98:2 and 
98% conversion. 
 
7.6.2 TP 1b: Preparation of C(3) Zincated Chromone (6) on 2 mmol Scale 
A dry and argon flushed flask, equipped with a magnetic stirring bar and a 
rubber septum is charged with chromone (5, 2.0 mmol) in dry THF (2 mL). 
The base TMPZnCl·LiCl (3, 1.2 equiv.) is added dropwise at 25 °C and the 
reaction mixture is stirred for the given time. The completion of the metallation is checked by 
GC-analysis of reaction aliquots quenched with iodine indicating a regioselectivity of 
C(3):C(2)=97:3 and full conversion. Subsequent reactions with electrophiles are carried out 
under the indicated conditions. After complete conversion, the mixture is quenched with sat. 
aq. NH4Cl solution and extracted with EtOAc (3 × 20 mL). The combined organic extracts are 
dried over anhydrous Na2SO4, filtered and concentrated in vacuo. 
 
7.6.3 TP 2a: Preparation of C(2) Zincated Chromone (8) on 50 mmol Scale 
A dry and argon flushed flask, equipped with a magnetic stirring bar and a 
rubber septum was charged with chromone (5, 7.31 g, 50 mmol) and dry 
MgCl2 (0.4 м in THF, 250 mL) at 0 °C. The base TMPZnCl·LiCl (3, 
1.2 equiv.) was added dropwise at −5 °C over 30 min., through an addition funnel. The 
reaction mixture was warmed to 0 °C and stirred for additional 2 h. The completion of the 
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metallation was checked by GC-analysis of reaction aliquots quenched with iodine indicating 
a regioselectivity of C(2):C(3)=92:8 and full conversion. 
7.6.4 TP 2b: Preparation of C(2) Zincated Chromone (8) on 2 mmol Scale 
A dry and argon flushed flask, equipped with a magnetic stirring bar and a 
rubber septum is charged with chromone (5, 2.0 mmol) and dry MgCl2 (0.4 м 
in THF). The base TMPZnCl·LiCl (3, 1.2 equiv.) is added dropwise at 0 °C 
and the reaction mixture is stirred for the given time. The completion of the metallation is 
checked by GC-analysis of reaction aliquots quenched with iodine indicating a 
regioselectivity of C(2):C(3)=97:3 and full conversion. Subsequent reactions with 
electrophiles are carried out under the indicated conditions. After complete conversion, the 
mixture is quenched with sat. aq. NH4Cl solution and extracted with EtOAc (3 × 20 mL). The 
combined organic extracts are dried over anhydrous Na2SO4, filtered and concentrated in 
vacuo. 
 
7.6.5 TP 3: Preparation of C(3) Zincated Pyran (24) 
A dry and argon flushed flask, equipped with a magnetic stirring bar and a rubber 
septum is charged pyrone (23, 1 mL, 0.5 м in THF). The base TMPZnCl·LiCl (3, 
1.2 equiv.) is added at 0 °C, and the reaction stirred for 2 h. The completion of the 
metallation was checked by TLC of reaction aliquots quenched with iodine. Subsequent 
reactions with electrophiles are carried out under the indicated conditions. After complete 
conversion, the mixture is quenched with sat. aq. NH4Cl solution and extracted with EtOAc (3 
× 20 mL). The combined organic extracts are dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. 
  
7.6.6 TP 4: Preparation of C(2) Zincated Pyran (26) 
A dry and argon flushed flask, equipped with a magnetic stirring bar and a rubber 
septum was charged pyrone (23, 1 mL, 0.5 м in THF). The base 
TMP2Zn·2LiCl·2MgCl2 (4, 0.6 equiv.) was added dropwise at −35 °C and the 
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reaction mixture was stirred for 2 h. The completion of the metallation was checked by TLC 
of reaction aliquots quenched with iodine. Subsequent reactions with electrophiles are carried 
out under the indicated conditions. After complete conversion, the mixture was quenched with 
sat. aq. NH4Cl (10 mL) and extracted with EtOAc (3 × 20 mL). The combined organic 
extracts are dried over anhydrous Na2SO4, filtered and concentrated in vacuo. 
 
 
7.6.7 TP5: Preparation of C(5)-Metallated 1,3-dimethyluracil (35) with 
TMPMgCl·LiCl (1) 
A dry and argon flushed flask, equipped with a magnetic stirring bar and a 
rubber septum was charged with 1,3-dimethyluracil (34, 280 mg, 2.0 mmol) 
in dry THF (2 mL). The base TMPMgCl·LiCl (1, 1.2 equiv.) was added 
dropwise at −40 °C and the reaction mixture was stirred for 4 h. The completion of the 
metallation is checked by GC-analysis of reaction aliquots quenched with iodine indicating a 
regioselectivity of C(5):C(6) = 95:5. Subsequent reactions with electrophiles are carried out 
under the indicated conditions. After complete conversion, the mixture was quenched with 
sat. aq. NaCl (10 mL) and extracted with CH2Cl2 (3 × 20 mL). The combined organic extracts 
are dried over anhydrous Na2SO4, filtered and concentrated in vacuo. 
 
7.6.8 TP6: Preparation of C(6)-Metallated 1,3-dimethyluracil (37) with 
TMP2Zn·2LiCl·2MgCl2 (4)   
A dry and argon flushed flask, equipped with a magnetic stirring bar and a 
rubber septum was charged with 1,3-dimethyluracil (34, 280 mg, 2.0 mmol) in 
dry THF (2 mL). The base TMP2Zn·2LiCl·2MgCl2 (4, 0.6 equiv.) was added 
dropwise at −30 °C and the reaction mixture was stirred for 2 days. The completion of the 
metallation is checked by GC-analysis of reaction aliquots quenched with iodine indicating a 
regioselectivity of C(5):C(6) = 4:96. Subsequent reactions with electrophiles are carried out 
under the indicated conditions. After complete conversion, the mixture was quenched with 
sat. NH4Cl (10 mL) and extracted with EtOAc (3 × 20 mL). The combined organic extracts 
are dried over anhydrous Na2SO4, filtered and concentrated in vacuo. 
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7.6.9 TP7: Preparation of C(6)-Metallated 1,3-dimethoxymethyluracil (44) with 
TMP2Zn·2LiCl·2MgCl2
 
(4) 
A dry and argon flushed flask, equipped with a magnetic stirring bar and a 
rubber septum was charged with 1,3-dimethoxymethyluracil (40, 529 mg, 
2.0 mmol) in dry THF (2 mL). The base TMP2Zn·2LiCl·2MgCl2 (4, 0.6 
equiv.) was added dropwise at −30 °C and the reaction mixture was stirred for 
48 h. The completion of the metallation was checked by GC-analysis of reaction aliquots 
quenched with iodine, indicating a regioselectivity of C(5):C(6) = 0:100. Subsequent 
reactions with electrophiles are carried out under the indicated conditions. After complete 
conversion, the mixture was quenched with sat. aq. NH4Cl (10 mL) and extracted with EtOAc 
(3 × 20 mL). The combined organic extracts are dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. 
 
7.6.10 TP8: Preparation of C(6)-Metallated 1,3-diethylmethyluracil (45) with 
TMP2Zn·2LiCl·2MgCl2 (4) 
A dry and argon flushed flask, equipped with a magnetic stirring bar and a 
rubber septum was charged with 1,3-dieethoxymthylmethyluracil (41, 585 mg, 
2.0 mmol) in dry THF (2 mL). The base TMP2Zn·2LiCl·2MgCl2 (4, 0.6 
equiv.) was added dropwise at −30 °C and the reaction mixture was stirred for 
48 h. The completion of the metallation was checked by GC-analysis of reaction aliquots 
quenched with iodine, indicating a regioselectivity of C(5):C(6) = 0:100. Subsequent 
reactions with electrophiles are carried out under the indicated conditions. After complete 
conversion, the mixture was quenched with sat. NH4Cl (10 mL) and extracted with EtOAc (3 
× 20 mL). The combined organic extracts are dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. 
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7.6.11 TP9: Preparation of C(5)-Metallated Protected Uridine (48) with 
TMPMgCl·LiCl (1) 
A dry and argon flushed flask, equipped with a magnetic stirring bar and 
a rubber septum was charged with protected uridine (47, 0.5 mL, 0.5 м 
in THF). The base TMPMgCl·LiCl (1, 1.2 equiv.) was added dropwise 
at −40 °C and the reaction mixture was stirred for 24 h. The completion 
of the metallation was checked by TLC of reaction aliquots quenched 
with iodine. A regioselectivity of C(5):C(6) = 2:98 was observed. Subsequent reactions with 
electrophiles are carried out under the indicated conditions. After complete conversion, the 
mixture was quenched sat. aq. NaCl (10 mL) and extracted with CH2Cl2 (3 × 20 mL). The 
combined organic extracts are dried over anhydrous Na2SO4, filtered and concentrated in 
vacuo. 
 
7.6.12 TP10: Preparation of C(6)-Metallated Protected Uridine (60) with 
TMP2Zn·2LiCl·2MgCl2 (4):  
A dry and argon flushed flask, equipped with a magnetic stirring bar and a 
rubber septum was charged with protected uridine (47, 0.5 mL, 0.5 м in 
THF). The base TMP2Zn·2LiCl·2MgCl2 (4, 0.6 equiv.) was added 
dropwise at −30 °C and the reaction mixture was stirred for 2 days. The 
completion of the metallation was checked by TLC of reaction aliquots 
quenched with iodine. A regioselectivity of C(5):C(6) = 97:3 was observed. Subsequent 
reactions with electrophiles are carried out under the indicated conditions. After complete 
conversion, the mixture was quenched with sat. aq. NH4Cl (10 mL) solution and extracted 
with EtOAc (3 × 20 mL). The combined organic extracts are dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. 
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7.6.13 TP11: Preparation of C(6)-Metallated Cytidine (58) with 
TMP2Zn·2LiCl·2MgCl2 (4): 
A dry and argon flushed flask, equipped with a magnetic stirring bar and 
a rubber septum was charged with protected cytidine (57, 0.5 м in THF). 
The base TMP2Zn·2LiCl·2MgCl2 (4, 0.6 equiv.) was added dropwise at 
−30 °C and the reaction mixture was stirred for 4 h. The completion of 
the metallation was checked by TLC of reaction aliquots quenched with 
iodine. Subsequent reactions with electrophiles are carried out under the indicated conditions. 
After complete conversion, the mixture was quenched with sat. aq. NH4Cl (10 mL) and 
extracted with EtOAc (3 × 20 mL). The combined organic extracts are dried over anhydrous 
Na2SO4, filtered and concentrated in vacuo. 
 
7.6.14 TP12: Preparation of ((3,5-Dimethylisoxazol-4-yl)methyl)zinc(II) Chloride 
(63) 
In a dry and argon-flushed Schlenk-flask, equipped with a magnetic stirrer and 
a septum, zinc dust (490 mg, 12.5 mmol, 1.2 equiv.) and LiCl (318 mg, 12.5 
mmol, 1.2 equiv.) were dried under vacuum with a heat gun for 15 min. After 
cooling to room temperature, THF (10 mL) and 1,2-dibromoethane (5 drops) were added, and 
the reaction mixture was heated under reflux for 5 seconds. 5 drops of TMSCl were added to 
the suspension, and the reaction mixture was heated under reflux for 5 seconds. After cooling 
to room temperature, 4-(chloromethyl)-3,5-dimethylisoxazole (62, 713 mg, 10 mmol) was 
added dropwise and the resulting mixture was heated to 50 °C for 1 day. The solution was 
titrated at 0 °C prior to use with iodine, showing a yield of 80-85%. Larger scale reactions (30 
mmol) provided higher concentrations of up to 90%.  
7.6.15 TP12a-12d: Reaction of ((3,5-Dimethylisoxazol-4-yl)methyl)zinc(II) 
Chloride (63) in the Benzylic Position  
TP12a:  
The freshly prepared zinc reagent (63) was cooled to -40 °C, CuCN·2LiCl
 
(1 м solution in THF) was added and the reaction mixture was stirred for 30 min. Allylation 
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was achieved by adding allylbromide (1 equiv.) at −40 °C, stirring at −40 °C for 10 min and 
6 h at 25 °C. Upon completion, the reaction was cooled down to −60 °C and quenched with 
methanol (1 equiv.). Aqueous NaCl was added, and the resulting mixture was extracted three 
times with EtOAc. The combined organic extracts were dried over Na2SO4, filtered and 
concentrated in vacuo.  
TP12b: The freshly prepared zinc reagent (63, 1 equiv.) was cooled to −40 °C, CuCN·2LiCl
 
(1 м solution in THF,) was added and the reaction mixture was stirred for 30 min. Acylation 
was achieved by acid chloride (1 equiv.) at −40 °C, and warming up to −20 °C for 24 h. Upon 
completion the reaction was cooled down to −60 °C and quenched with methanol (1 equiv.). 
Aqueous NaCl was added and the resulting mixture was extracted three times with EtOAc. 
The combined organic extracts were dried over Na2SO4, filtered and concentrated in vacuo.  
TP12c: The freshly prepared zinc reagent (63, 1 equiv.) reacted in a Negishi cross-coupling
 
reaction with aryl iodides (1 equiv.) in the presence of PEPPSI-iPr
 
(1 mol %) for 24 h at 
25 °C. Upon completion, the reaction was cooled down to −60 °C and quenched with 
methanol (1 equiv.). Aqueous NaCl was added and the resulting mixture was extracted three 
times with EtOAc. The combined organic extracts were dried over MgSO4, filtered and 
concentrated in vacuo.  
TP12d: In a dry and Argon flushed Schlenk-flask, was added zinc reagent 63 (1 equiv.) and 
BF3 (2 equiv., 50 % in Et2O) at 25 °C. After stirring for 10 min, the aldehyde (1 equiv., 1 м in 
THF) was added. The reaction was stirred for 4 h. Upon completion the reaction was cooled 
to −60 °C and quenched with methanol (1 equiv.). Aqueous NaCl was added and the resulting 
mixture was extracted three times with EtOAc. The combined organic extracts were dried 
over MgSO4, filtered and concentrated in vacuo.  
 
7.6.16 TP 13a-b: Reaction of ((3,5-Dimethylisoxazol-4-yl)methyl)zinc(II) Chloride 
(63) in the Allylic Position 
TP13a: In a dry and Argon flushed Schlenk-flask, was added zinc reagent 63 
(1 equiv.) and LaCl3·2LiCl (2 equiv., 0.5 M in THF) at -60 °C. After stirring 
for 10 min, the aldehyde (1.0, 1.5 or 2.0 equiv., 1 м in THF) was added. The reaction was 
stirred for 1 h at −60 °C, and slowly warmed to room temperature for 24 h. Upon completion, 
the reaction was cooled down to −60 °C and quenched with methanol (1 equiv.). Aqueous 
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NaCl was added and the resulting mixture was extracted three times with EtOAc. The 
combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo.  
TP13b: In a dry and Argon flushed Schlenk-flask, was added zinc reagent 63 (1 equiv.) and 
MgCl2 (2 equiv., 0.4 м in THF) at 25 °C. After stirring for 10 min, the aldehyde (1 equiv., 1 м 
in THF) was added. The reaction was stirred for 4 h. Upon completion, the reaction was 
cooled down to −60 °C and quenched with methanol (1 equiv.). Aqueous NaCl was added and 
the resulting mixture was extracted three times with EtOAc. The combined organic extracts 
were dried over MgSO4, filtered and concentrated in vacuo.  
7.6.17 TP 14: Preperation of TBS-Protected Isoxazolines 68 
TP14: To a solution of alcohol 66 (1 equiv., 0.1 м CH2Cl2) was added 
dropwise 2,6-lutidine (2.5 equiv.) at 0 °C. TBSOTf (2.2 equiv.) was added, 
and the reaction mixture was slowly warmed to room temperature. Completion of the reaction 
was checked using TLC. Upon completion, the resulting mixture was cooled back to 0 °C and 
slowly quenched with aq. NH4Cl. After warming to room temperature, the layers were 
separated and the aqueous layer was extracted three times with CH2Cl2. The combined 
organic extracts were washed with sat. aq. NaCl, dried over MgSO4 filtered and concentrated 
in vacuo.  
7.6.18 TP15a-b: Reductive N-O Bond Cleavage of the Obtained Isoxazolines  
 TP15a: To a refluxing solution of isoxazoline 68 and NH4Cl (10 equiv.) in 
ethanol:H2O (1:1) was added Fe powder (10 equiv.) under nitrogen. The 
solution was heated to 80 °C for 1-3 days. Completion of the reaction was checked using 
TLC. If not noted differently, crude 
1
H-NMR analysis confirmed full conversion of the 
reaction. Upon completion, the reaction mixture was cooled to room temperature, diluted with 
EtOAc and filtered through Celite
®
. The resulting solid was washed with CH2Cl2 and EtOAc 
TP15b: Isoxazoline 68 (1 equiv.) and Mo(CO)6 (2 equiv.) was dissolved in MeCN:H2O (10:1) 
and heated at 80 °C, in a pressure vial. The reaction conversion was monitored by TLC. Upon 
compleation, the reaction was cooled to room temperature and filtered trough Celite
®
 and the 
solids were washed with EtOAc:i-hexane (8:2). After filtration, the solvent was removed in 
vacuo.  
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7.7 Preparation of Chromone Derivatives 7b-d, 9a-c 
7.7.1 NMR Experments 
7.7.1.1 1H-NMR-Spectra of C(3) Zincated Chromone in THF at varying temperatures 
 
 
Figure 18: 
1
H-NMR of crude reaction
 
mixture of chromone (5) treated with TMPZnCl·LiCl (3, 1.2 equiv.), 
measured at varying temperatures (1) 25 °C, (2) 35 °C, (3) 45 °C (4) 55 °C. 
 
7.7.1.2 NMR-Spectra of C(3) Zincated Chromone in THF after the addition of ZnCl2  
A dry and argon flushed flask, equipped with a magnetic stirring bar and a rubber septum is 
charged with chromone (5, 2.0 
mmol) in dry THF-d8 (2 mL). 
The base TMPZnCl·LiCl (4, 1.2 
equiv. in THF-d8) is added 
dropwise at 25 °C and the 
reaction mixture is stirred for 30 
min. Completion of the 
metalation is checked by GC-analysis of reaction aliquots quenched with iodine. After 
completion ZnCl2 (1.0 м in THF-d8, 4 mL, 4 mmol) was added, and the solvent was partially 
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removed. The solution was cannulated into a dry and argon flushed NMR-tube. The C(3) 
zincated chromone was characterized by 1H, 13C, COSY, HSQC, and HSBC spectra which 
confirms its identity. 
1
H NMR (400 MHz, THF-d8) δ = 8.28 (d, J = 7.04 Hz, 1H), 8.16 (s, 1H), 7.95 (t, J = 7.70, 
1H), 7.70 (d, J = 8.79, 1H), 7.60 (t, J = 7.29 Hz, 1H). 
13
C NMR (400 MHz, THF-d8) δ = 187.8, 162.6, 157.3, 135.2, 128.7, 126.2, 125.8, 122.9, 
118.3. 
 
 
 
 
 
Figure 19: The COSY
 
NMR of C(3) zicated Chromone in THF, after the addition of ZnCl2 (2 equiv.)  
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Figure 20: The HSQC-NMR of C(3) zicated Chromone in THF, after the addition of ZnCl2 (2 equiv.)  
 
Figure 21: The HMBC-NMR of C(3) zicated Chromone in THF, after the addition of ZnCl2 (2 equiv.)  
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7.7.1.3 NMR-Spectra C(3) Zincated Chromone in Dioxane 
A dry and argon flushed flask, equipped 
with a magnetic stirring bar and a rubber 
septum is charged with chromone (5, 
2.0 mmol) in dry THF (2 mL). The base 
TMPZnCl·LiCl (4; 1.2 equiv. in THF) is 
added dropwise at 25 °C and the reaction 
mixture is stirred for 30 min. Completion of 
the metalation is checked by GC-analysis of reaction aliquots quenched with iodine. After 
completion the solvent is removed and the crude residue is redesolved in dioxane. The 
solution was cannulated into a dry and argon flushed NMR-tube. The C(3) zincated chromone 
was characterized by 
1
H, 
13
C, COSY, HSQC, and HSBC spectra which confirms its identity. 
1
H NMR (400 MHz, Dioxane) δ = 8.28 (d, J = 7.70 Hz, 1H), 8.08 (s, 1H), 7.92 (t, J = 7.48 
Hz, 1 H), 7.74 (d, J = 8.57, 1H), 7.60 (t, J = 7.55 Hz, 1H).   
13
C NMR (400 MHz, Dioxane) δ = 187.3, 161.1, 157.5, 133.9, 131.2, 125.1, 124.9 123.7, 
118.6. 
 
 
Figure 22: The COSY-NMR of C(3) zicated Chromone in Dioxane  
 D. Experimental Section 
 
87 
 
Figure 23: The HSQC-NMR of C(3) zicated Chromone in Dioxane  
 
 
Figure 24: The HMBC-NMR of C(3) zicated Chromone in Dioxane  
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7.7.1.4 NMR-Spectra of C(2) Zincated Chromone in  
 
A dry and argon flushed flask, equipped 
with a magnetic stirring bar and a rubber 
septum is charged with chromone (5, 2.0 
mmol) in dry THF (2 mL). The base 
TMP2Zn·2LiCl·2MgCl2 (5, 0.55 equiv.) is 
added dropwise at -30 °C and the reaction mixture is stirred for 1 h. The completion of the 
metalation is checked by GC-analysis of reaction aliquots quenched with iodine. After 
completion the solvent was removed and the crude residue was dissolved in Dioxane. The 
solution was cannulated into a dry and argon flushed NMR-tube. The C(3) zincated chromone 
was characterized by 1H, 13C, COSY, HSQC, and HSBC spectra which confirms its identity. 
 
1
H NMR (400 MHz, Dioxane) δ = 8.25 (1H), 7.70 (1H), 7.59 (1H), 7.40 (1H), 7.01 (1H). 
13
C NMR (400 MHz, Dioxane) δ = 218.6, 174.9, 160.5, 133.3, 125.5, 124.6, 123.6, 121.8, 
118.6. 
 
 
Figure 25:  The COSY-NMR of C(2) zicated Chromone in THF, after the addition of ZnCl2 (2 equiv.).  
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Figure 26: The HSQC-NMR of C(2) zicated Chromone in THF, after the addition of ZnCl2 (2 equiv.).   
 
 
Figure 27: The HMBC-NMR of C(2) zicated Chromone in THF, after the addition of ZnCl2 (2 equiv.).   
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7.7.1.5 NMR-Spectra of BF3 Complexes of Chromone THF 
A dry and argon flushed 
NMR-tube is charged with 
chromone (5, 0.5 mmol) 
and dissolved in dry THF-
d8 (0.5 mL). To the 
solution is added BF3·OEt2 (1 mmol).  
 
1
H NMR (MHz, THF) δ = 7.51 (d, J = 7.51 Hz, 1H), 7.82 (t, J = 8.14 Hz, 1H), 8.07 (d, 8.17 
Hz 1H), 8.14 (t, J =7.91 Hz), 8.45 (d, J = 8.14 Hz, 1H), 9.10 (d. J = 5.72 Hz, 1H). 
13
C NMR (400 MHz, THF) δ = 108.79 (q, 
4
JCF = 2.31) 119.09 (s, 1C), 120.80 (s, 1C), 125.61 
(s, 1C),128.05 (s, 1C), 137.88 (s, 1C), 158.05 (s, 1H), 178.75 (q, 
3
JCF = 2.11). 
 
 
 
Figure 28: The 
13
C-NMR of a solution of Chromone and BF3·OEt2  in THF at varying temperatures confirm the 
coordination of the carbonyl group to Lewis acid BF3: 1) 
13
C-NMR Spectra at -60 °C 2) 
13
C-NMR Spectra at -
60 °C. 
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Figure 29: The 
1
H-NMR of a solution of Chromone and BF3·OEt2  (2.8 equiv.) in THF at -60 °C. 
7.7.2 Preparation of 3-Allyl-4H-chromen-4-one (7b) on 50 mmol Scale.  
The C(3) zincated chromone (6, 50 mmol) was prepared according to TP1a, 
cooled to −50 °C, and CuCN·2LiCl (60 mL, 1.0 м solution in THF, 
60 mmol, 1.2 equiv.) was added through an addition funnel over 30 minutes. 
After further 30 min. of stirring at the same temperature, allyl bromide 
(7.26 g, 60 mmol, 1.2  equiv.) was added, and the resulting mixture was warmed up to 25 °C 
and stirred at 25 °C for 12 h. The reaction mixture was then cooled to −10 °C and quenched 
with MeOH (10 mL). Then NH4Cl/NH3 (50 mL, 2 м in H2O) was added and the resulting 
mixture was stirred for 2 h at 25 °C. The solution was extracted with CH2Cl2 (3 × 300 mL), 
and the combined organic extracts were dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. Purification of the crude product by flash chromatography (EtOAc:i-
hexane 1:10) furnished the compound 7b (8.43 g, 45 mmol, 91%) as a yellow oil. 
HRMS (EI) for C12H10O2: calcd. 186.0681 (M
+
); found 186.0657. 
1
H NMR (300 MHz, CDCl3) δ = 3.20 (dd, J=6.63, 1.11 Hz, 2 H), 5.01 - 5.14 (m, 2 H), 5.71 - 
6.02 (m, 1 H) 7.27 - 7.44 (m, 2 H), 7.51 - 7.64 (m, 1 H), 7.69 (s, 1 H), 8.18 (dd, J=8.02, 1.66 
Hz, 1 H). 
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13
C NMR (75 MHz, CDCl3) δ = 29.6, 117.1, 118.0, 123.0, 123.8, 124.9, 125.9, 133.3, 134.6, 
152.6, 156.4, 177.3. 
IR (ATR): 𝜈 (cm-1) = 3077 (w), 3068 (w), 3017 (vw), 2970 (w), 2941 (vw), 2900 (w), 1632 
(s), 1608 (s), 1573 (m), 1464 (s), 1429 (m), 1398 (s), 1353 (s), 1321 (m), 1297 (m), 1282 (m), 
1264 (w), 1226 (w), 1210 (m), 1181 (m), 1156 (s), 1141 (s), 1111 (m), 1027 (w), 1005 (m), 
961 (m), 924 (s), 909 (s), 896 (s), 868 (w), 846 (s), 802 (m), 769 (s), 756 (vs), 712 (m), 690 
(s). 
m.p.: 34 - 36 °C 
 
7.7.3 Preparation of 3-(3,4-difluorobenzoyl)-4H-chromen-4-one (7c) 
The C(3) zincated chromone (6, 50 mmol) was prepared according to 
TP1a, cooled to −50 °C, and CuCN·2LiCl (60 mL, 1.0 м solution in 
THF, 60 mmol, 1.2 equiv.) was added through an addition funnel over 
30 min. After further 1 h of stirring at the same temperature, 3,4-
difluorobenzoyl chloride (10.6 g, 60 mmol, 1.2 equiv.) was added, and the resulting mixture 
was warmed up to 25 °C over 12 h. The reaction mixture was stirred for additional 36 h until 
GC analysis indicated full conversion. The reaction mixture was then cooled to −40 °C and 
quenched with MeOH (10 mL). Then NH4Cl/NH3 (50 mL, 2м in H2O) solution was added 
and the resulting mixture was stirred for 2 h at 25 °C. The solution was extracted with CH2Cl2 
(3 × 300 mL), the combined organic extracts were washed with sat. aq. Na2CO3 (50 mL), 
dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The obtained solid was 
washed with cold Et2O, the remaining solid is recrystallized from hot acetone. The compound 
7c was obtained in 60% yield (8.61 g, 30 mmol) as a pale orange solid.  
HRMS (EI) for C16H8F2O3: calcd 286.04415 (M
+
); found 286.0445. 
1
H NMR (300 MHz, CDCl3) δ = 7.13 - 7.32 (m, 1 H), 7.44 - 7.60 (m, 2 H), 7.60 - 7.67 (m, 1 
H), 7.67 - 7.89 (m, 2 H), 8.26 (dd, J=7.46, 1.66 Hz, 1 H), 8.34 (s, 1 H). 
13
C NMR (75 MHz, CDCl3) δ = 117.2, 117.4, 118.4, 118.7 (d,d , J=18.23, 1.68), 124.6, 
124.9, 126.3, 126.4, 126.9 (d,d J=7.57, 3.65), 134.2 (d,d, J=4.77, 3.65), 134.6, 159.4 (dd, J= 
266.47, 12.90), 153.9 (dd, J=273.48, 12.90), 156.0, 159.2, 174.5, 189.5. 
IR (ATR): ?̃? (cm-1) = 1665 (m), 1652 (m), 1645 (m), 1615 (m), 1604 (w), 1596 (w), 1563 
(w), 1515 (m), 1464 (m), 1434 (m), 1384 (w), 1348 (w), 1338 (w), 1317 (m), 1299 (m), 1282 
(m), 1273 (w), 1234 (w), 1213 (w), 1194 (w), 1172 (w), 1151 (w), 1128 (w), 1110 (m), 1099 
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(w), 996 (w), 929 (w), 908 (w), 856 (m), 829 (m), 797 (w), 771 (m), 762 (vs), 757 (s), 729 
(m), 701 (w), 686 (w), 656 (m).  
m.p.: 190 - 191 °C 
 
7.7.4 Preparation of 4-(4-oxo-4H-chromen-3-yl)benzaldehyde (7d) 
The C(3) zincated chromone (6, 50 mmol) was prepared according to 
TP1a, warmed to 25 °C and reacted with bromobenzaldehyde (11.1 g, 
60 mmol, 1.2 equiv.) in the presence of Pd(PPh3)4 (0.558 g, 1 mol %) 
for 18 h. The reaction mixture was then cooled to −10 °C and quenched 
with MeOH (10 mL). Then sat. aq. NH4Cl (50 mL) was added and the resulting mixture was 
stirred for 2 h at 25 °C. The solution was extracted with CH2Cl2 (3 × 300 mL), dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The obtained solid was recrystallized 
from CH2Cl2:heptane. When no more pure product crystallized the remaining mother liquid 
was concentrated and purified by column chromatography (i-hexane:EtOAc 9.5:0.5 to 8:2). 
Compound 7d was obtained in 84 % yield (10.4 g, 42 mmol) as a yellow solid.  
HRMS (EI) for C16H10O3: calcd. 249.05572 (M
+
); found 249.0549. 
1
H NMR (300 MHz, CDCl3) δ = 7.43 - 7.56 (m, 2 H), 7.68 - 7.77 (m, 1 H), 7.79 (d, J=8.29 
Hz, 2 H), 7.97 (d, J=8.29 Hz, 2 H), 8.12 (s, 1 H), 8.33 (d, J=9.68 Hz, 1 H), 10.07 (s, 1 H) 
13
C NMR (75 MHz, CDCl3) δ = 118.1, 124.3, 124.4, 125.6, 126.4, 129.4, 129.8, 134.00, 
135.9, 138.2, 153.7, 156.1, 175.7, 191.8. 
IR (ATR): 𝜈 (cm-1) = cm-1 (intensity), 1699 (m), 1695 (m), 1630 (m), 1615 (m), 1598 (m), 
1558 (m), 1458 (m), 1369 (m), 1357 (m), 1289 (m), 1230 (m), 1214 (m), 1171 (m), 1115 (m), 
1047 (m), 1014 (m), 897 (m), 888 (m), 857 (m), 831 (s), 824 (s), 764 (vs). 
m.p.: 198 - 200 °C 
 
7.7.5 Preparation of 2-(2-methylbenzoyl)-4H-chromen-4-one (9b) 
The C(2) zincated chromone (8, 50 mmol) was prepared according to 
TP2a, cooled to −50 °C and CuCN·2LiCl (60 mL, 1 м solution in THF, 
60 mmol, 1.2 equiv.) was added, through an addition funnel over 30 
minutes. After further 1 h of stirring at the same temperature, 2-
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methylbenzoyl chloride (9.24 g, 60 mmol, 1.2 equiv.) was added. The reaction mixture was 
stirred at −40 °C for 1 h before it was warmed slowly to 25 °C over 12 h. The reaction 
mixture was then cooled to −40 °C and quenched with MeOH (10 mL). Then NH4Cl/NH3 (50 
mL, 2 м in H2O) was added and the resulting mixture was stirred for 2 h at 25 °C. The 
solution was extracted with CH2Cl2 (3 × 300 mL), the combined organic extracts were 
washed with sat. aq. Na2CO3 (50 mL) dried over anhydrous Na2SO4, filtration and 
concentrated in vacuo. The obtained solid was washed with EtOH and the filtrate was 
concentrated in vacuo. The obtained solid was recrystallized from CH2Cl2/heptane. When no 
more pure product crystallized the remaining mother liquid was concentrated and purified by 
column chromatography (CH2Cl2). The compound 9b was obtained in 60 % yield (10.7 g, 40 
mmol, 81%) as an orange solid.  
HRMS (EI) for C17H12O3: calcd 265.08647 (M+H); found. 265.08589. 
1
H NMR (300 MHz, CDCl3) δ = 2.46 (s, 3 H), 6.79 (s, 1 H), 7.20 - 7.40 (m, 2 H), 7.40 - 7.54 
(m, 3 H), 7.58 (dd, J=8.57, 1.11 Hz, 1 H), 7.75 (ddd, J=8.57, 6.91, 1.66 Hz, 1 H), 8.22 (dd, 
J=7.88, 1.80 Hz, 1 H). 
13
C NMR (75 MHz, CDCl3) δ = 20.1, 115.8, 118.8, 124.5, 125.5, 125.8, 125.9, 129.4, 131.6, 
132.1, 134.9, 134.9, 138.4, 155.9, 157.6, 178.6, 190.7. 
IR (ATR): 𝜈 (cm-1) = 1679 (m), 1648 (s), 1615 (m), 1598 (m), 1569 (m), 1487 (w), 1469 (m), 
1456 (m), 1387 (m), 1377 (s), 1330 (w), 1303 (m), 1288 (w), 1255 (m), 1239 (s), 1214 (m), 
1158 (m), 1145 (w), 1130 (m), 1092 (m), 1083 (w), 1039 (w), 1027 (m), 977 (m), 869 (s), 853 
(m), 843 (m), 797 (m), 778 (vs), 756 (s), 740 (vs), 729 (s), 712 (m), 668 (s).  
m.p.: 95 °C 
7.7.6 Preparation of ethyl 5-(4-oxo-4H-chromen-2-yl)furan-2-carboxylate (9c) 
The obtained C(2) zincated chromone (8, 50 mmol) was prepared 
according to TP2b, warmed to 25 °C and reacted with ethyl 5-
bromofuran-2-carboxylate (13.1 g, 60 mmol, 1.2 equiv.) in the 
presence of Pd(dba)2 (565 mg, 2 mol %) and tfp (465 mg, 4 mol %) 
for 25 h. The reaction mixture was then cooled to 0 °C and quenched with MeOH (10 mL). 
Then sat. aq. NH4Cl (50 mL) is added and the resulting mixture was stirred for 2 h at 25 °C. 
The solution was extracted with CH2Cl2 (3 × 300 mL), the combined organic extracts were 
dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The obtained crude product 
 D. Experimental Section 
 
95 
was recrystallized from hot acetone. Compound 9c was obtained in 62 % yield (8.88 g, 31 
mmol) as a gray solid.  
HRMS (EI) for C16H12O5: calcd 284.06847 (M
+
); found 284.0666. 
1
H NMR (300 MHz, CDCl3) δ = 1.41 (t, J=7.05 Hz, 3 H), 4.41 (q, J=7.10 Hz, 2 H), 6.91 (s, 1 
H), 7.14 - 7.21 (m, 1 H), 7.30 (d, J=3.32 Hz, 1 H), 7.42 (t, J=7.60 Hz, 1 H), 7.51 (d, J=7.46 
Hz, 1 H), 7.61 - 7.77 (m, 1 H), 8.21 (dd, J=7.88, 1.80 Hz, 1 H).  
13
C NMR (75 MHz, CDCl3) δ = 14.3, 61.6, 107.4, 113.6, 118.0, 119.0, 124.3, 125.5 125.8, 
134.0, 146.8, 148.8, 153.8, 155.8, 158.00, 177.5. 
IR (ATR): 𝜈 (cm-1) = 3149 (w), 3111 (w), 3096 (w), 3054 (w), 3045 (w), 2977 (w), 1723 (s), 
1636 (s), 1607 (s), 1577 (m), 1557 (m), 1503 (w), 1475 (m), 1468 (s), 1413 (s), 1371 (s), 1362 
(s), 1332 (m), 1287 (s), 1256 (m), 1250 (m), 1227 (s), 1152 (s), 1131 (s), 1116 (m), 1074 (m), 
1059 (m), 1025 (m), 1016 (s), 962 (m), 885 (s), 878 (s), 869 (m), 842 (s), 823 (s), 820 (s), 784 
(vs), 763 (s), 755 (vs), 733 (m), 703 (m), 672 (s).  
m.p.: 120-151 °C 
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7.8 Natural Product Synthesis 
7.8.1 Preparation of 5,7,4’-tetramethoxyflavone (12, TMF) 
A dry and argon flushed 10 mL Schlenk-flask equipped with a magnetic stirring bar, and a 
septum was charged with 5,7-dimethoxy chromone (11, 206 mg, 1 
mmol) and dissolved in THF (1mL). TMP2Zn·2MgCl2·2LiCl (4, 1 
mL, 0.6 м in THF, 0.6 mmol, 1.2 equiv.) was added. The reaction 
was stirred for 30 min and completion of the metallation was 
checked by TLC of reaction aliquots quenched with I2 in dry THF. After complete metallation 
the organozinc reagent reacted in a Negishi cross-coupling within 30 min at 25 °C after the 
addition of p-iodanisole (279 mg, 1.2 mmol), Pd(dba)2 (22 mg, 4 mol%) and P(2-furyl)3 (19 
mg,  8 mol%). After complete conversion, the mixture was quenched with sat. aq. NH4Cl (12 
mL) and extracted with EtOAc (3 × 50 mL). The combined organic extracts were dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. Purification by flash chromatography 
(EtOAc:i-hexane 1:10) afforded the desired product 12 (229 mg, 0.73 mmol) as a geay solid 
in 73%yield. 
HRMS (EI) for C18H16O5: calcd. 312.0998; found 312.0987. 
MS (70 eV, EI) (m/z)(%): 313 (18), 312 (100), 311 (58), 283(29), 282(11), 281(19), 266 (30), 
142 (17), 132 (22). 
1
H NMR (400 MHz, acetone) δ = 3.87 (s, 3 H) 3.89 (s, 3 H) 3.94 (s, 3 H) 6.47 (d, J=2.34 Hz, 
1 H) 6.49 (s, 1 H) 6.76 (d, J=2.34 Hz, 1 H) 7.09 (m, J=8.77 Hz, 2 H) 7.95 (m, J=8.97 Hz, 2 
H) 
13
C NMR (101 MHz, acetone) δ = 54.98, 55.37, 55.50, 93.02,  95.91, 107.01, 108.89, 114.31, 
123.73, 127.53, 159.67, 159.99, 160.89, 162.18, 163.99, 175.44.  
IR (ATR): 𝜈 (cm-1) = 2930 (w), 2836 (VW), 2361 (w), 2341 (VW), 1642 (s), 1603 (s), 1595 
(s), 1567 (m), 1511 (m), 1489 (m), 1467 (m), 1450 (m), 1419 (m), 1386 (w), 1348 (s), 1295 
(w), 1255 (s), 1214 (s), 1194 (s), 1170 (m), 1162 (s), 1120 (s), 1110 (m), 1100 (m), 1055 (m), 
1031 (m), 951 (w), 907 (w), 830 (vs), 811 (w), 798 (m), 770 (m), 726 (w), 696 (w), 674 (w), 
654 (w). 
m.p.: 155 - 157 °C 
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7.8.2 Preparation of Isochrysin 17 
A dry and argon flushed 10 mL Schlenk-flask equipped with a magnetic 
stirring bar, and a septum was charged with 5,7-
bis((triisopropylsilyl)oxy)-chromenone (11, 490 mg, 1 mmol) dissolved 
in THF (1 mL). TMP2Zn·2MgCl2·2LiCl (4, 1 mL, 0.6 м in THF, 0.6 mmol, 1.2 equiv.) was 
added at -20 °C. The reaction was stirred for 30 min and completion of the metallation was 
checked by TLC of reaction aliquots quenched with I2 in dry THF. After complete metallation 
the organozinc reagent reacted in a Negishi cross-coupling within 1 h at 25 °C after the 
addition of iodobenzole (280 mg, 1.0 mmol), Pd(dba)2 (22 mg, 4 mol%) and P(2-furyl)3 
(18 mg, 8 mol%). After complete conversion, TBAF (624 mg, 2.4 equiv.) was added, and the 
reaction mixture was stirred for 20 min. The obtained reaction mixture was quenched with sat. 
aq. NaCl (10 mL) and extracted with EtOAc (3 x 50 mL). The combined organic extracts 
were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. Purification by flash 
column chromatography (EtOAc:i-hexane 1:10) afforded 17 (227mg, 0. 89 mmol, 89%) as a 
colorless solid. 
HRMS (EI) for C15H10O4: calcd. 254.05791; found 244.0568. 
MS (70 eV, EI) (m/z)(%): 255 (16), 254 (100), 253 (39), 124 (16). 
1
H NMR (400 MHz, acetone) δ = 6.28 (s, 1 H), 6.43 (s, 1 H), 7.37 (s, 2 H), 7.44 (s, 1 H), 7.60 
(d, J=6.85 Hz, 2 H), 8.22 (s, 1 H), 12.94 (s, 1H). 
13
C NMR (101 MHz, acetone) δ = 93.67, 99.06, 105.28, 123.24, 127.97, 128.14, 129.02, 
131.22, 154.24, 158.13, 163.02, 164.17, 180.42. 
 
7.8.3 Preparation of benzyl protected chrysin (21) 
A dry and argon flushed 10 mL Schlenk-flask equipped with a magnetic 
stirring bar, and a septum was charged with 5,7-bis(benzyloxy)-
chromenone (18, 200 mg, 0.55 mmol) and dissolved in THF (1 mL). 
TMP2Zn·2MgCl2·2LiCl (4, 0.91 mL, 0.73 м in THF, 0.66 mmol) was 
added at −30 °C. The reaction was stirred for 1 h and completion of the metallation was 
checked by TLC of reaction aliquots quenched with I2 in dry THF. After complete metallation 
the organozinc reagent (20) reacted in a Negishi cross-coupling within 1 h at 25 °C after the 
addition of iodo benzene (135 mg, 0.66 mmol), Pd(dba)2 (7 mg, 2 mol%) and P(2-furyl)3 
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(5 mg, 4 mol%). After complete conversion, the mixture was quenched with sat. aq. NH4Cl 
(10 mL) and extracted with EtOAc (3 × 50 mL). The combined organic extracts are dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. Purification by flash column 
chromatography (EtOAc:i-hexane 3:7) afforded 21 (173 mg, 0.40 mmol, 72%) as a colorless 
solid. 
HRMS (ESI) for C29H22O4: calcd. 434.4826 (M+H
+
); found 435.1592. 
1
H NMR (400 MHz, acetone-d6) δ = 5.27 (s, 4 H), 6.64 (s, 1 H), 6.71 (d, J = 2.15 Hz, 1 H), 
6.93 (d, J = 2.15 Hz, 1 H), 7.28 - 7.47 (m, 6 H), 7.48 - 7.60 (m, 5 H), 7.72 (d, J = 7.43 Hz, 2 
H), 7.96 - 8.07 (m, 2 H). 
13
C NMR (75 MHz, acetone-d6) δ = 70.22, 70.27, 94.50, 98.23, 108.58, 109.56, 125.86, 
126.69, 127.30, 127.81, 128.10, 128.20, 128.50, 128.95, 131.11, 131.66, 136.45, 137.20, 
159.67, 159.70, 160.10, 163.14, 175.49. 
IR (ATR): 𝜈 (cm-1) = 3061 (w), 3026 (w), 2955 (w), 2921 (w), 2853 (w), 2361 (w), 2341 (w), 
1644 (s), 1625 (m), 1605 (s), 1576 (m), 1560 (w), 1550 (w), 1495 (m), 1488 (m), 1450 (m), 
1370 (m), 1346 (s), 1297 (m), 1262 (m), 1212 (m), 1166 (s), 1124 (s), 1100 (s), 1078 (m), 
1054 (m), 1028 (m), 1010 (s), 976 (m), 908 (m), 882 (m), 846 (m), 836 (m), 816 (s), 803 (m), 
756 (vs), 730 (s), 696 (vs), 689 (vs), 667 (s). 
m.p.: 155-156 °C 
Lit. 
1
H NMR
131 
7.8.4 Preparation of benzyl protected biochanine A (20) 
A dry and argon flushed 10 mL Schlenk-flask equipped with a 
magnetic stirring bar, and a septum was charged with 5,7-
bis(benzyloxy)-chromenone (18, 100 mg, 0.28 mmol) dissolved in 
THF (1 mL). TMPZnCl·LiCl (3, 0.4 mL, 1.4 м in THF, 0.6 mmol) was added. The reaction 
was stirred for 30 min and completion of the metallation was checked by TLC of reaction 
aliquots quenched with I2 in dry THF. After complete metallation the organozinc reagent (19) 
reacted in a Negishi cross-coupling within 1 h at 25 °C after the addition of p-iodanisole 
(78 mg, 0.34 mmol), Pd(dba)2 (7 mg, 4 mol%) and P(2-furyl)3 (5 mg, 8 mol%). After 
complete conversion, the reaction mixture was quenched with sat. aq. NH4Cl (10 mL) and 
extracted with EtOAc (3 × 50 mL). The combined organic extracts were dried over anhydrous 
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Na2SO4, filtered and concentrated in vacuo. Purification by flash column chromatography 
(EtOAc:i-hexane 1:10) afforded the desired product 20 (123 mg, 0.26 mmol, 95%) as a 
colorless solid. 
HRMS (EI) for C30H24O5: calcd. 464.1624 (M
+
); found 264.1614.  
MS (70 eV, EI) m/z (%): 465 (32), 464 (100), 374 (23), 373 (32), 358 (12), 91 (70), 43 (17).  
1
H NMR (300 MHz, CDCl3) δ = 3.83 (s, 3 H), 5.10 (s, 2 H), 5.22 (s, 2 H), 6.52 (d, J=3.59 Hz, 
2 H), 6.95 (d, J=8.57 Hz, 2 H), 7.18 - 7.53 (m, 10 H), 7.59 (d, J=7.46 Hz, 2 H), 7.74 (s, 1 H). 
13
C NMR (75 MHz, CDCl3) δ = 55.31, 70.47, 70.81, 94.04, 98.30, 110.54, 113.85, 124.44, 
126.19, 126.75, 127.60, 127.63, 128.42, 128.57, 128.75, 130.44, 135.68, 136.28, 149.99, 
159.49, 159.82, 160.26, 162.70, 175.19. 
IR (ATR): 𝜈 (cm-1) = 3079 (vw), 3067 (vw), 3031 (vw), 3006 (w), 2905 (vw), 2869 (vw), 
2846 (vw), 2361 (w), 2342 (w), 1654 (s), 1646 (s), 1614 (vs), 1583 (m), 1570 (m), 1511 (m), 
1498 (m), 1449 (m), 1434 (m), 1376 (m), 1364 (m), 1302 (m), 1290 (s), 1258 (s), 1248 (s), 
1215 (s), 1200 (m), 1190 (m), 1174 (s), 1164 (s), 1109 (w), 1086 (s), 1071 (s), 1066 (s), 1028 
(m), 984 (m), 892 (w), 878 (m), 840 (s), 824 (s), 802 (m), 793 (m), 774 (w), 741 (s), 731 (vs), 
694 (s). 
m.p.: 157-160 °C 
 
7.8.5 Preparation of Crysin (16) 
A suspension of 21 (43 mg, 0.1 mmol) in EtOH (10 mL) was treated 
with 20% Pd(OH)2/C (7 mg) under a flow of hydrogen for 12 h at 25 °C. 
Completion of the reaction was checked by TLC. The reaction mixture 
was then filtered trough Celite and eluted with EtOH. The filtrate was 
concentrated in vacuo. Purification by flash column chromatography (EtOAc:i-hexane, 1:9 to 
3:7) furnished crysin (16, 21 mg, 83%) as a colorless solid. 
HRMS (EI) for C15H10O4: calcd. 254.0579 (M
+
); found 254.0576. 
MS (70 eV, EI) m/z (%):255 (21), 254 (100), 253 (10), 226 (17), 152 (21), 124 (14). 
1
H NMR (400 MHz, acetone-d6) δ = 6.28 (d, J=2.14 Hz, 1 H), 6.58 (d, J=2.14 Hz, 1 H), 6.79 
(s, 1 H), 7.47 - 7.69 (m, 3 H), 8.07 (dd, J=7.99, 1.75 Hz, 2 H), 9.71 (s, 1 H), 12.90 (s, 1 H). 
13
C NMR (101 MHz, acetone-d6) δ = 93.95, 98.96, 104.66, 105.27, 126.33, 129.07, 131.36, 
131.78, 158.01, 162.48, 163.77, 164.20, 182.22. 
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IR (ATR): 𝜈 (cm-1) = 3081 (w), 3010 (w), 2925 (w), 2856 (w), 2712 (w), 2634 (w), 2361 
(vw), 2349 (vw), 2253 (vw), 2210 (vw), 2044 (vw), 2017 (vw), 1646 (s), 1608 (s), 1578 (m), 
1555 (m), 1498 (s), 1448 (s), 1425 (m), 1352 (vs), 1313 (m), 1273 (m), 1247 (m), 1188 (w), 
1168 (vs), 1157 (s), 1120 (m), 1103 (m), 1077 (w), 1031 (m), 1026 (m), 999 (w), 977 (w), 
908 (m), 840 (m), 807 (s), 782 (m), 748 (m), 732 (m), 693 (m), 674 (m). 
Lit. 
1
H NMR
132 
7.8.6 Preparation of Biochanin A (14)  
A suspension of 20 (50 mg, 0.1 mmol) in EtOAc (10 mL) was 
treated with 20% Pd(OH)2/C (7 mg) under a flow of hydrogen for 
48 h at 25 °C. Completion of the reaction was checked by TLC. 
The reaction mixture was then filtered trough Celite and eluted with EtOH. The filtrate was 
concentrated in vacuo. Purification by flash column chromatography (i-hexane:EtOAc, 1:9 to 
3:7) furnished Biochanin A (14, 25 mg, 88%) as a colorless solid. 
HRMS (EI) for C16H12O5: calcd. 284.0685 (M
+
); found 284.0669.  
MS (70 eV, EI) m/z (%):285 (13), 284 (100), 132.0547 (11). 
1
H NMR (400 MHz, acetone-d6) δ =3.84 (s, 3 H), 6.29 (dd, J=2.14, 1.17 Hz, 1 H), 6.41 (dd, 
J=2.15, 1.37 Hz, 2 H), 7.00 (d, J=8.97 Hz, 2 H), 7.55 (d, J=8.97 Hz, 2 H), 8.20 (d, J=1.17 Hz, 
1 H), 13.01 (s, 1H).  
13
C NMR (101 MHz, acetone-d6) δ = 54.67, 93.60, 98.85, 105.23, 113.60, 122.94, 123.29, 
130.17, 153.52, 158.14, 159.76, 162.71, 163.97, 180.56. 
IR (ATR): 𝜈 (cm-1) = 3338 (m), 3286 (w), 3088 (w), 3042 (w), 2923 (w), 2853 (w), 2361 (w), 
2341 (w), 1652 (s), 1613 (s), 1601 (m), 1571 (s), 1505 (m), 1488 (m), 1447 (s), 1407 (m), 
1386 (m), 1361 (m), 1330 (m), 1290 (m), 1276 (m), 1253 (s), 1207 (m), 1173 (vs), 1153 (s), 
1060 (m), 1046 (vs), 1021 (s), 988 (s), 934 (m), 909 (m), 877 (m), 836 (s), 813 (vs), 796 (s), 
754 (s), 697 (vs), 674 (m), 668 (m). 
Lit. 
1
H NMR
133
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7.9 4-Pyrone Derivatives 25a-d, 27a-c 
7.9.1 Preparation of 3-iodo-4H-pyran-4-one (25a) 
 To a solution of γ-pyrone (23, 1 mL, 0.5 м in THF, 0.5 mmol) was added 
TMPZnCl·LiCl (3, 0.5 mL, 1.2 м in THF, 0.6 mmol, 1.2 equiv.) at 0 °C. The 
reaction mixture was stirred for 2 h according to TP3 and reacted with iodine 
(0.7 mL, 1 м in THF, 0.7 mmol, 1.4 equiv.). The regioselectivity of of the metallation is 
checked by 
1
H-NMR indicating C(3):C(2) = 98:2. The crude product was purified by flash 
column chromatography (SiO2, EtOAc:i-hexane 3:7) furnishing compound 25a (89 mg, 0.40 
mmol, 80%) as a yellowish solid. 
HRMS (EI) for C5H3IO2: calcd. 221.9806 (M
+
); found 221.9176. 
MS (70 eV, EI) m/z (%): 221 (100), 151 (13), 126 (7), 52 (11). 
1
H NMR (300MHz, CDCl3) δ = 6.40 (d, J=5.68 Hz, 1 H), 7.76 (dd, J=5.73, 0.96 Hz, 1 H), 
8.18 (d, J=1.01 Hz, 1 H). 
13
C NMR (75MHz, CDCl3) δ = 93.83, 114.27, 155.21, 158.04, 173.41. 
IR (ATM): 𝜈 (cm-1) = 3099 (vw), 3069 (vw), 1744 (vw), 1685 (w), 1632 (vs), 1609 (m), 1539 
(vw), 1399 (w), 1360 (w), 1310 (s), 120-5 (w), 1088 (w), 1027 (m), 945 (m), 911 (vw), 894 
(w), 832 (m).  
m.p.: 73 - 75 °C 
7.9.2 Preparation of 3-allyl-4H-pyran-4-one (25b) 
To a solution of γ-pyrone (23, 1 mL, 0.5 м in THF, 0.5 mmol) was added 
TMPZnCl·LiCl (3, 0.5 mL, 1.2 м in THF, 0.6 mmol, 1.2 equiv.) at 0 °C. The 
reaction mixture was stirred for 2 h according to TP3. The freshly prepared zinc 
reagent 24 was cooled to −40 °C, CuCN·2LiCl (1 м solution in THF, 0.7 mL, 0.7 mmol, 
1.4 equiv.) was added and the reaction mixture was stirred for 30 min. Allylation was 
achieved by adding allyl bromide (84 mg, 0.7 mmol, 1.4 equiv.) at −40 °C, stirring at −40 °C 
for 5 min and 1 h at 25 °C. The crude product was purified by flash column chromatography 
(SiO2, EtOAc:i-hexane 4:6) furnishing compound 25b (44 mg, 0.32 mmol, 65%) as a 
yellowish solid. 
HRMS (EI) for C8H8O2: calcd. 136.1479 (M
+
); found 136.0520. 
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MS (70 eV, EI) m/z (%): 136 (100), 137 (11), 135 (43), 121 (88), 108 (12), 107 (21), 91 (11), 
79 (35), 53 (15), 77 (18), 71 (57), 67 (59), 66 (45), 65 (48), 63(13). 
1
H NMR (300 MHz, CDCl3) δ = 3.02 - 3.17 (m, 2 H), 5.08 (ddd, J=1.54, 1.06, 0.87 Hz, 1 H), 
5.10 - 5.16 (m, 1 H), 5.76 - 5.97 (m, 1 H), 6.31 (dd, J=5.75, 0.61 Hz, 1 H), 7.54 - 7.64 (m, 1 
H), 7.69 (dt, J=5.76, 0.94 Hz, 1 H). 
13
C NMR (75 MHz, CDCl3) δ = 29.39, 116.57, 117.47, 128.82, 133.86, 152.52, 155.10, 
177.88. 
IR (ATM): ?̃? (cm-1) = 3460 (w), 3078 (w), 2979 (vw), 2911 (vw), 1710 (w), 1645 (vs), 1605 
(s), 1427 (m), 1386 (w), 1364 (w), 1322 (s), 1287 (w), 1224 (m), 1149 (m), 1132 (m), 1124 
(m), 984 (m), 915 (m), 855 (m), 836 (s), 780 (w), 741 (w), 655 (m). 
 
7.9.3 Preparation of 3-(4-chlorophenyl)-4H-pyran-4-one (25c) 
 To a solution of γ-pyrone (23, 1 mL, 0.5 м in THF, 0.5 mmol) was added 
TMPZnCl·LiCl (3, 0.5 mL, 1.2 м in THF, 0.6 mmol, 1.2 equiv.) at 0 °C. The 
reaction mixture was stirred for 2 h according to TP3. The zinc reagent 24 
reacted in a Negishi cross-coupling reaction by adding Pd(dba)2 (6 mg, 2 mol%), P(2-furyl)3 
(5 mg, 4 mol%) and 1-chloro-4-iodobenzene (166 mg, 0.7 mmol, 1.4 equiv.) within 1 h at 25 
°C. The crude product was purified by flash column chromatography (SiO2, EtOAc:i-hexane 
4:6) yielding compound 25c (94 mg, 0.45 mmol, 90%) as a colorless liquid. 
HRMS (EI) for C11H7ClO2: calcd. 206.6251 (M
+
); found 206.0129. 
MS (70 eV, EI) m/z (%): 208 (18), 206 (69), 136 (100), 115 (14), 101 (16), 89 (11), 74 (11), 
44 (15), 43(14), 43 (15). 
1
H NMR (300 MHz, CDCl3) δ = 6.45 (d, J=5.81 Hz, 1 H), 7.38 (m, 2 H), 7.44 (m, 2 H), 7.75 
(dd, J=5.81, 1.11 Hz, 1 H), 7.87 (d, J=1.11 Hz, 1 H). 
13
C NMR (75 MHz, CDCl3) δ =117.99, 128.71, 129.45, 129.54, 129.94, 134.58, 152.83, 
154.79, 176.43. 
IR (ATR): 𝜈 (cm-1) = 3086 (w), 3055 (w), 1673 (w), 1644 (vs), 1611 (s), 1595 (s), 1571 (w), 
1558 (w), 1489 (m), 1427 (m), 1399 (m), 1365 (m), 1331 (m), 1302 (w), 1270 (s), 1192 (m), 
1107 (w), 1089 (s), 1012 (s), 948 (s), 909 (w), 904 (w), 896 (w), 858 (m), 851 (w), 838 (s), 
824 (m), 811 (m), 756 (w), 747 (m), 712 (w). 
m.p.: 115 - 116 °C. 
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7.9.4 Preparation of 3-allyl-4H-pyran-4-one (25d) 
To a solution of γ-pyrone (23, 1 mL, 0.5 м in THF, 0.5 mmol) was added 
TMPZnCl·LiCl (3, 0.5 mL, 1.2 м in THF, 0.6 mmol, 1.2 equiv.) at 0 °C. The 
reaction mixture was stirred for 2 h according to TP3. The zinc reagent 24 was 
treated with CuCN·2LiCl (0.7 mL, 1 м solution in THF, 0.7 mmol, 1.4 equiv.) for 30 min at 
−60 °C. Acylation was achieved by adding pivaloyl chloride (84 mg, 0.7 mmol, 1.4 equiv.) at 
−40 °C and warming up to −4 °C. The reaction mixture was stirred at −4 °C until completion 
of the reaction. The crude product was purified by flash column chromatography (SiO2, 
EtOAc:i-hexane 4:6) yielding compound 25d (55 mg, 0.3 mmol, 61%) as a yellow liquid. 
HRMS (EI) for C10H12O3: calcd. 180.2005 (M
+
); found 180.0784. 
MS (70 eV, EI) m/z (%):124 (39), 123 (13), 96 (100), 57 (13), 52 (11), 41 (12). 
1
H NMR (300 MHz, CDCl3) δ =1.24 (s, 9 H), 6.40 (d, J=5.85 Hz, 1 H), 7.69 - 7.74 (m, 2 H). 
13
C NMR (75 MHz, CDCl3) δ =26.05, 44.89, 118.63, 132.54, 153.11, 155.00, 175.08, 207.46. 
IR (ATR): 𝜈 (cm-1) = 3078 (vw), 3073 (vw), 2974 (w), 2937 (vw), 2869 (vw), 1708 (vs), 
1651 (s), 1609 (w), 1598 (m), 1559 (w), 1479 (w), 1418 (m), 1360 (s), 1322 (m), 1221 (s), 
1155 (m), 1092 (w), 1036 (w), 989 (m), 923 (m), 860 (m), 841 (m), 810 (w). 
 
7.9.5 Preparation of 2-iodo-4H-pyran-4-one 27a 
To a solution of γ-pyrone (23, 1 mL, 0.5 м in THF, 0.5 mmol) was added 
TMP2ZnCl·MgCl2·2LiCl (4, 0.5 mL, 0.6 м in THF, 0.3 mmol, 0.6 equiv.) at −35 °C. 
The reaction mixture was stirred for 2 h according to TP4 and reacted with iodine 
(0.7 mL, 1 м in THF, 0.7 mmol, 1.4 equiv.).  The regioselectivity of of the metallation is 
checked by 
1
H-NMR indicating C(3):C(2) = 1:15. The crude product was purified by flash 
column chromatography (SiO2, EtOAc:i-hexane 3:7) furnishing compound 27a (53 mg, 0.24, 
48%) as a green liquid. 
HRMS (EI) for C5H3IO2:  calcd. 221.9177 (M
+
); found 221.9175. 
 
1
H NMR (300 MHz, CDCl3) δ = 6.35 (dd, J=5.94, 2.35 Hz, 1 H), 6.84 (d, J=2.21 Hz, 1 H), 
7.67 (d, J=5.81 Hz, 1 H).  
13
C NMR (75 MHz, CDCl3) δ = 117.30, 119.09, 130.00, 156.85, 175.76. 
IR (ATR): 𝜈 (cm-1) = 3415 (w), 3089 (w), 2977 (m), 2928 (m), 2850 (w), 1661 (s), 1633 (s), 
1575 (s), 1490 (m), 1441 (s), 1401 (s), 1370 (s), 1334 (s), 1288 (s), 1254 (vs), 1226 (vs), 1196 
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(vs), 1175 (vs), 1162 (s), 1126 (s), 1093 (s), 1071 (s), 1046 (s), 1018 (s), 940 (m), 930 (m), 
891 (m), 861 (m), 839 (m), 834 (m), 801 (s), 687 (m). 
7.9.6 Preparation of 2-(4-methoxyphenyl)-4H-pyran-4-one (27b) 
To a solution of γ-pyrone (23, 1 mL, 0.5 м in THF, 0.5 mmol) was added 
TMP2ZnCl·MgCl2·2LiCl (4, 0.5 mL, 0.6 м in THF, 0.3 mmol, 0.6 equiv.) 
at −35 °C. The reaction mixture was stirred for 2 h according to TP4. The 
zinc reagent reacted in a Negishi cross-coupling reaction by adding 
Pd(dba)2 (6 mg, 2 mol%), P(2-furyl)3 (5 mg, 4 mol%) and 1-iodo-4-methoxybenzene (140 mg, 
0.7 mmol, 1.4 equiv.) within 12 h at 25 °C. The crude product was purified by flash column 
chromatography (SiO2, EtOAc:i-hexane 3:7) furnishing compound 27b (58 mg, 0.29 mmol, 
56%) as a yellow liquid. 
HRMS (EI) for C12H10O3: calcd. 202.0629 (M
+
); found 202.0629. 
1
H NMR (300 MHz, CDCl3) δ = 3.84 (s, 3 H), 6.32 (dd, J=5.94, 2.35 Hz, 1 H), 6.66 (d, 
J=2.49 Hz, 1 H), 6.96 (m, 2 H), 7.68 (m, 2 H), 7.78 (d, J=5.81 Hz, 1 H). 
13
C NMR (75 MHz, CDCl3) δ = 55.45, 110.87, 114.44, 116.83, 123.40, 127.42, 154.54, 
162.20, 163.94, 179.16. 
IR (ATR): 𝜈 (cm-1) = 3069 (w), 2956 (m), 2922 (m), 2836 (m), 1642 (s), 1602 (s), 1593 (s), 
1575 (s), 1563 (m), 1508 (s), 1445 (m), 1427 (s), 1411 (s), 1362 (s), 1303 (m), 1260 (s), 1231 
(s), 1221 (s), 1197 (m), 1180 (s), 1123 (m), 1029 (s), 1016 (s), 1007 (m), 930 (s), 864 (s), 842 
(s), 814 (vs), 797 (s), 732 (m), 712 (m). 
Lit. 
1
H NMR
134
 
7.9.7 Preparation of 2-(2-methoxyphenyl)-4H-pyran-4-one (27c) 
To a solution of γ-pyrone (23, 1 mL, 0.5 м in THF, 0.5 mmol) was added 
TMP2ZnCl·MgCl2·2LiCl (4, 0.5 mL, 0.6 м in THF, 0.3 mmol, 0.6 equiv.) at 
−35 °C. The reaction mixture was stirred for 2 h according to TP4. The zinc 
reagent reacted in a Negishi cross-coupling reaction by adding Pd(dba)2 (6 mg, 2 mol%), P(2-
furyl)3 (5 mg, 4 mol%) and 1-iodo-2-methoxybenzene (140 mg, 0.7 mmol, 1.4 equiv.) within 
                                                 
134
 R. C. Barcelos, J. C. Pastre, V. Caixeta, D. B. Vendramini-Costa, J. E. de Carvalho, R. A. Pilli, Bioorg. Med. 
Chem. 2012, 20, 3635. 
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12 h at 25 °C. The crude product was purified by flash column chromatography (SiO2, 
EtOAc:i-hexane 4:6) yielding compound 27c (68 mg, 0.34 mmol, 67%) as a colorless solid. 
HRMS (EI) for C12H10O3: calcd 202.06299; found 202.0628. 
1
H NMR (300 MHz, CDCl3) δ = 3.86 (s, 3 H), 6.32 (dd, J=5.94, 2.63 Hz, 1 H), 6.90 - 7.13 
(m, 3 H), 7.34 - 7.50 (m, 1 H), 7.66 (dd, J=7.74, 1.66 Hz, 1 H), 7.80 (d, J=5.81 Hz, 1 H). 
13
C NMR (75 MHz, CDCl3) δ = 55.58, 111.68, 116.56, 117.35, 120.03, 120.67, 128.81, 
132.30, 155.06, 157.59, 161.37, 179.62. 
IR (ATR): 𝜈 (cm-1) = 3460 (w), 3078 (vw), 2943 (vw), 2840 (vw), 1636 (vs), 1591 (s), 1580 
(m), 1561 (m), 1492 (m), 1464 (m), 1454 (m), 1436 (m), 1414 (m), 1361 (m), 1289 (m), 1249 
(m), 1227 (m), 1181 (w), 1173 (w), 1128 (m), 1058 (w), 1020 (m), 1008 (m), 927 (s), 872 
(m), 826 (w), 796 (w), 757 (m), 722 (w). 
m.p.: 59 - 61 °C 
Lit. 
1
H NMR: 
135
 
  
                                                 
135
 (a) V. Rukachaisirikul, S. Kannai, S. Klaiklay, S. Phongpaichit, J.Sakayaroj, Tetrahedron, 2013, 69, 6981. (b) 
J. Toda, T. Saitoh, T. Oyama, Y. Horiguchi, T. Sano, Heterocycles 1996, 43, 2457. 
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7.10 Uracil Derivatives 36a-c, 38a-e, 43 a-d, 46a-d 
7.10.1 Preparation of 5-Iodo-1,3-dimethyluracil (36a) 
To a solution of 1,3-dimethyluracil (34, 140 mg, 1.0 mmol) in THF (1 mL) was 
added TMPMgCl·LiCl (1, 1 mL, 1.2 м in THF, 1.2 mmol, 1.2 equiv.) at −40 °C. 
The reaction mixture was stirred for 24 h according to TP5 and reacted with 
iodine (1.2 mL, 1 м in THF, 1.2 mmol, 1.2 equiv.). The crude product was purified by flash 
column chromatography (SiO2, EtOAc:i-hexane:Et3N 3:7:0.05) furnishing compound 36a 
(191 mg, mmol, 0.72 mmol, 72%) as a colorless solid. 
HRMS (ESI) for C6H7IN2O2: calcd. 266.0365 (M
+
); found 265.9548. 
MS (70 eV, EI) m/z (%): 266 (100), 208 (13), 167 (19). 
1
H-NMR (300 MHz, DMSO-d6) δ = 3.19 (s, 3 H), 3.28 (s, 3 H), 8.23 (s, 1 H). 
13
C-NMR (75 MHz, DMSO-d6) δ = 29.22, 36.87, 66.69, 149.44, 151.60, 160.74.  
IR (ATR): 𝜈 (cm-1) = 3068 (w), 3050 (w), 2955 (w), 1688 (s), 1634 (s), 1616 (s), 1509 (m), 
1475 (m), 1441 (s), 1425 (m), 1391 (m), 1352 (m), 1340 (s), 1262 (m), 1222 (m), 1143 (m), 
1070 (w), 1011 (m), 957 (m), 944 (s), 814 (m), 752 (vs). 
m.p.: 227 - 229 °C 
 
7.10.2 Preparation of 4-((1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-
yl)(hydroxy)methyl)benzonitrile (36b) 
To a solution of 1,3-dimethyluracil (34, 280 mg, 2.0 mmol) in THF 
(2 mL) was added TMPMgCl·LiCl (2 mL, 1.2 м in THF, 2.4 mmol) at 
−40 °C. The reaction mixture was stirred for 24 h according to TP5 
and reacted with p-cyanobenzaldehyde (314 mg, 1.2 equiv., 2.4 mmol) 
at 25 °C within 2 h. The crude product was purified by flash column chromatography (SiO2, 
EtOAc:i-hexane:EtOH 1:9:0.5) furnishing compound 36b (378 mg, 1.4 mmol, 70%) as a 
yellow solid. 
HRMS (ESI) for C14H13N3O2: calcd. 271.2713 (M
+
); found 271.0952. 
MS (70 eV, EI) m/z (%): 272 (15), 271 (100), 270 (28), 248 (68), 247 (30), 167 (37), 156 
(10), 141 (22), 140 (26), 129 (26), 42 (60).  
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1
H-NMR: (300 MHz, CDCl3) δ = 3.30 (s, 3 H) 3.36 (s, 3 H) 5.75 (s, 1 H) 7.02 (s, 1 H) 7.59 
(m, 4 H). 
13
C-NMR: (75 MHz, CDCl3) δ = 27.87, 37.27, 69.50, 111.64, 114.94, 118.61, 127.18, 
132.32, 140.35, 146.63, 151.18, 163.04.  
IR (ATR): 𝜈 (cm-1) = 3486 (w), 3062 (w), 2953 (w), 2927 (w), 2886 (w), 2858 (w), 2233 (m), 
1698 (s), 1655 (s), 1622 (vs), 1608 (s), 1503 (m), 1484 (m), 1457 (m), 1438 (m), 1404 (m), 
1388 (m), 1363 (m), 1346 (s), 1312 (m), 1236 (m), 1213 (m), 1186 (m), 1175 (m), 1163 (s), 
1088 (m), 1045 (m), 1027 (s), 1014 (m), 976 (m), 958 (m), 924 (m), 865 (m), 850 (m), 830 
(s), 797 (s), 780 (m), 763 (m), 754 (s), 722 (m), 682 (m), 656 (m). 
m.p.: 205 - 207 °C.  
 
7.10.3 Preparation of 5-(hydroxy(phenyl)methyl)-1,3-dimethyluracil (36c) 
 To a solution of 1,3-dimethyluracil (34, 140 mg, 1.0 mmol) in THF (1 mL) 
was added TMPMgCl·LiCl (1, 1 mL, 1.2 м in THF, 1.2 mmol, 1.2 equiv.) 
at −40 °C. The reaction mixture was stirred for 24 h according to TP5 and 
reacted with benzaldehyde (124 mg, 1.2 mmol, 1.2 equiv.) at 25 °C for 2 h. The crude product 
was purified by flash column chromatography (SiO2, EtOAc:i-hexane:EtOH 1:9:0.5 
furnishing compound 36c (182 mg, 0.74 mmol, 74%) as a colorless oil. 
HRMS (ESI) for C13H14N2O3: calcd. 246.2619 (M
+
); found 246.0998. 
MS (70 eV, EI) m/z (%): 247 (14), 246 (100), 229 (11), 228 (37), 227 (19), 199 (15), 169 
(25), 167 (24), 143 (14), 141 (10), 105 (11), 77 (11). 
1
H-NMR (400 MHz, MeOH-d4) δ = 3.23 (s, 3 H), 3.37 (s, 3 H), 5.68 (s, 1 H), 7.15 - 7.25 (m, 
1 H), 7.25 - 7.33 (m, 2 H), 7.34 - 7.45 (m, 2 H), 7.51 (d, J=0.98 Hz, 1 H). 
13
C-NMR (100 MHz, MeOH-d4) δ = 26.67, 35.97, 68.65, 116.07, 126.39, 127.10, 127.82, 
140.89, 142.55, 151.74, 162.81. 
IR (ATR): 𝜈 (cm-1) = 3415 (w), 3062 (vw), 3029 (vw), 2953 (w), 2925 (w), 1694 (s), 1653 
(vs), 1625 (vs), 1557 (m), 1511 (w), 1482 (s), 1452 (s), 1397 (m), 1367 (m), 1339 (s), 1240 
(m), 1171 (m), 1083 (m), 1058 (m), 1033 (m), 1021 (m), 1002 (m), 967 (w), 915 (m), 830 
(m), 795 (w), 763 (s), 755 (s), 729 (m), 715 (s), 698 (s), 674 (m), 665 (m). 
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7.10.4 Preparation of 5-(hydroxy(4-methoxyphenyl)methyl)-1,3-
dimethylpyrimidine-2,4(1H,3H)-dione (36d)  
To a solution of 1,3-dimethyluracil (34, 280 mg, 2.0 mmol) in THF 
(2 mL) was added TMPMgCl·LiCl (1, 2 mL, 1.2 м in THF, 
2.4 mmol) at −40 °C. The reaction mixture was stirred for 24 h 
according to TP5 and reacted with p-methoxybenzaldehyde (326 mg, 1.2 equiv., 2.4 mmol) at 
25 °C for 2 h. The crude product was purified by flash column chromatography (SiO2, 
EtOAc:i-hexane:EtOH 1:9:0.5) furnishing the compound 36d (259 mg, 0.97 mmol, 48%) as a 
colorless oil. 
HRMS (EI) for C14H16N2O4: calcd. 276.2878 (M
+
); found 276.1104.  
MS (70 eV, EI) m/z (%): 276 (100), 240 (62), 158 (46), 140 (70), 137 (31), 77 (30), 42 (60). 
1
H-NMR: (400 MHz, CDCl3) δ = 3.21 (s, 3 H), 3.25 (d, J=2.73 Hz, 3 H), 3.73 (d, J=2.92 Hz, 
3 H), 5.60 (d, J=2.53 Hz, 1 H), 6.69 - 6.85 (m, 2 H), 6.92 (s, 1 H), 7.16 - 7.31 (m, 2 H). 
13
C-NMR: (101 MHz, CDCl3) δ =27.76, 37.10, 55.22, 69.40, 113.82, 116.23, 127.75, 133.02, 
140.03, 151.36, 159.16, 163.21.  
IR (ATR): 𝜈 (cm-1) = 3424 (w), 3068 (vw), 3000 (vw), 2955 (w), 2838 (vw), 1696 (s), 1655 
(vs), 1629 (vs), 1586 (m), 1510 (s), 1481 (s), 1456 (s), 1367 (m), 1339 (m), 1302 (m), 1244 
(s), 1171 (s), 1110 (m), 1085 (m), 1059 (m), 1027 (s), 966 (w), 920 (m), 833 (s), 792 (m), 758 
(s), 732 (s), 699 (m). 
 
7.10.5 Preparation of 5-(cyclohex-2-en-1-yl)-1,3-dimethyluracil (36e) 
To a solution of 1,3-dimethyluracil (34, 280 mg, 2.0 mmol) in THF (1 mL) 
was added TMPMgCl·LiCl (1, 2 mL, 2.4 м in THF, 2.4 mmol, 1.2 equiv.) at 
−40 °C. The reaction mixture was stirred for 24 h according to TP5. To the 
freshly prepared magnesium reagent was added CuCN·2LiCl (1 M solution 
in THF, 2.4 mL, 2.4 mmol, 1.2 equiv.) and the reaction mixture was stirred for 30 min at 
−40 °C. Allylation was achieved by adding 3-bromocyclohexene (644 mg, 4.0 mmol, 
2 equiv.) at −40 °C, stirring at −40 °C for 10 min and 1 h at 25 °C. The crude product was 
purified by flash column chromatography (SiO2, EtOAc:i-hexane:Et3N 1:9:0.05 to 3:7:0.05) 
furnishing the compound 36e (248 mg, 1.13 mmol, 56%) as a yellow solid. 
HRMS (EI) for C12H16N2O2: calcd. 220.2676; found 220.1200 (M
+
). 
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MS (70 eV, EI) m/z (%): 220 (63), 217 (26), 166 (48), 127 (23), 81 (23), 57 (27), 55 (23), 46 
(39), 45 (100), 44 (94). 
1
H-NMR (400 MHz, MeOH-d4) δ = 1.44 - 1.55 (m, 1 H), 1.54 – 1.57 (m, 2H), 1.76 - 1.93 (m, 
1 H), 1.94 - 2.07 (m, 2 H), 3.27 (s, 3 H), 3.36 (s, 3 H), 3.39 (td, J=5.82, 3.03 Hz, 1 H), 5.44 - 
5.57 (m, 1 H), 5.82 - 5.94 (m, 1 H), 7.17 (s, 1 H).
  
13
C-NMR (101 MHz, MeOH-d4) δ = 19.44, 24.64, 26.92, 28.06, 32.47, 35.80, 116.24, 
127.21, 129.59, 140.88, 151.75, 163.62. 
IR (ATR): 𝜈 (cm-1) = 3063 (w), 3019 (w), 2919 (w), 2864 (w), 2854 (w), 2834 (w), 1692 (s), 
1657 (vs), 1637 (vs), 1572 (w), 1509 (w), 1452 (s), 1428 (s), 1372 (m), 1341 (s), 1308 (w), 
1296 (w), 1288 (w), 1248 (w), 1235 (m), 1221 (m), 1189 (w), 1173 (m), 1154 (w), 1132 (w), 
1089 (m), 1058 (w), 1026 (m), 999 (w), 990 (w), 975 (m), 948 (m), 931 (w), 918 (w), 893 
(w), 883 (m), 862 (w), 853 (w), 821 (w), 785 (m), 767 (m), 752 (s), 738 (s), 726 (s), 674 (m). 
m.p.: 74 – 76 °C 
7.10.6 Preparation of 5-(furan-2-carbonyl)-1,3-dimethyluracil 
(36f)  
To a solution of 1,3-dimethyluracil (34, 350 mg, 2.5 mmol) in THF (1 mL) 
was added TMPMgCl·LiCl (1, 2.5 mL, 1.2 м in THF, 2.5 mmol, 1 equiv.) 
at −40 °C. The reaction mixture was stirred for 24 h according to TP5. To the freshly 
prepared magnesium reagent was added CuCN·2LiCl (2.5 mL, 1 м solution in THF, 
2.5 mmol, 1 equiv.) and the reaction mixture was stirred for 30 min. Acylation was achieved 
by adding furoyl chloride (393 mg, 2.4 mmol) at −40 °C and warming up to −10 °C within 12 
h. The crude product was purified by flash column chromatography (SiO2, 
EtOAc:i-hexane:Et3N 1:9:0.05 to 3:7:0.05) furnishing compound 36f (391, 1.7 mmol, 66%) as 
a colorless solid. 
HRMS (ESI) for C11H10N2O4: calcd. 234.2110, found 234.0623. 
1
H NMR (400 MHz, DMSO-d6) δ =3.17 (s, 3 H), 3.37 (s, 3 H), 6.71 (dd, J=3.61, 1.66 Hz, 1 
H), 7.38 (dd, J=3.70, 0.78 Hz, 1 H), 8.01 (dd, J=1.75, 0.78 Hz, 1 H), 8.28 (s, 1 H). 
13
C NMR (101 MHz, DMSO-d6) δ = 28.06, 37.40, 111.31, 112.95, 121.38, 148.63, 149.14,  
151.31, 152.03, 160.41, 177.02.  
IR (ATR): 𝜈 (cm-1) = 3142.00 (w), 3129.00 (w), 3097.00 (w), 2952.00 (w), 1706.00 (m), 
1695.00 (m), 1658.00 (s), 1647.00 (s), 1600.00 (m), 1554.00 (m), 1520.00 (w), 1470.00 (m), 
1458.00 (m), 1437.00 (s), 1401.00 (m), 1390.00 (s), 1364.00 (s), 1297.00 (s), 1243.00 (m), 
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1208.00 (m), 1167.00 (m), 1121.00 (m), 1097.00 (m), 1041.00 (s), 998.00 (m), 940.00 (s), 
923.00 (m), 893.00 (m), 881.00 (s), 863.00 (m), 818.00 (s), 787.00 (s), 773.00 (s), 753.00 
(vs), 697.00 (m), 683.00 (s). 
m.p.: 139 - 140°C 
 
7.10.7 Preparation of 5-(cyclopropanecarbonyl)-1,3-dimethyluracil (36g) 
To a solution of 1,3-dimethyluracil (34, 140 mg, 1.0 mmol) in THF (1 mL) 
was added TMPMgCl·LiCl (1, 1 mL, 1.2 м in THF, 1.2 mmol, 1.2 equiv.) at 
−40 °C. The reaction mixture was stirred for 24 h according to TP5. To the 
freshly prepared magnesium reagent was added CuCN·2LiCl (1.2 mL, 1 м solution in THF, 
1.2 mmol) and the reaction mixture was stirred for 30 min. Acylation was achieved by adding 
cyclopropanecarbonyl chloride (125 mg, 1.2 mmol, 1.2 equiv.) at -40 °C and warming up to -
20 °C within 12 h. The crude product was purified by flash column chromatography (SiO2, 
EtOAc:i-hexane:Et3N 1:9:0.05 to 3:7:0.05) furnishing compound 36g (148 mg, mmol, 0.71 
mmol, 71%) as a colorless solid. 
HRMS (ESI) for C10H12N2O3: calcd. 208.2139, found 208.2139. 
1
H NMR (400 MHz, acetone) δ = 0.88 - 0.94 (m, 2 H), 0.94 - 1.00 (m, 2 H), 3.27 (s, 3 H), 
3.30 - 3.43 (m, 1 H), 3.52 (s, 3 H), 8.25 (s, 1 H). 
13
C NMR (101 MHz, acetone) δ = 11.06, 18.37, 27.18, 36.88, 110.84, 149.81, 149.82, 
161.37, 196.07. 
IR (ATR): 𝜈 (cm-1) = 3103.00 (vw), 3057.00 (w), 3006.00 (w), 2958.00 (w), 1704.00 (m), 
1659.00 (m), 1644.00 (s), 1594.00 (s), 1516.00 (m), 1476.00 (m), 1442.00 (s), 1424.00 (m), 
1417.00 (m), 1391.00 (m), 1351.00 (m), 1338.00 (s), 1197.00 (m), 1186.00 (m), 1119.00 (m), 
1086.00 (m), 1071.00 (m), 1064.00 (w), 1047.00 (m), 1030.00 (m), 996.00 (s), 987.00 (s), 
972.00 (m), 887.00 (s), 778.00 (vs), 758.00 (vs), 693.00 (m), 665.00 (m). 
m.p.: 154 - 156 °C 
 
7.10.8 Preparation of 5-(4-chlorophenyl)-1,3-dimethyluracil (36h) 
To a solution of 1,3-dimethyluracil (34, 140 mg, 1.0 mmol) in THF 
(1 mL) was added TMPMgCl·LiCl (1, 1 mL, 1.2 м in THF, 1.2 mmol, 
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1.2 equiv.) at −40 °C. The reaction mixture was stirred for 24 h according to TP5, 
transmetalated to the corresponding zinc reagent by adding ZnCl2 (1.2 mL, 1 м solution in 
THF, 2.4 mmol, 1.2 equiv.) and reacted in a Negishi cross-coupling
 
reaction by adding 
Pd(dba)2 (11 mg, 2 mol%), P(2-furyl)3 (9 mg, 4 mol%)
[136]
 and p-chloro-iodobenzene (285 mg 
, 1.2 mmol) at 25 °C for 2 h. The crude product was purified by flash column chromatography 
(SiO2, EtOAc:i-hexane:Et3N 1:9:0.05 to 3:7:0.05) furnishing compound 36h (195 mg, 0.78 
mmol, 78%) as a colorless solid. 
HRMS (EI) for C12H11ClN2O2: calcd. 250.6809 (M
+
); found 250.0499.  
MS (70 eV, EI) m/z (%): 252 (30), 251 (12), 250 (100), 193 (22), 154 (12), 151 (38). 
1
H-NMR (300 MHz, DMSO-d6) δ = 3.22 (s, 3 H), 3.37 (s, 3 H), 7.43 (m, J=8.57 Hz, 2 H), 
7.60 (m, J=8.85 Hz, 2 H), 8.03 (s, 1 H). 
13
C-NMR (75 MHz, DMSO-d6) δ = 28.22, 36.99, 110.53, 128.49, 130.07, 132.11, 132.84, 
143.39, 151.32, 162.05. 
IR (ATR): 𝜈 (cm-1) = 2945 (w), 2922 (m), 2852 (w), 1692 (s), 1644 (vs), 1488 (m), 1451 (s), 
1404 (m), 1357 (s), 1290 (m), 1210 (m), 1124 (m), 1115 (m), 1094 (m), 1006 (m), 970 (m), 
932 (m), 842 (s), 835 (s), 822 (s), 774 (s), 753 (vs), 720 (m), 704 (m). 
m.p.: 171 - 173 °C 
 
7.10.9 Preparation of 4-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-
yl)benzonitrile (36i) 
To a solution of 1,3-dimethyluracil (34, 280 mg, 2.0 mmol) in THF 
(2 mL) was added TMPMgCl·LiCl (1, 2 mL, 2.4 м in THF, 2.4 mmol, 
1.2 equiv.) at −40 °C. The reaction mixture was stirred for 24 h 
according to TP5. The freshly prepared magnesium reagent was transmetalated to the 
corresponding zinc reagent by adding ZnCl2 (2.4 mL, 1 м solution in THF, 2.4 mmol, 1.2 
equiv.) and reacted in a Negishi cross-coupling
 
reaction by adding Pd(OAc)2 (9 mg, 2%), 
XantPhos (46 mg, 4%) and p-bromobenzonitrile (436 mg, 2.4 mmol, 1.2 equiv.) at 50 °C for 
3 days. The crude product was purified by flash column chromatography (SiO2, 
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EtOAc:i-hexane:Et3N 1:9:0.05 to 3:7:0.05) furnishing compound 36i (375 mg, 1.5 mmol, 
78%) as a yellow solid. 
HRMS (EI) for C13H11N3O2: calcd. 241.2453 (M
+
); found 241.0843.  
MS (70 eV, EI) m/z (%): 242 (15), 241 (100), 184 (20), 183 (60), 127 (18), 115 (13), 41 (60). 
1
H-NMR (400 MHz, DMSO-d6) δ = 3.25 (s, 3 H), 3.41 (s, 3 H), 7.84 (m, 4 H), 8.22 (s, 1 H). 
13
C-NMR (101 MHz, DMSO-d6) δ = 28.30, 37.21, 109.78, 109.91, 119.41, 128.81, 132.46,  
139.04, 144.82, 151.26, 161.85. 
IR (ATR): 𝜈 (cm-1) = 3106 (w), 3076 (w), 3005 (w), 2954 (w), 2225 (m), 1706 (s), 1648 (vs), 
1606 (s), 1508 (m), 1480 (s), 1451 (s), 1428 (s), 1409 (s), 1395 (m), 1366 (m), 1345 (s), 1321 
(m), 1295 (m), 1265 (m), 1200 (m), 1186 (m), 1117 (m), 1004 (m), 968 (m), 916 (s), 840 (s), 
832 (m), 770 (m), 753 (s), 737 (s), 704 (m), 687 (m). 
m.p.: 213 - 215 °C 
 
7.10.10 Preparation of 1,3-dimethyl-5-(1-(phenylsulfonyl)-1H-indol-3-
yl)uracil (36j) 
To a solution of 1,3-dimethyluracil (34, 280 mg, 2.0 mmol) in THF 
(2 mL) was added TMPMgCl·LiCl (1, 2 mL, 1.2 м in THF, 2.4 mmol, 
1.2 equiv.) at −40 °C. The reaction mixture was stirred for 24 h 
according to TP5, transmetalated to the corresponding zinc reagent by 
adding ZnCl2 (2.4 mL, 1 м solution in THF, 2.4 mmol, 1.2 equiv.) and reacted in a Negishi 
cross-coupling
 
reaction by adding Pd(dba)2 (22 mg, 2 mol%), P(2-furyl)3 (19 mg, 4 mol%) 
and 3-iodo-1-(phenylsulfonyl)-indole (920 mg , 2.4 mmol, 1.2 equiv.) at 25 °C for 12 h. The 
crude product was purified by flash column chromatography (SiO2, EtOAc:i-hexane:Et3N 
1:1:0.01 furnishing compound 36j (578 mg, 1.46 mmol, 73%) as a colorless solid. 
HRMS (EI) for C20H17N3O4S: calcd. 395.4317 (M
+
); found 395.0930. 
MS (70 eV, EI) m/z (%): 396 (9), 395 (41), 255 (18), 254 (100), 197 (39), 156 (22), 128 (12). 
1
H-NMR (400 MHz, CDCl3) δ = 3.43 (s, 3 H), 3.49 (s, 3 H), 7.24 - 7.28 (m, 1 H), 7.31 - 7.36 
(m, 1 H), 7.40 - 7.46 (m, 2 H), 7.50 - 7.56 (m, 3 H), 7.90 - 7.94 (m, 2 H), 8.01 (s, 1 H), 8.03 
(d, J=8.14 Hz, 1 H). 
13
C-NMR (101 MHz, CDCl3) δ = 28.35, 37.30, 106.82, 113.81, 114.01, 120.07, 123.56, 
124.95, 125.56, 126.87, 128.84, 129.34, 133.94, 134.84, 137.97, 140.09, 151.12, 162.00.  
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IR (ATR): 𝜈 (cm-1) = 3170 (vw), 3091 (vw), 3065 (vw), 2955 (vw), 2923 (vw), 2851 (vw), 
1699 (s), 1653 (s), 1578 (w), 1546 (w), 1485 (w), 1456 (m), 1446 (s), 1428 (w), 1405 (vw), 
1362 (m), 1353 (s), 1332 (m), 1312 (w), 1264 (w), 1209 (m), 1183 (m), 1171 (s), 1162 (s), 
1141 (s), 1115 (s), 1100 (m), 1083 (m), 1032 (w), 1026 (w), 1021 (w), 1004 (m), 976 (m), 
942 (w), 930 (w), 907 (m), 859 (w), 847 (w), 823 (w), 816 (m), 772 (m), 752 (s), 742 (vs), 
726 (vs), 709 (w), 685 (s), 663 (s). 
m.p.: 108 °C 
7.10.11 Preparation of 5-(3-fluoro-6-methoxyquinolin-4-yl)-1,3-
dimethyluracil (36k)  
To a solution of 1,3-dimethyluracil (34, 280 mg, 2.0 mmol) in THF 
(2 mL) was added TMPMgCl·LiCl (1, 2 mL, 1.2 м in THF, 2.4 mmol, 
1.2 equiv.) at −40 °C. The reaction mixture was stirred for 24 h 
according to TP5. The magnesium reagent was transmetalated to the 
corresponding zinc reagent by adding ZnCl2 (2.4 mL, 1 м solution in THF, 2.4 mmol, 
1.2 equiv.) and reacted in a Negishi cross-coupling
 
reaction by adding Pd(dba)2 (22 mg, 
2 mol%), P(2-furyl)3 (19 mg, 4 mol%) and 3-fluoro-4-iodo-6-methoxyquinoline (727 mg, 
2.4 mmol, 1.2 equiv.) at 25 °C for 12 h. The crude product was purified by flash column 
chromatography (SiO2, EtOAc:i-hexane:Et3N 1:1:0.01 furnishing compound 36k (358 mg, 
1.14 mmol, 56%) as a colorless solid. 
MS (70 eV, EI) m/z (%): 316 (18), 315 (100), 314 (27), 300 (17), 272 (10).  
HRMS (EI) for C16H14FN3O3: calcd. 315.2991 (M
+
); found 315.1015.
 
1
H-NMR (400 MHz, CDCl3) δ = 3.45 (s, 3 H), 3.50 (s, 3 H), 3.85 (s, 3 H), 6.85 (d, J=2.73 
Hz, 1 H), 7.32 (dd, J=9.16, 2.73 Hz, 1 H), 7.35 (s, 1 H), 8.01 (d, J=9.16 Hz, 1 H), 8.68 (s, 1 
H).
 
 
13
C-NMR (101 MHz, CDCl3) δ = 28.41, 37.40, 55.64, 103.25 (d, J= 5.37 Hz), 104.16, (s, 1 
C) 120.63 (d, J= 2.69 Hz), 121.60 (d, J=12.76 Hz),  129.37, 131.52, 138.25 (d, J=28.79 Hz),   
141.67, 143.76 (d, J=1.15 Hz),  151.51, 154.43 (d, J=255 Hz),  158.89, 161.07. 
IR (ATR): 𝜈 (cm-1) = 3341 (vw), 3106 (vw), 2952 (w), 2842 (w), 1701 (m), 1649 (vs), 1621 
(s), 1510 (m), 1476 (m), 1447 (m), 1432 (s), 1393 (m), 1377 (m), 1356 (m), 1344 (s), 1299  
(m), 1259 (w), 1227 (s), 1196 (s), 1162 (m), 1130 (s), 1091 (s), 1059 (m), 1029 (m), 1013 (s), 
964 (m), 931 (m), 921 (m), 881 (m), 846 (m), 834 (s), 804 (s), 790 (s), 777 (m), 758 (vs), 713 
(m), 694 (m), 656 (m). 
 D. Experimental Section 
 
114 
m.p.: 208 - 210 °C. 
7.10.12 Preparation of 1,3-Dimethyl-5-pivaloyluracil (36l)  
To a solution of 1,3-dimethyluracil (34, 140 mg, 1.0 mmol) in THF (1 mL) 
was added TMPMgCl·LiCl (1, 1 mL, 1.2 м in THF, 1.2 mmol) at −40 °C. 
The reaction mixture was stirred for 24 h according to TP5. To the freshly 
prepared magnesium reagent was added CuCN·2LiCl (1.2 mL, 1 м solution in THF, 
1.2 mmol, 1.2 equiv.) and the reaction mixture was stirred for 30 min. Acylation was achieved 
by adding pivaloyl chloride (145 mg, 1.2 mmol, 1.2 equiv.) at −40 °C and warming up to 
−20 °C within 12 h. The crude product was purified by flash column chromatography (SiO2, 
EtOAc:i-hexane:Et3N 1:9:0.05 to 3:7:0.05) furnishing the compound 36l (187 mg, 0.83 mmol, 
83%) as a colorless solid. 
HRMS (EI) for C11H16N2O3: calcd. 224.2563 (M
+
); found 224.1157. 
MS (70 eV, EI) m/z (%): 167 (28), 167 (100), 140 (34), 57 (13), 42 (66), 40 (16). 
1
H-NMR (300 MHz, DMSO-d6) δ = 1.17 (s, 9 H), 3.17 (s, 3 H), 3.33 (s, 3 H), 7.95 (s, 1 H). 
13
C-NMR (75 MHz, DMSO-d6) δ = 26.66, 28.08, 37.19, 44.46, 113.99, 146.33, 151.31, 
160.79, 206.09.  
IR (ATR): 𝜈 (cm-1) = 3067 (w), 2963 (w), 2926 (w), 2872 (w), 1777 (w), 1705 (s), 1651 (vs), 
1609 (s), 1520 (m), 1478 (m), 1443 (s), 1390 (m), 1356 (s), 1342 (s), 1284 (m), 1221 (m), 
1179 (m), 1049 (m), 1026 (w), 986 (s), 967 (s), 941 (m), 934 (m), 846 (m), 794 (m), 785 (m), 
760 (s), 738 (m), 663 (w). 
m.p.: 103 - 105 °C 
  
7.10.13 Preparation of 6-Iodo-1,3-dimethyluracil (38a)  
38a was prepared according to TP6 from 1,3-dimethyluracil (34, 140 mg, 
1.0 mmol) dissolved in THF (1.0 mL). TMP2Zn·2MgCl2·2LiCl (4, 1 mL, 0.71 м 
in THF, 0.7 mmol, 0.7 equiv.) was added at −30 °C to the solution, stirred for 
48 h and reacted with iodine (1.2 mL, 1 м in THF, 1.2 mmol). The crude product 
was purified by flash column chromatography (SiO2, EtOAc:i-hexane:Et3N 1:9:0.5) yielding 
compound 38a (216 mg, 0.81 mmol, 81%) as a colorless solid. 
HRMS (EI) for C6H7IN2O2: calcd. 266.0365 (M
+
); found 265, 9536. 
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MS (70 eV, EI) m/z (%): 267 (6), 266 (95), 83 (4), 82 (100), 57 (6), 54 (8), 52 (6).  
1
H-NMR (300 MHz, DMSO-d6) δ = 3.10 (s, 3 H), 3.52 (s, 3 H), 6.41 (s, 1 H). 
13
C-NMR (75 MHz, DMSO-d6) δ = 28.24, 41.68, 112.99, 116.97, 149.99, 161.23. 
IR (ATR): 𝜈 (cm-1) = 3092.00 (m), 1684.00 (s), 1652.00 (s), 1647.00 (s), 1631.00 (vs), 
1617.00 (s), 1576.00 (s), 1429.00 (s), 1423.00 (vs), 1377.00 (s), 1353.00 (s), 1282.00 (m), 
1232.00 (m), 1228.00 (m), 1205.00 (m), 1158.00 (m), 1109.00 (m), 1056.00 (w), 1007.00 
(m), 951.00 (m), 845.00 (m), 831.00 (m), 751.00 (vs), 691.00 (m) 
m.p.: 183 - 184 °C. 
 
7.10.14 Preparation of ethyl 2-((1,3-dimethyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)methyl)acrylate (38b)  
38b was prepared from 1,3-dimethyluracil (34, 140 mg, 1.0 mmol) 
dissolved in THF (1 mL). TMP2Zn·2MgCl2·2LiCl (4, 1 mL, 0. 71 м in 
THF, 0.7 mmol, 0.7 equiv.) was added at −30 °C to the solution, 
according to TP6 and stirred for 48 h. The freshly prepared zinc reagent 
was transmetalated to copper by adding CuCN·2LiCl (1.2 mL, 1 м solution in THF 1.2 mmol, 
1.2 equiv.) and stirring for 30 min. Allylation was achieved by adding ethyl 
2-(bromomethyl)acrylate (231 mg, 1.2 mmol) at −40 °C, stirring for 10 min at –40 °C and 1 h 
at 25 °C. The crude product was purified by flash column chromatography (SiO2, 
EtOAc:i-hexane:Et3N 1:10: to EtOAc:i-hexane 3:7) providing compound 38b (175 mg, 
0.69 mmol, 69%) as a colorless solid. 
HRMS (EI) for C12H16N2O4: calcd. 252.2664 (M
+
); found 252.1104.  
MS (70 eV, EI) m/z (%): 252 (38), 223 (65), 179 (86), 150 (26), 149 (21), 122 (40), 94 (32), 
82 (60), 46 (37). 
1
H-NMR (300 MHz, DMSO-d6) δ = 1.21 (t, J=7.05 Hz, 3 H), 3.14 (s, 3 H), 3.25 (s, 3 H), 3.57 
(s, 2 H), 4.16 (q, J=7 Hz, 2 H), 5.47 (s, 1 H), 5.73 (d, J=0.55 Hz, 1 H), 6.28 (d, J=0.55 Hz, 1 
H). 
13
C-NMR (75 MHz, DMSO-d6) δ =14.43, 27.92, 31.76, 34.42, 61.35, 100.79, 128.52, 135.64, 
152.50, 153.49, 161.94, 165.81.  
IR (ATR): 𝜈 (cm-1) = 3111 (vw), 3000 (w), 2970 (w), 2939 (w), 1711 (s), 1690 (vs), 1647 
(vs), 1630 (s), 1624 (s), 1467 (s), 1445 (s), 1433 (s), 1412 (m), 1407 (m), 1388 (s), 1367 (m), 
1337 (s), 1307 (m), 1237 (s), 1211 (m), 1172 (s), 1148 (s), 1096 (m), 1015 (m), 993 (m), 982 
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(s), 957 (m), 933 (m), 897 (m), 879 (m), 858 (m), 835 (s), 829 (s), 825 (s), 790 (m), 754 (vs), 
664 (m). 
m.p.: 67 - 68 °C 
7.10.15  Preparation of 6-benzoyl-1,3-dimethyluracil (38c)  
38c was prepared from 1,3-dimethyluracil (34, 140 mg, 1.0 mmol) 
dissolved in THF (1 mL). TMP2Zn·2MgCl2·2LiCl (4, 1 mL, 0.7 м in THF, 
0.7 mmol, 0.7 equiv.) was added to the solution at −30 °C according to 
TP6 and stirred for 48 h. The freshly prepared zinc reagent was 
transmetalated to copper by adding CuCN·2LiCl (1 м solution in THF, 1.2 mL, 1.2 mmol, 1.2 
equiv.) and stirring for 30 min. Acylation was achieved by adding benzoyl chloride (168 mg, 
1.2 mmol) at −40 °C and warming up to −8 °C within 12 h. The crude product was purified by 
flash column chromatography (SiO2, EtOAc:i-hexane:Et3N 1:9:0.5 to 3:7:0.5) providing 
compound 38c (204 mg, 0.84 mmol, 84%) as a colorless oil. 
HRMS (EI) for C13H12N2O3: calcd. 244.2460 (M
+
); found 244.0845. 
MS (70 eV, EI) m/z (%): 244 (62), 216 (37), 215 (42), 159 (19), 158 (21), 105 (100), 82 (81), 
77 (63). 
1
H-NMR (300 MHz, DMSO-d6) δ = 3.09 (s, 3 H), 3.21 (s, 3 H), 5.85 (s, 1 H), 7.46 - 7.70 (m, 
2 H), 7.70 - 7.89 (m, 1 H), 7.92 - 8.13 (m, 2 H). 
13
C-NMR (75 MHz, DMSO-d6) δ = 28.09, 33.72, 100.86, 129.77, 130.68, 134.27, 136.01, 
150.28, 151.93, 162.07, 189.50.  
IR (ATR): 𝜈 (cm-1) = 3706 (vw), 3086 (vw), 3064 (vw), 2954 (vw), 1705 (s), 1651 (vs), 1594 
(s), 1580 (m), 1519 (w), 1476 (m), 1446 (s), 1432 (s), 1399 (m), 1364 (s), 1312 (m), 1252 (s), 
1210 (m), 1180 (m), 1159 (m), 1073 (w), 1053 (w), 1024 (w), 994 (m), 914 (m), 844 (m), 827 
(m), 805 (m), 758 (s), 726 (s), 699 (s), 687 (s), 668 (s). 
7.10.16 Preparation of 6-(4-methoxyphenyl)-1,3-
dimethyluracil (38d) 
38d was prepared according to TP6 from 1,3-dimethyluracil (34, 
140 mg, 1.0 mmol) dissolved in THF (1.0 mL). TMP2Zn·2MgCl2·2LiCl 
(4, 1 mL, 0.71 м in THF, 0.7 mmol, 0.7 equiv.) was added to the solution at −30 °C and 
stirred for 48 h. The zinc reagent reacted in a Negishi cross-coupling reaction by adding 
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Pd(dba)2 (22 mg, 2 mol%), P(2-furyl)3 (19 mg, 4 mol%) and p-methoxyiodobenzene (280 mg, 
1.2 mmol) within 2 h at 25 °C. The crude product was purified by flash column 
chromatography (SiO2, EtOAc:i-hexane:Et3N 2:8:0.5) yielding compound 38d (207 mg, 0.84 
mmol, 84%) as a colorless solid. 
HRMS (EI) for C13H14N2O3: calcd. 246.2619 (M
+
); found 246.0996. 
MS (70 eV, EI) m/z (%): 247 (16), 246 (100), 245 (85), 188 (26), 160 (11), 133 (11). 
1
H-NMR (400 MHz, MeOH-d4) δ = 3.19 (s, 3 H), 3.29 (s, 3 H), 3.82 (s, 3 H), 5.59 (s, 1 H), 
7.01 (m, J=8.80 Hz, 2 H), 7.34 (m, J=8.80 Hz, 2 H). 
13
C-NMR (101 MHz, MeOH-d4) δ = 26.96, 33.84, 54.59, 101.00, 113.91, 125.34, 129.28, 
152.64, 155.84, 161.21, 163.24. 
IR (ATR): 𝜈 (cm-1) = 2954 (w), 2923 (w), 2869 (w), 2846 (w), 1699 (m), 1687 (s), 1645 (vs), 
1603 (s), 1570 (m), 1514 (s), 1443 (s), 1429 (s), 1414 (s), 1391 (m), 1368 (s), 1299 (m), 1254 
(s), 1226 (m), 1206 (m), 1178 (s), 1164 (m), 1151 (m), 1119 (m), 1027 (s), 1015 (m), 1010 
(m), 1001 (s), 846 (s), 839 (s), 813 (vs), 791 (m), 761 (vs), 738 (m), 716 (m), 704 (m), 699 
(m), 688 (m), 659 (m). 
m.p.: 88 – 89 °C 
7.10.17 Preparation of (E)-1,3-dimethyl-6-(3-oct-1-en) uracil (38e) 
38e was prepared according to TP6 from 1,3-dimethyluracil (34, 
140 mg, 1.0 mmol) dissolved in THF (1.0 mL). 
TMP2Zn·2MgCl2·2LiCl (4, 1 mL, 0.71 м in THF, 0.7 mmol, 0.74 
equiv.) was added to the solution at −30 °C and stirred for 48 h. The 
zinc reagent reacted in a Negishi cross-coupling reaction by adding Pd(dba)2 (11 mg, 
4 mol%), P(2-furyl)3 (9.5 mg, 2 mol%) and (141 mg, 0.59 mmol, 1.2 equiv.) within 2 h at 
25 °C. The crude product was purified by flash column chromatography (SiO2, EtOAc:i-
hexane:Et3N 2:8:0.5) yielding compound 38e (185 mg, 0.74 mmol, 74%) as a colorless oil. 
HRMS (EI) for C13H14N2O3: calcd. 250.168 (M
+
), found 250.1683. 
MS (70 eV, EI) m/z (%): 250 (60), 207 (12), 194 (13), 193 (100), 180 (11), 167 (30). 
1
H-NMR (400 MHz, MeOH-d4) δ =6.33 (m, 1H), 6.13 (m, 1H), 5.74 (s, 1H), 3.37 (s, 3H), 
3.32 (s, 3H), 2.21 (m, 2H), 1.57-1.18 (m, 8H), 0.96-0.76 (m, 3H). 
13
C-NMR (101 MHz, MeOH-d4) δ =162.69, 152.35, 152.07, 142.13, 121.29, 98.42, 32.92, 
32.25, 31.48, 28.69, 28.33, 27.84, 22.47, 14.09. 
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IR (ATR): 𝜈 (cm-1) = 3063 (w), 3019 (w), 2919 (w), 2864 (w), 2854 (w), 2834 (w), 1692 (s), 
1657 (vs), 1637 (vs), 1572 (w), 1509 (w), 1452 (s), 1428 (s), 1372 (m), 1341 (s), 1308 (w), 
1296 (w), 1288 (w), 1248 (w), 1235 (m), 1221 (m), 1189 (w), 1173 (m), 1154 (w), 1132 (w), 
1089 (m), 1058 (w), 1026 (m), 999 (w), 990 (w), 975 (m), 948 (m), 931 (w), 918 (w), 893 
(w), 883 (m), 862 (w), 853 (w), 821 (w), 785 (m), 767 (m), 752 (s), 738 (s), 726 (s), 674 (m). 
m.p.: 67 - 68 °C 
7.10.18 Preparation of 6-iodo-1,3-bis(methoxymethyl)uracil (43a) 
To a solution of 1,3-bis(methoxymethyl) uracil (40, 400 mg, 2 mmol) was 
added TMP2Zn·2MgCl2·2LiCl (4, 1.7 mL, 0.71 м in THF, 1.2 mmol) at 
−30 °C. The reaction mixture was stirred for 48 h according to TP7 and reacted 
with iodine (2.4 mL, 1 м in THF, 2.4 mmol). The crude product was purified by flash column 
chromatography (SiO2, EtOAc:i-hexane:Et3N 1:9:0.05) yielding compound 43a (457 mg, 
1.40 mmol, 70%) as a yellow solid. 
HRMS (EI) for C8H11IN2O4: calcd. 326.0884 (M
+
); found 325.9749. 
MS (70 eV, EI) m/z (%):  326 (4), 311 (8), 296 (10), 283 (33), 251 (6), 222 (9), 86 (5), 56 (5), 
45 (100). 
1
H-NMR (200 MHz, CDCl3) δ = 3.39 (s, 3 H), 3.41 (s, 3 H), 5.30 (s, 2 H), 5.43 (s, 2 H), 6.49 
(s, 1 H). 
13
C-NMR (101 MHz, CDCl3) δ = 57.14, 57.93, 72.59, 82.52, 110.67, 116.25, 149.93, 160.56.  
IR (ATR): 𝜈 (cm-1) = 2958 (vw), 2935 (vw), 2834 (vw), 1706 (m), 1650 (vs), 1576 (m), 1436 
(m), 1419 (s), 1402 (m), 1371 (s), 1350 (m), 1330 (m), 1303 (w), 1248 (w), 1194 (m), 1181 
(m), 1156 (m), 1100 (s), 1087 (s), 1018 (m), 983 (m), 926 (m), 913 (s), 817 (s), 772 (s), 724 
(m), 671 (s). 
m.p.:90 - 92 °C 
 
7.10.19 Preparation of 1,3-bis(methoxymethyl)-6-pivaloylpyrimidine-
2,4(1H,3H)-dione (43b) 
To a solution of 1,3-bis(methoxymethyl) uracil (40, 800 mg, 4 mmol) was 
added TMP2Zn·2MgCl2·2LiCl (4, .4 mL, 0. 71 м in THF, 2.4 mmol, 2.4 
equiv.) at –30 °C. The reaction mixture was stirred for 48 h according to 
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TP7. The zinc reagent 44 was treated with CuCN·2LiCl (4.8 mL, 1 м solution in THF, 
4.8 mmol, 1.2 equiv.) for 30 min at −40 °C. Acylation was achieved by adding pivaloyl 
chloride (576 mg, 4.8 mmol) at −40 °C and warming up to −10 °C over 12 h. The reaction 
mixture was stirred at −10 °C until completion of the reaction. The crude product was purified 
by flash column chromatography (SiO2, EtOAc:i-hexane:Et3N) yielding compound 43b 
(778 mg, 2.7 mmol, 68%) as a yellow liquid. 
HRMS (EI) for C13H20N2O5: calcd. 284.3083 (M
+
); found 284.1360. 
MS (70 eV, EI) m/z (%): 252 (9), 241 (11), 209 (8), 140 (6), 138 (18), 73 (8), 57 (25), 45 
(100).  
1
H-NMR (300 MHz, CDCl3) δ = 1.28 (d, J=1.11 Hz, 9 H), 3.31 (d, J=1.11 Hz, 3 H), 3.43 (d, 
J=1.11 Hz, 3 H), 5.17 (d, J=1.11 Hz, 2 H), 5.35 (d, J=1.11 Hz, 2 H), 5.77 (d, J=0.83 Hz, 1 H). 
13
C-NMR (75 MHz, CDCl3) δ = 27.49, 44.71, 56.74, 57.94, 72.25, 74.72, 100.04, 148.98, 
151.67, 161.56, 205.3. 
IR (ATR): 𝜈 (cm-1) = 2972 (w), 2832 (vw), 1720 (m), 1696 (m), 1665 (vs), 1617 (m), 1447 
(s), 1414 (m), 1383 (m), 1366 (m), 1335 (s), 1252 (w), 1226 (w), 1196 (m), 1171 (m), 1150 
(m), 1086 (vs), 1039 (m), 1023 (w), 986 (m), 915 (s), 844 (m), 828 (m), 799 (w), 779 (m), 767 
(m), 739 (w), 683 (w). 
 
7.10.20 Preparation of 6-(cyclopropanecarbonyl)-1,3-
bis(methoxymethyl)pyrimidine-2,4(1H,3H)-dione (43c)  
To a solution of 1,3-bis(methoxymethyl) uracil (40, 100 mg, 0.5 mmol) 
was added TMP2Zn·2MgCl2·2LiCl (4, 0.5 mL, 0.71 м in THF, 0.3 mmol, 
0.6 equiv.) at −30 °C. The reaction mixture was stirred for 48 h according 
to TP7.  The zinc reagent 44 was treated with CuCN·2LiCl (0.6 mL, 1 м solution in THF, 
0.6 mmol, 1.2 equiv.) for 30 min at −40 °C. Acylation was achieved by adding 
cyclopropaneyl chloride (62 mg, 0.6 mmol, 1.2 equiv.) at −40 °C and warming up to –10 °C 
over 12 h. The reaction mixture was stirred at –10 °C until completion of the reaction. The 
crude product was purified by flash column chromatography (SiO2, EtOAc:i-hexane:Et3N) 
yielding compound 43c (61 mg, 0.23 mmol, 45%) as a yellow liquid. 
HRMS (EI) for C12H16N2O5: calcd. 268.2658 (M
+
); found 268.1057. 
MS (70 eV, EI) m/z (%): 238 (6), 237 (4), 236 (10), 225 (7), 180 (5), 164 (15), 150 (4), 69 
(12), 45 (100). 
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1
H-NMR (300 MHz, CDCl3) δ = 1.10 - 1.24 (m, 2 H), 1.24 - 1.37 (m, 2 H), 2.16 - 2.37 (m, 1 
H), 3.32 (s, 3 H), 3.46 (s, 3 H), 5.36 (s, 2 H), 5.40 (s, 2 H), 6.13 (s, 1 H). 
13
C-NMR (75 MHz, CDCl3) δ = 13.76, 20.81, 56.57, 57.98, 72.33, 74.75, 103.35, 150.09, 
151.69, 161.92, 197.34. 
IR (ATR): 𝜈 (cm-1) = 3092 (vw), 2941 (w), 2831 (vw), 1720 (m), 1665 (vs), 1619 (m), 1450 
(m), 1415 (m), 1373 (s), 1335 (s), 1250 (w), 1195 (m), 1172 (m), 1158 (m), 1085 (s), 1030 
(m), 989 (m), 948 (s), 916 (s), 884 (m), 843 (m), 828 (m), 768 (m), 758 (m), 740 (m), 697 
(m). 
 
7.10.21 Preparation of 1,3-bis(methoxymethyl)-6-(2-
methylbenzoyl)pyrimidine-2,4(1H,3H)-dione (43d) 
To a solution of 1,3-bis(methoxymethyl) uracil (40, 100 mg, 0.5 mmol) 
was added TMP2Zn·2MgCl2·2LiCl (4, 0.4 mL, 0. 71 м in THF, 
0.3 mmol, 0.6 equiv.) at –30 °C. The reaction mixture was stirred for 48 h 
according to TP7. The zinc reagent 44 was treated with CuCN·2LiCl (0.6 mL, 1 м solution in 
THF, 0.6 mmol) for 30 min at −40 °C. Acylation was achieved by adding 2-methylbenzoyl 
chloride (93 mg, 0.6 mmol) at −40 °C and warming up to −10 °C over 12 h. The reaction 
mixture was stirred at −10 °C until completion of the reaction. The crude product was purified 
by flash column chromatography (SiO2, EtOAc:i-hexane:Et3N) yielding compound 43d 
(114 mg, 0.36 mmol, 72%) as a yellow liquid.
 
HRMS (EI) for C16H18N2O5: calcd. 318.3245 (M
+
); found 318.1207. 
MS (70 eV, EI) m/z (%): 286 (26), 231 (17), 214 (36), 199 (14), 119 (42), 105 (12), 91 (36), 
65(12), 45 (100). 
1
H-NMR (300 MHz, CDCl3) δ = 2.60 (s, 3 H), 3.28 (s, 3 H), 3.49 (s, 3 H), 5.40 (s, 2 H), 5.42 
(s, 2 H), 5.76 (s, 1 H), 7.27 - 7.38 (m, 2 H), 7.53 (dd, J=19.77, 7.60 Hz, 2 H). 
13
C-NMR (75 MHz, CDCl3) δ = 21.15, 56.53, 58.06, 72.37, 74.89, 104.99, 125.72, 132.06, 
132.32, 133.34, 133.57, 141.13, 149.75, 151.77, 161.70, 189.92. 
IR (ATR): 𝜈 (cm-1) = 3089 (vw), 2937 (w), 2830 (vw), 1718 (m), 1664 (vs), 1619 (m), 1600 
(m), 1570 (w), 1486 (w), 1450 (s), 1413 (m), 1381 (m), 1335 (s), 1303 (w), 1287 (w), 1241 
(s), 1194 (m), 1168 (m), 1146 (m), 1131 (w), 1088 (s), 1065 (m), 982 (m), 917 (s), 901 (s), 
832 (m), 801 (w), 782 (m), 767 (m), 741 (s), 685 (m), 666 (m). 
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7.10.22 Preparation of 1,3-bis(ethoxymethyl)-6-iodopyrimidine-2,4(1H,3H)-
dione (46a) 
To a solution of 1,3-bis(ethoxymethyl) uracil (41, 66 mg, 0.29 mmol) was 
added TMP2Zn·2MgCl2·2LiCl (4, 1 mL, 0. 35 м in THF, 0.35 mmol, 1.2 
equiv.) at −30 °C. The reaction mixture was stirred for 48 h according to 
TP8 and reacted with iodine (0.35 mL, 1 м in THF, 0.35 mmol, 1.2 equiv.). The crude 
product was purified by flash column chromatography (SiO2, EtOAc:i-hexane:Et3N 
1:10:0.05) yielding compound 46a (83 mg, 0.23 mmol, 81%) as a colorless liquid. 
HRMS (ESI) C10H15IN2O4: calcd. 354.14447 (M
+
); found 354.0322. 
1
H NMR (300 MHz, CDCl3) δ = 1.22 (m, 6 H), 3.41 - 3.77 (m, 4 H), 5.38 (s, 2 H), 5.50 (s, 2 
H), 6.52 (s, 1 H). 
13
C NMR (75 MHz, CDCl3) δ = 15.02, 15.16, 65.21, 66.03, 71.16, 81.09, 110.63, 116.32, 
149.96, 160.69, 
IR (ATR): 𝜈 (cm-1) = 3065 (w), 2975 (w), 2932 (w), 2884 (w), 1709 (m), 1653 (vs), 1587 
(m), 1485 (w), 1437 (m), 1425 (s), 1377 (s), 1348 (m), 1337 (m), 1308 (m), 1242 (m), 1186 
(m), 1161 (m), 1099 (s), 1083 (vs), 1024 (m), 1014 (m), 1007 (m), 981 (s), 928 (m), 865 (m), 
838 (m), 817 (m), 773 (s), 725 (m), 676 (m). 
 
7.10.23 Preparation of 1,3-Bis(ethoxymethyl)-6-pivaloylpyrimidine-
2,4(1H,3H)-dione (46b) 
 To a solution of 1,3-bis(ethoxymethyl) uracil (41, 66 mg, 0.29 mmol) was 
added TMP2Zn·2MgCl2·2LiCl (4, 1 mL, 0. 35 м in THF, 0.35 mmol, 1.2 
equiv.) at −30 °C. The reaction mixture was stirred for 48 h according to 
TP8. The freshly prepared zinc reagent was transmetalated to copper by adding CuCN·2LiCl 
(1 м solution in THF, 0.35 mL, 0.35 mmol, 1.2 equiv.) and stirring for 30 min. Acylation was 
achieved by adding pivaloyl chloride (36 mg, 0.3 mmol, 1.0 equiv.) at −40 °C and warming 
up to −10 °C over 12 h. The crude product was purified by flash column chromatography 
(SiO2, EtOAc:i-hexane:Et3N 9:1:0.05) yielding compound 46b (74 mg, 0.24 mmol, 82%) as a 
colorless liquid. 
HRMS (ESI) for C15H24N2O5Na
+
: calcd. 335.35522 (M+Na); found 335.15745. 
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1
H NMR (300 MHz, CDCl3) δ = 1.18 (q, J=7.00 Hz, 6 H), 1.29 (s, 9 H), 3.54 (q, J=6.91 Hz, 2 
H), 3.64 (q, J=7.00 Hz, 2 H), 5.21 (s, 2 H), 5.38 (s, 2 H), 5.75 (s, 1 H). 
13
C NMR (75 MHz, CDCl3) δ = 14.59, 15.12, 27.55, 44.63, 65.08, 65.98, 70.81, 73.14, 
100.05, 149.16, 151.69, 161.59, 205.59. 
IR (ATR): ?̃? (cm-1) =  2976 (w), 2935 (w), 2878 (vw), 1721 (m), 1671 (vs), 1616 (w), 1445 
(m), 1418 (w), 1395 (w), 1381 (w), 1367 (w), 1336 (m), 1238 (w), 1186 (w), 1153 (w), 1094 
(m), 985 (w), 920 (w), 843 (w), 829 (w), 801 (vw), 768 (w).  
 
7.10.24 Preparation of Ethyl 2-((1,3-bis(ethoxymethyl)-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)methyl)acrylate (46c)  
To a solution of 1,3-bis(ethoxymethyl) uracil (41, 66 mg, 0.29 mmol) 
was added TMP2Zn·2MgCl2·2LiCl (4, 1 mL, 0. 35 м in THF, 0.35 
mmol, 1.2 equiv.) at −30 °C. The reaction mixture was stirred for 48 h 
according to TP8. The freshly prepared zinc reagent was 
transmetalated to copper by adding CuCN·2LiCl (1 м solution in THF, 0.35 mL, 0.35 mmol, 
1.2 equiv.) and stirring for 30 min. Allylation was achieved by adding 
2-(bromomethyl)acrylate (68 mg, 0.35 mmol, 1.2 equiv.) at –40 °C, stirring for 10 min at 
−40 °C and 1 h at 25 °C. The crude product was purified by flash column chromatography 
(SiO2, EtOAc:i-hexane:Et3N 9:1:0.05) yielding compound 46c (66 mg, 0.19 mmol, 67%) as a 
colorless liquid. 
HRMS (ESI) for C16H24N2O6Na
+
: calcd. 363.36522 (M+Na); found 353.15217.  
1
H NMR (300 MHz, CDCl3) δ = 1.18 (t, J=7.05, 1.94 Hz, 3 H), 1.19 (t, J= 7.15 Hz, 3 H), 
1.28 (t, J=7.05 Hz, 3 H), 3.44 - 3.74 (m, 6 H), 4.20 (q, J=7.19 Hz, 2 H), 5.33 (s, 2 H), 5.37 (s, 
2 H), 5.55 (s, 1 H), 5.67 (s, 1 H), 6.40 (s, 1 H). 
13
C NMR (75 MHz, CDCl3) δ = 14.08, 14.98, 15.14, 33.56, 61.41, 64.99, 65.82, 70.72, 73.30, 
102.41, 128.66, 135.18, 152.78, 153.44, 161.98, 165.52. 
IR (ATR): 𝜈 (cm-1) = 3540 (vw), 2977 (w), 2932 (w), 2907 (w), 2877 (vw), 1710 (s), 1664 
(vs), 1444 (s), 1368 (m), 1351 (m), 1284 (m), 1245 (m), 1220 (m), 1150 (m), 1090 (vs), 1072 
(s), 1024 (s), 979 (m), 880 (m), 843 (m), 823 (m), 773 (m). 
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7.10.25 Preparation of Ethyl 4-(1,3-bis(ethoxymethyl)-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)benzoate (46d) 
To a solution of 1,3-bis(ethoxymethyl) uracil (41, 66 mg, 0.29 
mmol) was added TMP2Zn·2MgCl2·2LiCl (4, 1 mL, 0. 35 м in 
THF, 0.35 mmol, 1.2 equiv.) at −30 °C according to TP8. The zinc 
reagent reacted in a Negishi cross-coupling reaction by adding 
Pd(dba)2 (11 mg, mol%), P(2-furyl)3 (8 mg, mol%) and ethyl-p-iodobenzoate (91 mg, 0.35 
mmol, 1.2 equiv.) within 12 h at 25 °C. The crude product was purified by flash column 
chromatography (SiO2, EtOAc:i-hexane:Et3N 2:8:0.05) yielding compound 46d (88 mg, 0.23 
mmol, 81%) as a colorless liquid. 
HRMS (ESI) for C19H24N2O6Na
+
: calcd. 399.39822 (M+Na); found 399.152123. 
1
H NMR (400 MHz, CDCl3) δ = 1.12 (t, J=7.04 Hz, 3 H), 1.19 (t, J=7.04 Hz, 3 H), 1.37 (t, 
J=7.14 Hz, 3 H), 3.52 (q, J=7.04 Hz, 2 H), 3.68 (q, J=7.04 Hz, 2 H), 4.37 (q, J=7.24 Hz, 2 H), 
4.96 (s, 2 H), 5.42 (s, 2 H), 5.66 (s, 1 H), 7.53 (d, J=8.22 Hz, 2 H), 8.10 (d, J=8.02 Hz, 2 H). 
13
C NMR (101 MHz, CDCl3) δ = 14.24, 15.03, 15.16, 61.38, 65.20, 65.93, 70.78, 74.70, 
103.82, 128.39, 129.69, 132.23, 136.63, 152.50, 154.42, 161.69, 165.50. 
IR (ATR): 𝜈 (cm-1) = 2976 (w), 2929 (vw), 2900 (vw), 2878 (vw), 1716 (s), 1671 (vs), 1606 
(w), 1441 (m), 1404 (w), 1383 (w), 1367 (w), 1347 (w), 1274 (m), 1231 (w), 1180 (w), 1159 
(w), 1101 (m), 1024 (w), 986 (w), 947 (w), 866 (w), 830 (w), 778 (w), 711 (w). 
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7.11 Uridine Derivatives 49a-n and 51a-f 
7.11.1 Preparation of Uridine Derivative 49a 
To a solution of uridine derivate 47 (0.5 mL, 0.5 м in THF, 0.25 mmol) 
was added TMPMgCl·LiCl (1, 0.40 mL, 1.1 м in THF, 0.45 mmol, 
1.8 equiv.) at −40 °C. The reaction mixture was stirred for 24 h according 
to TP9 and reacted with iodine (110 mg, 0.45 mmol) for 30 min. The crude 
product was purified by flash column chromatography (SiO2, EtOAc:i-
hexane/NEt3 2:8:0.05) furnishing the compound 49a (99 mg, 0.17 mmol, 70%) as a yellow 
liquid.  
HRMS (EI) for C20H33IN2O7Si: calcd. 553.0867 (M-Me); found 553.0856. 
MS (70 eV, EI) m/z (%): 511 (100), 451 (20) 339 (84), 309 (20), 307 (20), 277 (44), 229 (42), 
171 (65), 143 (34), 129 (75). 
1
H-NMR (300 MHz, CDCl3) δ = 0.11 (d, J=0.83 Hz, 6 H), 0.89 - 0.91 (m, 9 H), 1.36 (s, 3 H), 
1.58 (s, 3 H), 3.43 (s, 3 H), 3.76 - 3.82 (m, 1 H), 3.89 - 3.95 (m, 1 H), 4.41 - 4.45 (m, 1 H), 
4.69 - 4.75 (m, 2 H), 5.38 - 5.47 (m, 2 H), 5.83 (d, J=1.94 Hz, 1 H), 7.97 (s, 1 H). 
 13
C-NMR (75 MHz, CDCl3) δ = -5.40, -5.06, 18.38, 25.21, 26.00, 27.18, 58.15, 63.53, 67.76, 
73.47, 80.90, 85.86, 87.22, 94.41, 113.83, 143.59, 150.63, 159.80. 
IR (ATR): 𝜈 (cm-1) = 3459 (vw),2953 (w), 2929 (w), 2856 (w), 2228 (w), 1713 (m), 1661 (s), 
1608 (w), 1503 (w), 1459 (s), 1408 (w), 1382 (m), 1373 (m), 1361 (m), 1254 (m), 1212 (m), 
1157 (m), 1126 (m), 1083 (s), 1068 (s), 1018 (m), 969 (m), 939 (w), 916 (m), 833 (vs), 815 
(s), 778 (s), 730 (s), 686 (w), 675 (m), 665 (m). 
 
7.11.2 Preparation of Uridine Derivative 49b 
 To a solution of uridine derivate 47 (0.5 mL, 0.5 м in THF, 
0.25 mmol) was added TMPMgCl·LiCl (1, 0.27 mL, 1.1 м in 
THF, 0.30 mmol, 1.2 equiv.) at −40 °C. The reaction mixture was 
stirred for 24 h according to TP9. The magnesium reagent was 
transmetallated to the corresponding zinc reagent by adding ZnCl2 
(0.38 mL, 1 м solution in THF, 0.38 mmol, 1.5 equiv.) and stirring 
for 30 min at −40 °C. The zinc reagent reacted in a Negishi cross-coupling reaction by adding 
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Pd(dba)2 (11 mg, 8 mol%), P(2-furyl)3 (9 mg, 15 mol%) and 4-iodoanisole (88 mg, 
0.38 mmol, 1.5 equiv.) at 25 °C for 12 h. The crude product was purified by flash column 
chromatography (SiO2, EtOAc:i-hexane/ NEt3 2:8:0.05) furnishing compound 49b (111 mg, 
0.20 mmol, 81%) as a colorless solid.  
HRMS (EI) for C27H40N2O8Si: calcd. 548.7006 (M
+
); found 548.2553. 
MS (70 eV, EI) m/z (%): 548 (27), 492 (29), 491 (96), 319 (95), 287 (28), 257 (21), 230 (30). 
1
H-NMR (400 MHz, CDCl3) δ = -0.11 (s, 3 H), -0.04 (s, 3 H), 0.76 (s, 9 H), 1.35 (s, 3 H), 
1.58 (s, 3 H), 3.45 (s, 3 H), 3.75 - 3.89 (m, 2 H), 3.79 (s, 3 H), 4.35 (q, J=2.73 Hz, 1 H), 4.73 
(dd, J=6.24, 2.73 Hz, 1 H), 4.83 (dd, J=6.24, 2.73 Hz, 1 H), 5.43 (q, J=9.55 Hz, 2 H), 5.88 (d, 
J=2.73 Hz, 1 H), 6.88 (m, 2 H), 7.38 (m, 2 H), 7.56 (s, 1 H). 
13
C-NMR (101 MHz, CDCl3) δ = -5.64, -5.56, 18.25, 25.29, 25.79, 27.21, 55.32, 58.01, 
63.51, 72.31, 80.80, 85.41, 87.08, 94.19, 113.87, 113.91, 114.24, 125.19, 129.66, 135.90, 
150.60, 159.39, 162.08.  
IR (ATR): 𝜈 (cm-1) = 2987 (w), 2952 (w), 2930 (w), 2856 (w), 1712 (m), 1658 (s), 1609 (m), 
1576 (w), 1514 (m), 1453 (m), 1413 (w), 1382 (m), 1373 (m), 1290 (m), 1247 (s), 1212 (m), 
1179 (m), 1157 (m), 1126 (m), 1080 (s), 1032 (s), 1005 (m), 970 (m), 918 (m), 831 (vs), 812 
(m), 795 (m), 779 (s), 760 (m), 733 (s), 701 (m), 679 (w), 666 (m). 
m.p.: 112-113 °C 
 
7.11.3 Preparation of Uridine Derivative 94c 
To a solution of uridine derivate 47 (1 mL, 0.5 м in THF, 0.5 
mmol) was added TMPMgCl·LiCl (1, 0.6 mL, 1.0 м in THF, 0.6 
mmol, 1.2 equiv.) at −40 °C. The reaction mixture was stirred for 
24 h according to TP9. The magnesium reagent was 
transmetalated to the corresponding zinc reagent by adding 
ZnCl2 (0.6 mL, 1 м solution in THF, 0.6 mmol, 1.2 equiv.) and 
stirring for 30 min at −40 °C. The zinc reagent reacted in a Negishi cross-coupling reaction by 
adding Pd(dba)2 (11 mg, 8 mol%), P(2-furyl)3 (9 mg, 12 mol%) and ethyl-p-iodobenzoate 
(165 mg, 0.6 mmol, 1.2 equiv.) at 25 °C for 12 h. The crude product was purified by flash 
column chromatography (SiO2, EtOAc:i-hexane/ NEt3 2:8:0.05) furnishing compound 49c 
(192 mg, 0.32 mmol, 66%) as a colorless liquid.  
HRMS (EI) for C29H42N2O9Si: calcd. 575.2425 (M-Me); found 575.2412. 
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MS (70 eV, EI) m/z (%): 534 (33), 533 (100), 475 (15), 362 (19), 361 (75), 329 (21), 299 
(19), 229 (18), 171 (35), 143 (17), 129 (67). 
1
H-NMR (400 MHz, CDCl3) δ = -0.16 (s, 3 H), -0.07 (s, 3 H), 0.72 (s, 9 H), 1.35 (s, 3 H), 
1.37 (t, J=7.12 Hz, 3 H), 1.58 (s, 3 H), 3.45 (s, 3 H), 3.44 - 3.89 (m, 2 H), 4.36 (q, J=7.02 Hz, 
2 H), 4.42 (q, J=2.53 Hz, 1 H), 4.71 (dd, J=6.14, 2.24 Hz, 1 H), 4.82 (dd, J=6.34, 2.63 Hz, 1 
H), 5.43 (q, J=9.55 Hz, 2 H), 5.86 (d, J=2.73 Hz, 1 H), 7.56 (d, J=8.58 Hz, 2 H), 7.74 (s, 1 H), 
8.02 (d, J=8.58 Hz, 2 H). 
13
C-NMR (101 MHz, CDCl3) δ = -5.68, -5.59, 14.30, 18.19, 25.21, 25.72, 27.16, 58.06, 
60.98, 63.58, 72.33, 80.93, 85.79, 87.44, 94.77, 113.15, 113.82, 128.14, 129.61, 129.65, 
137.40, 137.50, 150.47, 161.49, 166.25.  
IR (ATR): 𝜈 (cm-1) = 2981 (w), 2953 (w), 2931 (w), 2856 (w), 1711 (s), 1660 (vs), 1608 (m), 
1567 (vw), 1513 (w), 1453 (s), 1410 (m), 1382 (m), 1369 (m), 1268 (vs), 1212 (m), 1183 (m), 
1157 (m), 1124 (s), 1099 (vs), 1081 (vs), 1021 (s), 1006 (m), 969 (m), 917 (m), 857 (s), 833 
(vs), 814 (m), 786 (s), 776 (s), 759 (m), 729 (s), 709 (m), 664 (m). 
 
7.11.4 Preparation of Uridine Derivative 49d 
 To a solution of uridine derivate 47 (0.5 mL, 0.5 м in THF, 
0.25 mmol) was added TMPMgCl·LiCl (1, 0.40 mL, 1.1 м in THF, 
0.45 mmol, 1.8 equiv.) at −40 °C. The reaction mixture was stirred for 
24 h according to TP9. The magnesium reagent was transmetalated to 
the corresponding zinc reagent by adding ZnCl2 (0.6 mL, 1 м solution 
in THF, 0.6 mmol, 1.2 equiv.) and stirring for 30 min at −40 °C. The 
zinc reagent reacted in a Negishi cross-coupling reaction by adding Pd(dba)2 (11 mg, 
8 mol%), P(2-furyl)3 (9 mg, 12 mol%) and 3-iodopyridine (61 mg, 0.3 mmol) for 30 min. The 
crude product was purified by flash column chromatography (SiO2, EtOAc:i-hexane/NEt3 
2:8:0.05) furnishing compound 49d (95 mg, 0.18 mmol, 73%) as a yellow liquid.  
HRMS (ESI) for C25H37N3O7Si calcd 520.2474 (M+H
+
); found 520.2468. 
1
H NMR (300 MHz, CDCl3)  δ = -0.14 (s, 3 H), -0.06 (s, 3 H), 0.72 (s, 9 H), 1.35 (s, 3 H) 
1.58 (s, 3 H) 3.45 (s, 3 H), 3.69 - 3.82 (m, 1 H), 3.82 - 3.96 (m, 1 H), 4.40 (q, J=2.49 Hz, 1 
H), 4.71 (dd, J=6.08, 2.49 Hz, 1 H), 4.80 (dd, J=6.08, 2.76 Hz, 1 H), 5.36 - 5.50 (m, 2 H), 
5.89 (d, J=2.76 Hz, 1 H), 7.22 - 7.33 (m, 1 H), 7.75 (s, 1 H), 7.90 (dt, J=8.02, 1.94 Hz, 1 H), 
8.54 (dd, J=4.70, 1.66 Hz, 1 H), 8.61 (d, J=1.93 Hz, 1 H). 
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13
C NMR (75 MHz, CDCl3) δ = -5.67, -5.61, 18.16, 25.23, 25.67, 27.17, 58.06, 63.52, 72.36, 
80.84, 85.72, 87.29, 94.46, 111.06, 113.90, 123.05, 129.09, 136.20, 136.94, 148.59, 148.99, 
150.49,161.61. 
IR (ATR): 𝜈 (cm-1) = 2986 (w), 2953 (w), 2932 (w), 2893 (w), 2857 (w), 1714 (m), 1661 (vs), 
1454 (s), 1414 (w), 1383 (m), 1374 (m), 1362 (m), 1292 (m), 1256 (m), 1212 (m), 1185 (w), 
1157 (m), 1125 (m), 1083 (s), 1006 (w), 970 (m), 919 (w), 835 (s), 814 (m), 779 (s), 712 (m). 
 
7.11.5 Preperation of Uridine Derivative 49e 
To a solution of uridine derivate 47 (1 mL, 0.5 м in THF, 0.5 mmol) 
was added TMPMgCl·LiCl (1, 0.8 mL, 1.1 м in THF, 0.45 mmol, 1.8 
equiv.) at −40 °C. The reaction mixture was stirred for 24 h 
according to TP9. The freshly prepared magnesium reagent was 
transmetalated to the corresponding copper reagent by adding 
CuCN·2LiCl (1 м solution in THF, 0.60 mL, 0.60 mmol, 1.2 equiv.) and stirring for 30 min.  
Allylation was achieved by adding ethyl 2-(bromomethyl)acrylate (84 mg, 0.6 mmol, 1.2 
equiv.) at −40 °C, stirring for 10 min at −40 °C and 1 h at 25 °C. The crude product was 
purified by flash column chromatography (SiO2, EtOAc:i-hexane/NEt3 2:8:0.05) furnishing 
compound 49e reacted(238 mg, 0.43 mmol, 86%) as a colorless liquid.  
HRMS (EI) for C26H42N2O9Si: calcd. 554.7052; found 539.2412 (M-Me). 
MS (70 eV, EI) m/z (%): .539. (11), 498 (30), 497 (100), 326 (21), 325 (94), 293 (28), 263 
(22), 229 (13), 171 (36), 143 (13), 129 (42), 117 (14). 
1
H-NMR (400 MHz, CDCl3) δ = 0.01 (3 H), 0.02 (3H), 0.82 (s, 9 H), 1.24 (t, J=7.12 Hz, 3 
H), 1.30 (s, 3 H), 1.52 (s, 3 H), 3.17 - 3.35 (m, 2 H), 3.37 (s, 3 H), 3.67 - 3.89 (m, 2 H), 4.14 
(q, J=7.15 Hz, 2 H), 4.20 - 4.30 (m, 1 H), 4.70 (dd, J=6.34, 3.02 Hz, 1 H), 4.79 (dd, J=6.24, 
2.73 Hz, 1 H), 5.19 - 5.37 (m, 2 H), 5.65 (d, J=1.36 Hz, 1 H), 5.72 (d, J=2.73 Hz, 1 H), 6.19 
(d, J=1.17 Hz, 1 H), 7.37 (s, 1 H). 
 13
C-NMR (101 MHz, CDCl3) δ = -5.50, -5.41, 14.15, 18.29, 25.29, 25.82, 27.18, 29.60, 
57.85, 60.75, 63.54, 72.05, 80.89, 84.98, 87.16, 94.34, 110.62, 113.88, 127.03, 136.90, 
138.05, 150.69, 162.64, 166.36. 
IR (ATR): 𝜈 (cm-1) = 2981 (w), 2953 (w), 2931 (w), 2856 (w), 1711 (s), 1666 (vs), 1456 (m), 
1371 (m), 1326 (w), 1279 (m), 1253 (m), 1209 (m), 1183 (m), 1176 (m), 1156 (m), 1134 (s), 
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1083 (vs), 1028 (s), 1006 (m), 975 (m), 940 (m), 919 (m), 870 (m), 834 (vs), 815 (s), 776 (s), 
733 (m), 677 (m), 666 (m). 
 
7.11.6 Preparation of Uridine Derivative 49f  
To a solution of uridine derivate 47 (1 mL, 0.5 м in THF, 0.5 mmol) 
was added TMPMgCl·LiCl (1, 0.8 mL, 1.1 м in THF, 0.88 mmol, 
1.8 equiv.) at −40 °C. The reaction mixture was stirred for 24 h 
according to TP9. The freshly prepared magnesium reagent was 
transmetalated to the corresponding copper reagent by adding 
CuCN·2LiCl (1 м solution in THF, 0.60 mL, 0.60 mmol, 1.2 equiv.) and stirring for 30 min.  
Allylation was achieved by adding 3-bromocyclohex-1-ene (97 mg, 0.6 mmol) at −40 °C, 
stirring for 10 min at −40 °C and 1 h at 25 °C. The crude product was purified by flash 
column chromatography (SiO2, EtOAc:i-hexane/NEt3 2:8:0.05) furnishing the compound 49f 
as a diastereomeric mixture 48:42 (158 mg, 0.30 mmol, 60%) as a colorless liquid.  
HRMS (EI) for C26H42N2O7Si calcd. 522.7064; found 507.2517(M-Me). 
1
H NMR (300 MHz, CDCl3) δ = -0.03, -0-04 (s, 3 H), 0.05, 0.05 (s, 3 H) 0.86, 0.87 (s, 9 H) 
1.34, 1.34,  (s, 3H), 1.55, 1.55* (s, 3 H), 1.48-1.67, 1.48-1.67 * (m, 3 H) 1.88 - 2.03, 1.88 - 
2.03* (m, 3 H) 3.43, 3.43* (s, 3 H), 3.45-3.50, 3.45 - 3.50*  (m, 1 H), 3.73 - 3.84, 3.73 - 3.84*  
(m, 2 H), 4.19 - 4.24, 4.24 - 4.28  (m, 1 H), 4.73-4.78, 4.73-4.78*  (m, 1 H), 4.94 - 4.98, 4.94 - 
4.98* (m, 1 H), 5.34, 5.34 (m, 2 H), 5.45-5.49*, 5.49-5.52 (m, 1 H), 5.62 (d, J=2.49 Hz, 1 H), 
5.91 - 5.95
*
, 5.88 - 5.92  (m., 1 H), 7.04*, 7.09 (s, 1H). 
13
C NMR (75 MHz, CDCl3) δ = -5.44, -5.38 (s, 1 C), -5.33, -5.30 (s, 1 C), 18.33, 18.39 (s, 1 
C), 19.64, 19.80 (s, 1 C), 24.97*, 24.99 (s, 1 C), 25.33, 25.40* (s, 1 C), 25.87,  25.90* (s, 1 C) 
27.16, 27.21* (s, 1 C), 28.13, 28.17* (s, 1 C) 32.68, 32.79* (s, 1 C), 57.92, 57.92* (s, 1 C), 
63.66*, 63.74 (s, 1 C), 72.08, 72.11* (s, 1 C), 81.17*, 81.25 (s, 1 C), 84.37*, 84.81 (s, 1 C), 
87.76*,  87.86 (s, 1 C), 95.61*,  95.71 (s, 1 C), 113.88, 114.04* (s, 1 C), 117.28, 117.55* (s, 1 
C), 127.19, 127.25* (s, 1 C), 130.42*, 130.53 (s, 1 C), 137.26, 137.56* (s, 1 C) 150.58*, 
150.62 (s, 1 C) 162.59, 162.60* (s, 1 C).  
IR (ATR): 𝜈 (cm-1) = 2928 (m), 2856 (w), 1713 (m), 1662 (vs), 1453 (m), 1381 (m), 1372 
(m), 1361 (m), 1256 (m), 1210 (m), 1183 (w), 1158 (m), 1128 (m), 1083 (vs), 1005 (m), 972 
(m), 938 (w), 916 (m), 873 (m), 834 (vs), 815 (m), 776 (s), 758 (m), 729 (s), 662 (m). 
 
 D. Experimental Section 
 
129 
7.11.7 Preparation of Uridine Derivative 49g 
To a solution of uridine derivate 47 (0.5 mL, 0.5 м in THF, 0.25 mmol) 
was added TMPMgCl·LiCl (1, 0.40 mL, 1.1 м in THF, 0.45 mmol, 
1.8 equiv.) at −40 °C. The reaction mixture was stirred for 24 h according 
to TP9. The freshly prepared magnesium reagent was transmetallated to 
the corresponding copper reagent by adding CuCN·2LiCl (1 м solution in 
THF, 0.35 mL, 0.35 mmol) and stirring for 30 min. MeI was added at −40 °C and warmed to 
25 °C within 6 h, and stirred for further 48 h at 25 °C. The crude product was purified by flash 
column chromatography (SiO2, EtOAc:i-hexane/NEt3 2:8:0.05) furnishing compound 49g 
(35 mg, 0.08 mmol, 31%) as a yellow liquid.  
HRMS (ESI) for C21H37N2O7Si
+
 calcd. 457,61845 (M+H
+
); found 457.23609. 
1
H NMR (600 MHz, CDCl3) δ = 0.07 (d, J=6.31 Hz, 6 H), 0.88 (s, 9 H), 1.34 (s, 3 H), 1.57 (s, 
3 H), 1.92 (s, 3 H), 3.42 (s, 3 H), 3.78 (d, J=11.53, 1 H), 3.90 (d, J=11.53 Hz, 1 H), 4.30 (s, 1 
H), 4.73 (s, 2 H), 5.28 - 5.48 (m, 2 H), 5.87 (s, 1 H), 7.32 (s, 1 H). 
13
C NMR (151 MHz, CDCl3) δ = -5.49, -5.39, 13.22, 18.32, 25.33, 25.84, 27.24, 57.85, 
63.37, 72.09, 80.54, 85.19, 86.51, 93.16, 109.85, 113.99, 135.01, 150.99, 163.45. 
IR (ATR): ?̃? (cm-1) =  2988 (w), 2952 (m), 2929 (m), 2858 (w), 1714 (m), 1671 (vs), 1462 
(m), 1383 (w), 1372 (m), 1364 (w), 1278 (m), 1254 (m), 1214 (m), 1184 (w), 1157 (w), 1127 
(m), 1090 (s), 1035 (w), 974 (w), 918 (w), 859 (m), 836 (s), 774 (m). 
 
7.11.8 Preparation of Uridine Derivative 49h 
49h was prepared according to TP9 from uridine derivate (47, 0.5 mL, 
0.5 м in THF, 0.25 mmol). To the solution was added TMPMgCl·LiCl 
(1, 0.27 mL, 1.1 M in THF, 0.30 mmol, 1.2 equiv.) at −40 °C and the 
solution was stirred for 24 h. The magnesium reagent was treated with 
CuCN·2LiCl (0.3 mL, 1 м solution in THF, 0.3 mmol, 1.2 equiv.) for 
30 min at −40 °C. Acylation was achieved by adding cyclopropanecarbonyl chloride (31 mg, 
0.3 mmol) at −40 °C and warming up to −10 °C within 12 h. The reaction mixture was stirred 
at −10 °C until completion of the reaction. The crude product was purified by flash column 
chromatography (SiO2, EtOAc:i-hexane/ NEt3 2:8:0.05) furnishing compound 49h (91 mg, 
0.18 mmol, 71%) as a colorless liquid. 
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HRMS (EI) for C24H39N2O8Si: calcd. 510.6526; found 511.2464 (M
+
). 
MS (70 eV, EI) m/z (%): .454 (26), 453 (100), 395 (11), 282 (12), 281 (57), 251 (12), 249 
(15), 229 (12), 249 (15), 229 (12), 219 (21), 171 (33), 143 (16), 129 (25), 117 (13). 
1
H-NMR (300 MHz, CDCl3) δ = 0.04 (s, 3 H), 0.02 (s, 3 H), 0.80 (s, 9H), 0.97-1.03 (m, 2 H), 
1.14-1.18 (m, 2 H), 1.36 (s, 3 H), 1.58 (s, 3 H), 3.29 (tt, J=7.84, 4.60 Hz, 1 H), 3.46 (s, 3 H), 
3.77 (dd, J=11.61, 3.04 Hz, 1 H), 3.87 (dd, J=11.61, 3.04 Hz, 1 H), 4.48 - 4.59 (m, 1 H), 4.71 
(dd, J=5.94, 1.52 Hz, 1 H), 4.83 (dd, J=5.94, 2.35 Hz, 1 H), 5.42 (q, J=9.40 Hz, 2 H), 5.75 (d, 
J=2.49 Hz, 1 H), 8.45 (s, 1 H). 
13
C-NMR (75 MHz, CDCl3) δ = -5.81, -5.56, 12.70, 18.23, 19.41, 25.05, 25.76, 27.05, 58.04, 
63.84, 72.17, 81.59, 86.43, 88.39, 96.52, 111.53, 113.45, 145.65, 150.50, 161.12, 196.77.  
IR (ATR): 𝜈 (cm-1) = 2987 (w), 2951 (w), 2931 (w), 2856 (w), 1720 (m), 1678 (vs), 1659 (s), 
1594 (m), 1453 (s), 1410 (m), 1384 (s), 1362 (m), 1351 (m), 1321 (m), 1288 (m), 1272 (m), 
1252 (m), 1212 (m), 1158 (m), 1122 (s), 1090 (vs), 1053 (s), 1021 (m), 990 (m), 969 (m), 919 
(m), 872 (m), 860 (m), 833 (vs), 814 (m), 780 (s). 
7.11.9 Preparation of Uridine Derivative 49i 
 To a solution of uridine derivate 47 (0.5 mL, 0.5 м in THF, 0.25 mmol) 
was added TMPMgCl·LiCl (1, 0.40 mL, 1.1 м in THF, 0.45 mmol, 
1.8 equiv.) at −40 °C. The reaction mixture was stirred for 24 h 
according to TP9. The freshly prepared magnesium reagent was treated 
with morpholine-4-carbaldehyde (34 mg, 0.29 mmol) at −40 °C and the 
reaction mixture was allowed to warm up to 25 °C over 12 h. The crude product was purified 
by flash column chromatography (SiO2, EtOAc:i-hexane/NEt3 2:8:0.05) furnishing compound 
49i (38 mg, 0.08 mmol, 32%) as a yellow liquid.  
HRMS (ESI) for C21H35N2O8Si
+
 calcd. 471,60145 (M+H
+
); found 471.21543. 
1
H NMR (400 MHz, CDCl3) δ =  -0.06 (s, 3 H), 0.00 (s, 3 H), 0.76 (s, 9 H), 1.33 (s, 3 H), 
1.55 (s, 3 H), 3.41 (s, 3 H), 3.75 (dd, J=11.74, 2.45 Hz, 1 H), 3.94 (dd, J=11.98, 1.96 Hz, 1 
H), 4.55 (s, 1 H), 4.67 (dd, J=5.87, 1.22 Hz, 1 H), 4.75 (dd, J=5.87, 2.45 Hz, 1 H), 5.22 - 5.48 
(m, 2 H), 5.74 (d, J=2.45 Hz, 1 H), 8.39 (s, 1 H), 10.00 (s, 1 H). 
13
C NMR (101 MHz, CDCl3) δ = -5.73, -5.42, 18.29, 25.08, 25.82, 27.11, 58.21, 63.84, 
71.91, 81.59, 86.58, 88.44, 96.49, 109.78, 113.58, 144.40, 150.38, 161.73, 186.50. 
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IR (ATR): 𝜈 (cm-1) = 2985(w), 2953 (w), 2933 (w), 2884 (w), 2858 (w), 1727 (m), 1697 (s), 
1672 (vs), 1605 (s), 1462 (s), 1421 (w), 1382 (m), 1359 (m), 1280 (m), 1256 (m), 1213 (m), 
1184 (w), 1158 (w), 1092 (s), 1008 (w), 969 (m), 918 (w), 860 (m), 836 (s), 778 (s). 
 
7.11.10 Preparation of Uridine Derivative 49j 
To a solution of uridine derivate 47 (0.5 mL, 0.5 м in THF, 0.25 mmol) 
was added TMPMgCl·LiCl (1, 0.40 mL, 1.1 м in THF, 0.45 mmol, 
1.8 equiv.) at −40 °C. The reaction mixture was stirred for 24 h 
according to TP9 and reacted with ethyl cyanoformate (30 mg, 
0.3 mmol, 1.2 equiv.) at −40 °C and subsequent warming up to −10 °C 
for 12 h. The crude product was purified by flash column chromatography (SiO2, EtOAc:i-
hexane/NEt3 2:8:0.05) furnishing compound 49j (57 mg, 0.11 mmol, 44%) as a yellow liquid.  
HRMS (ESI) for C23H39N2O9Si
+
: calcd. 515.65445 (M+H
+
); found 515.2424. 
1
H NMR (300 MHz, CDCl3) δ =  0.02 (s, 3 H), 0.03 (s, 3 H), 0.80 (s, 9 H), 1.34 (t, J= 7.19. 3 
H), 1.36 (s, 3 H), 1.57 (s, 3 H), 3.43 (s, 3 H), 3.73 - 3.84 (m, 1 H), 3.87 - 3.96 (m, 1 H), 4.19 - 
4.39 (m, 2 H), 4.55 (s, 1 H), 4.71 (d, J=6.08 Hz, 1 H), 4.84 (dd, J=5.81, 2.21 Hz, 1 H), 5.37 
(q, J=9.40 Hz, 2 H), 5.72 (d, J=1.94 Hz, 1 H), 8.49 (s, 1 H). 
13
C NMR (75 MHz, CDCl3 δ =  -5.78,  -5.59,  14.30,  18.21,  25.03,  25.70,  27.03,  58.12,  
61.25,  63.88,  72.10,  81.57,  86.39,  88.47,  96.61,  103.93,  113.45,  146.66,  150.37,  
158.80,  163.04. 
IR (ATR): 𝜈 (cm-1) = 2986.00 (w), 2966.00 (w), 2949.00 (m), 2934.00 (m), 2857.00 (w), 
1752.00 (s), 1735.00 (s), 1728.00 (s), 1709.00 (vs), 1675.00 (vs), 1624.00 (m), 1532.00 (w), 
1454.00 (s), 1373.00 (s), 1365.00 (m), 1355.00 (m), 1266.00 (s), 1227.00 (s), 1217.00 (s), 
1188.00 (m), 1158.00 (m), 1123.00 (s), 1091.00 (vs), 1029.00 (m), 970.00 (m), 918.00 (w), 
861.00 (m), 835.00 (s), 797.00 (m), 778.00 (m). 
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7.11.11 Preparation of Uridine Derivative 49k 
To a solution of uridine derivate 47 (1 mL, 0.5 м in THF, 
0.50 mmol) was added TMPMgCl·LiCl (1, 0.6 mL, 1.0 м in 
THF, 0.3 mmol, 1.2 equiv.) at −40 °C. The reaction mixture was 
stirred for 24 h according to TP9. The magnesium reagent was 
reagent with 4-(hydroxymethyl)benzonitrile (79 mg, 0.6 mmol, 
1.2 equiv.) at −40 °C, stirring for 10 min at −40 °C and 1 h at 
25 °C. The crude product was purified by flash column chromatography (SiO2, EtOAc:i-
hexane/ NEt3 2:8:0.05) furnishing compound 49k (212 mg, 0.37 mmol, 74%) as a 1:1 
diastereomeric mixture.  
HRMS (EI) for C27H36N3O8Si: calcd  558,68355 (M-Me), found 558.2268. 
1
H NMR (300 MHz, CDCl3) δ = 0.06, 0.07 (s, 3H), 0.07, 0.08 (s, 3H), 0.87. 0.87 (s, 9H),  
1.36 (s, 3 H), 1.57 (s, 3 H),  3.40, 3.41 (s, 3 H), 3.74  - 3.81 (m, 2 H), 4.32 - 4.35 (m, 1 H), 
4.70 - 4.74 (m, 1 H), 4.78 (s, 1 H), 4.84, 4.86 (d, J= 2.49, 1 H), 5.26 - 5.38 (m, 2 H), 5.62*, 
5.72  (s, 1H), 5.67, 5.70* (d, J=2.49 Hz, 1 H),  7.42*, 7.40 (d, J= 7.42, 7.40, 1H), 7.46-7.47, 
7.49-7.50 (m, 1H), 7.52-7.53, 7.55-7.56 (m, 1H), 7.64-7.64 (m, 2H),  
13
C NMR (75 MHz, CDCl3) δ = -5.48, -5.42 (s, 1 C), -5.35, -5.30 (s, 1 C),  18.30, 18.31 (s, 1 
C), 25.27 (s, 1 C), 25.86 (s, 1 C), 27.16 (s, 1 C), 58.05, 58.07 (s, 1 C), 63.60, 64.19 (s, 1 C), 
69.89, 70.65 (s, 1 C) ,72.02 (s, 1 C), 80.95, 81.07 (s, 1 C) 85.17, 85.22 (s, 1 C), 87.55, 87.62 
(s, 1 C) 95.20*, 95.31 (s, 1 C), 111.72, 111.81 (s, 1 C) 113.95, 114.03 (s, 1 C) 114.45, 114.75 
(s, 1 C) 118.58, 118.60* (s, 1 C), 126.99, 127.22 (s, 1 C), 132.29, 132.31 (s, 1 C), 137.28, 
137.46 (s, 1 C), 146.37, 146.57 (s, 1 C). 150.19, 150.27* (s, 1 C) 162.54, 162.69* (s, 1 C). 
IR (ATR): 𝜈 (cm-1) = 3454.00 (w), 2988.00 (w), 2952.00 (w), 2931.00 (w), 2856.00 (w), 
2228.00 (w), 1713.00 (m), 1662.00 (vs), 1608.00 (w), 1503.00 (w), 1460.00 (s), 1410.00 (w), 
1373.00 (m), 1361.00 (m), 1254.00 (m), 1213.00 (m), 1157.00 (m), 1126.00 (m), 1085.00 
(vs), 1019.00 (m), 972.00 (m), 940.00 (w), 918.00 (w), 835.00 (vs), 816.00 (m), 780.00 (s). 
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7.11.12 Preparation of Uridine Derivative 49l 
To a solution of uridine derivate 47 (0.5 mL, 0.5 м in THF, 
0.25 mmol) was added TMPMgCl·LiCl (1, 0.3 mL, 1.0 м in THF, 
0.30 mmol, 1.2 equiv.) at −40 °C. The reaction mixture was stirred 
for 24 h according to TP9. The magnesium reagent reacted with 
furan-2-carbaldehyde (29 mg, 0.30 mmol, 1.2 equiv.) for 10 min at 
−40 °C and 12 h at 25 °C. The crude product was purified by flash 
column chromatography (SiO2, EtOAc:i-hexane/ NEt3 2:8:0.05) furnishing the compound 49l 
(58 mg, 0.11 mmol, 43%) as a as a 1:1 diastereomeric mixture. 
 
HRMS (ESI) for C25H37N2O8Si
+
: calcd 521,23137 (M-OH), found 521.23093. 
1
H NMR (400 MHz, CDCl3) δ = 0.00 (d, 3 H), 0.02 (d, 3 H), 0.81 (s, 9 H) 1.31 (s, 3 H) 1.53 
(s, 3 H) 3.38, 3.38 (s, 3 H), 3.71 - 3.75 (m, 2 H), 4.28-4.31 (m, 1 H) 4.68, 4.67 (dd, J=6.36, 
J=2.69 Hz, 1 H), 4.80-4.83 (m, 1 H), 5.31 (q, J=9.54 Hz, 2 H), 5.63*, 5.59 (s, 1H), 5.70, 5.67 
(d, J= 5.69, J= 5.66, 1 H), 6.29-6.33 (m, 2 H), 7.32-7.34 (m, 1H), 7.41, 7.44* (s, 1 H). 
13
C NMR (101 MHz, CDCl3) δ = -5.53, -5.48 (s, 1 C), -5.34, 5.37 (s, 1 C), 18.33, 18.36 (s, 1 
C), 25.29, 25.31 (s, 1 C), 25.87, 25.90 (s, 1 C), 27.19, 27.22 (s, 1 C), 58.05, 58.07 (s, 1 C), 
63.63 (s, 1 C), 65.11*, 65.55 (s, 1 C) 71.99 (s, 1 C), 81.14 (s, 1 C) 85.31, 85.43 (s, 1 C) 87.50, 
87.76 (s, 1 C), 95.04*, 95.37 (s, 1 C) 107.56, 107.60 (s, 1 C) 110.60, 110.62 (s, 1 C) 112.78, 
112.93* (s, 1 C) 113.88, 113.93 (s, 1 C) 137.60, 137.75, (s, 1 C)  142.34 (s, 1 C) 150.40, 
150.46* (s, 1 C) 153.51, 153.56 (s, 1 C) 162.69*, 162.90 (s, 1 C). 
IR (ATR): 𝜈 (cm-1) = cm-1 (Intensity), 2954.00 (w), 2931.00 (m), 2857.00 (w), 2362.00 (w), 
2342.00 (VW), 1761.00 (w), 1715.00 (m), 1669.00 (vs), 1616.00 (w), 1461.00 (s), 1374.00 
(m), 1362.00 (m), 1257.00 (m), 1214.00 (m), 1184.00 (w), 1158.00 (m), 1091.00 (s), 1009.00 
(m), 971.00 (w), 918.00 (w), 837.00 (s), 816.00 (w), 780.00 (m), 668.00 (w). 
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7.11.13 Preparation of Uridine Derivative 49m 
To a solution of uridine derivate 47 (0.5 mL, 0.5 м in THF, 0.25 
mmol) was added TMPMgCl·LiCl (1, 0.3 mL, 1.0 м in THF, 0.3 
mmol, 1.2 equiv.) at −40 °C. The reaction mixture was stirred for 24 h 
according to TP9. The magnesium reagent reacted with 
cyclopropanecarbaldehyde (21 mg, 0.3 mmol, 1.2 equiv.) at –40 °C, 
and subsequently stirred for 10 min at –40 °C and 12 h at 25 °C. The 
crude product was purified by flash column chromatography (SiO2, EtOAc:i-hexane/ NEt3 
2:8:0.05) furnishing compound 49m (38 mg, 0.07 mmol, 30%) as a diastereomeric mixture 
1:1.   
HRMS (ESI) for C24H40N2NaO8Si: calcd. 535,24461 (M+Na
+
), found 535.24502. 
1
H NMR (300 MHz, CDCl3) δ = -0.00, (s, 3 H), 0.01 (s, 3 H), 0.22 - 0.30, 0.47 - 0.54 (m, 2 
H) 0.40 - 0.46, 0.56 - 0.63 (m, 2 H), 0.81 (s, 9 H), 1.09 - 1.18 (m , 1 H), 1.31, (s, 3H) 1.52 (s, 
3 H), 3.39 (s, 3 H), 3.71 – 3.73*, 3.81-3.82 (m, 2 H), 3.74-3.80 (m 1 H), 4.26-4.29 (m, 1 H), 
4.68, 4.69* (d, J=2.93 Hz, 1 H), 4.81*, 4.83 (d, J=2.45 Hz, 1 H), 5.28 - 5.35 (m, 2 H), 5.68, 
5.70* (d, J=2.45 Hz, 1 H), 7.47, 7.51* (s, 1 H). 
13
C NMR (101 MHz, CDCl3) δ = -5.42, -5.39 (s, 1 C) -5.31, -5.26 (s, 1 C), 2.80, 2.85* (s, 1 
C) 3.63*, 3.71 (s, 1 C) 15.70, 15.94* (s, 1 C) 18.36, 18.39* (s, 1 C), 25.33 (s, 1 C), 25.90, 
25.93 (s, 3 C), 27.22 (s, 1 C), 58.04, 58.06* (s, 1 C), 63.63 (s, 1 C), 72.09 (s, 1 C) 72.59*, 
73.27 (s, 1 C), 80.98, 81.00 (s, 1 C), 85.15, 85.19 (s, 1 C), 87.44, 87.60 (s, 1 C), 94.90*, 95.15 
(s, 1 C), 114.02, 114.04 (s, 1 C), 115.41, 115.54* (s, 1 C), 136.31*, 136.41 (s, 1 C) 150.49, 
150.54* (s, 1 C), 163.29, 163.33* (s, 1 C). 
IR (ATR): 𝜈 (cm-1) =  cm-1 (Intensity), 3483.00 (VW), 3082.00 (VW), 2989.00 (w), 2953.00 
(w), 2931.00 (w), 2857.00 (w), 2361.00 (VW), 2340.00 (VW), 1713.00 (m), 1663.00 (vs), 
1458.00 (s), 1382.00 (m), 1373.00 (m), 1362.00 (m), 1255.00 (m), 1213.00 (m), 1158.00 (m), 
1129.00 (m), 1085.00 (vs), 1031.00 (m), 970.00 (m), 920.00 (m), 870.00 (m), 835.00 (vs), 
779.00 (s).  
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7.11.14 Preparation of Uridine Derivative 49n 
To a solution of uridine derivate 47 (2 mL, 0.5 м in THF, 1 mmol) was 
added TMPMgCl·LiCl (1, 1.2 mL, 1.0 м in THF, 1.2 mmol, 1.2 equiv.) 
at −40 °C. The reaction mixture was stirred for 24 h according to TP9. 
The magnesium reagent reacted with dimethyl disulfide (113 mg, 
1.2 mmol, 1.2 equiv.) at −40 °C and reacted 1 h at 25 °C. The crude 
product was purified by flash column chromatography (SiO2, EtOAc:i-hexane/ NEt3 2:8:0.05) 
furnishing compound 49n (206 mg, 0.42 mmol, 42%).  
HRMS (ESI) for C21H36N2NaO7SSi
+
: calcd. 511.19047 (M+Na
+
); found 511.19910. 
1
H NMR (300 MHz, CDCl3) δ = -0.04 (s, 3 H), -0.10 (s, 3 H), 0.72 - 1.06 (m, 9 H), 1.29 - 
1.47 (m, 3 H), 1.52 - 1.64 (m, 3 H), 2.23 - 2.37 (m, 3 H), 3.31 - 3.50 (m, 3 H), 3.72 - 3.86 (m, 
1 H), 3.86 - 4.00 (m, 1 H), 4.28 - 4.47 (m, 1 H), 4.62 - 4.81 (m, 2 H), 5.27 - 5.49 (m, 2 H), 
5.85 (d, J=1.38 Hz, 1 H), 7.82 (s, 1 H). 
13
C NMR (75 MHz, CDCl3) δ = -5.52, -5.33, 17.25, 18.35, 25.26, 25.92, 27.21, 58.06, 63.50, 
72.61, 80.82, 85.51, 86.98, 93.96, 109.05, 113.91, 140.40, 150.70, 161.38.  
IR (ATR): 𝜈 (cm-1) = 2980.00 (w), 2954.00 (m), 2929.00 (m), 2856.00 (w), 1752.00 (s), 
1735.00 (s), 1728.00 (s), 1709.00 (vs), 1675.00 (vs), 1624.00 (m), 1454.00 (s), 1373.00 (s), 
1365.00 (m),  
1355.00 (m), 1266.00 (s), 1227.00 (s), 1217.00 (s), 1188.00 (m), 1158.00 (m), 1123.00 (s), 
1091.00 (vs), 1029.00 (m), 970.00 (m), 918.00 (w), 861.00 (m), 835.00 (s), 797.00 (m), 
778.00 (m). 
 
7.11.15 Preparation of Uridine Derivative 51a 
51 was prepared according to TP10 from uridine derivate (47, 1 mL, 
0.25 м in THF, 0.25 mmol). TMP2Zn·2MgCl2·2LiCl (4, 0.42 mL, 0.71 M 
in THF, 0.30 mmol, 1.2 equiv.) was added to the solution at −30 °C, stirred 
for 72 h and reacted with iodine (127 mg, 0.5 mmol) for 30 min. The crude 
product was purified by flash column chromatography (SiO2, EtOAc:i-
hexane/NEt3 2:8:0.05) furnishing compound 51a (135 mg, 0.24 mmol, 
95%) as a colorless liquid. 
HRMS (ESI) for C20H33IN2O7Si: calcd. 568.4752; found 553.0868 (M-Me
+
). 
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MS (70 eV, EI) m/z (%): 511 (17), 542 (12), 385 (17), 340 (16), 339 (100), 309 (13), 276 
(20), 229 (26), 213 (17), 170 (34), 142 (19), 129 (36). 
1
H-NMR (300 MHz, CDCl3) δ = 0.04 (s, 3 H), 0.05 (s, 3 H), 0.89 (s, 9 H), 1.34 (s, 3 H), 1.56 
(s, 3 H), 3.42 (s, 3 H), 3.77 - 3.82 (m, 2 H), 4.14 - 4.21 (m, 1 H), 4.86 (dd, J=6.36, 4.42 Hz, 1 
H), 5.20 (dd, J=6.50, 1.24 Hz, 1 H), 5.28 (s, 2 H), 6.09 (d, J=1.11 Hz, 1 H), 6.51 (s, 1 H). 
13
C-NMR (75 MHz, CDCl3) δ = -5.27, -5.25, 18.47, 25.42, 25.94, 27.24, 58.01, 63.98, 72.31, 
81.96, 84.45, 89.81, 102.58, 112.28, 113.80, 116.43, 148.04, 160.52. 
IR (ATR): 𝜈 (cm-1) = 2986 (w), 2952 (w), 2929 (w), 2884 (w), 2855 (w), 1719 (m), 1665 (vs), 
1584 (m), 1435 (m), 1424 (m), 1372 (m), 1363 (m), 1347 (m), 1332 (m), 1252 (m), 1207 (m), 
1196 (m), 1156 (m), 1131 (m), 1082 (vs), 1064 (s), 1005 (m), 948 (m), 917 (m), 876 (s), 833 
(vs), 816 (s), 770 (s), 673 (m), 662 (m). 
 
7.11.16 Preparation of Uridine Derivative 51b 
51b was prepared according to TP10 from uridine derivate 47 
(0.5 mL, 0.5 м in THF, 0.25 mmol). TMP2Zn·2MgCl2·2LiCl (4, 
0.42 mL, 0.71 м in THF, 0.30 mmol, 1.2 equiv.) was added to the 
solution at −30 °C, stirred for 72 h and reacted in a Negishi cross-
coupling reaction by adding Pd(dba)2 (11 mg, 8 mol%), P(2-furyl)3 
(9 mg, 15 mol%) and 1-chloro-4-iodobenzene (90 mg, 0.38 mmol) 
at 25 °C for 12 h. The crude product was purified by flash column chromatography (SiO2, 
EtOAc:i-hexane/ NEt3 2:8:0.05) furnishing the compound 51b (116 mg, 0.21 mmol, 84%) as 
a yellow liquid. 
HRMS (ESI) for C26H37ClN2O7Si: calcd. 553.1197 (M
+
); found 553.2152.  
MS (70 eV, EI) m/z (%): 495 (15), 325 (35), 324 (18), 323 (100), 293 (10), 171 (16). 
1
H-NMR (300 MHz, CDCl3) δ = 0.06 (s, 6 H), 0.90 (s, 9 H), 1.29 (s, 3 H), 1.39 (s, 3 H), 3.47 
(s, 3 H), 3.82 - 3.86 (m, 2 H), 4.02 - 4.08 (m, 1 H), 4.84 (dd, J=6.36, 4.42 Hz, 1 H), 5.21 (dd, 
J=6.50, 1.52 Hz, 1 H), 5.37 (s, 2 H), 5.43 (d, J=1.38 Hz, 1 H), 5.66 (s, 1 H), 7.40 - 7.51 (m, 4 
H). 
13
C-NMR (75 MHz, CDCl3) δ = -5.24, -5.22, 18.44, 25.36, 25.91, 27.09, 57.99, 64.14, 71.95, 
82.07, 84.06, 89.32, 93.60, 103.85, 113.62, 129.41, 129.60, 130.87, 136.98, 151.12, 153.98, 
161.64. 
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IR (ATR): 𝜈 (cm-1) = 2987 (vw), 2952 (w), 2929 (w), 2884 (w), 2855 (w), 1717 (m), 1671 
(vs), 1621 (w), 1493 (w), 1471 (w), 1440 (m), 1405 (m), 1383 (m), 1372 (m), 1357 (m), 1252 
(m), 1208 (m), 1159 (w), 1140 (m), 1088 (vs), 1067 (s), 1015 (m), 969 (w), 954 (m), 901 (m), 
868 (m), 834 (vs), 774 (s), 729 (s), 681 (w), 667 (m), 663 (w).  
 
7.11.17 Preparation of Uridine Derivative 51c 
51c was prepared according to TP10 from uridine derivate 47 (0.5 
mL, 0.5 м in THF, 0.25 mmol). TMP2Zn·2MgCl2·2LiCl (4, 0.42 
mL, 0.71 M in THF, 0.30 mmol, 1.2 equiv.) was added to the 
solution at −30 °C, stirred for 72 h and reacted in a Negishi cross-
coupling reaction by adding Pd(dba)2 (11 mg, 8 mol%), P(2-furyl)3 
(9 mg, 15 mol%) and 4-iodobenzonitrile (69 mg, 0.30 mmol) at 25 °C for 12 h. The crude 
product was purified by flash column chromatography (SiO2, EtOAc:i-hexane/ NEt3 3:7:0.05) 
furnishing the compound 51c (94 mg, 0.17 mmol, 69%) as a colorless liquid. 
HRMS (ESI) for C27H37N3O7Si: calcd. 543.6841(M-H
+
); found 542.2323. 
MS (70 eV, EI) m/z (%): 486 (16), 428 (10), 315 (20), 314 (100), 284 (11), 252 (13). 
1
H-NMR (400 MHz, CDCl3) δ = 0.04 (s, 6 H), 0.88 (s, 9 H), 1.27 (s, 3 H), 1.36 (s, 3 H), 3.46 
(s, 3 H), 3.80 - 3.82 (m, 2 H), 4 - 4.05 (m, 1 H), 4.82 (dd, J=6.43, 4.48 Hz, 1 H), 5.20 (dd, 
J=6.43, 1.36 Hz, 1 H), 5.27 (d, J=1.56 Hz, 1 H), 5.35 (s, 2 H), 5.66 (s, 1 H), 7.61 (br. s., 2 H), 
7.78 - 7.81 (m, 2 H). 
13
C-NMR (101 MHz, CDCl3) δ = -5.24, -5.24, 18.43, 25.31, 25.89, 27.05, 58.06, 64.03, 
72.00, 81.96, 83.95, 89.44, 93.77, 104.31, 113.71, 114.68, 117.65, 129.03, 132.84, 136.69, 
150.89, 152.99, 161.34.  
IR (ATR): 𝜈 (cm-1) = 2952 (w), 2931 (w), 2856 (w), 1718 (m), 1671 (vs), 1624 (w), 1605 (w), 
1504 (w), 1471 (w), 1441 (m), 1406 (m), 1387 (m), 1384 (m), 1373 (m), 1356 (m), 1270 (w), 
1253 (m), 1207 (m), 1159 (w), 1140 (m), 1084 (s), 1067 (s), 1021 (m), 1006 (m), 970 (w), 
952 (m), 939 (w), 916 (m), 901 (m), 868 (m), 833 (vs), 816 (m), 775 (s), 731 (s), 684 (w), 664 
(m). 
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7.11.18 Preparation of Uridine Derivative 51d 
51d was prepared according to TP10 from uridine derivate 47 (0.5 mL, 
0.5 м in THF, 0.25 mmol). TMP2Zn·2MgCl2·2LiCl (4, 0.42 mL, 0.71 м 
in THF, 0.30 mmol, 1.2 equiv.) was added to the solution at −30 °C, 
stirred for 72 h and reacted in a Negishi cross-coupling reaction by 
adding Pd(dba)2 (11 mg, 8 mol%), P(2-furyl)3 (9 mg, 15 mol%) and 2-
iodothiophen (63 mg, 0.30 mmol) at 25 °C for 12 h. The crude product was purified by flash 
column chromatography (SiO2, EtOAc:i-hexane/ NEt3 2:8:0.05) furnishing the compound 51d 
(127 mg, 0.25 mmol, 99%) as an orange liquid. 
HRMS (ESI) for C24H36N2O7SSi: calcd. 524.6023 (M
+
); found 524.1998. 
1
H-NMR (400 MHz, CDCl3) δ = 0.04 (s, 3H), 0.05 (s, 3 H), 0.88 (s, 9 H), 1.30 (s, 3 H), 1.42 
(s, 3 H), 3.45 (s, 3 H), 3.81 - 3.87 (m, 2 H), 4.08 - 4.13 (m, 1 H), 4.86 (dd, J=6.43, 4.29 Hz, 1 
H), 5.22 (dd, J=6.43, 1.36 Hz, 1 H), 5.35 (s, 2 H), 5.83 (d, J=1.36 Hz, 1 H), 5.84 (s, 1 H), 7.15 
(dd, J=5.17, 3.61 Hz, 1 H), 7.47 (dd, J=3.70, 1.17 Hz, 1 H), 7.51 (dd, J=5.07, 1.17 Hz, 1 H). 
13
C-NMR (101 MHz, CDCl3) δ = -5.25, -5.21, 18.45, 25.40, 25.92, 27.11, 57.95, 64.22, 
71.93, 82.15, 84.28, 89.54, 93.41, 104.44, 113.50, 128.18, 129.21, 130.47, 132.39, 148.24, 
151.18, 161.53. 
MS (70 eV, EI) m/z (%): 467 (9), 409 (6), 297 (8), 296 (16), 295 (100), 232 (8), 177 (7), 171 
(7), 129 (13). 
IR (ATR): 𝜈 (cm-1) = 3092 (vw), 2951 (w), 2929 (w), 2855 (w), 1716 (m), 1668 (vs), 1610 
(m), 1519 (vw), 1471 (w), 1438 (m), 1403 (w), 1383 (m), 1372 (m), 1359 (m), 1345 (m), 
1253 (m), 1208 (m), 1159 (m), 1134 (m), 1083 (s), 1067 (s), 1006 (m), 971 (w), 944 (m), 916 
(m), 877 (m), 865 (m), 834 (vs), 773 (s), 755 (m), 729 (s), 709 (s), 681 (m), 666 (m). 
7.11.19 Preparation of Uridine Derivative 51e 
51e was prepared according to TP10 from uridine derivate 47 (0.25 
mL, 0.5 м in THF, 0.12 mmol). TMP2Zn·2MgCl2·2LiCl (4, 0.19 mL, 
0.71 м in THF, 0.14 mmol, 1.2 equiv.) was added to the solution at 
−30 °C, stirred for 72 h and reacted in a Negishi cross-coupling 
reaction by adding Pd(PPh3)4 (11.5 mg, 4 mol%) and (E)-1-iodooct-
1-ene (60 mg, 0.25 mmol) at 25 °C for 12 h. The crude product was 
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purified by flash column chromatography (SiO2, EtOAc:i-hexane/ NEt3 2:8:0.05) furnishing 
the compound 51e (107 mg, 0.19 mmol, 76%) as a yellow liquid. 
HRMS (ESI) for C28H49N2O7Si
+
: calcd 553.79145; found 553.33017. 
1
H-NMR (600 Hz, CDCl3) δ = 0.04 (s, 3 H), 0.04 (s, 3 H), 0.88 (s, 9 H), 0.90 (s, 3 H), 1.29 - 
1.32 (m, 4 H), 1.33 (s, 3 H), 1.45 - 1.49 (m, 2 H), 1.53 (s, 3 H), 1.58 (m., 2 H), 2.23 - 2.27 (m 
, 2 H), 3.43 (s, 3 H), 3.77 - 3.85 (m, 2 H), 4.15 (dt, J=7.20, 4.77 Hz, 1 H), 4.87 (dd, J=6.31, 
4.39 Hz, 1 H), 5.22 (dd, J=6.45, 1.24 Hz, 1 H), 5.31 (s, 2 H), 5.71 (s, 1 H), 5.74 (s, 1 H), 6.20 
- 6.27 (m, 1 H), 6.27 - 6.40 (m, 1 H). 
13
C-NMR (MHz, CDCl3) δ = -5.27, -5.26, 14.04, 18.49, 22.55, 25.40, 25.94, 27.22, 28.31, 
28.74, 31.55, 32.95, 57.79, 64.17, 71.78, 81.96, 84.09, 89.47, 92.84, 100.50, 113.55, 121.22, 
143.11, 151.09, 152.97, 162.35. 
IR (ATR): 𝜈 (cm-1) = 2954 (w), 2929 (m), 2856 (w), 1717 (m), 1673 (vs), 1616 (w), 1444 
(m), 1382 (m), 1372 (m), 1360 (m), 1254 (w), 1210 (w), 1159 (w), 1138 (w), 1090 (m), 1009 
(w), 974 (w), 940 (w), 916 (w), 872 (w), 838 (m), 776 (w). 
 
7.11.20 Preparation of Uridine Derivative 51f 
51f was prepared according to TP10 from uridine derivate 47 
(0.5 mL, 0.5 м in THF, 0.25 mmol). TMP2Zn·2MgCl2·2LiCl (4, 
0.42 mL, 0.7 м in THF, 0.30 mmol, 1.2 equiv.) was added to the 
solution at −30 °C and was stirred for 72 h. The zinc reagent was 
treated with CuCN·2LiCl (0.3 mL, 1 м solution in THF, 0.3 mmol, 
1.2 equiv.) for 30 min at −40 °C. Acylation was achieved by 
adding pivaloyl chloride (36 mg, 0.3 mmol) at −40 °C and 
warming up to 0 °C within 12 h. The reaction mixture was stirred at 0 °C until completion of 
the reaction. The crude product was purified by flash column chromatography (SiO2, 
EtOAc:i-hexane/NEt3 2:8:0.05) furnishing compound 51f (128 mg, 0.24 mmol, 99%) as a 
colorless liquid.  
HRMS (EI) for C25H42N2O8Si: calcd. 526.6951; found 511.2476 (M-Me
+
). 
MS (70 eV, EI) m/z (%): 411 (7), 298 (15), 297 (100), 265 (9), 235 (9), 170 (11) 129 (12). 
1
H-NMR (300 MHz, CDCl3) δ = 0.03 (s, 6 H), 0.87 (s, 9 H), 1.31 (s, 12 H), 1.49 (s, 3 H), 
3.44 (s, 3 H), 3.72 - 3.86 (m, 2 H), 4.09 - 4.18 (m, 1 H), 4.81 (dd, J=6.63, 4.15 Hz, 1 H), 5.09 
(d, J=1.38 Hz, 1 H), 5.19 (dd, J=6.36, 1.66 Hz, 1 H), 5.26 - 5.38 (m, 2 H), 5.56 (s, 1 H). 
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13
C-NMR (75 MHz, CDCl3) δ =  -5.33, -5.31, 18.37, 25.37, 25.85, 26.70, 27.16, 45.26, 58.03, 
63.64, 71.93, 81.94, 84.17, 89.49, 95.59, 98.66, 113.90, 150.23, 151.48, 161.50, 205.39. 
IR (ATR): 𝜈 (cm-1) = 2955 (w), 2932 (w), 2856 (w), 1724 (m), 1704 (m), 1674 (vs), 1617 
(w), 1479 (w), 1471 (w), 1446 (m), 1406 (w), 1390 (m), 1383 (m), 1371 (m), 1355 (m), 1252 
(m), 1207 (m), 1178 (w), 1158 (w), 1137 (m), 1084 (s), 1065 (s), 1006 (m), 945 (m), 916 (m), 
888 (m), 868 (m), 834 (vs), 816 (m), 798 (m), 773 (s), 731 (s), 669 (w). 
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7.12 Preperation of 5,6-Disubstituited Uracils and Uridines, 52-57 
7.12.1 Preperation of 5,6-Disubstituited Uracil 52 
To a solution of 6-iodo-1,3-dimethyl-5-pivaloyl uracil (36l, 123 mg, 
0.54 mmol) in THF (1 mL) was added TMPMgCl·LiCl (1, 1.2 м in THF, m 
0.75 mL, 0.9 mmol) at −40 °C. The reaction mixture was stirred for 24 h. 
Upon full conversion, iodine (1.2 M in THF, 0.75 mL, 0.9 mmol) was added 
and the reaction was stirred at 25 °C for 1 h. The mixture was quenched with sat. aq. Na2S2O3 
(10 mL) extracted with CH2Cl2 (3 × 20 mL) and dried over MgSO4 and concentrated in vacuo. 
The crude product was purified by flash column chromatography (SiO2, EtOAc:i-hexane:Et3N 
1:1:0.01) furnishing compound 52 (70 mg, 0.20 mmol, 36%) as a colorless solid. 
HRMS (EI) for C11H15IN2O: calc. 350.0128 (M
+
); found 350.0140. 
MS (EI, 70 eV) m/z (%): 350.01 (100), 351.02 (13), 352.02 (8) 
1
H-NMR (200 MHz, CDCl3) δ = 3.73 (s, 3H), 3.33 (s, 3H), 1.34 (s, 9H). 
13
C-NMR (75 MHz, CDCl3) δ = 207.30, 165.17, 148.98, 124.19, 112.68, 45.09, 34.69, 27.99, 
27.42. 
m.p.: 151-153 °C 
 
7.12.2 Preperation of Pyrazole 54 
To a solution of 6-Iodo-1,3-dimethyl-5-pivaloyl uracil (52, 1 м in DMF, 
0.1 mL) was added N2H4 (1 м in THF, 0.15 mL, 0.15 mmol, 1.5 equiv.). The 
reaction mixture was stirred for 1 h at 60 °C. Upon completion, the reaction 
was quenched with sat. aq. NaCl (10 mL), extracted with CH2Cl2 (3 × 
20 mL), dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
flash column chromatography (SiO2, EtOAc:i-hexane:Et3N 2:8:0.05 furnishing compound 54 
(21 mg, 0.09 mmol, 87%) as a colorless solid. 
HRMS (EI) for C11H15IN3: calc. 236.1273 (M
+
); found 236.1216. 
MS (EI, 70 eV) m/z (%): 237 (13), 236 (81), 235 (23), 222 (16), 221 (100), 137 (13) 
1
H-NMR (300 MHz, CDCl3) δ = 10.21 (s, 1H), 3.52 (s, 3H), 3.40 (s, 3H), 1.53(s, 9H). 
13
C-NMR (75 MHz, CDCl3) δ = 158.86, 155.42, 152.47, 152.00, 97.26, 32.71, 29.74, 28.14, 
27.85. 
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IR (ATR): 𝜈 (cm-1) 3222.00 (m), 3165.00 (w), 3129.00 (w), 3073.00 (w), 3042.00 (w), 
2988.00 (w), 2965.00 (m), 2919.00 (w), 2876.00 (w), 2854.00 (w), 1706.00 (s), 1661.00 (s), 
1596.00 (vs), 1522.00 (s), 1492.00 (m), 1436.00 (m), 1426.00 (s), 1417.00 (m), 1405.00 (m), 
1367.00 (m), 1351.00 (m), 1307.00 (s), 1294.00 (s), 1241.00 (s), 1010.00 (s), 981.00 (s), 
925.00 (s), 786.00 (m), 774.00 (m), 743.00 (s), 708.00 (s). 
m.p.: 255-257 °C 
 
7.12.3 Preparation of Isoxazole 55 
To a solution of 6-Iodo-1,3-dimethyl-5-pivaloyl uracil (52, 1 м in DMF, 
0.1 mL, 0,1 mmol) was added NH2OH·HCl (9 mg, 0.13 mmol, 1.3 equiv.). 
The reaction mixture was stirred for 1 h at 60 °C. Upon completion, the 
reaction was quenched with sat. aq. NaCl (10 mL), extracted with CH2Cl2 
(3 × 20 mL), dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
flash column chromatography (SiO2, EtOAc:i-hexane:Et3N 2:8:0.05 furnishing compound 55 
(13 mg,  0.05 mmol, 55%) as a colorless solid. 
HRMS (EI) for C11H15N3O3: calc. 237.1113 (M
+
); found 236.1066. 
MS (EI, 70 eV) m/z (%): 237 (40), 222 (79), 196 (12), 195 (33), 182 (23), 181 (50), 126 (12), 
125 (14), 124 (42), 67 (812), 58 (34), 57 (90), 56 (16), 55 (14), 53 (14), 43 (36). 
1
H-NMR (300 MHz, CDCl3) δ = 3.49 (s, 3H), 3.37 (s, 3H), 1.52(s, 9H). 
13
C-NMR (75 MHz, CDCl3) δ = 185.76, 158.77, 155.01, 151.02, 97.98, 35.38, 30.29, 28.31, 
27.10. 
IR (ATR): 𝜈 (cm-1) 2976.00 (w), 2930.00 (w), 2874.00 (w), 2857.00 (w), 2361.00 (w), 
2340.00 (w), 1724.00 (s), 1673.00 (vs), 1613.00 (vs), 1551.00 (m), 1497.00 (m), 1424.00 (s), 
1372.00 (m), 1362.00 (s), 1302.00 (s), 1272.00 (s), 1250.00 (m), 1182.00 (m), 1012.00 (s), 
786.00 (s), 742.00 (vs). 
m.p.: 230-232 °C 
  
 D. Experimental Section 
 
143 
7.12.4 Preparation of 5,6-Disubstituited Uridine 53 
To a solution of Uridine derivate 49n (1 mL, 0.50 м in THF, 0.50 mmol) 
was added TMPMgCl·2LiCl (1, 0.6 mL, 1.0 м in THF, 0.30 mmol, 
1.2 equiv.) at −20 °C. The reaction mixture was stirred for 20 min. The 
magnesium reagent reacted with iodine (0.6 mL, 1.0 м in THF, 0.30 
mmol, 1.2 equiv.) at −20 °C, stirring for 10 min at –20 °C and 10 min at 
25 °C. The crude product was purified by flash column chromatography (SiO2, EtOAc:i-
hexane/ NEt3 2:8:0.05) furnishing the compound 53 (267 mg, 0.43 mmol, 87%) as a yellow 
liquid.  
HRMS (ESI) for C20H32IN2O7SSi
-
 calcd 599,53302 (M-Me); found 599.04743. 
1
H NMR (400 MHz, CDCl3) δ = 0.04 (s, 3 H), 0.04 (s, 3 H), 0.88 (s, 9 H), 1.34 (s, 3 H), 1.55 
(s, 3 H), 2.38 (s, 3 H), 3.43 (s, 3 H), 3.70 - 3.89 (m, 2 H), 4.01 - 4.22 (m, 1 H), 4.86 (dd, 
J=6.53, 4.39 Hz, 1 H), 5.18 (dd, J=6.53, 1.27 Hz, 1 H), 5.33 (s, 2 H), 6.40 (d, J=1.36 Hz, 1 
H). 
13
C NMR (101 MHz, CDCl3) δ = -5.26, -5.24, 17.94, 18.48, 25.42, 25.95, 27.23, 58.25, 
63.99, 73.24, 82.00, 84.66, 89.89, 105.07, 113.81, 120.75, 126.49, 148.46, 157.30. 
IR (ATR): 𝜈 (cm-1) = 3469 (w), 2987 (w), 2952 (w), 2928 (m), 2856 (w), 1715 (s), 1661 (vs), 
1531 (s), 1434 (m), 1422 (s), 1372 (s), 1358 (s), 1258 (m), 1209 (s), 1187 (m), 1158 (m), 
1138 (m), 1089 (vs), 1065 (vs), 970 (s), 958 (s), 919 (m), 878 (s), 864 (s), 835 (s), 808 (s), 
766 (vs), 665 (s). 
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7.13 Cytidine Derivatives 59a-d 
7.13.1 Preparation of Cytidine Derivative 59a 
Compound 59a was prepared according to TP10 from cytidine derivate 57 
(1.00 mL, 0.20 м in THF, 0.20 mmol). To the solution 
TMP2Zn·2MgCl2·2LiCl (4, 0.50 mL, 0.5 м in THF, 0.25 mmol, 1.2 equiv.) 
was added at −30 °C and subsequently stirred for 4 h. The obtained zinc 
species 58 reacted with iodine (63 mg, 0.25 mmol) for 30 min. The crude 
product was purified by flash column chromatography (SiO2, EtOAc:i-
hexane/NEt3 2:8:0.05) furnishing the compound 59a (95 mg, 0.12 mmol, 61%) as a colorless 
liquid. 
HRMS (ESI) for C28H47IN3O9Si: calcd. 724.2126; found 724.2122. 
1
H NMR (400 MHz, acetone) δ =  0.02 (s, J=1.17, 3 H),  0.02 (s, J=1.17, 3 H),  0.87 (s, 9 H), 
1.32 (s, 3 H), 1.50 (s, 3 H), 1.54 (s, 18 H), 3.83 (d, J=1.17 Hz, 1 H), 3.85 (s, 1 H), 4.16 (td, 
J=6.55, 3.72 Hz, 1 H), 4.87 (dd, J=6.36, 3.81 Hz, 1 H), 5.26 (dd, J=6.46, 1.17 Hz, 1 H), 6.23 
(d, J=0.98 Hz, 1 H), 7.65 (s, 1 H), 
13
C NMR (101 MHz, acetone) δ = -5.96, -5.82, 17.99, 24.51, 25.39, 26.54, 26.89, 64.06, 
82.90, 84.41, 84.82, 90.89, 102.96, 109.83, 112.79, 118.26, 149.04, 151.53, 161.29, 
IR (ATR): 𝜈 (cm-1) = 3426.00 (w), 3265.00 (w), 2977.00 (w), 2934.00 (w), 1710.00 (s), 1638 
(vs), 1549 (m), 1495 (m), 1421 (m), 1369 (s), 1273 (s), 1254 (s), 1146 (vs), 1102 (s), 1065 (s), 
1043 (m), 1013 (m), 868 (m), 803 (m), 767 (m), 734 (w), 661 (w). 
 
7.13.2 Preparation of Cytidine Derivative 59b 
Compound 59b was prepared according to TP10 from cytidine derivate 
57 (0.50 mL, 0.20 м in THF, 0.10 mmol). TMP2Zn·2MgCl2·2LiCl (4, 
0.16 mL, 0.72 м in THF, 0.11 mmol, 1.1 equiv.) was added to the 
solution at −30 °C, and subsequently stirred for 4 h. The obtained zinc 
species 58 reacted with iodobenzene (24 mg, 0.12 mmol, 1.2 equiv.) for 
30 min. The crude product was purified by flash column 
chromatography (SiO2, EtOAc:i-hexane/NEt3 2:8:0.05) furnishing compound 57b (29 mg, 
0.04 mmol, 43%) as a colorless liquid. 
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HRMS (ESI) for C34H52N3O9Si
+
:calcd. 674,34673; found 674.34650. 
1
H NMR (300 MHz, acetone-d6) δ =  0.07 (s, 3 H), 0.07 (s, 3 H), 0.91 (s, 9 H), 1.27 (s, 3 H), 
1.32 (s, 3 H), 1.57 (s, 18 H), 3.91 (s, 1 H,) 3.94 (s, 1 H), 4.01 - 4.12 (m, 1 H), 4.88 (dd, 
J=6.36, 3.87 Hz, 1 H), 5.28 (dd, J=6.50, 1.24 Hz, 1 H), 5.63 (s, 1 H), 6.91 (s, 1 H), 7.62 (s, 5 
H). 
13
C NMR (75 MHz, acetone-d6) δ = -5.90, -5.78, 18.02, 24.44, 25.40, 26.40, 26.95, 64.25, 
83.10, 84.20, 84.53, 90.57, 93.94, 97.52, 112.56, 128.47, 128.97, 130.65, 133.58, 149.38, 
153.93, 160.71, 161.62. 
IR (ATR): 𝜈 (cm-1) =  2980 (w), 2952 (w), 2932 (w), 2929 (w), 2887 (w), 2856 (w), 1781 
(m), 1745 (s), 1685 (s), 1608 (m), 1596 (m), 1574 (w), 1537 (m), 1492 (w), 1467 (w), 1461 
(w), 1413 (m), 1395 (m), 1370 (m), 1308 (vs), 1284 (m), 1251 (s), 1209 (m), 1159 (s), 1131 
(vs), 1092 (m), 1057 (m), 1033 (w), 973 (w), 879 (w), 837 (m), 816 (w), 789 (w), 776 (m), 
701 (w). 
 
7.13.3 Preparation of Cytidine Derivative 59c 
 Compound 59c was prepared according to TP10 from cytidine 
derivate 57 (1.00 mL, 0.20 м in THF, 0.20 mmol). 
TMP2Zn·2MgCl2·2LiCl (4, 0.32 mL, 0.72 м in THF, 0.23 mmol, 
1.1 equiv.) was added to the solution at −30 °C, stirred for 4 h. 
The zinc reagent 58 was treated with CuCN·2LiCl (0.3 mL, 1 м 
solution in THF, 0.3 mmol, 1.5 equiv.) for 30 min at −40 °C. 
Acylation was achieved by adding bromocyclohex-1-ene (48 mg, 
0.23 mmol, 1.1 equiv.) at −40 °C and warming up to 0 °C. The reaction mixture was stirred at 
0 °C until completion. The crude product was purified by flash column chromatography 
(SiO2, EtOAc:i-hexane/NEt3 2:8:0.05) furnishing compound 59c (70 mg, 0.10 mmol, 52%, dr 
= 91:19) as a colorless liquid. 
HRMS (ESI) for C34H56N3O9Si
+
: calcd. 678.37803 (M+H
+
), found 678.37798. 
Major isomer:
  1
H NMR (400 MHz, Acetone) δ = = 0.00 (s, 3 H), 0.01 (s, 3 H), 0.86 (9 H), 
1.31 (s, 3 H), 1.48 (s, 3 H), 1.53 (s, 18 H), 1.68 - 1.73 (m, 3 H), 2.07 - 2.12 (m, 3 H), 3.77 - 
3.79 (m, 1 H), 3.84 (d, J=3.18 Hz, 1 H), 3.86 (d, J=1.96 Hz, 1 H), 4.10 - 4.13 (m, 1 H), 4.86 
(dd, J=6.48, 3.79 Hz, 1 H), 5.29 (dd, J=6.48, 1.10 Hz, 1 H), 5.64 - 5.68 (m, 1 H), 5.98 (m, 1 
H), 6.03 - 6.07 (m, 1 H), 6.87 (m, 1 H).  
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Major isomer:
 13
C NMR (101 MHz, acetone) δ = -5.9 (1 C, 
1
JSiC = 56.9), -5.8 ( 1 C, 
1
JSiC = 
56.9), 0.89 (3 C), 18.0 (l C), 19.6 (1 C), 24.6 (1 C), 24.8 (1 C), 27.0 (6 C), 28.8 (1 C), 25.4 (1 
C), 26.6 (1 C), 37.7 (1 C), 64.2 (1 C), 83.2 (1 C), 84.3 (1 C), 84.4 (2 C), 90.5 (1 C), 92.0 (1 
C), 95.7 (1 C), 112.8 (1 C), 125.4 (1 C); 149.5 (2 C), 131.0 (1 C), 154.4 (1 C), 162.1 (1 C), 
164.8 (1 C). 
IR (ATR): 𝜈 (cm-1) = 2979 (w), 2930 (w), 2856 (w), 1779 (m), 1743 (s), 1716 (m), 1680 (s), 
1603 (m), 1538 (m), 1472 (w), 1460 (w), 1420 (m), 1394 (m), 1381 (m), 1369 (s), 1300 (s), 
1248 (s), 1209 (m), 1156 (s), 1133 (vs), 1098 (s), 1084 (s), 1054 (s), 1047 (s), 975 (m), 937 
(m), 876 (m), 835 (vs), 815 (m), 789 (m), 776 (s), 727 (m). 
 
7.13.4 Preparation of Cytidine Derivative 59d 
Compound 59d was prepared according to TP10 from cytidine derivate 57 (1 mL, 0.20 м in 
THF, 0.20 mmol). To the solution was added TMP2Zn·2MgCl2·2LiCl 
(4, 0.32 mL, 0.72 м in THF, 0.23 mmol, 1.1 equiv.) at −30 °C and 
subsequently stirred for 4 h. The zinc reagent 60 was treated with 
CuCN·2LiCl (0.3 mL, 1 м solution in THF, 0.3 mmol, 1.5 equiv.) for 
30 min at −40 °C. Acylation was achieved by adding 
cyclopropanecarbonyl chloride (31 mg, 0.3 mmol, 1.5 equiv.) at −40 °C and warming up to 
0 °C within 12 h. The reaction mixture was stirred at 0 °C until completion. The crude 
product was purified by flash column chromatography (SiO2, EtOAc:i-hexane/NEt3 2:8:0.05) 
furnishing compound 69d (69 mg, 0.10 mmol, 52%) as a colorless liquid. 
HRMS (ESI) for C32H51N3O10Si
+
: calcd 666,86345; found 666.3414 (M
+
-Me).  
1
H NMR (400 MHz, acetone) δ = 0.00 (s, 3H), 0.01 (s, 3H), 0.84 (s, 9 H), 1.21 - 1.33 (m, 4 
H), 1,27 (s, 3H), 1.44 (s, 3 H), 1.52 (s, 18 H), 2.33 - 2.59 (m, 1 H), 3.78 - 3.86 (m, 2 H), 4.06- 
4.10 (m, 1 H), 4.78 (dd, J=6.48, 4.03 Hz, 1 H), 5.22 (dd, J=6.60, 1.22 Hz, 1 H), 5.72 (d, 
J=1.22 Hz, 1 H), 7.11 (s, 1 H). 
13
C NMR (101 MHz, acetone) δ =  -5.93, -5.80, 13.39, 13.97, 18.04, 21.64, 24.66, 25.43, 
26.61, 26.95, 63.94, 82.67, 84.47, 84.93, 90.09, 94.74, 94.77, 113.11, 149.21, 153.07, 156.96, 
162.34, 197.93. 
IR (ATR): ?̃? (cm-1) = 2980.00 (w),2955 (w),2932 (w),2856 (w),1782 (m),1745 (s),1689 
(s),1604 (m),1540 (w),1472 (w),1461 (w),1426 (w),1383 (m),1371 (s),1349 (w),1311 
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(vs),1251 (s),1210 (m),1157 (s),1128 (vs),1083 (s),1062 (m),1026 (m),1005 (w),967 (w),876 
(w),838 (s),815 (m),779 (m). 
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7.14 Regioselective Reaction of Zinc Species 63 with Various Electrophiles 
at the Benzylic Position 64a-i  
7.14.1 Preparation of 4-(Cyclohex-2-en-1-ylmethyl)-3,5-dimethylisoxazole (64a)  
Compound 64a was prepared according to TP12a from zinc species 63 
(1 mmol, 0.4 м in THF), CuCN·2LiCl (1.2 mmol, 1 м in THF, 1.2 equiv.) and 
3-bromocyclohex-1-ene (160 mg, 1 mmol, 1 equiv.). The crude product was 
purified by flash column chromatography (SiO2, EtOAc:i-hexane 1:9) furnishing product 64a 
(139 mg, 0.73 mmol, 73%) as a colorless oil.  
HRMS (EI) for C12H17NO: calcd 191.1310 (M
+
); found 191.1342. 
MS (EI, 70eV), m/z(%): 191 (8), 176 (14), 148 (21), 112 (18), 111 (16), 110 (82). 
1
H NMR (300 MHz, CDCl3): δ = 1.07 - 1.23 (m, 1 H), 1.38 - 1.55 (m, 1 H), 1.59 - 1.74 (m, 2 
H), 1.94 (d, J=2.49 Hz, 2 H), 2.15 (d, J=2.49 Hz, 3 H), 2.10 – 2.31 (m, 3 H), 2.24 (d, J=2.21 
Hz, 3 H), 5.43 (d, J=9.95 Hz, 1 H), 5.58 - 5.74 (m, 1 H). 
13
C NMR (75 MHz, CDCl3): δ = 10.28, 11.05, 21.01, 25.22, 28.75, 28.85, 35.61, 112.06, 
127.98, 130.35, 159.71, 165.12. 
IR (ATR): 𝜈 (cm-1) = 3232, 3026, 2925, 2857, 2843, 1735, 1670, 1636, 1448, 1422, 1260, 
1193, 891, 742, 721, 693. 
 
7.14.2 Preparation of Ethyl 4-(3,5-dimethylisoxazol-4-yl)-2-methylenebutanoate 
(64b)  
64b was prepared according to TP12a from zinc species 63 (1 mmol, 0.4 м in 
THF), CuCN·2LiCl (1.2 mmol, 1 м in THF, 1.2 equiv.) and 
2-(bromomethyl)acrylate (191 mg, 1 mmol, 1 equiv.). The crude product was 
purified by flash column chromatography (SiO2, EtOAc:i-hexane 1:9) 
furnishing product 64b (171 mg, 0.77 mmol, 77%) as a colorless oil.  
HRMS (EI) for C12H17NO3: calcd 223.1208 (M
+
); found 223.1203. 
MS (EI, 70eV), m/z(%): 223 (5), 111 (10), 110 (100), 68 (58). 
1
H NMR (300 MHz, CDCl3): δ = 1.26 (t, J=7.05 Hz, 3 H), 2.16 (s, 3 H), 2.22 (s, 3 H), 2.32 - 
2.47 (m, 4 H), 4.16 (q, J=7.00 Hz, 2 H), 5.44 (d, J=1.11 Hz, 1 H), 6.10 (d, J=1.38 Hz, 1 H). 
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13
C NMR (75 MHz, CDCl3): δ = 10.04, 10.79, 14.14, 21.60, 32.40, 60.68, 112.56, 125.91, 
139.44, 159.49, 164.95, 166.68. 
IR (ATR): 𝜈 (cm-1) = 2983, 2964, 2931, 2872, 1710, 1631, 1447, 1425, 1369, 1324 , 1302, 
1253, 1193, 1142, 1056, 1025, 947, 890, 861, 818, 750, 735, 693, 661. 
7.14.3 Preparation of 2-(3,5-Dimethylisoxazol-4-yl)-1-(furan-2-yl)ethan-1-one 
(64c) 
64c was prepared according to TP12b from zinc species 63 (0.8 mmol, 0.4 м in 
THF), CuCN·2LiCl (0.95 mmol, 1 м in THF, 1.2 equiv.) and 2-furoyl chloride 
(104 mg, 0.8 mmol, 1 equiv.). The crude product was purified by flash column 
chromatography (SiO2, EtOAc:i-hexane 1:9) furnishing product 64c (133 mg, 
0.64 mmol, 81%) as a colorless solid.  
HRMS (EI) for C11H11NO3: calcd. 205.0739 (M
+
); found 205.0741.
  
MS (EI, 70eV), m/z(%): 205 (22), 163 (17), 162 (61), 110 (23), 95 (100). 
1
H NMR (300 MHz, CDCl3): δ = 2.14 (d, J=1.38 Hz, 3 H), 2.27 (d, J=1.11 Hz, 3 H), 3.79 (s, 
2 H), 6.51-6.53 (m, 1 H), 7.20 (d, J=3.59 Hz, 1 H), 7.57 (s, 1 H). 
13
C NMR (75 MHz, CDCl3) δ =  10.22, 11.09, 32.14, 106.85, 112.62, 117.54, 146.63, 152.03, 
159.89, 166.50, 184.65. 
IR (ATR): 𝜈 (cm-1) =3144, 3122, 3114, 3095, 2962, 2928, 2849, 1735, 1646, 1561, 1460, 
1454, 1422, 1392, 1332, 1281, 1259, 1238, 1200, 1191, 1163, 1084, 1071, 1040, 994, 915, 
880, 785, 777, 745, 695, 682. 
m.p.: 89-91 °C 
7.14.4 Preparation of 64d 
1-(3,5-Dimethylisoxazol-4-yl)-3,3-dimethylbutan-2-one (64d) was prepared 
according to TP12b from zinc species 63 (0.8 mmol, 0.4 м in THF), 
CuCN·2LiCl (0.95 mmol, 1 м in THF, 1.2 equiv.) and pivaloyl chloride 
(0.96 mg, 0.8 mmol, 1 equiv.). The crude product was purified by flash column 
chromatography (SiO2, EtOAc:i-hexane 1:9) furnishing product 64d (116 mg, 0.54 mmol, 
74%) as a colorless solid.  
HRMS (EI) for C11H17NO2: calcd 195.1259 (M
+
); found 195.1302. 
MS (EI, 70eV), m/z(%): 139 (11), 110 (10), 68 (16), 57 (100). 
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1
H NMR (300 MHz, CDCl3): δ = 1.19 (s, 9 H), 2.07 (d, J=1.38 Hz, 3 H), 2.21 (s, 3 H), 3.45 
(s, 2 H). 
13
C NMR (75 MHz, CDCl3): δ =10.17, 11.02, 26.38, 20.11, 44.20, 107.67, 159.74, 166.94, 
211.09. 
IR (ATR): 𝜈 (cm-1) = 3014, 2890, 1698, 1649, 1454, 1444, 1428, 1411, 1378, 1317, 1263, 
1217, 1200, 1187, 1097, 1075, 1043, 1025, 925, 893, 883, 813, 791, 746, 740, 681. 
7.14.5 Preparation of 1-Cyclopropyl-2-(3,5-dimethylisoxazol-4-yl)ethan-1-one 
(64e)  
64e was prepared according to TP12b from zinc species 63 (0.8 mmol, 0.4 м 
in THF), CuCN·2LiCl (0.95 mmol, 1 м in THF, 1.2 equiv.) and 
cyclopropanecarbonyl chloride (83 mg, 0.8 mmol, 1 equiv.). The crude 
product was purified by flash column chromatography (SiO2, EtOAc:i-hexane 
1:9) furnishing the products 64e (121 mg, 0.67 mmol, 84%) as a colorless solid.  
HRMS (EI) for C10H13NO2: calcd179.0946 (M
+
); found 179.0934. 
MS (EI, 70eV), m/z(%): 179 (6), 137 (9), 136 (32), 110 (11). 
1
H NMR (300 MHz, CDCl3): δ = 0.79 - 0.92 (m, 2 H), 0.92 - 1.03 (m, 2 H), 1.84-1.91 (m, 
1H), 2.09 (d, J=1.11 Hz, 3 H), 2.24 (d, J=0.83 Hz, 3 H), 3.47 (s, 2 H). 
13
C NMR (75 MHz, CDCl3): δ =  10.12, 10.99, 11.31, 19.83, 37.09, 107.40, 159.71, 166.10, 
206.26. 
IR (ATR): 𝜈 (cm-1) 2965, 2934, 2916, 2870, 1707, 1644, 1479, 1455, 1427, 1410, 1395, 
1366, 1328, 1265, 1221, 1197, 1064, 1005, 936, 887, 810, 746, 719, 671. 
m.p.: 52-54 °C 
7.14.6 Preparation of Ethyl 4-((3,5-dimethylisoxazol-4-yl)methyl)benzoate (64f)  
64f was prepared according to TP12c from zinc species 63 (1.0 mmol, 
0.4 м in THF) ethyl-p-iodobenzoate and (248 mg, 0.9 mmol, 0.9 equiv.) in 
the presence of PEPPSI-iPr (5 mg, 1 mol %). The crude product was 
purified by flash column chromatography (SiO2, EtOAc:i-hexane 1:9) 
furnishing product 64f (203 mg, 0.78 mmol, 87%) as a yellow oil.  
HRMS (EI) for C15H17NO3: calcd 259.1208 (M
+
), found: 259.1207 
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MS (EI, 70eV), m/z(%):260 (18), 259 (100), 258 (36), 231 (30), 230 (69), 216 (20), 215 (14), 
214 (87), 189 (20), 188 (29), 187 (10), 186 (56), 149 (18), 145 (21), 144 (28), 143 (10), 131 
(13), 115 (15), 103 (12), 102 (12), 77 (11), 43 (41).  
1
H NMR (300 MHz, CDCl3): δ = 1.39 (t, J=7.06 Hz, 3 H), 2.08 (s, 3 H), 2.32 (s, 3 H), 3.74 
(s, 2 H), 4.38 (q, J=7.02 Hz, 2 H), 7.18 (d, J=8.17 Hz, 2 H), 7.98 (d, J=8.17 Hz, 2 H). 
13
C NMR (75 MHz, CDCl3): δ =10.29, 11.03, 14.32, 28.23, 60.93, 111.63, 128.02, 128.93, 
129.91, 143.98, 159.78, 165.65, 166.33. 
IR (ATR): 𝜈 (cm-1) = 2987, 1705, 1610, 1478, 1449, 1416, 1365, 1278, 1179, 1124, 1107, 
1020, 880, 743, 730.  
 
7.14.7 Preparation of 4-(4-Chlorobenzyl)-3,5-dimethylisoxazole (64g)  
64g was prepared according to TP12c from zinc species 63 (0.8 mmol, 0.4 м in THF) and 1-
chloro-4-iodobenzene (190 mg, 0.8 mmol, 1 equiv.) in the presence of 
PEPPSI-iPr (5 mg, 1 mol %). The crude product was purified by flash column 
chromatography (SiO2, EtOAc:i-hexane 1:9) furnishing product 64g (151 mg, 
0.68 mmol, 85%) as a yellow oil.  
HRMS (EI) for C12H12ClNO2: calcd 221.0607 (M
+
); found 221.0608. 
MS (EI, 70eV), m/z(%): 223 (28), 222 (10), 221 (100), 220 (18), 186 (30), 180 (11), 179 (13), 
178 (36), 167 (11), 165 (49).  
1
H NMR (300 MHz, CDCl3): δ = 2.06 (s, 3 H), 2.29 (s, 3 H), 3.63 (s, 2 H), 7.02 (d, J=8.29 
Hz, 2 H), 7.24 (d, J=8.57 Hz, 2 H). 
13
C NMR (75 MHz, CDCl3): δ = 10.27, 10.99, 27.53, 111.86, 128.71, 129.33, 132.25, 137.23, 
159.76, 165.51. 
IR (ATR): 𝜈 (cm-1) = 3030, 2991, 2962, 2925, 2846, 1639, 1489, 1422, 1406, 1257, 1198, 
1186, 1089, 1039, 1014, 901, 887, 804, 758.50, 741, 695. 
7.14.8 Preparation of 4-((3,5-Dimethylisoxazol-4-yl)methyl)benzonitrile (64h)  
64h was prepared according to TP12c from zinc species 63 (0.8 mmol, 0.4 м 
in THF) and 4-iodobenzonitrile (183 mg, 0.8 mmol, 1 equiv.) in the presence 
of PEPPSI-iPr (5 mg, 1 mol %). The crude product was purified by flash 
column chromatography (SiO2, EtOAc:i-hexane 1:9) furnishing product 64h 
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(110 mg, 0.52 mmol, 65%) as a yellow oil.  
HRMS (EI) for C12H12ClNO2: calcd 212.0947 (M
+
); found 212.0936. 
MS (EI, 70eV), m/z(%): 213 (10), 212 8100), 211 (31), 170 (24), 169 (60), 156 (49), 155 
(11), 140 (10), 128 (32).  
1
H NMR (300 MHz, CDCl3): δ = 2.03 (s, 3 H), 2.28 (s, 3 H), 3.72 (s, 2 H), 7.19 (d, J=8.57 
Hz, 2 H), 7.54 (d, 8.57 Hz, 2 H). 
13
C NMR (75 MHz, CDCl3): δ = 10.24, 11.01, 28.25, 110.49, 111.02, 118.65, 128.80, 132.42, 
144.40, 159.57, 165.87. 
IR (ATR): 𝜈 (cm-1) = 2961, 2922, 2854, 2224, 1639, 1606, 1501, 1448, 1421, 1411, 1260, 
1200, 1187, 1176, 1117, 1039, 902, 884, 844, 820, 767, 742, 721, 697, 661. 
 
7.14.9 Preparation of 3,5-Dimethyl-4-(thiophen-2-ylmethyl)isoxazole (64i) 
 64i was prepared according to TP12c from zinc species 63 (0.8 mmol, 0.4 м in 
THF) and 2-iodothiophene (167 mg, 0.8 mmol, 1 equiv.) in the presence of 
PEPPSI-iPr (5 mg, 1 mol %). The crude product was purified by flash column 
chromatography (SiO2, EtOAc:i-hexane 1:9) furnishing product 64i (110 mg, 0.57 mmol, 
71%) as a yellow oil. 
HRMS (ESI) for C12H12ClNO2: calcd 194.06341(M
+
); found194.06336. 
1
H NMR (300 MHz, CDCl3): δ = 2.15 (s, 3 H), 2.32 (s, 3 H), 3.83 (s, 2 H), 6.66 - 6.76 (m, 1 
H), 6.90 (dd, J=5.11, 3.46 Hz, 1 H), 7.13 (dd, J=5.25, 1.11 Hz, 1 H). 
13
C NMR (75 MHz, CDCl3): δ = 10.12, 10.94, 22.76, 112.33, 123.97, 124.60, 126.89, 142.21, 
159.57, 165.41. 
IR (ATR): 𝜈 (cm-1) = 3115, 3074, 2995, 2967, 2921, 1638, 1450, 1422, 1307, 1261, 1192, 
1138, 1076, 1034, 1010, 886, 849, 827, 759, 741, 691. 
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7.15 Benzylic Addition of Zinc Species 1 to Aldehydes forming Products 
67a-c 
7.15.1 Preparation of 1-(3,4-Dichlorophenyl)-2-(3,5-dimethylisoxazol-4-yl)ethan-
1-ol (67a) 
67a was prepared according to TP12d from zinc reagent 63 (0.42 mmol, 
0.42 м in THF, 1 equiv.), BF3·OEt2 (0.21 mL, 0.84 mmol, 50% in Et2O, 
2 equiv.), and 3,4-dichlorobenzaldehyde (0.42 mL, 0.42 mmol, 1 м in THF, 
1 equiv.). Purification by flash chromatography (i-hexane:EtOAc 8:2) 
furnishing 67a as a colorless solid (66 mg, 0.23 mmol, 55%). 
HRMS (EI) for C13H13Cl2NO2: calcd 286.15200 (M+H
+
); found 286.0384. 
MS (EI): 288 (1), 286 (1), 176 (60), 175 (11), 174 (100), 172 (24), 148 (28), 146 (49), 144 
(16).   
1
H NMR (300 MHz, CDCl3): δ = 2.08 (s, 3 H) 2.13 (s, 3 H) 2.65 (d, J=6.38 Hz, 2 H) 4.74 (t, 
J=6.38 Hz, 1 H) 7.05 - 7.10 (m, 1 H) 7.37 - 7.42 (m, 2 H).  
13
C NMR (75 MHz, CDCl3): δ = 10.12, 10.91, 32.37, 72.66, 109.32, 125.15, 127.76, 130.39, 
131.65, 132.65, 143.76, 159.90, 166.65. 
IR (ATR): 𝜈 (cm-1) = 3296, 1636, 1467, 1455, 1420, 1391, 1380, 1335, 1257, 1191, 1128, 
1076, 1051, 1029, 974, 912, 903, 883, 854, 825, 777, 745, 703, 684, 678. 
m.p.: 131 °C 
7.15.2 Preparation of 1-(4-Chlorophenyl)-2-(3,5-dimethylisoxazol-4-yl)ethan-1-ol 
(67b)  
67b was prepared according to TP12d from zinc reagent 63 (0.80 mmol, 0.4 м 
in THF, 1 equiv.), BF3·OEt2 (0.42 mL, 1.6 mmol, 50% in Et2O, 2 equiv.), and 
4-dichlorobenzaldehyde (0.80 mL, 0.8 mmol, 1 м in THF, 1 equiv.). 
Purification by flash chromatography (i-hexane:EtOAc 8:2) furnishing 67b as 
a colorless oil (132 mg, 0.52 mmol, 65%). 
HRMS (EI) for C13H15ClNO2: calcd 252.07858 (M+H
+
), found 252.07834. 
1
H NMR (300 MHz, CDCl3): δ = 2.02 (s, 3 H), 2.07 (s, 3 H), 2.68, 4.76 (ABX, δA=2.67, 
δB=2.64, δx=4.76, JAB= 14.38 Hz, JAX= 6.36 Hz, JBX= 6.30 Hz, 2H), 2.92 (s, 1 H), 7.09 - 7.22 
(m, 2 H), 7.22 - 7.39 (m, 2 H). 
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13
C NMR (75 MHz, CDCl3): δ = 10.01, 10.79, 32.41, 73.15, 109.56, 127.22, 128.54, 133.43, 
142.04, 160.06, 166.60. 
IR (ATR): 𝜈 (cm-1) =3326, 2924, 1636, 1490, 1455, 1422, 1404, 1371, 1338, 1308, 1259, 
1239, 1191, 1105, 1088, 1074, 1051, 1013, 972, 901, 862, 852, 818, 756, 745, 712, 679. 
 
7.15.3 Preparation of 2-(3,5-Dimethylisoxazol-4-yl)-1-phenylethan-1-ol (67c)  
67c was prepared according to TP12d from zinc reagent 63 (0.80 mmol, 0.4 м 
in THF, 1 equiv.), BF3·OEt2 (0.42 mL, 1.6 mmol, 50% in Et2O, 2 equiv.), and 
benzaldehyde (0.80 mL, 0.8 mmol, 1 м in THF, 1 equiv.). Purification by flash 
chromatography (i-hexane:EtOAc 8:2) furnishing 67c as a colorless oil 
(108 mg, 0.50 mmol, 62%). 
HRMS (EI) for C13H15NO2: 218,1181 (M+H
+
); found 218.1206. 
1
H NMR (200 MHz, CDCl3): δ = 1.95 (s, 3 H), 1.99 (s, 3 H) 2.58-2.77, 4.73 (ABX, δA=2.69, 
δB= 2.65, δx= 4.73, JAB= 14.47 Hz, JAX= 6.23 Hz, JBX= 6.41 Hz, 2H), 3.04 (s, 1 H), 7.04 - 
7.49 (m, 6 H) 
13
C NMR (75 MHz, CDCl3): δ = 9.91, 10.66, 32.43, 73.88, 109.75, 125.86, 127.75, 128.43, 
143.49, 160.22, 166.56. 
IR (ATR): 𝜈 (cm-1) = 3373, 3092, 3066, 3029, 2925, 2859, 1744, 1720, 1689, 1634, 1493, 
1452, 1423, 1328, 1260, 1193, 1093, 1060, 1026, 909, 890, 842, 760, 737, 699, 679.   
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7.16 Allylic Addition of Zinc Species 1 with Aldehydes 66a-l 
7.16.1 Preparation of (S)-(3,4-Dichlorophenyl)((R)-3,5-dimethyl-4-methylene-4,5-
dihydroisoxazol-5-yl)methanol (66a)  
66a was prepared according to TP13a from zinc reagent 63 (1.5 mmol, 
1.5 equiv.), LaCl3·2LiCl (2.00 mmol, 0.5 м in THF, 2 equiv.), and 3,4-
dichlorobenzaldehyde (1.0 mmol, 1.0 mL, 1 м in THF, 0.66 equiv.). 
Purification by flash chromatography (i-hexane:EtOAc 8:2) furnishing 
66a as a white solid (263 mg, 0.92 mmol, 92%, dr= 96:4). 
66a could also be prepared according to TP13b from zinc reagent 63 (0.3 mmol) to produce 
the title compound in 73% yield (dr= 94:6). 
HRMS (EI) for C13H14Cl2NO2: calcd 286.0323 (M+H
+
), found 286.0370. 
MS (EI, 70 eV): m/z (%) = 178 (4), 175 (73), 173 (54), 145 (21), 111 (98), 96 (24), 83 “0), 82 
(21), 75 (22), 70 (100), 68 (79), 55 (17), 43 (56). 
1
H NMR (200 MHz, CDCl3): δ = 1.37 (s, 3 H), 1.97 (s, 3 H), 2.92 (s, 1 H), 4.63 (s, 1 H), 4.69 
(s, 1 H), 5.31 (s, 1 H), 7.14 - 7.33 (m, 1 H), 7.33 - 7.55 (m, 2 H). 
13
C NMR (101 MHz, acetone d6): δ = 8.67, 21.25, 75.93, 88.31, 108.31, 128.09, 129.19, 
129.99, 130.42, 130.60, 141.45, 152.42, 154.12. 
IR (ATR): 𝜈 (cm-1) =3268, 2983, 2955, 2924, 2852, 2722, 2677, 2339, 1723, 1644, 1589, 
1564, 1469, 1452, 1416, 1395, 1384, 1372, 1296, 1251, 1199, 1130, 1073, 1030, 909, 889, 
855, 821, 752, 744.  
m.p.: 86 - 96 °C 
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Figure 38: Molecular structure of compound 66a in the crystal, DIAMOND representation, thermal ellipsoids 
are drawn at 50% probability level. 
 
Figure 39: Crystal structure of compound 66a, chains formed by O-H···N hydrogen bonds, O-H 0.83(2) Å, 
H···N 1.98(2) Å, O···N 2.798(2) Å, O-H-N 172(2)°, DIAMOND representation, thermal ellipsoids are drawn at 
50% probability level; symmetry codes: i) 1-x, 0.5+y, 0.5-z; ii) x, 1+y, z; iii) 1-x, -0.5+y, 0.5-z. 
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Table 13: Details for X-ray data collection and structure refinement for compound 66a. 
Empirical formula C13H13Cl2NO2 
Formula mass 286.14 
T [K] 100(2) 
Crystal size [mm] 0.384 × 0.247 × 0.088 
Crystal description colorless block 
Space group P21/c 
a [Å] 10.5625(3) 
b [Å] 10.6780(3) 
c [Å] 11.7851(4) 
β [°] 92.663(3) 
V [Å
3
] 1327.76(7) 
Z 4 
ρcalcd [g cm
-3
] 1.431 
μ [mm
-1
] 0.481 
F(000) 592 
Θ range [°] 4.19 – 30.03 
Index ranges -6 ≤ h ≤ 6 
 -17 ≤ k ≤ 14 
 -36 ≤ l ≤ 37 
Reflns. collected 13283 
Reflns. obsd. 3100 
Reflns. unique 3867 
 (Rint = 0.0388) 
R1, wR2 (2σ data) 0.0370, 0.0824 
R1, wR2 (all data) 0.0521, 0.0910 
GOOF on F
2
 1.044 
Peak/hole [e Å
-3
] 0.396, -0.330 
 
Single crystals of compound 66a, suitable for X-ray diffraction, were obtained by slow 
evaporation of CH2Cl2 solutions at ambient temperature. The crystals were introduced into 
perfluorinated oil and a suitable single crystal was carefully mounted on the top of a thin 
glass wire. Data collection was performed with an Oxford Xcalibur 3 diffractometer 
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equipped with a Spellman generator (50 kV, 40 mA) and a Kappa CCD detector, operating 
with Mo-Kα radiation (λ = 0.71071 Å). Data collection was performed with the CrysAlis 
CCD software;
137
 CrysAlis RED software
138
 was used for data reduction. Absorption 
correction using the SCALE3 ABSPACK multiscan method
139
 was applied. The structures 
were solved with SHELXS-97,
140
 refined with SHELXL-97
141
 and finally checked using 
PLATON.
142
 Details for data collection and structure refinement are summarized in Table 
1. 
CCDC 993119 contains supplementary crystallographic data. These data can be obtained free 
of charge from The Cambridge Crystallographic Data Center via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Table 13: Molecular structure of compound 66a in the crystal; selected atom distances (in Å). 
Cl1 – C12 1.737(2) C2 – C3          1.459(2) 
Cl2 – C11 1.736(2) C3 – C4          1.488(2) 
O1 – N1 1.418(2) C7 – C8        1.516(2) 
O1 – C1        1.467(2) C8 – C13         1.394(2) 
O2 – C7        1.414(2) C8 – C9          1.397(2) 
N1 – C3        1.289(2) C9 – C10         1.388(2) 
C1 – C6          1.520(2) C10 – C11         1.388(2) 
C1 – C7        1.564(2) C11 – C12         1.394(2) 
C1 – C2        1.505(2) C12 – C13         1.389(2) 
C2 – C5          1.333(2)   
 
Table 14. Molecular structure of compound 66a in the crystal; selected bond angles (in °). 
N1 – O1 – C1        109.0(1) C1 – C7 – C8        112.8(1) 
                                                 
137
 CrysAlis CCD, Oxford Diffraction Ltd., Version 1.171.27p5 beta (release 01-04-2005 CrysAlis171.NET) 
(compiled Apr 1 2005, 17:53:34). 
138
 CrysAlis RED, Oxford Diffraction Ltd., Version 1.171.27p5 beta (release 01-04-2005 CrysAlis171.NET) 
(compiled Apr 1 2005, 17:53:34).  
139
 SCALE3 ABSPACK – An Oxford Diffraction Program (1.0.4, gui:1.0.3) (C), Oxford Diffraction, Ltd., 2005. 
140
 G. M. Sheldrick (1997) SHELXS-97: Program for Crystal Structure Solution, University of Göttingen, 
Germany. 
141
 G. M. Sheldrick (1997) SHELXL-97: Program for the Refinement of Crystal Structures, University of 
Göttingen, Germany. 
142
 A. L. Spek (1999) PLATON: A Multipurpose Crystallographic Tool, Utrecht University, Utrecht, The 
Netherlands. 
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O1 – N1 – C3        109.9(1) O2 – C7 – C1        108.5(1) 
O1 – C1 – C2        103.3(1) C7 – C8 – C9        121.2(1) 
O1 – C1 – C6        108.9(1) C7 – C8 – C13       120.0(1) 
C2 – C1 – C6        114.5(1) C9 – C8 – C13       118.9(1) 
C2 – C1 – C7        109.6(1) C8 – C9 – C10       120.7(1) 
O1 – C1 – C7        107.0(1) C9 – C10 – C11       120.1(1) 
C6 – C1 – C7        112.9(1) Cl2 – C11 – C12       121.0(1) 
C1 – C2 – C5        129.4(1) C10 – C11 – C12       119.6(1) 
C3 – C2 – C5        126.2(1) Cl2 – C11 – C10       119.4(1) 
C1 – C2 – C3        104.5(1) Cl1 – C12 – C11       120.8(1) 
N1 – C3 – C4        121.6(1) C11 – C12 – C13       120.3(1) 
C2 – C3 – C4        125.9(1) Cl1 – C12 – C13       118.9(1) 
N1 – C3 – C2        112.6(1) C8 – C13 – C12       120.5(1) 
O2 – C7 – C8        109.2(1)   
 
Table 15. Molecular structure of compound 66a in the crystal; selected torsion angles (in °). 
N1 – O1 – C1 – C2          9.1(1) C5 – C2 – C3 – N1       -174.0(2) 
N1 – O1 – C1 – C6        131.2(1) C5 – C2 – C3 – C4            5.8(2) 
N1 – O1 – C1 – C7       -106.5(1) O2 – C7 – C8 – C9         20.0(2) 
C1 – O1 – N1 – C3         -6.0(2) O2 – C7 – C8 – C13      -159.2(1) 
O1 – N1 – C3 – C2         -0.1(2) C1 – C7 – C8 – C9       -100.8(2) 
O1 – N1 – C3 – C4       -179.9(1) C1 – C7 – C8 – C13        80.1(2) 
O1 – C1 – C2 – C3         -8.8(1) C7 – C8 – C9 – C10      -180.0(2) 
O1 – C1 – C2 – C5        171.1(2) C13 – C8 – C9 – C10          -0.8(2) 
C6 – C1 – C2 – C3       -127.0(1) C7 – C8 – C13 – C12       179.7(1) 
C6 – C1 – C2 – C5           52.9(2) C9 – C8 – C13 – C12           0.6(2) 
C7 – C1 – C2 – C3        105.0(1) C8 – C9 – C10 – C11           0.4(2) 
C7 – C1 – C2 – C5        -75.2(2) C9 – C10 – C11 – Cl2       180.0(1) 
O1 – C1 – C7 – O2        176.6(1) C9 – C10 – C11 – C12           0.2(2) 
O1 – C1 – C7 – C8        -62.2(1) Cl2 – C11 – C12 – Cl1        -0.8(2) 
C2 – C1 – C7 – O2         65.3(1) Cl2 – C11 – C12 – C13       179.8(1) 
C2 – C1 – C7 – C8       -173.6(1) C10 – C11 – C12 – Cl1       178.9(1) 
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C6 – C1 – C7 – O2        -63.6(1) C10 – C11 – C12 – C13          -0.5(2) 
C6 – C1 – C7 – C8         57.5(2) Cl1 – C12 – C13 – C8       -179.3(1) 
C1 – C2 – C3 – N1          5.9(2) C11 – C12 – C13 – C8            0.1(2) 
C1 – C2 – C3 – C4       -174.4(1)   
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7.16.2 Preparation of (S)-((R)-3,5-Dimethyl-4-methylene-4,5-dihydroisoxazol-5-
yl)(phenyl)methanol (66b)  
66b was prepared according to TP13a from zinc reagent 63 (17.3 mmol, 
0.4 м in THF, 1.5 equiv.), LaCl3·2LiCl (23 mmol, 0.5 м in THF, 
2 equiv.), and benzaldehyde (11.5 mmol, 11.5 mL, 1 м in THF, 0.66 
equiv.). Purification by flash chromatography (i-hexane:EtOAc 8:2) furnishing 66b as a white 
solid (2.28 g, 10.53 mmol, 91%, dr= 95:5).  
66b could also be prepared according to TP13b from zinc reagent 63 (0.4 mmol) to produce 
the title compound in 67% yield (dr= 95:5). 
HRMS (EI) for C13H17NO2: calcd 218.1181(M+H
+
), found 218.1190.  
1
H NMR (200 MHz, CDCl3): δ = 1.42 (s, 3 H), 1.97 (s, 3 H), 2.60 (s, 1 H), 4.59 (s, 1 H), 4.75 
(s, 1 H), 5.28 (s, 1 H), 7.31 - 7.37 (m, 5 H) 
13
C NMR (100 MHz, acetone-d6): δ = 155.64, 150.13, 137.08, 128.06, 127.81, 127.56, 
109.85, 89.35, 78.18, 23.12, 9.71.   
IR (ATR): 𝜈 (cm-1) = 3345, 3100, 3063, 3026, 2991, 2982, 2955, 2924, 2853, 1819, 1725, 
1641, 1602, 1491,  1453, 1429, 1415, 1398, 1372, 1326, 1234, 1219, 1179, 1092, 1080, 1055, 
907, 877, 809, 788, 733. 
m.p.: 107 - 110 °C 
 
7.16.3 Preparation of (S)-(4-Chlorophenyl)((R)-3,5-dimethyl-4-methylene-4,5-
dihydroisoxazol-5-yl)methanol (66c) 
66c was prepared according to TP13a from zinc reagent 63 (16 mmol, 
0.4 м in THF, 1.5 equiv.), LaCl3·2LiCl (21 mmol, 0.5 м in THF, 
2 equiv.), and 4-chlorobenzaldehyde (10.7 mol, 1 м in THF, 0.66 
equiv.). Purification by flash chromatography (i-hexane:EtOAc 8:2) furnishing 66c as a white 
solid (2.48 g, 9.88 mmol, 92%, dr= 96:4).  
66c could also be prepared according to TP13b from zinc reagent 63 (0.21 mmol) to produce 
the title compound in 81% yield (dr= 95:5). 
HRMS (EI) for C13H14ClNO2: calcd 251.0713 (M
+
), found 252.0778. 
MS (EI, 70 eV): m/z (%)= 205 (53), 139 (34), 111 (39), 110 (26), 82 (31), 77 (100), 68 (43), 
55 (12), 43 (33). 
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1
H NMR (400 MHz, CDCl3): δ = 1.38 (s, 3 H), 1.96 (s, 3 H), 2.69 (s, 1 H), 4.59 (s, 1 H), 4.68 
(s, 1 H), 5.27 (s, 1 H), 7.28 (s, 4 H).
  
13
C NMR (400 MHz, CDCl3):
 
δ = 9.72, 22.84, 77.46, 89.05, 109.96, 127.76, 129.12, 133.86, 
135.59, 150.07, 155.66.  
IR (ATR): 𝜈 (cm-1) = 3353, 3097, 3017, 2989, 2925, 2897, 1804, 1790, 1738, 1643, 1593, 
1489, 1436, 1402, 1370, 1314, 1289, 1238, 1186, 1086, 1063 1013, 898, 835, 808, 761. 
m.p.:111 - 113 °C 
 
7.16.4 4-((S)-((R)-3,5-Dimethyl-4-methylene-4,5-dihydroisoxazol-5-
yl)(hydroxy)methyl)benzonitrile (66d) 
 66d was prepared according to TP13a from zinc reagent 63 (22 mmol, 
0.4 м in THF, 1.5 equiv.), LaCl3·2LiCl (30 mmol, 0.5 м in THF, 
2 equiv.), and 4-formylbenzonitrile (15 mmol, 1 м in THF, 0.67 equiv.). 
Purification by flash chromatography (i-hexane:EtOAc 8:2) furnishing 66d as a white solid 
(3.49 g, 14.4 mmol, 96%, dr= 94:6).  
66d could also be prepared according to TP13b from zinc reagent 63 (0.21 mmol) to produce 
the title compound in 82% yield (dr= 94:6). 
HRMS (EI) for C14H14N2O2: calcd 243.1133 (M+H
+
), found  343.1055. 
MS (EI, 70 eV): m/z (%) = 243 (2), 220 (6), 205 (22), 140 (8), 133 (6), 132 (72), 110 (82), 
104 (68), 82 (35), 77 (45), 70 841), 69 (24), 68 (100), 55 (13), 51 (12), 43 (58). 
1
H NMR (300 MHz, CDCl3): δ = 1.38 (s, 3 H), 1.95 (s, 3 H), 2.93 (d, J=3.59 Hz, 1 H), 4.70 
(m, 2 H), 5.30 (s, 1 H), 7.48 (m, 2 H), 7.60 (m, 2 H). 
 13
C NMR (75 MHz, CDCl3): δ = 9.69, 22.29, 77.18, 88.68, 110.01, 111.76, 118.71, 128.56, 
131.35, 142.87, 150.42, 155.55.  
IR (ATR): 𝜈 (cm-1) = 3348, 3095, 2992, 2927, 2900,1707, 1688, 1643, 1609, 1592, 1489, 
1447, 1437, 1403, 1373, 1308, 1242, 1201, 1189, 1086, 1067, 1014, 912, 894, 843, 836, 822, 
809, 761, 742. 
m.p.: 95 - 98 °C 
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7.16.5 Methyl 4-((S)-((R)-3,5-dimethyl-4-methylene-4,5-dihydroisoxazol-5-yl) 
(hydroxy)methyl) benzoate (66e) 
66e was prepared according to TP13a from zinc reagent 63 
(22.5 mmol, 0.4 м in THF, 1.5 equiv.), LaCl3·2LiCl (30 mmol, 0.5 м 
in THF, 2 equiv.), and methyl 4-formylbenzoate (15 mmol, 1 м in 
THF, 0.66 equiv.). Purification by flash chromatography (i-Hexane:EtOAc 8:2) furnishing 
66e as a white solid (3.893 g, 14 mmol, 94%, dr= 95:5).  
66e could also be prepared according to TP13b from zinc reagent 63 (0.21 mmol) to produce 
the title compound in 79% yield (dr= 93:7). 
HRMS (EI) for C15H17NO4: calcd 276.1235 (M+H
+
), found 276.1232. 
MS (EI, 70 eV): m/z (%): 245 (6), 244 (29), 164 (100), 134 821), 128 (5), 121 (6), 110 (81), 
106 (32), 96 (27), 77 (49), 68 (43), 59 (26), 42 (25). 
1
H NMR (300 MHz, CDCl3): δ =1.40 (s, 3 H), 1.95 (s, 3 H), 2.79 (d, J=3.87 Hz, 1 H), 3.91 (s, 
3 H), 4.57 (s, 1 H), 4.76 (d, J=3.59 Hz, 1 H), 5.27 (s, 1 H), 7.42 (m, 2 H), 7.98 (m, 2 H). 
13
C NMR (75 MHz, CDCl3): δ = 9.70, 22.87, 52.14, 77.75, 89.01, 110.04, 127.82, 128.79, 
129.79, 142.18, 150.02, 155.68, 166.90. 
IR (ATR): 𝜈 (cm-1) = 3351, 21991, 2945, 2923, 1726, 1640, 1611, 1438, 1406, 1309, 1272, 
1259, 1189, 1178, 1102, 1088, 1016, 961, 918, 898, 858, 803, 781, 737. 
m.p.: 80 - 82 °C 
 
7.16.6 Preparation of (S)-((R)-3,5-Dimethyl-4-methylene-4,5-dihydroisoxazol-5-
yl)(3-fluorophenyl)methanol (66f): 
 66f was prepared according to TP13a from zinc reagent 63 (1.5 mmol, 
0.4 м in THF, 1.5 equiv.), LaCl3·2LiCl (2 mmol, 0.5 м in THF, 
2 equiv.), and 3-fluorobenzaldehyde (1 mmol, 1 м in THF, 0.66 equiv.). 
Purification by flash hromatography (i-hexane:EtOAc 8:2) furnishing 66f as a white solid 
(205 mg, 0.87 mmol, 87%, dr= 95:5).  
HRMS (EI) for C13H14FNO2: calcd 236.1086 (M+H
+
); found 236.1111. 
MS (EI, 70 eV): m/z (%) = 236 824), 218 (7), 176 (8), 133 (7), 125 815), 123 830), 112 (36), 
110 (30), 97 (47), 95 (38), 82 (72), 77 (28), 70 (15), 68 (100), 55 (18).  
 D. Experimental Section 
 
164 
1
H NMR (400 MHz, CDCl3): δ =1.37 (s, 3H), 1.93 (s, 3H), 3.07 (d, J= 3.70, 1H), 4.63 (d, 
J=0.70, 1H),  4.67 (d J= 3.31, 1H), 5.28 (d, J= 0.78, 1H), 6.94-9.99 (m, 1H), 7.04-7.07 (m, 
1H), 7.09-7.11 (m, 1H), 7.22- 7.28 (m, 1H). 
13
C NMR (101 MHz, acetone-d6): δ = 8.68, 21.43, 76.51, 88.49, 108.11, 113.78 (d, J= 
21.41), 114.69 (d, J= 22.19), 123.99, 128.68 (d, J= 8.17), 143.27 (d, J= 7.01), 152.43, 154.06, 
162.07 (d, J= 242).  
IR (ATR): 𝜈 (cm-1) = 3460, 3092, 2987, 2964, 2918, 1645, 1613, 1587, 1485, 1449, 1438, 
1412, 1396, 1370, 1287, 1253, 1233, 1159, 1136, 1114, 1078, 1052, 1038, 1015, 970, 917, 
906, 898, 884, 873, 863, 794, 760, 741, 726, 708, 692, 676. 
m.p.:96 - 97 °C 
 
7.16.7 Preparation of (S)-((R)-3,5-Dimethyl-4-methylene-4,5-dihydroisoxazol-5-
yl)(4-methoxyphenyl)methanol (66g)  
66g was prepared according to TP13a from zinc reagent 63 (17 mmol, 
0.4 м in THF, 1.5 equiv.), LaCl3·2LiCl (23 mmol, 0.5 м in THF, 
2 equiv.), and p-anisaldehyde (11.5 mmol, 1 equiv., 1 м in THF). 
Purification by flash chromatography (i-hexane:EtOAc 8:2) furnishing 
66g as a white solid (2.44 g, 9.8 mmol, 86%, dr= 95:5).  
66g could also be prepared according to TP13b from zinc reagent 63 (0.3 mmol) to produce 
the title compound in 84% yield (dr= 95:5). 
HRMS (EI) for C14H18NO3: calcd 248.1286 (M+H
+
); found 248.1289. 
MS (EI, 70 eV): m/z (%): 248 (3), 230 (5), 138 (39), 135 (100), 122 (7), 112 (6), 111 (30), 
109 (62), 92 (13), 83 (11), 82 (16), 77 (49), 68 (27), 66 (17), 65 (11), 43 (23). 
1
H NMR (300 MHz, CDCl3): δ = 1.39 (s, 3 H), 1.96 (s, 3 H), 2.54 (d, J=3.59 Hz, 1 H), 3.80 
(s, 3 H), 4.58 (s, 1 H), 4.69 (d, J=3.32 Hz, 1 H), 5.26 (s, 1 H), 6.83-6.86 (m, 2 H), 7.15 - 7.34 
(d, 2 H).  
13
C NMR (75 MHz, CDCl3): δ = 9.70, 23.17, 55.21, 77.86, 89.48, 109.73, 112.97, 128.88, 
129.18, 150.14, 155.62, 159.39. 
IR (ATR): 𝜈 (cm-1) = 3346, 2971, 2933, 2840, 1683, 1683, 1639, 1609, 1579, 113, 1440, 
1401, 1368, 1314, 1302, 1244, 1183, 1171, 1120, 1086, 1063, 1031, 908, 838, 819, 775, 760. 
m.p.: 103 °C 
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7.16.8 Preparation of  (R)-(5-Bromothiophen-2-yl)((R)-3,5-dimethyl-4-methylene-
4,5-dihydroisoxazol-5-yl) methanol (66h) 
 66h was prepared according to TP13a from zinc reagent 63 (17 mmol, 
0.4 м in THF, 1.5 equiv.), LaCl3·2LiCl (22.6 mmol, 0.50 м in THF, 
2 equiv.), and 5-bromothiophene-2-carbaldehyde (11.3 mmol, 1 м in THF, 
0.66 equiv.). Purification by flash chromatography (i-hexane:EtOAc 8:2) 
furnishing 66h as a white solid (3.14 g, 10.4 mmol,  92%, dr= 93:7).  
HRMS (EI) for C11H12BrNO2S: calcd 301.9850 (M+H
+
), found 301.9858. 
MS (EI, 70 eV): m/z (%)= 301 (1), 193 (34), 111 (100), 110 (21), 84 (75), 83 (16), 81 (15), 70 
(31), 68 (22), 55 (5), 42 (8). 
1
H NMR (300 MHz, CDCl3): δ = 1.46 (s, 3 H), 1.99 (s, 3 H), 2.80 (d, J=4.70 Hz, 1 H), 4.79 
(d, J=3.87 Hz, 1 H), 4.89 (s, 1 H), 5.32 (s, 1 H), 6.78 (d, J=3.87 Hz, 1 H), 6.91 (d, J=3.87 Hz, 
1 H). 
13
C NMR (75 MHz, CDCl3): δ = 9.72, 22.38, 75.02, 88.56, 109.93, 112.00, 125.93, 129.13, 
142.56, 150.45, 155.54. 
IR (ATR): 𝜈 (cm-1) = 32466, 2925, 2849, 1641, 1442, 1400, 1371, 1312, 1252, 1148, 1118, 
1070, 1054, 1014, 969, 909, 874, 849, 804, 760, 749. 
m.p.: 117 - 118 °C 
 
7.16.9 Preparation of (S)-1-((R)-3,5-Dimethyl-4-methylene-4,5-dihydroisoxazol-5-
yl)-3-phenylpropan-1-ol (66i) 
66i was prepared according to TP13b from zinc reagent 63 (1.35 mmol, 
0.45 м in THF, 1 equiv.), MgCl2 (2.7 mmol, 0.4 м in THF, 2 equiv.), 3-
phenylpropanal and (1.35 mmol, 1 м in THF, 1 equiv.). Purification by 
flash chromatography (i-hexane:EtOAc 8:2) furnishing 66i as a colorless oil (193 mg, 0.79 
mmol, 58%, dr= 39:61). 
HRMS (ESI) for C15H20NO2: cacd 246,14940 (M+H
+
); found 346.14868. 
Major isomer
 1
H NMR (MHz, CDCl3): δ = 1.39 (s, 3H), 1.59-1.81 (m, 1H), 1.83-1.94 (m, 
1H), 2.00 (s, 3H), 2.58-2.67 (m, 1H), 2.56 (s, 1H), 2.88 -2.95 (m, 1H), 3.41-3.47 (m, 1H), 
5.02 (s, 1H), 5.27 (s, 1H), 7.16-7.20 (m, 3H), 7.24-7.28 (m, 2H). Minor isomer 
1
H NMR 
(MHz, CDCl3): δ = 1.39 (s, 3H), 1.59-1.81 (m, 1H), 1.83-1.94 (m,1H), 2.00 (s, 3H), 2.44 (s, 
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1H), 2.58-2.67 (m, 1H), 2.88 -2.95 (1H), 3.47-3.50 (m, 1H), 5.11 (s, 1H), 5.29 (s.1 H), 7.14-
7.17 (m, 3H), 7.24-7.28 (m, 2H). 
Major isomer 
13
C NMR (MHz, CDCl3): δ =9.86, 22.64, 31.83, 32.54, 75.80, 89.53, 108.23, 
125.98, 128.49, 128.62, 141.93, 152.05, 155.13. Minor isomer 
13
C NMR (MHz, CDCl3): δ = 
9.86, 22.37, 32.05, 32.40, 75.45, 89.18, 108.40, 125.98, 128.50, 128.63, 141.93, 152.05, 
155.31. 
IR (ATR): 𝜈 (cm-1) = 3411, 3092, 3062, 3024, 2989, 2954, 2924, 2860, 1715, 1640, 1602, 
1495, 1453, 1396, 1378, 1309, 1263, 1177, 1151, 1062, 1044, 1030, 1012, 895, 820, 743, 728, 
698, 675. 
 
7.16.10  (S)-1-((R)-3,5-Dimethyl-4-methylene-4,5-dihydroisoxazol-5-
yl)hexan-1-ol (66j) 
66j was prepared according to TP13b from zinc reagent 63 (1.35 mmol, 
0.45 м in THF, 1 equiv.), MgCl2 (2.7 mmol, 0.4 м in THF, 2 equiv.), and 
hexanal (1.35 mmol, 1 м in THF, 1 equiv.). Purification by flash 
chromatography (i-hexane:EtOAc 8:2) furnishing 66j as a colorless oil 
(117 mg, 0.55 mmol, 41%, dr = 33:67). 
HRMS (ESI) for C12H22NO2: calcd 212.16505 (M+H
+
), found 212.1645. 
Major isomer 
 1
H NMR (300 MHz, CDCl3) δ = 0.82 - 0.90 (m, 3 H), 1.22-1.33 (m, 6 H) 1.40 
(s, 3 H), 1.50-1.60 (m, 2 H), 2.02 (s, 3H), 3.38-3.46 (m, 1 H), 5.06 (d, J=0.83 Hz, 1 H), 5.30 
(d, J=0.83 Hz, 1 H). Minor isomer 
1
H NMR (300 MHz, CDCl3) 0.82 - 0.90 (m, 3 H), 1.24 (m, 
6H), 1.37 (s, 3H), 1.49-1.60 (m, 2H), 2.02 (s, 3 H), 3.36 - 3.47 (m, 1 H), 5.06 (d, J=0.83 Hz, 1 
H) 5.30 (d, J=0.84 Hz, 1 H). 
Major isomer
 13
C NMR (75 MHz, CDCl3) δ = 9.76, 14.02, 22.50, 22.58, 25.96, 29.73, 31.68, 
76.45, 89.49, 107.95, 151.98, 155.08. Minor isomer
 13
C NMR (75 MHz, CDCl3) δ = 9.76, 
14.02, 21.99, 22.59, 25.75, 29.96, 31.70, 76.08, 89.17, 107.98, 152.14, 155.21. 
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7.16.11 Preparation of ((S)-1-((R)-3,5-Dimethyl-4-methylene-4,5-
dihydroisoxazol-5-yl)-2-ethylbutan-1-ol (66k) 
66k was prepared according to TP13b from zinc reagent 63 (1.35 mmol, 
0.45 м in THF, 1 equiv.), MgCl2 (2.7 mmol, 0.4 м in THF, 2 equiv.), and 
2-ethylbutanal (1.35 mmol, 1 м in THF, 1 equiv.). Purification by flash 
chromatography (i-hexane:EtOAc 8:2) furnishing 66k as a colorless oil (93 mg, 0.44 mmol 
33%, dr= 7:93). 
HRMS (ESI) for C12H22NO2: calcd 212,1650 (M+H
+
), found 212.16451.  
1
H NMR (300 MHz, CDCl3) δ = 0.84 (t, J=7.33 Hz, 6 H), 1.03-1.10 (m, 1 H), 1.20-1.14, (m, 
1 H), 1.28 - 1.37, (m, 2 H) ,1.46 (s, 3 H), 1.56 - 1.68 (m, 1 H),  2.00 (s, 4 H), 3.33 (s, 1H), 
5.98 (s, 1 H), 5.25 (s, 1 H). 
13
C NMR (75 MHz, CDCl3) δ = 9.81, 11.52, 12.23, 20.72, 23.73, 24.35, 42.37, 77.05, 90.29, 
107.52, 153.25, 154.85. 
IR (ATR): ?̃? (cm-1) = 3426, 2959, 2930, 2873, 1640, 1462, 1395, 1379, 1138, 1098, 1048, 
1013, 981, 895, 856, 783, 734, 705, 674.  
 
7.16.12 Preparation of ((S)-1-((R)-3,5-Dimethyl-4-methylene-4,5-
dihydroisoxazol-5-yl)-2-methylpropan-1-ol (66l):  
66l was prepared according to TP13b from zinc reagent 63 (1.35 mmol, 
0.45 м in THF, 1 equiv.), MgCl2 (2.7 mmol, 0.4 м in THF, 2 equiv.), and 
isobutyraldehyde (1.35 mmol, 1 м in THF, 1 equiv.). Purification by flash chromatography (i-
hexane:EtOAc 8:2) furnishing 66l as a colorless oil (94 mg, 0.51 mmol, 38%, dr=21:79). 
HRMS (ESI) for C10H18NO2: cacd 184.13375 (M+H
+
), found 184.13317. 
1
H NMR (300 MHz, CDCl3) δ = 0.91 (d, J=6.63 Hz, 3 H), 0.98 (d, J=6.91 Hz, 3 H), 1.46 (s, 3 
H), 1.75 - 1.88 (m, 1 H), 1.90 (s, 1 H), 2.01 (s, 3 H), 3.15 (dd, J=8.43, 3.73 Hz, 1 H), 5.05 (s, 
1 H), 5.30 (s, 1 H). 
13
C NMR (75 MHz, CDCl3) δ = 9.86, 16.90, 22.24, 23.80, 29.24, 80.26, 89.89, 107.69, 
153.16, 154.79. 
IR (ATR): ?̃? (cm-1) = 3411, 2958, 2928, 2871, 1640, 1470, 1450, 1440, 1415, 1393, 1367, 
1349, 1260, 1168, 1138, 1129, 1098, 1037, 1013, 982, 895, 735, 706, 674. 
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7.16.13 Hammett-Plot  for Isoxazolines Established for LaCl3•2LiCl 
Accelerated Addition of Zinc Reagent 1 with Substituted Benzaldehydes 4. 
 
 
Figure 13: Hammett-plot for isoxazolines established for LaCl3•2LiCl accelerated addition of zinc reagent 1 
with substituted benzaldehydes 65. 
 
7.17 TBS Protection of Isoxazolines 68a-g 
7.17.1 Preparation of (R)-5-((S)-((Tert-butyldimethylsilyl)oxy)(3,4-
dichlorophenyl)methyl)-3,5-dimethyl-4-methylene-4,5-
dihydroisoxazole (68a) 
68a was prepared according to TP14 from 66a (286 mg, 1 mmol) 0.1 м 
in CH2Cl2, 2,6-lutidine (0.29 mL, 2.5 equiv.) and TBSOTf (0.50 mL, 2.2 mmol, 2.2 equiv.). 
Flash column chromatography (SiO2, EtOAc:i-hexane 1:10) furnishing compound 68a 
(397 mg, 0.99 mmol, 99%) as a colorless solid. 
93
94
95
96
97
-0,3 -0,2 -0,1 0 0,1 0,2 0,3 0,4 0,5 0,6 0,7
dr 
S s 
66b 66g 
   
66c 
66f 66e 
66a 
66d 
Table 16 
isoxazolines m- p- sm sp S s dr  
66a Cl Cl 0,37 0,23 0,6 96 24,00 
66b  H 0 0 0 95 19,00 
66c  Cl  0,23 0,23 94 15,67 
66d  CN  0,66 0,66 94 15,67 
66e  COOMe  0,45 0,45 95 19,00 
66f F  0,34  0,34 95 19,00 
66g  OMe  -0,27 -0,27 95 19,00 
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HRMS (EI) for C19H27Cl2NO2Si: calcd 289.0320 (M-TBS), found 289.0395. 
MS (EI, 70 eV): m/z (%) = 347 (5), 327 (12), 291 (55), 289 (100), 197 (10), 75 813), 73 (27), 
69 (5), 57 (8), 43 85).  
1
H NMR (400 MHz, acetone-d6): δ = ppm -0.20 (s, 3 H), 0.07 (s, 3 H), 0.88 (s, 9 H), 1.34 (s, 
3 H), 1.85 (s, 3 H), 4.69 (s, 1 H), 5.08 (s, 1 H), 5.41 (s, 1 H), 7.31 - 7.40 (m, 1 H), 7.49 (d, 
J=8.41 Hz, 1 H), 7.57 (d, J=1.76 Hz, 1 H). 
13
C NMR (101 MHz, acetone-d6): δ = ppm -5.77, -5.54, 8.69, 17.76, 21.66, 25.26, 77.61, 
88.45, 108.58, 128.32, 129.27, 130.33, 130.61, 130.77, 140.80, 151.62, 154.05. 
IR (ATR): 𝜈 (cm-1) = 2952, 2926, 2887, 2833, 1470, 1437, 1416, 1394, 1366, 1366, 1360, 
1347, 1260, 1252, 1201, 1154, 1130, 1116, 1089, 1071, 1032, 1012, 1004, 948, 938, 876, 849, 
834, 778, 741, 734, 721, 706, 675. 
m.p.:75.8 - 76.2 °C 
 
7.17.2 Preparation of (R)-5-((S)-((tert-Butyldimethylsilyl)oxy)(4-
chlorophenyl)methyl)-3,5-dimethyl-4-methylene-4,5-dihydroisoxazole (68b) 
68b was prepared according to TP14 from 66c (332 mg, 1.3 mmol) 
0.1 м in CH2Cl2, 2,6-lutidine (0.37 mL, 3.2 mmol, 2.5 equiv.) and 
TBSOTf (0.66 mL, 2.9 mmol, 2.2 equiv.). Flash column chromatography 
(SiO2, EtOAc:i-hexane 1:10) furnishing compound 68b (424 mg, 1.2 mmol, 89%) as a 
colorless oil  
HRMS (EI) for C19 H28ClNO2Si: calcd 366.1656 (M+H
+
), found 366.1439. 
MS (EI, 70eV), m/z(%): 310 (15), 308 (41), 257 (100), 256 (46), 255 (32). 
1
H NMR (300 MHz, CDCl3): δ = -0.25 (s, 3 H), 0.01 (s, 3 H), 0.86 (s, 9 H), 1.29 (s, 3 H), 
1.93 (s, 3 H), 4.48 (s, 1 H), 4.88 (s, 1 H), 5.26 (s, 1 H), 7.26 (m, 4 H). 
13
C NMR (75 MHz, CDCl3): δ = -5.06, -4.81, 9.68, 18.11, 21.74, 25.78, 78.02, 88.72, 108.81, 
127.49, 129.48, 133.44, 137.97, 151.49, 154.54. 
IR (ATR): 𝜈 (cm-1) = 658, 667, 672, 688, 697, 707, 731, 757, 776, 817, 834, 856, 884, 897, 
938, 1006, 1014, 1035, 1087, 1108, 1145, 1148, 1159, 1192, 1251, 1361, 1371, 1406, 1452, 
1462, 1471, 1490, 1596, 1642, 2856, 2883, 2893, 2929, 2955. 
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7.17.3 Preparation of 4-((S)-((tert-Butyldimethylsilyl)oxy)((R)-3,5-dimethyl-4-
methylene-4,5-dihydroisoxazol-5-yl)methyl)benzonitrile (68c) 
68c was prepared according to TP14 from 66d (299 mg, 1.23 mmol) 
0.1 м in CH2Cl2, 2,6-lutidine (0.36 mL, 3.1 mmol, 2.5 equiv.) and 
TBSOTf (0.62 mL, 2.7 mmol, 2.2 equiv.). Flash column 
chromatography (SiO2, EtOAc:i-hexane 1:10) furnishing compound 68c (427 mg, 1.20 mmol, 
97%) as colorless oil.  
HRMS (ESI) for C20H28N2O2Si: calcd 356.1920 (M+H
+
), found 357.1993. 
1
H NMR (300 MHz, CDCl3): δ = -0.30 (s, 3 H), -0.02 (s, 3 H), 0.83 (s, 9 H), 1.27 (s, 3 H), 
1.88 (s, 3 H), 4.47 (s, 1 H), 4.94 (s, 1 H), 5.27 (s, 1 H), 7.42 - 7.49 (m, 2 H), 7.49 - 7.58 (m, 2 
H). 
13
C NMR (75 MHz, CDCl3): δ = -5.06, -4.83, 9.62, 18.05, 21.39, 25.74, 77.98, 88.40, 109.19, 
111.50, 118.75, 128.90, 131.10, 145.02, 151.48, 154.57. 
IR (ATR): 𝜈 (cm-1) = 662, 673, 728, 778, 835, 855, 890, 908, 938, 1006, 1013, 1019, 1078, 
1093, 1115, 1122, 1158, 1200, 1253, 1259, 1361, 1372, 1396, 1410, 1437, 1452, 1463, 1472, 
1502, 1609, 2230, 2856, 2883, 2928, 2955. 
 
7.17.4 Preparation of methyl 4-((S)-((tert-butyldimethylsilyl)oxy)((R)-3,5-
dimethyl-4-methylene-4,5-dihydroisoxazol-5-yl)methyl)benzoate (68d) 
 68d was prepared according to TP14 from 66e (302 mg, 1.1 mmol) 
0.1 м in CH2Cl2, 2,6-lutidine (0.31 mL, 2.6 mmol, 2.5 equiv.) and 
TBSOTf (0.50 mL, 2.2 mmol, 2.0 equiv.). Flash column 
chromatography (SiO2, EtOAc:i-hexane 1:10) furnishes compound 66d (310 mg, 0.80 mmol, 
72%) as a colorless oil. 
HRMS (ESI) for C21H31NO4Si: calcd 390.2100 (M+H
+
), found 390.2097.  
1
H NMR (300 MHz, CDCl3): δ = -0.28 (s, 3 H), -0.01 (s, 3 H), 0.83 (s, 9 H), 1.28 (s, 3 H), 
1.90 (s, 3 H), 3.87 (s, 3 H), 4.54 (s, 1 H), 4.87 (s, 1 H), 5.26 (s, 1 H), 7.40 (d, J=8.57 Hz, 2 H), 
7.94 (d, J=8.57 Hz, 2 H). 
13
C NMR (75 MHz, CDCl3): δ = -5.08, -4.88, 9.64, 18.09, 21.76, 25.75, 51.98, 78.35, 88.66, 
108.92, 128.20, 128.58, 129.49, 144.64, 151.41, 154.53, 166.96. 
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IR (ATR): 𝜈 (cm-1) = 657, 670, 684, 701, 707, 730, 776, 814, 834, 854, 859, 890, 939, 966, 
1006, 1013, 1019, 1035, 1089, 1110, 1159, 1176, 1191, 1252, 1257, 1275, 1309, 1347, 1361, 
1371, 1397, 1414, 1435, 1462, 1472, 1611, 1642, 1721, 2856, 2893, 2929, 2952. 
 
7.17.5  (R)-5-((S)-((tert-Butyldimethylsilyl)oxy)(phenyl)methyl)-3,5-dimethyl-4-
methylene-4,5-dihydroisoxazole (68e) 
 68e was prepared according to TP14 from 66b (207 mg, 0.95 mmol) 
0.1 м in CH2Cl2, 2,6-lutidine (0.21 mL, 1.8 mmol, 2.5 equiv.) and 
TBSOTf (0.47 mL, 2.1 mmol, 2.2 equiv.). Flash column 
chromatography (SiO2, EtOAc:i-hexane 1:10) furnishes compound 68e (309 mg, 0.93 mmol, 
98%) as a colorless oil.  
HRMS (EI) for C19H29NO2Si: calcd 316.1732 (M-Me), found 316.1725. 
MS (EI, 70eV), m/z(%): 316 (6), 295 815), 274 (95), 222 (100), 200 (32). 
1
H NMR (300 MHz, CDCl3): δ = -0.25 (s, 3 H), 0.01 (s, 3 H), 0.86 (s, 9 H), 1.30 (s, 3 H), 
1.94 (s, 3 H), 4.55 (s, 1 H), 4.84 (s, 1 H), 5.26 (s, 1 H), 7.18 - 7.40 (m, 5 H). 
13
C NMR (75 MHz, CDCl3): δ = -5.07, -4.86, 9.70, 18.13, 22.03, 25.80, 78.68, 88.99, 108.69, 
127.22, 127.63, 128.19, 139.27, 151.44, 154.51. 
IR (ATR): 𝜈 (cm-1) = 668, 683, 699, 712, 727, 775, 817, 833, 856, 881, 899, 939, 949, 1006, 
1011, 1029, 1065, 1082, 1095, 1145, 1159, 1175, 1193, 1218, 1250, 1351, 1361, 1370, 1390, 
1397, 1411, 1452, 1462, 1472, 1493, 1512, 1641, 2856, 2883, 2891, 2928, 2955. 
7.17.6 Preparation of (R)-5-((S)-((tert-butyldimethylsilyl)oxy)(4-
methoxyphenyl)methyl)-3,5-dimethyl-4-methylene-4,5-dihydroisoxazole 
(68f)  
68f was prepared according to TP14 from 66g (1.13 g, 4.6 mmol) 
0.1 м in CH2Cl2, 2,6-lutidine (1.36 mL, 11.7 mmol, 2.5 equiv.) and 
TBSOTf (2.32 mL, 10.2 mmol, 2.2 equiv.). Flash column 
chromatography (SiO2, EtOAc:i-hexane 1:10) furnishes compound 68f (1.45 g, 4.02 mmol, 
87%) as a colorless oil. 
HRMS (ESI) for C20H31NO3Si: calcd 362.2151 (M+H
+
); found 362.12148.  
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1
H NMR (300 MHz, CDCl3): δ = -0.25 (s, 3 H), 0.00 (s, 3 H), 0.85 (s, 9 H), 1.28 (s, 3 H), 
1.93 (s, 3 H), 3.79 (s, 3 H), 4.49 (s, 1 H), 4.83 (s, 1 H), 5.24 (s, 1 H), 6.80 (d, J=8.57 Hz, 2 H), 
7.23 (d, J=8.85 Hz, 2 H). 
13
C NMR (75 MHz, CDCl3): δ = -5.09, -4.83, 9.70, 18.13, 22.05, 25.81, 55.10, 78.31, 89.16, 
108.52, 112.61, 129.22, 131.46, 151.50, 154.48, 159.06.  
IR (ATR): 𝜈 (cm-1) = 664, 672, 681, 690, 696,  707, 716, 732, 749, 776, 791, 834, 858, 883, 
899, 938, 949, 1006, 1011, 1035, 1077, 1087, 1112, 1172, 1197, 1246, 1280, 1302, 1314, 
1360, 1370, 1397, 1410, 1441, 1463, 1471, 1511, 1584, 1611, 1641, 2856, 2883, 2893, 2928, 
2955. 
 
7.17.7 Preparation of  (R)-5-((R)-(5-Bromothiophen-2-yl)((tert-
butyldimethylsilyl)oxy)methyl)-3,5-dimethyl-4-methylene-4,5-
dihydroisoxazole (68g)  
68g was prepared according to TP14 from 66h (409 mg, 1.35 mmol) 0.1 м 
in CH2Cl2, 2,6-lutidine (0.39 mL, 3.3 mmol, 2.5 equiv.) and TBSOTf 
(0.68 mL, 3 mmol, 2.2 equiv.). Flash column chromatography (SiO2, 
EtOAc:i-hexane 1:10) furnishes compound 68g (555 mg, 1.33 mmol, 99%) 
as a colorless oil. 
HRMS (ESI) for C17H26BrNO2SSi: calcd 416.0715 (M+H
+
); found 416.0712. 
1
H NMR (300 MHz, CDCl3): δ = 0.13 (s, 3 H), 0.02 (s, 3 H), 0.89 (s, 9 H), 1.36 (s, 3 H), 1.98 
(s, 3 H), 4.65 (s, 1 H), 4.98 (s, 1 H), 5.31 (s, 1 H), 6.72 (d, J=3.87 Hz, 1 H), 6.88 (d, J=3.59 
Hz, 1 H). 
13
C NMR (75 MHz, CDCl3): δ = -5.01, -4.97, 9.74, 18.09, 21.60, 25.76, 75.47, 88.44, 109.34, 
111.56, 125.72, 128.85, 144.96, 151.05, 154.71. 
IR (ATR): 𝜈 (cm-1) = 665, 673, 701, 712, 735, 753, 777, 815, 835, 893, 939, 969, 1006, 1011, 
1041, 1054, 1077, 1083, 1116, 1159, 1208, 1251, 1275, 1345, 1361, 1371, 1390, 1397, 1415, 
1437, 1462, 1471, 1642, 2856, 2883, 2927, 2955. 
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7.18 Reduction of TBS-Protected Isoxazoline to the Corresponding β-
Hydroxy carbonyl Derivatives 69a-g . 
 
7.18.1 Preparation of (4R,5S)-5-((tert-Butyldimethylsilyl)oxy)-5-(3,4-
dichlorophenyl)-4-hydroxy-4-methyl-3-methylenepentan-2-one (69a) 
69a was prepared according to TP15a from a suspension of 68a 
(150 mg, 0.37 mmol) and NH4Cl (153 mg, 3 mmol, 10 equiv.) in 
EtOH:H2O (1:1, 30 mL) and Fe powder (165 mg, 3 mmol, 10 equiv.). 
The reaction mixture was heated at 80 °C for 3 days. The crude 
product was worked up according to TP15a and purified by flash column chromatography 
(SiO2, EtOAc:i-hexane 0.01-9.99) furnishing compound 69a (90 mg, 0.22 mmol, 60%) as a 
colorless solid.  
69a could also be prepared according to TP15b from 68a (1 mmol), to produce the compound 
in 18% yield. 
HRMS (ESI) for C19H28Cl2O3Si: calcd 401.1106 (M-H); found 401.1113. 
1
H NMR (400 MHz, CDCl3): δ = -0.24 (s, 3 H), 0.03 (s, 3 H), 0.71 - 0.93 (s, 9 H), 1.38 (s, 3 
H), 2.27 (s, 3 H), 3.82 (s, 1 H), 5.01 (s, 1 H), 5.97 (s, 1 H), 5.98 (s, 1 H), 6.96 - 7.09 (m, 1 H), 
7.23 - 7.32 (m, 2 H). 
13
C NMR (101 MHz, CDCl3): δ = -5.10, -4.61, 18.03, 24.75, 25.75, 27.46, 77.07, 77.08, 
127.11, 128.42, 129.28, 129.63, 131.13, 131.43, 141.41, 149.91, 201.41.  
IR (ATR): 𝜈 (cm-1) = 670, 699, 712, 731, 776, 793, 817, 835, 864, 909, 939, 956, 972, 1005, 
1029, 1055, 1072, 1085, 1129, 1136, 1153, 1203, 1219, 1251, 1258, 1293, 1360, 1389, 1453, 
1463, 1471, 1494, 1614, 1671, 1713, 2856, 2893, 2928, 2953. 
 
7.18.2 1-((tert-Butyldimethylsilyl)oxy)-1-(3,4-dichlorophenyl)propan-2-one (70)  
70 was formed as the byproduct in the reaction 68a (400 mg, 1 mmol) and Mo(CO)6 (258 mg, 
2 mmol) in MeCN:H2O (17 mL, 10:1) at 80 °C.  The crude product was 
worked up according TP15b and purified by flash column chromatography 
(SiO2, EtOAc:i-hexane 1:9) furnishing compound 70 (129 mg, 0.39 mmol, 
39%) as a colorless solid. 
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HRMS (ESI) for C15H22Cl2O2Si: calcd 331.0693 (M-H), found 331.0695. 
1
H NMR (400 MHz, CDCl3): δ = 0.01 (s, 3 H), 0.09 (s, 3 H), 0.95 (s, 9 H), 2.11 (s, 3 H), 4.96 
(s, 1 H), 7.25-7.27 (m, 1H), 7.40-7.43 (m, 1 H), 7.53 - 7.53 (m, 1 H).  
13
C NMR (101 MHz, CDCl3): δ = -5.19, -4.97, 18.16, 23.96, 25.67, 80.02, 125.07, 127.72, 
130.49, 132.17, 132.76, 138.86, 208.21. 
IR (ATR): 𝜈 (cm-1) =  3354, 2989, 2923, 2895, 2853, 1489, 1448, 1400, 1369, 1086, 1062, 
1013, 897, 834, 808, 760, 695, 674. 
m.p.: 111 - 113 °C 
 
7.18.3 Preparation of (4R,5S)-5-((tert-Butyldimethylsilyl)oxy)-5-(4-chlorophenyl)-
4-hydroxy-4-methyl-3-methylenepentan-2-one (69b) 
69b was prepared according to TP15a from a suspension of 68b 
(36 mg, 0.1 mmol) and NH4Cl (53 mg, 1 mmol, 10 equiv.) in 
EtOH:H2O (1:1, 10 mL) and Fe powder (55 mg, 1 mmol, 10 equiv.). 
The reaction mixture was heated at 80 °C for 1 day. The crude product was worked up 
according to TP15a and purified by flash column chromatography (SiO2, EtOAc:i-hexane 
1:10) furnishing compound 69b (28 mg, 0.07 mmol, 76%) as a colorless solid. 
69b could also be prepared according to TP15b from 68b (0.1 mmol), to produce the title 
compound in 32% yield. 
HRMS (ESI) for C19H29ClO3Si: calcd  367.1501 (M-H); found 367.1504. 
1
H NMR (599 MHz, CDCl3): δ = -0.26 (s, 3 H), 0.03 (s, 3 H), 0.87 (s, 9 H), 1.40 (s, 3 H), 
2.25 (s, 3 H), 3.91 (s, 1 H), 5.03 (s, 1 H), 5.93 (s, 1H), 5.95 (s, 1 H), 7.07 - 7.22 (m, 4 H).
13
C 
NMR (151 MHz, CDCl3): δ = -5.11, -4.64, 18.06, 25.02, 25.78, 27.50, 77.23, 77.69, 127.49, 
127.99, 129.10, 133.00, 139.51, 150.13, 201.33.  
IR (ATR): 𝜈 (cm-1) = 672, 700, 742, 776, 834, 866, 913, 939, 956, 967, 1006, 1015, 1060, 
1252, 1296, 1361, 1401, 1407, 1463, 1472, 1491, 1598, 1673, 2858, 2886, 2911, 2954, 
3547.00 . 
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7.18.4 Preparation 4-((1S,2R)-1-((tert-Butyldimethylsilyl)oxy)-2-hydroxy-2-
methyl-3-methylene-4-oxopentyl)benzonitrile (69c):  
69c was prepared according to TP15a from a suspension of 68c 
(36 mg, 0.1 mmol) and NH4Cl (53 mg, 1 mmol, 10 equiv.) in 
EtOH:H2O (1:1, 10 mL) and Fe powder (55 mg, 1 mmol, 10 equiv.). 
The reaction mixture was refluxed for 2 days. The crude product was worked up according to 
TP15a and purified by flash column chromatography (SiO2, EtOAc:i-hexane 0.5:10) 
furnishing compound 69c (27 mg, 0.07 mmol, 75%) as a colorless solid. 
HRMS (ESI) for C20H29NO3Si: calcd 358,1843 (M-H), found 358.1843. 
1
H NMR (300 MHz, acetone-d6): δ = -0.21 (s, 3 H), 0.08 (s, 3 H), 0.90 (s, 9 H), 1.44 (s, 3 H), 
2.30 (s, 3 H), 4.34 (s, 1 H), 5.26 (s, 1 H), 5.91 (s, 1 H), 6.04 (s, 1 H), 7.44 (d, J=8.57 Hz, 2 H), 
7.63 (d, J=8.02 Hz, 2 H). 
13
C NMR (75 MHz, acetone-d6): δ = -4.75, -4.36, 18.82, 25.59, 26.25, 28.08, 77.63, 78.71, 
111.70, 119.54, 128.60, 129.94, 131.81, 148.10, 151.82, 201.94.  
IR (ATR): 𝜈 (cm-1) = 670, 682, 702, 744, 777, 795, 822, 834, 858, 874, 912, 938, 963, 978, 
1003, 1022, 1068, 1085, 1126, 1182, 1204, 1252, 1258, 1273, 1301, 1361, 1392, 1408, 1420, 
1451, 1463, 1471, 1508, 1611, 1664, 2228, 2858, 2930, 2952, 3536.  
MP: 82.5 - 83 °C 
 
7.18.5 methyl 4-((1S,2R)-1-((tert-butyldimethylsilyl)oxy)-2-hydroxy-2-methyl-3-
methylene-4-oxopentyl)benzoate (69d) 
69d was prepared according to TP15a from a suspension of 68d 
(39 mg, 0.1 mmol), NH4Cl (53 mg, 1 mmol, 10 equiv.) and Fe 
powder (55 mg, 0.1 mmol, 10 equiv.) in EtOH:H2O (1:1, 10 mL). 
The reaction mixture was heated at 80 °C for 3 day. The crude product was worked up 
according to TP15a and purified by flash column chromatography (SiO2, EtOAc:i-hexane 
0.01:9.99) furnishing the compound 69d (28 mg, 0.07 mmol, 71%) as a colorless solid. 
69d could also be prepared according to TP15b from 68d (0.1 mmol), to produce the title 
compound in 27% yield. 
HRMS (ESI) for C21H32O5Si: calcd 392.5613 (M
+
); found 392.1977. 
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1
H NMR (400 MHz, CDCl3): δ = -0.27 (s, 3 H), 0.04 (s, 3 H), 0.86 (s, 9 H), 1.41 (s, 3 H), 
2.24 (s, 3 H), 3.88 (s, 3 H), 3.93 (s, 1 H), 5.11 (s, 1 H), 5.90 (s. 1H), 5.92 (s, 1H), 7.27 (d, 
J=8.85 Hz, 2 H) 7.89 (d, J=8.29 Hz, 2 H) 
13
C NMR (400 MHz, CDCl3): δ = -5.11, -4.69, 18.07, 25.06, 25.76, 27.47, 51.98, 77.20, 
78.03, 127.79, 128.01, 128.62, 129.13, 146.27, 150.03, 167.06, 201.29. 
IR (ATR): 𝜈 (cm-1) = 657, 671, 687, 699, 712, 726, 775, 793, 816, 836, 862, 913, 939, 956, 
969, 1005, 1019, 1063, 1108, 1136, 1156, 1177, 1191, 1218, 1252, 1259, 1274, 1360, 1390, 
1397, 1419, 1435, 1463, 1472, 1611, 1672, 1721, 2856, 2883, 2929, 2952, 3541. 
 
7.18.6 Preparation of (4R,5S)-5-((tert-Butyldimethylsilyl)oxy)-4-hydroxy-4-methyl 
-3-methylene-5-phenylpentan-2-one (69e) 
69e was prepared according to TP15a from a suspension of 68e (165 mg, 
0.50 mmol), NH4Cl (265 mg, 5 mmol, 10 equiv.) and Fe powder (275 mg, 
5 mmol, 10 equiv.) in EtOH:H2O (1:1, 50 mL). The reaction mixture was heated at 80 °C for 
2 days. The crude product was worked up according to TP5a and purified by flash column 
chromatography (SiO2, EtOA/i-hexane 0.10:9.90) furnishing compound 69e (114 mg, 0.34 
mmol, 68%) as a colorless solid. 
HRMS (ESI) for C19H30O3Si: calcd 333,1891 (M-H), found 333.1891. 
1
H NMR (400 MHz, CDCl3): δ = -0.27 (s, 3 H), 0.03 (s, 3 H), 0.86 (s, 9 H), 1.41 (s, 3 H), 
2.24 (s, 3 H), 4.04 (s, 1 H), 5.03 (s, 1 H), 5.89 (s, 1 H), 5.91 (s, 1 H), 7.19 (s, 5 H). 
13
C NMR (101 MHz, CDCl3): δ = -5.13, -4.70, 18.10, 25.15, 25.80, 27.53, 77.46, 78.56, 
127.26, 127.28, 127.51, 127.80, 140.85, 150.34, 201.42.  
IR (ATR): ν ̃ (cm
-1
) = 657, 671, 684, 687, 699, 726, 775, 793, 816, 836, 862, 913, 939, 957, 
969, 1005, 1019, 1062, 1109, 1136, 1156, 1177, 1192, 1252, 1259, 1275, 1361, 1390, 1419, 
1435, 1463, 1471, 1611, 1672, 1721, 2856, 2885., 2929, 2952, 3541. 
 
7.18.7 (4R,5S)-5-((tert-Butyldimethylsilyl)oxy)-4-hydroxy-5-(4-methoxyphenyl)-4-
methyl-3-methylenepentan-2-one (69f) 
69f was prepared according to TP15a from a suspension of 68f 
(333 mg, 0.92 mmol) and NH4Cl (530 mg, 10 mmol, 10 equiv.) in 
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EtOH:H2O (1:1, 100 mL) and Fe powder (550 mg, 10 mmol, 10 equiv.). The reaction mixture 
was heated at 80 °C for 1 day. The crude product was worked up according to TP15a and 
purified by flash column chromatography (SiO2, EtOAc:i-hexane 0.5:10) furnishing 
compound 69f (198 mg, 0.54 mmol, 59%) as a colorless oil. 
HRMS (ESI) for C20H32O4Si: calcd 364.2070 (M
+
); found 364.2031. 
1
H NMR (300 MHz, CDCl3): δ = -0.27 (s, 3 H), 0.02 (s, 3 H), 0.86 (s, 9 H), 1.40 (s, 3 H), 
2.22 (s, 3 H), 3.76 (s, 3 H), 3.99 (s, 1 H), 4.98 (s, 1 H), 5.88 (s, 1 H), 5.92 (s, 1 H), 6.71- 7.74 
(m, 2 H), 7.08- 7.11 (m, 2H). 
13
C NMR (75 MHz, CDCl3): δ = ppm -5.13, -4.65, 18.09, 25.26, 25.81, 27.51, 55.02, 77.55, 
78.12, 112.62, 127.30, 128.87, 133.11, 150.51, 158.74, 201.34.  
IR (ATR): 𝜈 (cm-1) = 671, 746, 777, 834, 867, 956, 1006, 1037, 1056, 1174, 1245, 1295, 
1360, 1391, 1463, 1471, 1512, 1586, 1612, 1674, 2857, 2887, 2931, 2954, 3000, 3546. 
 
7.18.8 (4R,5R)-5-(5-Bromothiophen-2-yl)-5-((tert-butyldimethylsilyl)oxy)-4-
hydroxy-4-methyl-3-methylenepentan-2-one (69g) 
69g was prepared according to TP15a from a suspension of 68g 
(42 mg, 0.1 mmol) and NH4Cl (53 mg, 1 mmol, 10 equiv.) in 
EtOH:H2O (1:1, 10 mL) was added Fe powder (55 mg, 1 mmol, 10 
equiv.). The reaction mixture was heated at 80 °C for 2 days. The crude product was worked 
up according to TP and purified by flash column chromatography (SiO2, EtOAc:i-hexane 
0.5:10) furnishing the compound 69g (29 mg, 0.07 mmol, 69%) as a colorless solid. 
69g could also be prepared according to TP15a from 68g (0.1 mmol), to produce the title 
compound in 28% yield. 
HRMS (ESI) for C17H27BrO3SSi: calcd 419.4490 (M+H
+
); found 419.0728. 
1
H NMR (300 MHz, CDCl3): δ = 0.14 (s, 3 H), 0.08 (s, 3 H), 0.88 (s, 9 H), 1.44 (s, 3 H), 2.23 
(s, 3 H), 3.58 (s, 1 H), 5.35 (s, 1 H), 6.00 (s, 1 H), 6.17 (s, 1 H), 6.46 (d, J=3.87 Hz, 1 H), 6.76 
(d, J=3.87 Hz, 1 H). 
13
C NMR (75 MHz, CDCl3): δ = -5.14, -4.90, 18.07, 25.28, 25.74, 27.43, 75.16, 76.93, 
112.03, 125.86, 127.85, 128.09, 145.88, 149.70, 200.62. 
IR (ATR): 𝜈 (cm-1) = 665, 742, 780, 807, 833, 862, 906, 967, 1004, 1065, 1141, 1176, 1212, 
1251, 1298, 1361, 1399, 1438, 1470, 1615, 1622, 1662, 2853, 2926, 2953, 3476. 
MP 69 - 70 °C  
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7.19 Ozonolysis of TBS-Protected Isoxazoline to the Ketons 71a-71b 
7.19.1 (S)-5-((S)-((tert-butyldimethylsilyl)oxy)(phenyl)methyl)-3,5-
dimethylisoxazol-4(5H)-one (71a) 
71a was prepared from a solution of 68e (260 mg, 0.78 mmol) in CH2Cl2 
(15 mL) at 0 °C. A O3/O2 mixture was passed through the solution for 1 h. 
Completion of the reaction was checked using TLC. Upon completion, Me2S 
(0.1 mL) was added and the reaction mixtrure was stirred for further 12 h. The solvent was 
removed in vacuo and the crude product was purified by flash column chromatography (SiO2, 
EtOAc:i-hexane 1:10) furnishing the compound 71a (117 mg, 0.35 mmol, 45 %) as a 
colorless liquid. 
1
H NMR (200 MHz, CDCl3) δ =  -0.22 (s, 3 H), 0.05 (s, 3 H), 0.84 (s, 9 H), 1.33 (s, 3 H), 
1.88 (s, 3 H), 4.78 (s, 1 H), 7.26 (s, 6 H).
 
13
C NMR (75 MHz, CDCl3) δ =  -5.33, -4.90, 7.78, 18.07, 18.63, 25.59, 78.63, 86.87, 127.65, 
127.72, 128.35, 137.95, 153.68, 204.71. 
HRMS (EI) for C15H17N2O3Si: calcd 301.10134, found 301.997 (M-t-Bu) 
IR (ATR): 𝜈 (cm-1) =  2955, 2928, 2885, 2857, 1738, 1585, 1471, 1454, 1388, 1361, 1258, 
1095, 1070, 1029, 1005, 983, 939, 909, 853, 847, 775, 745, 698, 672. 
7.19.2 Preparation of 4-((S)-((tert-butyldimethylsilyl)oxy)((S)-3,5-dimethyl-4-oxo-
4,5-dihydroisoxazol-5-yl)methyl)benzonitrile (71b) 
71b was prepared from a solution of 68c (100 mg, 0.28 mmol) in CH2Cl2 
(15 mL) at 0 °C. A O3/O2 mixture was passed through the solution for 1 h. 
Completion of the reaction was checked using TLC. Upon completion, 
Me2S (0.1 mL) was added and the reaction mixtrure was stirred for further 12 h. The solvent 
was removed in vacuo and the crude product was purified by flash column chromatography 
(SiO2, EtOAc:i-hexane 1:10) furnishing the compound 71b (33 mg, 0.09 mmol, 33 %) as a 
colorless liquide. 
HRMS (EI) for C14H18O3N1Si: calcd. 276.1061, found 276.1063. 
1
H NMR (300 MHz, CDCl3) δ =  -0.22 (s, 3 H), 0.07 (s, 3 H), 0.84 (s, 9 H), 1.32 (s, 3 H), 
1.91 (s, 3 H), 4.81 (s, 1 H), 7.39 (m, J=8.02 Hz, 2 H), 7.60 (m, J=8.29 Hz, 2 H). 
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13
C NMR (75 MHz CDCl3) δ =  -5.27, -4.92, 7.85, 18.02, 18.57, 25.53, 77.71, 86.13, 112.38, 
118.51, 128.39, 131.68, 143.28, 153.80, 204.28. 
IR (ATR): 𝜈 (cm-1) = 2958, 2929, 2888, 2871, 2227, 1734, 1608, 1582, 1502, 1469, 1437, 
1411, 1385, 1361, 1260, 1252, 1197, 1119, 1096, 1016, 1005, 982, 905, 852, 837, 831, 790, 
779, 767, 732, 702, 676. 
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7.20 Acid Mediated Rearrangement of TBS-Protected Isoxazoline 72a-72b 
7.20.1 Preparation of (E)-4-(3-fluorostyryl)-3,5-dimethylisoxazole 72a  
To 66f (1 м in THF, 1 mL, 1 mmol) was added BF3 OEt2 (5 mL) at 25 °C. The 
reaction was wormed to 80 °C for 30 min. Completion of the reaction was 
checked using TLC. Upon completion, the resulting mixture was cooled back to 25 °C and 
slowly quenched with aqueous NH4Cl. The layers were separated and the aqueous layer was 
extracted three times with CH2Cl2. The combined organic extracts were washed with aqueous 
NaCl, dried over MgSO4 filtered and concentrated in vacuo. The crude product was purified 
by flash column chromatography (SiO2, EtOAc:i-hexane 0/10 to 1/10) furnishing the 
compound 72a as a colorless solid (135 mg, 0.62 mmol, 62% yield) 
HRMS (EI) for C13H12FNO: calcd 217,09029, found 217.0885. 
1
H NMR (400 MHz, CDCl3) δ = 2.41 (s, 3 H), 2.50 (s, 3 H), 6.72 - 6.75 (m, 2 H), 6.92 - 6.99 
(m, 1 H), 7.12 - 7.23 (m, 2 H), 7.27 - 7.36 (m, 1 H). 
13
C NMR: (101 MHz, CDCl3) δ =  11.59, 11.89, 112.39 (d, 21.88 Hz, 1C), 112.70, 114.50 (d, 
21.50 Hz, 1 C), 117.88, 122.05 (d, 2.69 Hz, 1C), 128.71 (d, 2.6 Hz, 1 C), 130.28 (d, 18.45 Hz, 
1C), 139.35 (d, 7.68Hz, 1 C), 158.23, 163.18 (d, 245.68), 166.11.  
IR (ATR): 𝜈 (cm-1) = 3046, 2977, 2931, 2839, 1655, 1610, 1602, 1579, 1486, 1446, 1426, 
1380, 1371, 1315, 1266, 1242, 1208, 1145, 1039, 955, 938, 890, 875, 771, 751, 733, 692, 670.  
7.20.2 Preparation of (E)-4-(4-chlorostyryl)-3,5-dimethylisoxazole 72b 
To 66c (1 м in THF, 1 mL, 1 mmol) and BF3 OEt2 (5 mL) at 25 °C, the reaction 
was wormed to 80 °C for 30 min. Completion of the reaction was checked using 
TLC. Upon completion, the resulting mixture was cooled back to 25 °C and slowly 
quenched with aqueous NH4Cl. The layers were separated and the aqueous layer 
was extracted three times with CH2Cl2. The combined organic extracts were washed with 
aqueous NaCl, dried over MgSO4 filtered and concentrated in vacuo. The crude product was 
purified by flash column chromatography (SiO2, EtOAc:i-hexane 0/10 to 1/10) furnishing the 
compound 72a as a colorless solid 72a (121 mg, 0.52 mmol, 52% yield) 
HRMS (ESI) for C13H13NCl: calcd 234.0680, found 234.0681 (M+H
+
). 
1
H NMR (300 MHz, CDCl3) δ = 2.40 (s, 3 H), 2.49 (s, 3 H), 6.71 (s, 2 H), 7.35 (m, 4 H). 
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13
C NMR (75 MHz, CDCl3) δ = 11.62, 11.91,112.80,117.14, 127.25, 128.60, 128.88, 133.32, 
135.68, 158.22, 165.94. 
IR (ATR): 𝜈 (cm-1) = 3012, 2968, 2928, 2854, 1649, 1597, 1489, 1447, 1424, 1404, 1379, 
1317, 1293, 1260, 1221, 1195, 1181, 1106, 1088, 1035, 1011, 959, 951, 886, 862, 853, 808, 
784, 774, 761,743 ,710, 679, 667.  
 
